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AbstrACt
Ulcerative colitis and Crohn’s disease are the principal 
forms of inflammatory bowel disease. Both represent 
chronic inflammation of the gastrointestinal tract, which 
displays heterogeneity in inflammatory and symptomatic 
burden between patients and within individuals over 
time. Optimal management relies on understanding and 
tailoring evidence-based interventions by clinicians in 
partnership with patients. This guideline for management 
of inflammatory bowel disease in adults over 16 years 
of age was developed by Stakeholders representing 
UK physicians (British Society of Gastroenterology), 
surgeons (Association of Coloproctology of Great 
Britain and Ireland), specialist nurses (Royal College of 
Nursing), paediatricians (British Society of Paediatric 
Gastroenterology, Hepatology and Nutrition), dietitians 
(British Dietetic Association), radiologists (British Society 
of Gastrointestinal and Abdominal Radiology), general 
practitioners (Primary Care Society for Gastroenterology) 
and patients (Crohn’s and Colitis UK). A systematic 
review of 88 247 publications and a Delphi consensus 
process involving 81 multidisciplinary clinicians and 
patients was undertaken to develop 168 evidence- 
and expert opinion-based recommendations for 
pharmacological, non-pharmacological and surgical 
interventions, as well as optimal service delivery in the 
management of both ulcerative colitis and Crohn’s 
disease. Comprehensive up-to-date guidance is provided 
regarding indications for, initiation and monitoring of 
immunosuppressive therapies, nutrition interventions, 
pre-, peri- and postoperative management, as well as 
structure and function of the multidisciplinary team and 
integration between primary and secondary care. Twenty 
research priorities to inform future clinical management 
are presented, alongside objective measurement of 
priority importance, determined by 2379 electronic 
survey responses from individuals living with ulcerative 
colitis and Crohn’s disease, including patients, their 
families and friends.
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1 IntroduCtIon
In the past decade there have been major advances in investiga-
tions, pharmacological, non-pharmacological and surgical inter-
ventions for both ulcerative colitis (UC) and Crohn’s disease. In 
light of this, the British Society of Gastroenterology (BSG) Clin-
ical Services and Standards Committee (CSSC) commissioned 
a new guideline for the management of inflammatory bowel 
disease (IBD) in adults. This was to replace the 2011 iteration of 
IBD guidelines from the Society.1 The aim of this document is to 
provide high-quality disease management guidance for health-
care professionals managing IBD, to ensure that investigation, 
treatment and monitoring decisions are based on the best avail-
able evidence, and to promote and improve best accepted prac-
tice. Where appropriate the guidelines refer to relevant National 
Institute for Health and Care Excellence (NICE) documents, 
with attention drawn to how this guidance can be incorporated 
into the UK National Health Service (NHS) infrastructure and 
funding pathways.
2 MethodoloGy
The guideline is of relevance to adults aged 16 years and over 
and was developed according to Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) method-
ology,2 in accordance with the principles of the AGREE II tool,3 
and in compliance with the BSG Guidelines Advice Document.4 
The completed document was formally peer reviewed by the 
BSG CSSC and BSG Council prior to submission for publica-
tion. The guideline writing process was supported by regular 
consultation from Professor Cathy Bennett (Systematic Research 
Ltd and Royal College of Surgeons in Ireland (RCSI)) and used 
a bespoke online platform developed by Dr Stuart Gittens (ECD 
Solutions: https://www. guideline. pub/ bsg- ibd/) to develop clin-
ical questions structured by Population, Intervention, Compar-
ator and Outcome (PICO) or Population, Exposure, Outcome 
(PEO) development, to assimilate evidence and to facilitate 
voting of draft statements and recommendations using a modi-
fied eDelphi process.
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After commissioning of the guideline by the BSG CSSC, a 
Guideline Development Group (GDG) was convened by the 
Chair of the IBD Section Committee of the BSG (ABH). A GDG 
Lead (CAL) and conflicts of interest Chair (TI) were appointed. 
Key Stakeholders from the following groups were represented: 
British Society of Gastroenterology (BSG), Association of 
Coloproctology of Great Britain and Ireland (ACPGBI), Royal 
College of Nursing (RCN), British Society of Paediatric Gastro-
enterology, Hepatology and Nutrition (BSPGHAN), British 
Dietetic Association (BDA), British Society of Gastrointestinal 
and Abdominal Radiology (BSGAR), and the Primary Care 
Society for Gastroenterology (PCSG). Patient representation was 
provided by Crohn’s and Colitis UK.
Members of the BSG IBD Section Committee were invited to 
take part in the GDG along with external clinicians with rele-
vant experience. The GDG and all conflicts of interest for 12 
months preceding GDG formation were vetted and approved by 
the BSG CSSC.
Clinical priorities to be covered by the guideline were set by 
the GDG including:
 ► Definitions, clinical features and diagnosis
 ► Investigations including imaging
 ► Treatment of active UC including surgery and acute severe 
UC (ASUC)
 ► Pouchitis management
 ► Treatment of active Crohn’s disease (ileal, ileocolonic, 
colonic, jejunal, upper GI, perianal)
 ► Maintenance treatment of Crohn’s disease
 ► Surgery for Crohn’s disease (including non-perianal fistu-
lising disease)
 ► Common considerations for drug groups to include mesala-
zines, corticosteroids, thiopurines, methotrexate, ciclo-
sporin, anti-TNF, vedolizumab, ustekinumab, tofacitinib and 
antibiotics
 ► Therapeutic monitoring including drug levels and drug 
toxicity/immunogenicity, and pre-treatment infection 
screening and vaccination
 ► Non-drug therapies including leucocyte apheresis and stem 
cell transplantation
 ► Nutrition and dietary therapy
 ► Lifestyle factors including smoking
 ► Pain and fatigue
 ► Psychological aspects
 ► Service delivery
 ► Primary care management of IBD
Where substantial up-to-date guidance existed on special 
circumstances—for example, pregnancy, osteoporosis, iron defi-
ciency, immunosuppression in the context of prior malignancy or 
histology—extensive systematic review would not be performed 
but summary data would be presented to encourage best prac-
tice with referencing to signpost other guidance. Guidance for 
surgical technique in IBD would not be extensively covered due 
to a concurrent guideline development process in this area led 
by the ACPGBI.5 Health economics and costs of drugs would 
not be assessed as part of the guideline, although cost would be 
mentioned as an important consideration when there is a choice 
of treatments.
A clinical framework was then designed to visually map and 
group patient management decisions and influencing clinical 
factors, including disease location and severity. Sub-categorisa-
tions were made to identify aspects pertinent to pharmacolog-
ical and non-pharmacological intervention, nutrition, imaging, 
surgery, primary care and service delivery. Four working groups 
were formed (led by NAK, TR, PH and PJS alongside CAL and 
ABH) to draft and develop a list of key thematic and sub-the-
matic clinical questions grouped into sections defined by the 
clinical framework that face IBD clinicians in everyday health-
care practice. These clinical questions were circulated to all 
stakeholder groups for review by members outside the GDG 
to ensure all relevant areas of clinical practice were covered. 
Following stakeholder review, the list was further developed 
producing 54 thematic questions with 360 associated clinical 
questions grouped around these themes (see online supplemen-
tary appendix 1).
Next, the clinical questions were further revised, refined and 
combined with the thematic questions in order to design the 
systematic review. Keyword tables derived from these ques-
tions and formulated according to PICO or PEO structure were 
generated on the online platform, and structured searches of 
electronic literature databases were performed. The litera-
ture searches were designed, run in electronic databases and 
exported to Endnote reference managing software, supported 
by information specialists at York Health Economics Consor-
tium. Searches of the Medline and EMBASE databases were 
performed in March 2017 and updated in March 2018. No date 
or study design limits were incorporated into searches in order 
to return all available evidence, including conference proceed-
ings (although conference proceeding returns were limited to 
5 years preceding the date of search). The search strategy used 
is presented in online supplementary appendix 2. In this way, 
systematic literature searches and reviews were undertaken to 
identify and synthesise evidence to support the creation of state-
ments with supporting narrative syntheses of evidence. A total 
of 87 959 references were returned after deduplication from 
these searches. Focused top-up searches using keywords were 
performed until June 2019 to ensure evidence was up to date 
at the time of submission for publication. GDG members were 
able to also propose papers or electronic documents (eg, NICE 
guidance) for inclusion in the literature databases throughout 
the guideline development process. In this manner an additional 
288 entries were added to the reference library to make a total 
of 88 247. References were cross-searched both manually using 
keywords and Boolean operators, and using a bespoke program-
matic algorithm (the latter cross-referencing content of abstract, 
title and keywords with contents of PEO and PICO tables), 
both facilitated by the online platform. Literature was assessed 
according to the pre-designed PEO and PICOs, and abstracts±-
full text assessed for relevance and quality. Evidence-based eval-
uative text and associated reference lists were developed along 
with draft statements and grouped/archived in a customised 
electronic database. Statements considered potential health 
benefits, side effects and risks of recommendations to patients, 
as well as cost and service implications. Full economic analyses 
were not undertaken.
Following statement revision by the GDG according to Delphi 
methodology, an ‘IBD guidelines eDelphi consensus group’ of 81 
clinicians and patients was formed consisting of representatives 
invited from all stakeholder groups listed above, and all members 
of the GDG except CB and SG who did not vote. A modified 
eDelphi mechanism process, employing the online platform, was 
then used to produce an evidence-based consensus, following 
a NICE accredited methodology. This consisted of three main 
rounds of anonymous web-based voting, using a custom-built 
online voting platform scoring each using a 5-point scale with 
updated iterations of the statements and evaluative text based on 
feedback after each round.
Following two rounds of anonymised voting, statements 
conforming to PICO/PEO which achieved consensus of 80% 
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agreement or higher were categorised according to the GRADE 
system for grading quality of evidence and strength of recom-
mendations. Assessments were made independently by two 
members of the GDG (blinded to one another’s assessment) 
using a custom-built electronic database by NAK in REDCap6 (at 
https:// surveys. exeteribd. org. uk/). All assessments were reviewed 
and where necessary moderated by CAL and ABH to determine 
agreement. To assess the quality of evidence for each statement, 
each member considered study type, risk of bias, inconsistency, 
indirectness, imprecision, publication bias, effect size, plausible 
confounding variables and dose–response gradient if applicable. 
The quality of evidence ranged from ‘high’ (further research is 
very unlikely to change confidence in the estimate of effect), 
‘moderate’ (further research is likely to have an important impact 
on confidence in the estimate of effect and may change the esti-
mate), ‘low’ (further research is very likely to have important 
impact on confidence in the estimate of effect and is likely to 
change the estimate), and ‘very low’ (any estimate of effect is 
very uncertain). The strength of recommendation was assessed 
based on considerations of desirable and undesirable anticipated 
effects, the certainty of the evidence of effects, any important 
uncertainty about or variability in how much people value the 
outcome, whether the balance of these effects favours the inter-
vention or comparison, the acceptability of intervention to key 
stakeholders and feasibility of intervention implementation. The 
strength of each recommendation was then recorded as ‘strong’ 
(meaning that benefits clearly outweigh risks and burdens or 
vice versa) and conditional recommendations as ‘weak’ (where 
benefits, risks and burdens are conditional, closely balanced or 
uncertain).
Where statements did not conform to PICO/PEO (such as 
subjective interventions or where outcomes were multiple) and 
evidence was indirect or of low quality, recommendations to 
inform clinical practice were presented as Good Practice Recom-
mendations and listed separately to GRADE recommendations, 
but still underwent consensus voting.
The GDG voted on all statements and Good Practice Recom-
mendations, and other eDelphi participants voted on one of 
three subsets of statements and Good Practice Recommenda-
tions in order to ensure adequate numbers of responses were 
obtained for each, that expertise was equally distributed across 
subject areas and that surgeon members of the group voted on 
all surgical-related topics. The total number of respondents 
per statement and recommendation are presented in online 
supplementary table 3. Statements and recommendations not 
reaching 80% consensus agreement following three rounds of 
voting were removed and are presented in online supplemen-
tary appendix 3.
Conflict of interest
To ensure transparency and declaration of any potential bias, 
all the GDG members were asked to declare a minimum of 12 
months competing financial and non-financial interests when 
they joined the group and during initial statement drafting. All 
members of the GDG and IBD guidelines eDelphi consensus 
group also declared conflicts of interest before each of the three 
rounds of Delphi consensus voting. This is in keeping with 
the NICE approved processes. The final submitted conflicts of 
interest for each member is shown in online supplementary table 
2. eDelphi participants were asked to abstain from voting where 
they either did not have sufficient knowledge to vote on a partic-
ular statement or where they identified themselves as having a 
conflict which precluded voting. The number of abstentions in 
the final round of voting is presented in online supplementary 
table 3.
Areas of unmet research priority identified by systematic 
review
Following systematic review, the original 414 clinical questions 
defined by the group, evaluative descriptions for each statement 
and the results of consensus voting were reviewed to deter-
mine where evidence was insufficient to provide recommenda-
tions for practice, or where further research was desirable to 
define and support best clinical practice. From this, 20 areas 
of research priority with associated questions were determined 
and described for a healthcare professional readership. General 
audience versions of these questions were then written and read-
ability assessed by the Flesch Reading Ease and Flesch-Kincaid 
Grade Level (see online supplementary table 4). The importance 
to patients, their relatives, partners, parents, friends and carers 
of these 20 research priority themes was determined by two 
electronic surveys conducted by the UK patient charity Crohn’s 
and Colitis UK during December 2018 and January 2019 using 
the general audience versions and asking survey respondents to 
score each priority on a Likert scale of 1–9 (1=not important 
and 9=very important). Survey 1 was promoted by social media 
and Survey 2 through a combination of social media and direct 
email to respondents to Survey 1 who agreed to be contacted for 
future survey.
revisions of the guideline
We suggest that every 2 years a formal assessment of the following 
should take place:
 ► Research objectives identified by the guidelines should be 
reviewed for evidence of additional studies, contributing to 
resolving the objective
 ► Review of new evidence that may change former 
recommendations
 ► Identification of any error in the guidelines after 
publication
 ► Exploration of any evidence of inequality in access to services 
between different social groups that can be addressed 
through guideline recommendations
 ► Review of any new technology or drugs or legislation, that 
will change former recommendations
We suggest the guidelines should be fully updated after 5 years. 
All materials are archived using the online system at https://www. 
guideline. pub/ bsg- ibd/.
note on drug nomenclature
In this document we have adopted the following descriptors: 
‘Immunosuppressive drugs’: corticosteroids, thiopurines, meth-
otrexate, calcineurin inhibitors, janus kinase inhibitors and all 
biologic drugs where the mode of action is immunosuppressive; 
‘Immunomodulators’: thiopurines and methotrexate; ‘biologics’: 
monoclonal antibody drugs.
3 ulCerAtIve ColItIs
3.1 diagnosis
Ulcerative colitis (UC) is a chronic inflammatory disease charac-
terised by mucosal inflammation starting distally in the rectum, 
with continuous extension proximally for a variable distance, 
often with an abrupt demarcation between inflamed and non-in-
flamed mucosa. Typically, patients with UC experience periods 
of relapse and remission. Up to 90% will have one or more 
relapses after the first attack, and early relapse or active disease 
 o
n
 O
ctober 1, 2019 at University of G
lasgow. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-318484 on 27 September 2019. Downloaded from 
9Lamb CA, et al. Gut 2019;0:1–106. doi:10.1136/gutjnl-2019-318484
Guidelines
in the first 2 years is associated with a worse disease course 
subsequently.7 8
In patients presenting with suspected UC, stool cultures and 
Clostridium difficile toxin assay should always be performed to 
rule out infective causes. While UC is often initially diagnosed 
at flexible (or rigid) sigmoidoscopy, it is important to confirm 
the diagnosis, extent and severity of disease by means of full 
ileocolonoscopy, usually within the first year, as this can more 
definitively confirm the diagnosis of UC versus Crohn’s disease 
and give information that may help to predict future disease 
course, including potential and risk stratification for dysplasia,9 
and thus will influence treatment choices. For histological assess-
ment at least two biopsy specimens should be taken from five 
sites throughout the examined bowel, including the ileum and 
rectum, during the initial endoscopic evaluation.1
Rectal sparing in UC has been described in up to >3% of 
patients,10 but more frequently patchy inflammation of the 
rectum may be seen in those who have been given empirical 
topical therapy.11 12 The presence of a ‘caecal patch’, isolated 
peri-appendiceal inflammation and backwash ileitis can occur in 
UC, but if the histology and clinical pattern are not otherwise 
typical of UC, then small bowel evaluation is required to exclude 
Crohn’s disease (see Section 4.1.3.1: Crohn’s disease, Cross-sec-
tional imaging: CT, MR and small bowel ultrasound). Backwash 
ileitis has been reported in up to 20% of patients with extensive 
colitis.13
3.1.1 Histology
No histological feature is diagnostic of UC, but the combina-
tion of basal plasmacytosis, diffuse crypt atrophy and distortion, 
villous surface irregularity and mucus depletion are suggestive of 
a diagnosis of UC in the correct clinical context.14 Uneven distri-
bution of inflammation within the colon or within biopsies can 
occur in patients with long-standing disease, or after treatment.
3.1.2 UC versus Crohn’s disease
In 5–15% of IBD patients, endoscopic and histological assess-
ments cannot distinguish between Crohn’s colitis and UC, 
and these patients are labelled as IBD-unclassified (IBD-U), or 
if features are still indeterminate after colectomy histology is 
assessed, described as indeterminate colitis.15–17 IBD-U is more 
common in children than adults.18 In a small proportion of UC 
patients their diagnosis is later changed to IBD-U or Crohn’s 
disease.19–21
3.2 Phenotypic classification
The Montreal classification22 in adults and Paris classifica-
tion23 in children (table 1) are useful in ascribing phenotypes 
to patients both for treatment and to assist with service delivery 
and research.24 Children developing IBD generally have more 
extensive disease than adults.25 Establishing the extent of the 
inflammation in a patient with UC is important for prognosis 
as the likelihood of colectomy is dependent on disease extent. 
A systematic review showed that the 10 year colectomy rate is 
19% for those with extensive colitis, 8% with left-sided colitis 
and 5% with proctitis; and male gender, young age and elevated 
inflammatory markers at diagnosis also increase the likelihood 
of colectomy.26 Backwash ileitis is also associated with more 
aggressive disease, and with primary sclerosing cholangitis.13 
Those with extensive colitis also have the highest risk of devel-
oping colorectal cancer.27 28
Disease extent can change after diagnosis.29 Up to half with 
proctitis or proctosigmoiditis will develop more extensive 
disease.8 26 30 Of patients with proctitis initially, 10% will ulti-
mately have extensive colitis.31 However, over time the extent of 
inflammation can also regress, and classification should always 
remain as the maximal extent.29 Endoscopic appearance may 
significantly underestimate the true extent (particularly in quies-
cent UC), and this should be confirmed by mapping biopsies.
3.3 Clinical and endoscopic disease activity
Definitions in relation to disease activity are shown in box 1. 
The Mayo Score for UC is widely used in clinical trials and may 
be applied to clinical practice as a composite clinical and endo-
scopic tool (table 2).32 The score of 0–12 includes a measure 
of stool frequency, rectal bleeding, a physician’s global assess-
ment and a measure of mucosal inflammation at endoscopy. The 
partial Mayo score uses the non-invasive components of the full 
score and correlates well to patient perceptions of response to 
therapy.33
There is wide variation in interpretation of disease activity 
endoscopically.34 The Ulcerative Colitis Endoscopic Index of 
Severity (UCEIS) has been developed to improve reliability 
(table 3).35 36 The Modified Mayo Endoscopic Score is another 
simple measure of endoscopic activity that correlates well with 
clinical and biological activity (table 4).37 Although both have 
been extensively validated, inter-observer variation remains a 
significant limitation for these visual scores.38 39
Symptomatic and endoscopic scores may be limited by their 
ability to quantify accurately the impact of disease on quality of 
life, including fatigue and psychosocial function, or if complex 
the indices may be difficult to apply to clinical practice.40 41 An 
increasing emphasis on patient reported outcomes measures 
(PROMs: standardised questionnaires filled out by patients 
without clinician involvement) in clinical trials may translate to 
routine clinical practice (box 1).42
3.4 treatment targets
The ultimate target of medical therapy is a contentious issue 
as there is no fully agreed or validated definition of remission, 
although many parameters have been suggested both clinically 
and endoscopically.43–45 Using mucosal healing as a treatment 
statement 1. Where ulcerative colitis is diagnosed by 
sigmoidoscopy, we recommend a full ileocolonoscopy to 
delineate disease extent, severity of inflammation and to 
exclude Crohn’s disease (GRADE: strong recommendation, very 
low-quality evidence. Agreement: 100%).
table 1 Montreal and Paris classification in UC
Montreal22 Paris23
Extent* E1 Ulcerative proctitis E1 Ulcerative proctitis
E2 Left-sided UC (distal to 
splenic flexure)
E2 Left-sided UC (distal to 
splenic flexure)
E3 Extensive (proximal to 
splenic flexure)
E3 Extensive (hepatic flexure 
distally)
E4 Pancolitis (proximal to 
hepatic flexure)
Severity S0 Clinical remission S0 Never severe†
S1 Mild UC S1 Ever severe†
S2 Moderate UC
S3 Severe UC
*Extent defined as maximal macroscopic inflammation.
†Severe defined by Paediatric Ulcerative Colitis Activity Index (PUCAI) ≥65.
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target is contentious because of the implications for clinical prac-
tice, with the need for more endoscopic assessment and likely 
escalation of therapy in asymptomatic patients.46 In an Austra-
lian retrospective study, 61% of 246 patients were in clinical 
remission, but only 35% were in both clinical and endoscopic 
remission (Mayo endoscopic subscore ≤1), and only 16% of 
the 246 patients were also in histological remission.47 Using the 
Mayo endoscopic subscore, there is no consensus on the value 
of achieving a score of 0 rather than 1, with documented differ-
ences in future disease course between the two.46 There is lack 
of clear evidence about the importance of histological remis-
sion as well as endoscopic remission.48 49 Histological remission 
has now become an end-point for some new drug trials in UC, 
but there remains lack of agreement about the definition, and 
the evidence of long-term benefit is only from observational 
studies.44 48 50–54 There is, however, growing evidence that the 
presence of endoscopic and histological inflammation is predic-
tive of future flares, lack of sustained remission, need for corti-
costeroids and colectomy.44 48 50–54 There is likewise evidence 
of the benefits of mucosal healing in reducing future risk of 
colorectal carcinoma55 (see Section 5.13: Chemoprevention and 
colorectal cancer surveillance). There is a growing consensus 
therefore that the target for UC should be clinical and/or 
patient-reported remission (defined as absence of rectal bleeding 
and return to normal bowel habit) combined with endoscopic 
remission (Mayo endoscopic subscore of ≤1).56 More evidence 
is needed of the implications for a more aggressive approach to 
achieving mucosal healing, including the acceptability to patients 
of increased medication with potential toxicity (often despite 
lack of clinical symptoms). A widely agreed definition is needed 
for both endoscopic healing and histological healing that can be 
used in clinical practice, and more evidence is also needed of the 
role of faecal calprotectin or other biomarkers as non-invasive 
surrogates for mucosal healing. Longer-term prospective studies 
of mucosal healing will be needed to provide evidence of the 
risks and benefits of this approach.
3.5 Initial treatment of active uC with 5-AsA
Oral 5-ASA (5-aminosalicylic acid) is the standard therapy for 
mild to moderately active UC. Meta-analyses support the effi-
cacy of oral 5-ASA for induction therapy for mild to moder-
ately active UC.57 58 Once daily dosing is as effective as divided 
doses.59 Doses ≥2 g/day are more effective than dosages <2 g/
day for remission (RR 0.91; 95% CI 0.85 to 0.98).60 The 
majority of patients with mild to moderate UC will respond to 
2–3 g 5-ASA (depending on formulation used) and higher doses 
can be used in those with more severe symptoms or those not 
responding initially.
3.5.1 5-ASA dose
The ASCEND trials investigated the dose–response effect of 
5-ASA (Asacol) for the induction of response in UC. ASCEND 
I randomised 301 patients with mild-moderately active UC to 
2.4 g or 4.8 g of mesalazine.61 At week 6, a similar proportion of 
patients experienced improvement in either group (51% vs 56%, 
p=NS). When results were stratified according to disease severity, 
patients with moderate disease had better response to 4.8 g/day, 
but there was no significant difference in dose–response in those 
with mildly active disease. ASCEND II confirmed that patients 
box 1 definitions in Ibd management
 ► steroid dependency: inability to wean systemic steroids 
below 10 mg prednisolone within 3 months without recurrent 
active disease, or symptomatic relapse of IBD within 
3 months of stopping steroids.1279
 ► steroid refractory: inability to induce symptomatic 
remission with systemic steroids.1279
 ► Mucosal healing: typically, this refers to absence of 
macroscopic mucosal inflammation or ulceration, although 
precise definitions between studies vary. While usually 
defined endoscopically, more recently there has also been 
interest in ‘histological healing’.56
 ► treat to target: the goal being more than symptomatic 
remission with the intention of reducing risk of future relapse 
or complications (eg, ileal strictures or colon cancer) resulting 
from uncontrolled but asymptomatic inflammation.56 360 
Future studies are required to define targets, the practicality 
of achieving targets and to examine the balance of benefit 
versus risk and cost.
 ► therapeutic drug monitoring (tdM): measurement of 
drug (±anti-drug antibody) levels to assess compliance, drug 
metabolism and immunogenicity with a view to guide dose 
adjustments or switch off therapy (eg, where patients are 
relapsing despite therapeutic levels, or have developed high 
titre anti-drug antibodies with low levels).
 ► Patient related outcome (Pro): a report directly from 
patients about how they feel or function in relation to their 
IBD and its therapy without interpretation by healthcare 
professionals. Provides an indication of the outcome of an 
intervention, or quality of care.1280
 ► Patient reported outcome measure (ProM): a tool or 
instrument used to measure PROs.1280
table 2 Mayo score for ulcerative colitis32
Mayo index 0 1 2 3
Stool frequency Normal 1–2/day more than normal 3–4/day more than normal 5/day more than normal
Rectal bleeding None Streaks of blood with stool <50% of 
the time
Obvious blood with stool most of time Blood passed without stool
Mucosa (endoscopic subscore) Normal or inactive 
disease
Mild disease (erythema, decreased 
vascular pattern, mild friability)
Moderate disease (marked erythema, lack of 
vascular pattern, friability, erosions)
Severe disease (spontaneous 
bleeding, ulceration)
Physician’s global assessment Normal Mild disease Moderate disease Severe disease
Mayo score=sum of scores for each of the four variables (maximum score 12).
Clinical response: reduction of baseline Mayo score by ≥3 points and a decrease of 30% from the baseline score with a decrease of at least one point on the rectal bleeding 
subscale or an absolute rectal bleeding score of 0 or 1.
Clinical remission: defined as a Mayo score ≤2 and no individual subscore >1.
Mucosal healing: defined as a mucosa subscore of ≤1.
Disease activity: Mild 3–5; Moderate 6–10; Severe 11–12.
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with moderately active UC had a better response to 4.8 g/day 
than 2.4 g/day (72% vs 59%, p=0.036).62 In the ASCEND III 
trial, 772 patients with moderately active UC were randomised 
to receive 2.4 g/day or 4.8 g/day mesalazine.63 Despite the large 
numbers in the study, there was no difference in the primary 
end-point of treatment success (complete clinical remission or 
partial response). There was a small but significant difference in 
remission, with 43% of patients on 4.8 g/day versus 35% of those 
on 2.4 g/day achieving remission at 6 weeks. Subgroup analysis 
showed that patients who had received steroid, oral 5-ASA and 
rectal therapies were more likely to respond to the higher dose.63 
4.8 g/day 5-ASA is associated with more rapid symptom resolu-
tion than 2.4 g/day,64 and higher rates of mucosal healing at 3 
and 6 weeks.65 Similarly, the 5-ASA MMX trials also showed that 
4.8 g/day was more effective than 2.4 g/day in the subpopulation 
with prior exposure to 5-ASA, and in those who had an incom-
plete response to 8 weeks of 5-ASA MMX at 2.4 g/day.66
A post-hoc analysis of the ASCEND I and II data also showed 
that there was greater mucosal healing in the 4.8 g/day group 
compared with 2.4 g/day.65 There is also evidence of the effect 
of escalating doses of 5-ASA from the DEAR trial.67 In this 
study patients with quiescent UC but with a raised faecal calpro-
tectin >50 µg/g had their current 5-ASA dose increased (from 
1.2 g (or nil) to 2.4 g, or from 2.4 g to 4.8 g/day). Compared 
with a control group there was a significant increase in patients 
remaining in clinical remission, and with a faecal calprotectin 
<50 µg/g at 6 weeks. Oral 5-ASA is no more effective than oral 
sulphasalazine,59 but may be better tolerated (RR for an adverse 
event 0.48, 95% CI 0.36 to 0.63).57
Following commencement of 5-ASA, 10–30% of patients are 
in symptomatic remission at week 2, 30–45% by week 4 and 
35–50% by week 8.68–71 High-dose 5-ASA should not be used 
routinely, but patients with symptoms that are failing to settle 
should have their dose increased.
3.5.2 Oral and enema 5-ASA
All UC patients (including those with extensive disease) should be 
offered a combination of oral and enema 5-ASA, and those with 
incomplete response to oral 5-ASA should have topical therapy 
added. The combination of oral and topical 5-ASA therapy is 
superior to monotherapy even in patients with pancolitis.72 73 
A meta-analysis of four studies in active UC confirmed a rela-
tive risk of no remission of 0.65 (95% CI 0.47 to 0.91) for 
combined oral and topical therapy over oral 5-ASA alone for 
induction of remission.74 A small study in 18 UC patients with 
frequent relapses on standard dose oral 5-ASA showed the bene-
fits of high-dose 5-ASA combined with 5-ASA enemas.75 Despite 
the evident benefits of enema therapy, the practical difficulty 
patients have in administering and retaining enemas remains a 
major obstacle, and support and education in this area is much 
needed.
3.5.3 Nephrotoxicity
5-ASA therapy may be associated with renal complica-
tions.76 77 It is important to obtain baseline renal function, as 
renal disease may also be a primary complication of IBD itself. 
Renal manifestations of IBD include nephrolithiasis, urinary 
obstruction, fistulisation, glomerular disease, protein-losing 
nephropathy, secondary amyloidosis and renal failure.76 78 
Nephrotic syndrome due to minimal-change nephropathy has 
been reported in a patient taking sulfasalazine, resolving with 
drug withdrawal and high-dose oral corticosteroids.79 Allergic 
reactions to sulfasalazine have recurred on challenge 5-ASA.80 
table 3 Ulcerative Colitis Endoscopic Index of Severity (UCEIS)35
descriptor (score most severe lesions) likert scale definition
Vascular pattern* Normal (1) Normal vascular pattern with arborisation of capillaries clearly defined, or with blurring or 
patchy loss of capillary margins
Patchy obliteration (2) Patchy obliteration of vascular pattern
Obliterated (3) Complete obliteration of vascular pattern
Bleeding* None (1) No visible blood
Mucosal (2) Some spots or streaks of coagulated blood on the surface of the mucosa ahead of the scope, 
that can be washed away
Luminal mild (3) Some free liquid blood in the lumen
Luminal moderate or severe (4) Frank blood in the lumen ahead of endoscope or visible oozing from mucosa after washing 
intraluminal blood, or visible oozing from a haemorrhagic mucosa
Erosions and ulcers* None (1) Normal mucosa, no visible erosions or ulcers
Erosions (2) Tiny (≤5 mm) defects in the mucosa, of a white or yellow colour with a flat edge
Superficial ulcer (3) Larger (>5 mm) defects in the mucosa, which are discrete fibrin-covered ulcers when compared 
with erosions, but remain superficial
Deep ulcer (4) Deeper excavated defects in the mucosa, with a slightly raised edge
UCEIS score=sum of all three descriptors in the worst affected area of the colon visible at endoscopy.
Remission, score ≤1.
*These three features account for 90% of variability in assessment of severity.
table 4 Modified Mayo Endoscopic Score37
Ascending transverse descending sigmoid rectum
Mayo endoscopic subscore: evaluated macroscopically at most severely inflamed part per segment 
(score 0–3: see table 2)
a b c d e
Maximal Extent in decimetres (during withdrawal) ME
Extended Modified Score (EMS) EMS = (a+b+c+d+e) x ME
Modified Mayo Endoscopic Score (MMES) MMES=EMS/(number of segments with score >0)
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Tubulointerstitial nephritis is a rare idiosyncratic reaction to 
5-ASA therapy.
A UK study evaluated 151 patients with renal impairment 
associated with 5-ASA use.81 The temporal association with 
the drug, improvement on 5-ASA withdrawal (in 30% of the 
cases) and the recurrent renal damage on re-challenge in five 
patients was consistent with a true relationship, and a suggestive 
genetic association in the HLA region (p=1×10–7) was identi-
fied. Permanent renal replacement therapy was required in 15 
patients. The median time on 5-ASA before renal impairment 
was 3 years (95% CI 2.3 to 3.7), and regular monitoring of renal 
function was uncommon. The frequency of 5-ASA nephrotox-
icity has been estimated at 1 in 4000 patient years.82 83 Given 
the unpredictable nature of this occurrence, it is suggested that 
patients on long-term 5-ASA therapy should have renal function 
checked, including eGFR before starting, after 2–3 months, and 
then annually long-term, although there are no data to support a 
particular surveillance interval. Those with impaired renal func-
tion should be monitored more closely.
3.6 Corticosteroids in mild to moderate uC
Prednisolone is superior to 5-ASA for induction of remission in 
UC,84 85 but has significant side effects and should be reserved 
for patients with failure of response or who are intolerant to 
oral and/or rectal 5-ASA (see Section 3.7:on Corticosteroids in 
moderate to severe UC).
3.6.1 Budesonide MMX
Randomised controlled trials have shown that oral budesonide 
MMX 9 mg daily is significantly more effective than placebo and 
can induce remission in mild to moderate UC, being as effec-
tive as 5-ASA.86–88 The CORE I and CORE II studies compared 
oral budesonide MMX 9 mg/day and 6 mg/day with placebo in 
patients with mild to moderate left-sided and extensive UC.87 
Additional control groups were included (Asacol 2.4 g/day 
(CORE I) and Entocort EC 9 mg (CORE II)), but the studies were 
not powered to demonstrate differences between budesonide 
MMX and these controls. In a pooled analysis of both trials, 
the week 8 combined clinical and endoscopic remission rates 
were 17.7% for budesonide MMX 9 mg versus 6.2% for placebo 
(p=0.0002). A Cochrane systematic review concluded that the 
quality of evidence was moderate, and benefit was not demon-
strated clearly for extensive UC but was significant for those 
with left-sided disease.89 Endoscopic healing rates were 27.6% 
versus 17.1% (p=0.009) for budesonide MMX and placebo, 
respectively.90 The 6 mg dose was not significantly better than 
placebo. Another placebo-controlled trial of budesonide MMX 
in mild to moderately active UC showed significant benefit in 
clinical, endoscopic and histological remission.91 Although no 
adequately powered comparative trials between budesonide 
MMX and conventional corticosteroids have been conducted to 
date, budesonide MMX may be considered as an alternative to 
conventional corticosteroids in patients with mild-moderate UC 
and failure of response to 5-ASA therapy.92
Budesonide has a lower rate of systemic adverse effects than 
conventional corticosteroids (33% vs 55%), and is not asso-
ciated with adrenal suppression or a significant reduction in 
bone mineral density.93 94 Ileal-release budesonide does not 
induce remission in mild-moderately active UC and was in fact 
inferior to placebo and 5-ASA in two studies and a systematic 
review.89 93 95
3.6.2 Beclomethasone dipropionate
Oral beclomethasone dipropionate is a second-generation corti-
costeroid and may also be an alternative to conventional corti-
costeroids. In a randomised controlled trial in 282 patients, oral 
beclomethasone dipropionate 5 mg daily for 4 weeks, then alter-
nate weekly for a further 4 weeks was shown to be non-inferior 
to prednisolone in efficacy, but there was also no difference in 
the co-primary end-point of steroid-related adverse events and 
reduction in morning cortisol below 150 nmol/L.96 In patients 
with active left-sided or extensive UC, oral beclomethasone 
dipropionate 5 mg/day has been demonstrated as equivalent to 
2.4 g 5-ASA,97 and has been shown as more effective when added 
to 5-ASA compared with 5-ASA alone.98
Although more expensive, topically-acting oral corticosteroids 
are an alternative to prednisolone in UC patients with mild to 
moderate disease and 5-ASA failure.
3.7 Corticosteroids in moderate to severe uC
Oral corticosteroids are effective for the induction of remission 
in patients with moderate to severe ulcerative colitis refractory 
to sulfasalazine or 5-ASA, and in patients who have responded 
to initial treatment with intravenous corticosteroids following 
hospitalisation for acute severe disease.84 85
In a meta-analysis of five randomised controlled trials, corti-
costeroids were superior to placebo for induction of remission in 
statement 6. We recommend that patients with mild to 
moderate ulcerative colitis in whom 5-ASA induction therapy 
fails or is not tolerated should be treated with oral prednisolone 
(GRADE: strong recommendation, high-quality evidence). We 
recommend that topically-acting oral corticosteroids such as 
budesonide MMX (GRADE: strong recommendation, moderate-
quality evidence) and we suggest that beclomethasone 
dipropionate (GRADE: weak recommendation, moderate-quality 
evidence) can be used as alternative treatments for those 
wishing to avoid systemic corticosteroids (Agreement: 93.2%).
statement 2. We suggest that symptomatic remission combined 
with mucosal healing should be the target of medical therapy 
in ulcerative colitis (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 95.7%).
statement 3. We recommend that mild to moderate ulcerative 
colitis should be managed with oral 5-ASA 2–3 g/day (GRADE: 
strong recommendation, high-quality evidence). We recommend 
the addition of 5-ASA enemas, rather than oral treatment 
alone (GRADE: strong recommendation, high-quality evidence. 
Agreement: 95.6%).
statement 4. We suggest that ulcerative colitis patients 
flaring on 5-ASA therapy should receive dose escalation to 
4–4.8 g/day orally alongside 5-ASA enemas (GRADE: weak 
recommendation, low-quality evidence. Agreement: 82.2%).
statement 5. We recommend that ulcerative colitis patients 
treated with 5-ASA should be monitored for the development of 
nephrotoxicity, with baseline renal function, repeated after 2–3 
months, and then annually (GRADE: strong recommendation, 
very low-quality evidence. Agreement: 90.9%).
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UC (RR of no remission, 0.65; 95% CI 0.45 to 0.93).99 Although 
the optimal dose and regimen for systemic corticosteroids in UC 
is uncertain, the current 40 mg dose recommendation is based 
on Baron’s studies where 40 mg was more effective than 20 mg/
day.100 There is no evidence of benefit with doses higher than 
40–60 mg/day,99 and doses above 40 mg may be associated with 
increased adverse effects.100 Approximately 50% of patients 
experience short-term corticosteroid-related adverse events such 
as acne, oedema, sleep and mood disturbance, glucose intoler-
ance and dyspepsia.99 100 Single daily dosing is as effective as 
split-dosing and causes less adrenal suppression.101 The dose 
should be tapered over 6–8 weeks.
3.7.1 Failure of oral corticosteroids
There is variation in the definition of severe ulcerative colitis. 
The Mayo score or Disease Activity Index32 does not include 
systemic symptoms (fever, anaemia or abnormal inflammatory 
markers), whereas the Truelove and Witts criteria for severe 
disease102 specify one or more of these. Patients with systemic 
symptoms of fever, severe pain, significant anaemia, or those 
who are generally unwell and not tolerating their symptoms 
should be admitted for inpatient management (see Section 
3.12:on Acute severe ulcerative colitis). Prolonging treatment 
with high-dose oral corticosteroids has a diminishing chance of 
achieving remission, and of those who do respond, there will be 
many who become corticosteroid-dependent (22% at 1 year in a 
study from the pre-biologic era103). There is however increasing 
risk of infective, metabolic and surgical complications for dete-
riorating patients who may require emergency admission and 
colectomy.104 105 There is no evidence from a meta-regression 
analysis that doses above 60 mg of methylprednisolone reduce 
colectomy rates in severe UC.106 Although there are few data 
on the time-course of response to oral corticosteroids, a study 
comparing oral prednisolone with prednisolone metasulpho-
benzoate showed that improvements in clinical and endoscopic 
disease activity may be seen within 2 weeks of treatment with 
oral prednisolone 40 mg/day,107 so patients not responding 
after 2 weeks should be considered for treatment escalation to 
biologics or admission to hospital, depending on how systemi-
cally unwell they are.
3.8 5-AsA maintenance therapy for uC
Maintenance 5-ASA therapy is advocated to decrease the risk 
and frequency of flares. The most recent Cochrane analysis 
showed a trend towards greater efficacy with higher doses 
(2 g or more).108 Rectal 5-ASA is also an effective maintenance 
therapy for distal ulcerative colitis.109 110 There are randomised 
controlled trials evaluating once daily dosing with all the major 
5-ASA formulations, and systematic reviews confirm that once 
daily dosing is as effective as divided dosing regimens.111–114 In 
community surveys, 5-ASA adherence is a major problem and 
some studies suggest that simplified dosing regimens are asso-
ciated with better adherence.115 Therefore, once daily dosing 
should be considered as a standard dosing regimen for all 5-ASA 
use.
In an evaluation of data from Cochrane analyses there were 
no differences between the various 5-ASA formulations in terms 
of efficacy,116 confirmed in the most recent Cochrane analysis.108 
There is little to choose between the different formulations of 
5-ASA in terms of efficacy, and the best drug should be selected 
taking into account patient preference for formulation (for 
instance granules or tablets, tablet size and number required 
daily), in order to maximise treatment adherence117 and consid-
ering cost.
3.9 treatment options for uC patients after 5-AsA failure
3.9.1 Thiopurines
While studies vary in quality, meta-analyses consistently report 
a benefit of thiopurines over placebo for the maintenance of 
steroid-induced remission in UC but not for induction of remis-
sion. Meta-analysis of three randomised controlled thiopurine 
maintenance studies favours thiopurines over placebo (RR 0.6, 
95% CI 0.37 to 0.95).118 In a further meta-analysis, OR was 2.59 
(95% CI 1.26 to 5.3), absolute risk reduction was 23% and the 
number-needed-to-treat (NNT) to prevent one recurrence was 
five.119 A recent Cochrane review included 232 patients from 
four maintenance studies of azathioprine versus placebo and 
showed a benefit of azathioprine over placebo (44% vs 65% 
failure, respectively, RR 0.68, 95% CI 0.54 to 0.86).120 The 
side effects of thiopurines, both short- and long-term, should 
be considered (see Section 5.2.2on Drug management: thiopu-
rines) in choice of therapy, and also in decisions about duration 
of therapy, particularly in older patients (see Section 5.2.7.1 
Stopping thiopurines).
3.9.2 Infliximab
In the ACT1 and ACT2 clinical trials, UC patients with active 
disease despite corticosteroids and/or thiopurines (and/or 5-ASA 
for ACT2 only) were treated with 5 or 10 mg/kg infliximab or 
placebo at weeks 0, 2 and 6, and followed to week 54 (ACT1) 
or week 30 (ACT2). Clinical response at week 8 was similar in 
both active doses, and pooled data from both trials were 67% 
for 5 mg/kg versus 33% for placebo.121 At week 30 combined 
statement 8. We recommend that oral 5-ASA should be the 
standard maintenance medical therapy in ulcerative colitis 
(GRADE: strong recommendation, high-quality evidence). We 
recommend that the choice of formulation should consider 
patient preference, likely adherence and cost. Once daily dosing 
is effective (GRADE: strong recommendation, high-quality 
evidence) and may improve adherence (Agreement: 100%).
statement 9. We recommend that ulcerative colitis patients on 
maintenance therapy with high-dose mesalazine, who required 
two or more courses of corticosteroids in the past year, or who 
become corticosteroid-dependent or refractory, require treatment 
escalation with thiopurine (GRADE: strong recommendation, 
moderate-quality evidence), anti-TNF therapy (GRADE: strong 
recommendation, high-quality evidence), vedolizumab (GRADE: 
strong recommendation, high-quality evidence) or tofacitinib 
(GRADE: strong recommendation, high-quality evidence). 
The choice of drug should be determined by clinical factors, 
patient choice, cost, likely adherence and local infusion capacity 
(Agreement: 96.6%).
statement 7. We recommend that moderate to severe 
ulcerative colitis should be treated with oral corticosteroids such 
as prednisolone 40 mg daily weaning over 6–8 weeks (GRADE: 
strong recommendation, high-quality evidence. Agreement: 
100%).
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clinical remission rates were 30% for 5 mg/kg (13% for placebo), 
with very similar remission rates sustained to week 54 in ACT1. 
Corticosteroid-free remission rates were 22% for 5 mg/kg at 
week 30, sustained to week 54 in ACT1. In the UC SUCCESS 
study, patients in whom corticosteroid therapy had failed and 
who were receiving infliximab and azathioprine combination 
therapy (40%) had significantly higher remission rates at week 
16, compared with infliximab alone (22%).122 10% of these 
patients had previously received immunomodulators, but not 
anti-TNF therapy. Cohort studies also show benefit of using 
infliximab for patients with corticosteroid-dependent UC, with 
steroid-free remission rates of 47% at 1 year, 77% colectomy-free 
at median 41.5 months, and better outcomes for those on combi-
nation therapy with thiopurines, and also in those who were 
thiopurine-naïve initially.123 124 Real-life experience of infliximab 
treatment in UC patients where conventional therapy had failed 
showed primary response rates vary from 67% (in a study from 
Leuven, starting infliximab prior to 2006 and including patients 
recruited to the ACT1 study),125 to 78% in a French multicentre 
study of patients treated from 2000 to 2009.126
3.9.3 Adalimumab
The ULTRA1 and ULTRA2 clinical trials127 128 showed that adali-
mumab 160 mg at week 0, 80 mg at week 2, followed by 40 mg 
fortnightly achieved remission at week 8 in 19% (placebo 9%) 
in ULTRA1 and 21% (placebo 11%) in the ULTRA2 study in 
patients naïve to anti-TNF therapy. The ULTRA2 maintenance 
study showed clinical remission rates at week 52 of 22% (12% 
placebo) in the anti-TNF naïve subgroup. Corticosteroid-free 
remission at week 52 in the same subgroup was 14% (placebo 
6%). In the open-label extension study (ULTRA3), 25% remained 
in clinical remission on fortnightly or weekly adalimumab at 4 
years after initial enrolment.129 Real-world data from the USA 
on the use of infliximab and adalimumab in UC patients naïve to 
anti-TNF therapy suggests comparable efficacy in the treatment 
of moderate to severe disease.130 131
3.9.4 Golimumab
The PURSUIT SC trial was an induction trial of golimumab, 
which included a dose-finding phase.132 1064 patients with UC 
that had failed to respond to either 5-ASA, oral corticosteroids, 
azathioprine or mercaptopurine, or who were steroid-depen-
dent, were enrolled. All patients were anti-TNF naïve. 42.8% 
were receiving steroids at baseline, and a third were on thio-
purines. Clinical response was achieved at week 6 in 51.0% on 
200 mg/100 mg, 54.9% at 400 mg/200 mg, both significantly 
better (p<0.0001) versus placebo response rate of 30.3%. Clin-
ical remission at week 6 was 17.8% (200 mg/100 mg), 17.9% 
400 mg/200 mg, p<0.0001 versus placebo (6.4%). Both clinical 
response and remission at week 6, correlated with drug levels. 
Real-world observational studies corroborate with PURSUIT 
study observations.133
Network meta-analyses comparing the different anti-TNF 
agents in UC present conflicting data on the relative efficacy of 
infliximab, adalimumab and golimumab.134–137
3.9.5 Vedolizumab
In the GEMINI I clinical trial of vedolizumab in active UC, 
patients were enrolled to a randomised cohort. 225 patients 
received intravenous vedolizumab 300 mg at day 1 and 15, 149 
patients received placebo and 521 patients were randomised 
to open-label vedolizumab in order to fulfil sample size 
requirements for the continuation maintenance study.138 139 
Of the anti-TNF naïve patients in the randomised induc-
tion phase, clinical response at 6 weeks was seen in 26.3% 
of 76 patients on placebo versus 53.1% of 130 patients on 
vedolizumab, an estimated 26.4% difference (95% CI 12.4% 
to 40.4%). Clinical remission at 6 weeks was seen in 6.6% 
on placebo and 23.1% on vedolizumab, an estimated differ-
ence of 15.5% (95% CI 5.1% to 25.9%). Of the randomised 
responders who entered the maintenance phase (including 
those from the open-label induction cohort) and who had 
been anti-TNF naïve at entry, the durable clinical response 
rate (response at both weeks 6 and 52) was 26.6% for the 
79 patients on placebo compared with 60.7% for the 145 
patients given vedolizumab (either 4-weekly or 8-weekly). 
The estimated difference from placebo was 34.3% (95% CI 
20.7% to 47.8%). The clinical remission rate at week 52 for 
the placebo group was 19.0%, and 46.9% for the combined 
vedolizumab group, an estimated difference from placebo of 
28.0% (95% CI 14.9% to 41.1%). There were no clinically 
important differences in safety between the vedolizumab and 
placebo groups during the maintenance study.139
A recently published retrospective study from the VICTORY 
consortium analysed safety and efficacy data from 321 UC 
patients receiving vedolizumab therapy (71% of whom had 
previously been treated with anti-TNF therapy).140 Primary effec-
tiveness outcomes were cumulative rates of clinical remission 
(defined as resolution of all UC-related symptoms on physician’s 
global assessment), endoscopic remission (defined as a Mayo 
endoscopic subscore of 0), corticosteroid-free remission and 
deep remission (clinical remission and endoscopic remission). In 
recognition of potential attrition bias, variability in follow-up 
and impact of right censoring, imputation analyses calculated 
12 month rates as 20%, 17%, 15% and 14% respectively. On 
multivariable analyses, prior exposure to anti-TNF therapy was 
associated with a reduced probability of achieving clinical remis-
sion (HR 0.53, 95% CI 0.38 to 0.75) and endoscopic remission 
(HR 0.51, 95% CI 0.29 to 0.88).
Until recently there has been limited reporting of vedoli-
zumab therapy outcomes for anti-TNF naïve patients with UC. 
However, a multicentre European retrospective study of 184 
patients (50 Crohn’s disease and 134 UC patients) showed 
a greater efficacy than that reported in anti-TNF experienced 
patients with response, clinical remission and steroid-free remis-
sion rates at week 14 of 79.1%, 39.5% and 36.6%, respectively, 
in UC.141 The VARSITY trial has now been reported in abstract 
form and is the first head-to-head comparison of two biologic 
agents in IBD.142 Seven hundred and sixty-nine patients with 
moderately to severely active UC who had failed conventional 
therapies were randomised to intravenous vedolizumab 300 mg 
at weeks 0, 2 and 6 and then every 8 weeks, versus adalimumab 
subcutaneously 160 mg at week 0, 80 mg at week 2, and then 
40 mg fortnightly, in a double-blind, double-dummy trial. Dose 
escalation was not permitted for either group. Recruitment of 
patients with previous anti-TNF therapy use was capped at 25% 
of the trial population. At 52 weeks, the primary end-point of 
clinical remission (a complete Mayo score ≤2 with no subscore 
>1) was achieved in 31.3% on vedolizumab versus 22.5% on 
adalimumab (p=0.006). Mucosal healing (Mayo endoscopic 
subscore ≤1) was 39.7% and 27.7%, respectively (p=0.0005). 
Corticosteroid-free remission rates (in those on steroids at base-
line) at week 52 were not significantly different between the 
vedolizumab and adalimumab groups. Although no similar data 
are available for comparison with infliximab, these data provide 
support for vedolizumab as a first-line biologic option for UC 
failing conventional therapy.
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3.9.6 Tofacitinib
A phase 2 dose-ranging induction study of the Janus kinase (JAK) 
inhibitor tofacitinib in patients with endoscopically confirmed 
active UC showed increased rates of clinical and endoscopic 
response and remission after 8 weeks of treatment that reached 
statistical significance for patients in the higher dosing arms 
of 10 mg and 15 mg oral twice daily.143 The OCTAVE-1 and 
OCTAVE-2 phase 3 induction studies confirmed the efficacy 
of a dose of 10 mg twice daily as induction therapy for active 
colitis.144 In these studies, the primary end-point of remission 
was defined clinically and endoscopically at week 8 by a total 
Mayo score ≤2, with no individual subscore >1 and a rectal 
bleeding subscore of 0. This was achieved by 18.5% and 16.6% 
of patients on active treatment in OCTAVE-1 and OCTAVE-2 
versus 8.2% and 3.6% of patients on placebo (p=0.007 and 
p<0.001, respectively). For patients who had not previously 
received anti-TNF therapy, remission at 8 weeks on placebo 
and tofacitinib was 12.5% and 23.7% respectively (difference 
11.2%; 95% CI 2.6% to 17.9%). Clinical responders to induc-
tion therapy (where response was defined as a decrease from 
baseline in the total Mayo score of ≥3 points and >30% with a 
rectal bleeding score decrease of at least one or a rectal bleeding 
subscore of 0 or 1) were eligible for enrolment in the mainte-
nance OCTAVE-SUSTAIN trial. Of patients randomised to 
tofacitinib pooled from both trials, 57.6% (521/905) had a clin-
ical response at week 8. This included both anti-TNF naïve and 
anti-TNF exposed patients. They were randomised 1:1:1 to oral 
tofacitinib 5 mg twice daily, 10 mg twice daily or placebo. After 
1 year, remission was achieved in 34.3% in the tofacitinib 5 mg 
group, 40.6% in the tofacitinib 10 mg group and 11.1% in the 
placebo group (p<0.001 for both treatment arms vs placebo).
In the OCTAVE open-label follow-on study, patients who 
responded to induction therapy with 10 mg twice daily, but 
were then randomised to placebo in the OCTAVE-SUSTAIN 
study and then relapsed, were retreated with 10 mg twice daily 
open-label.145 Of these, 75.8% responded at month 2 and 
67.5% at 1 year, showing that retreatment is effective after a 
break in therapy. The OCTAVE open-label study also showed 
that patients receiving 5 mg twice daily in the OCTAVE-SUS-
TAIN study who relapsed and were then treated with 10 mg 
twice daily open-label had a response rate of 58.6% at month 2 
and 68.8% at 1 year.146
Although total adverse events did not appear to differ signifi-
cantly between treatment and placebo groups, there was an 
increased risk of infections seen in tofacitinib treated patients 
during both induction and maintenance phases. In particular, 
herpes zoster occurred more often on active treatment, a finding 
consistent with prior experience of use of tofacitinib in patients 
with rheumatoid arthritis and psoriasis.147 148 Zoster vaccination 
should be considered before starting therapy in those aged over 70 
years and those over 50 years considered at particularly high risk 
(such as recurrent shingles). As a live vaccination it must not be 
given for 3 months after stopping biologics, and tofacitinib should 
not be started for 4 weeks after vaccination (see Section 5.2.1.3.2 
Live vaccines). Recent data from an open-label study149 in rheu-
matoid arthritis patients (over 50 years with at least one cardio-
vascular risk factor), comparing tofacitinib 5 mg or 10 mg twice 
daily with TNF-inhibitor therapy, have shown a five-fold increase 
in pulmonary embolus for the group on 10 mg twice daily tofaci-
tinib compared with TNF inhibitor therapy),150 and at present the 
European Medicines Agency safety committee advises that the high 
dose should not be used in patients at increased risk of pulmonary 
embolus (heart failure, malignancy, impending/recent surgery, 
inherited coagulation disorders, previous thromboembolism, 
combined contraceptive therapy or HRT).151 Further data are 
required on the risks for UC patients treated with JAK inhibitors.
No comparative data for tofacitinib with biologics are avail-
able, and NICE approval has been granted for the treatment of 
moderate to severely active UC where conventional treatments 
or biological agents have not been tolerated, or have failed.152 
Tofacitinib has the advantages of oral administration and, as a 
small molecule, immunogenicity is not an issue. This has to be 
weighed against the side effect profiles and costs of different 
agents.
3.9.7 Ustekinumab
The UNIFI trial, recently presented in abstract form, investi-
gated ustekinumab as induction and maintenance therapy in 
moderate to severely active UC in adults who had failed to 
respond or were intolerant to corticosteroids, immunomodu-
lators, anti-TNF therapy (one or more) or vedolizumab.153 154 
Patients were randomised 1:1:1 to receive a single IV dose 
of placebo, 130 mg ustekinumab, or approximately 6 mg/kg 
ustekinumab (weight-tiered dosing: patients weighing ≤55 kg 
received 260 mg; patients weighing >55 kg and ≤85 kg received 
390 mg; and patients weighing >85 kg received 520 mg), as 
in the UNITI Crohn’s studies. At week 8, 961 patients were 
evaluated. The primary end-point was clinical remission at 
week 8 (defined as a Mayo score ≤2 points, with no indi-
vidual subscore >1), and was achieved by 15.6% on 130 mg 
ustekinumab, 15.5% on the approximately 6 mg/kg dose and 
5.3% on placebo (p<0.001).153 Endoscopic healing (defined 
as Mayo endoscopy subscore of 0 or 1) was 26.3%, 27% and 
13.8% in the three groups, respectively (p<0.001). Clinical 
response (decrease from baseline Mayo score of ≥30% and 
≥3 points, with either a decrease from baseline in the rectal 
bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 
1) was 51.3%, 61.8% and 31.3% in the three groups, respec-
tively (p<0.001). Both active treatment groups had a signif-
icant improvement in IBDQ, mucosal healing (endoscopic 
healing as defined above), and histological healing (defined as 
0–<5% neutrophils in epithelium, no crypt destruction and 
no erosions, ulcerations or granulations) was 20.3%, 18.4% 
and 8.9% respectively at week 8. There was no difference in 
adverse events compared with placebo, with no malignancies, 
opportunistic infections or TB reported. In the maintenance 
continuation study, 523 patients with clinical response at week 
8 were re-randomised to placebo, 8-weekly or 12-weekly 
dosing, with week 44 remission rates of 24%, 38.4% and 
43.8%, respectively (p=0.002 for 8-weekly and p<0.001 for 
12-weekly vs placebo).154 Effects were seen in both anti-TNF 
naïve and anti-TNF refractory patients, but numerical benefits 
of 8-weekly dosing (compared with 12-weekly) were restricted 
to the anti-TNF refractory population. The safety profile was 
consistent with that observed in Crohn’s disease.
At the time of writing, ustekinumab does not have licensing 
or NICE approval for its use in UC. It should be noted that 
(unlike the UNITI studies in Crohn’s disease and the GEMINI 
studies of vedolizumab in UC) the UNIFI study permitted inclu-
sion of patients with failure of two classes of biologic (TNF 
inhibitors and vedolizumab) and results should be interpreted 
accordingly.
3.9.8 Methotrexate
Methotrexate has no role in the maintenance of remission in UC. 
A Cochrane review in 2015 of methotrexate use in comparison 
to placebo, 5-ASA, sulfasalazine and mercaptopurine does not 
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support its use in maintenance of remission in UC.155 In a Euro-
pean double-blind randomised trial, 111 patients were allocated 
to 25 mg/week parenteral methotrexate versus placebo alongside 
prednisolone for a flare of UC.156 Methotrexate was not superior 
to placebo (31.7% vs 19.6% remission, p=0.15) for the primary 
end-point of steroid-free remission at week 16 (Mayo score 
≤2 with no item >1 and complete withdrawal of steroids and 
no use of another immunosuppressant (IS), anti-TNF therapy 
or colectomy). Clinical remission at week 16 (Mayo score ≤2 
with no item >1) was, however, significantly higher on meth-
otrexate (41.7% vs 23.5% p=0.04). The MERIT study treated 
179 patients with active UC with open-label methotrexate 25 mg 
SC weekly, plus a tapering prednisolone course for 12 weeks. At 
16 weeks there was a 51% response rate, and 84 patients were 
randomised to continue 25 mg methotrexate SC or placebo. 
There was no difference in outcome at week 48, with 27% of 
those on methotrexate and 30% on placebo maintaining steroid-
free clinical remission with no need for additional therapies.157
3.9.9 Choice of immunosuppressive or biological therapy
Patients with chronic active UC failing 5-ASA therapy have in 
the past been offered thiopurine therapy. As the range of alterna-
tives grows and costs of biologics fall, there is strong justification 
for moving directly to other immunosuppressive drugs with less 
toxicity that may be easier to manage. Thiopurines still have a 
role as combination therapy and to reduce immunogenicity, but 
the therapeutic pyramid is changing rapidly.
Until the VARSITY study comparing vedolizumab with adali-
mumab,142 there had been no head-to-head studies comparing 
anti-TNF drugs, vedolizumab, tofacitinib and ustekinumab. 
Indirect means of comparison are much weaker and, at best, 
hypothesis-generating. Network meta-analyses have compared 
vedolizumab with anti-TNF drugs and show broadly similar 
benefits.158–160 In contrast, the VARSITY trial shows a signifi-
cant benefit for vedolizumab compared with adalimumab 40 mg 
every other week.142 Two network meta-analyses that include 
tofacitinib, one in abstract form, show comparable efficacy to 
anti-TNF agents and vedolizumab.161 162 The choice of which 
immunosuppressive agent to use depends on a number of 
factors (box 2). Patients may prefer to receive oral or subcu-
taneous therapy rather than intravenous therapy, although the 
latter may be preferred for patients where non-adherence may 
be an issue. Tofacitinib as an oral agent, with no concerns about 
immunogenicity, is an attractive choice, but with little real-world 
experience as yet. Gut-selective therapy may be considered safer 
because of concerns about risk of malignancy or infection; at 
present there is little long-term comparative safety data between 
vedolizumab and anti-TNF therapy to support this, although the 
long-term trial extension safety profile over 9 years from the 
GEMINI trials is very reassuring.163 The presence of significant 
extraintestinal manifestations may also be a consideration. Other 
practical issues are shown in box 2.
3.9.10 Therapeutic choice after anti-TNF failure
Infliximab and other anti-TNF drugs have been used in UC for 
many years, and it is therefore important to consider alterna-
tives for patients failing these drugs and who need to switch 
‘out of class’ (see Sections 5.2.4.5: Common Disease Consider-
ations, Primary non-response to anti-TNF therapy and 5.2.4.6: 
Common Disease Considerations, Secondary loss of response to 
anti-TNF therapy). It is important to note that surgery should 
always be discussed as an option in patients failing a therapeutic 
agent, particularly as there is generally a reduction in response to 
each successive immunosuppressive or biologic drug.
3.9.10.1 Vedolizumab after anti-TNF therapy
In the GEMINI I study of vedolizumab in active UC, 895 
patients were enrolled and randomised responders were re-ran-
domised to maintenance therapy or placebo.138 367 patients 
(41%) had prior failure of anti-TNF therapy. Of these patients, 
clinical response at week 6 was 39% for vedolizumab versus 
20.6% for placebo (difference 18.1%, 95% CI 2.8% to 33.5%). 
Of the randomised responders entering the maintenance phase 
who had prior anti-TNF failure, clinical remission at week 
52 was 36.1% for vedolizumab (given either 8- or 4-weekly) 
versus 5.3% for placebo (difference 29.5%, 95% CI 12.8% to 
46.1%). Vedolizumab is effective in patients with prior expo-
sure to anti-TNF drugs, although benefits are larger in those with 
no prior exposure.139 Data on clinical efficacy and safety from 
prospectively followed cohorts on vedolizumab are now avail-
able. In a recently reported GETAID study, 294 patients with 
active IBD (121 with UC), with an inadequate or loss of response 
to conventional therapy or at least one anti-TNF agent, were 
treated with vedolizumab.164 Concomitant use of corticosteroids, 
thiopurines or methotrexate was permitted. Among patients 
with UC, 36% were in steroid-free clinical remission and 50% 
had clinical response at week 14. In a review of safety data from 
vedolizumab trials, prior anti-TNF therapy was a risk factor for 
serious infection in UC patients (HR 1.99, 95% CI 1.16 to 3.42; 
p=0.0122). Eighteen vedolizumab exposed patients (<1%) 
were diagnosed with a malignancy including non-melanoma 
skin cancer, malignant melanoma, colon cancer, breast cancer, 
renal, liver and lung cancer; nearly all patients (except one with 
renal cancer) having had prior exposure to thiopurines and/or 
anti-TNF agents, making attribution difficult.165
3.9.10.2 Tofacitinib after anti-TNF therapy
In pooled data from the OCTAVE 1 and 2 trials, 589 patients 
had previously failed anti-TNF and had a week 8 clinical remis-
sion rate of 0.8% on placebo versus 11.4% on tofacitinib 10 mg 
twice daily (difference 10.6%, 95% CI 7.3% to 13.9%).166 
Mucosal healing at week 8 (Mayo endoscopic subscore of 0 or 1) 
in patients with prior anti-TNF exposure was 6.5% on placebo 
versus 22.2% on tofacitinib 10 mg twice daily (difference 
box 2 Factors to consider in choosing a biologic, 
immunosuppressive or immunomodulator therapy
 ► Route of administration (oral, subcutaneous, intramuscular, 
intravenous)
 ► Speed of response to induction therapy (consider need for 
bridging therapy)
 ► Potential immunogenicity and need for combination therapy
 ► Side effects including cancer risk
 ► Persistence (continuing drug without loss of response after 
initial improvement)
 ► Availability of infusion facilities and therapeutic drug 
monitoring
 ► Overall cost (including drug delivery and monitoring)
statement 10. We recommend that vedolizumab can be used in 
the induction and maintenance of remission of ulcerative colitis 
in patients where anti-TNF treatment has failed (GRADE: strong 
recommendation, high-quality evidence. Agreement: 97.7%).
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15.7%, 95% CI 10.0% to 21.4%). In OCTAVE-SUSTAIN, week 
52 remission data for placebo, tofacitinib 5 mg twice daily and 
10 mg twice daily in patients with prior anti-TNF failure were 
11.2%, 24.1% and 36.6%, respectively, for clinical remission 
and 12.4%, 30.1% and 39.8%, respectively, for mucosal healing.
3.10 Proctitis
3.10.1 5-ASA suppositories in proctitis
When treating mild to moderate proctitis, first-line therapy 
should be 5-ASA suppositories. These medications achieve 
much higher mucosal concentrations of the drug and work 
faster and better than oral 5-ASA monotherapy in disease 
which is confined to the rectum.167 Higher response rates are 
achieved if topical therapies are combined with oral 5-ASA,168 
thus patients not responding fully to suppositories should have 
early addition of oral therapy. Suppositories are preferred to 
enemas for proctitis as they deliver the drug specifically to the 
rectum (enemas tend to pool higher up in the sigmoid) and are 
also better tolerated/retained, as shown in a study comparing 
5-ASA suppositories with hydrocortisone foam enemas.169 
Topical 5-ASA is more effective than topical corticosteroid.170 
A Cochrane review did not show a dose–response relationship 
for rectal therapy (although this review assessed treatment 
of distal colitis, which included both proctitis and left-sided 
colitis up to the splenic flexure).171 A further review evaluating 
mucosal healing showed a dose–response relationship for oral 
but not rectal 5-ASA (again evaluating proctitis along with 
distal colitis).172 Divided doses are less convenient for patients. 
A study comparing 1 g 5-ASA suppository daily versus 500 mg 
three times daily showed more convenience and similar effi-
cacy (except for mucosal healing) for the once daily dose,173 
and a further study showed no difference between 1 g daily 
and 500 mg twice daily.174 Administering this dose at bedtime 
is practical for most patients, allowing the suppository to be 
retained for the longest possible time.171
3.10.2 Maintenance therapy for proctitis
Many patients respond promptly to 5-ASA suppositories, and 
if they have infrequent flares, are happy to start suppositories 
when they begin to flare and not take regular maintenance 
therapy. This is quite safe as the colorectal cancer risk in proctitis 
is similar to the general population. For many, however, regular 
preventive treatment is needed, and 5-ASA suppositories are the 
most effective maintenance therapy for proctitis.109 175 In long-
term treatment, however, this needs to be weighed against the 
importance of adherence, and some patients may choose not to 
use long-term rectal therapy and prefer oral therapy. It is worth 
noting that alternate night or every third night suppositories 
do not appear to reduce the rate of maintenance of remission 
substantially.170
3.10.3 Corticosteroid suppositories in proctitis
Steroid suppositories are also effective in proctitis but not as 
effective as 5-ASA and so their use should be confined to those 
who either do not tolerate or do not respond to 5-ASA.171 176 Oral 
5-ASA should be continued if possible. For those not responding 
to 5-ASA, the addition of a prednisolone 5 mg suppository in 
the morning while continuing 5-ASA suppositories at bedtime 
is worth trying. A novel budesonide suppository was studied 
in a four-group, prospective, double-blind, double-dummy 
randomised trial to treat UC proctitis with budesonide 2 mg, 
budesonide 4 mg, 5-ASA 1 g, or budesonide 2 mg plus 5-ASA 
1 g.177 The 8-week study conducted in Germany, Russia and the 
UK assessed a primary end-point of resolution of clinical symp-
toms for three consecutive days (score of 0 for rectal bleeding 
and stool frequency on modified UCDAI). Budesonide 4 mg was 
more effective than 2 mg, but no different from 5-ASA 1 g or the 
combination of budesonide 2 mg and 5-ASA 1 g.
3.10.4 Treatment options in refractory proctitis
A proctitis management flowchart is shown in figure 1. In severe 
or refractory proctitis, it is important to ensure that conven-
tional therapy has been delivered appropriately (with assess-
ment of adherence) and that the diagnosis is correct. Proximal 
constipation is common and may contribute to symptoms and 
poor response to therapy, as may co-existing irritable bowel 
syndrome. It is important to exclude other conditions that may 
be causing symptoms, including infection (lymphogranuloma 
venereum, Neisseria gonorrhoeae, herpes simplex virus, syphilis, 
Giardia duodenalis, amoebiasis), solitary rectal ulcer, psoriatic 
colitis, chemical colitis and rectal prolapse.178
If the diagnosis is correct and standard therapy has failed, 
then thiopurine therapy should be added,179 with escala-
tion to biologics if no response.180–182 Many UC trials have 
excluded proctitis, but a case series of infliximab therapy for 
proctitis confirms good response.183 Patients with refractory 
proctitis have disabling symptoms but are often systemically 
well and are usually very reluctant to have proctocolectomy, 
so many other therapies have been assessed. There are many 
other treatments based on small trials or case series—for 
example, rectal tacrolimus (0.5 mg/mL, dose 3 mL twice 
daily)—although active absorption results in significant serum 
levels and close monitoring and dose adjustment are required 
to avoid toxicity.184
3.11 stopping 5-AsA or thiopurine therapy
Evidence from many UC trials show that patients with a longer 
duration of remission have lower relapse rates, and duration of 
remission is an independent predictor, regardless of treatment 
statement 13. We suggest that patients with ulcerative 
proctitis who do not respond or are intolerant to 5-ASA 
suppositories and oral 5-ASA may be switched to corticosteroid 
suppositories (GRADE: weak recommendation, low-quality 
evidence. Agreement: 84.8%).
statement 14. We suggest that refractory ulcerative proctitis 
may require treatment with corticosteroids, immunomodulators 
and/or biological therapy (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 95.5%).
statement 11. We recommend that tofacitinib can be used in 
the induction and maintenance of remission of ulcerative colitis 
in patients where anti-TNF treatment has failed (GRADE: strong 
recommendation, high-quality evidence. Agreement: 91.1%).
statement 12. We recommend that mild or moderately 
active ulcerative proctitis should be treated with a 1 g 5-ASA 
suppository (GRADE: strong recommendation, high-quality 
evidence. Agreement: 100%).
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received.185 186 Trials have also shown that age is a risk factor 
with relapse rates inversely proportional to age.185 187 A study 
of mesalazine maintenance therapy evaluated patients with 
UC in established clinical, endoscopic and histological remis-
sion (on the basis of sigmoidoscopy), and divided them into a 
short remission group (1–2 years) and prolonged remission (>2 
years, with a median of 4 years). Patients were randomised to 
receive mesalazine 1.2 g daily or placebo. In the short remission 
group relapse rate at 1 year was 23% on mesalazine and 49% 
on placebo (p=0.035). In the prolonged remission group there 
was no significant difference whether on mesalazine (relapse in 
18%) or placebo (26%). The prolonged remission group were 
also older and had longer duration of disease.188
As well as consideration of the relapse-preventing value of 
5-ASA in prolonged remission, the other consideration is the 
potential colorectal cancer-preventing benefits. There are theo-
retical reasons why 5-ASA may have colorectal cancer preventive 
properties,189 but unclear whether 5-ASA has benefit inde-
pendently, or whether the documented benefit relates to mucosal 
healing. Colorectal cancer risk is related to inflammation.55 190 
Figure 1 Management of proctitis.
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Therefore, it is plausible that mucosal healing should be the main 
goal of colorectal cancer prevention, regardless of the treatment 
used.191 Patients should be advised that 5-ASA is a safe and effec-
tive long-term treatment, and should be advised that if they have 
documented prolonged clinical and endoscopic remission, there 
is no clear evidence whether continuing 5-ASA adds additional 
reduction in colorectal cancer risk, but if subsequent assess-
ment after stopping 5-ASA shows mucosal inflammation, 5-ASA 
should be restarted.
Most of the published data on withdrawal of thiopurines 
evaluates UC patients in remission for 1–2 years only. In the 
only randomised controlled withdrawal trial of azathioprine, 
there was a relapse rate of nearly 60% at the end of the first year 
in those who discontinued the drug while in corticosteroid-free 
clinical remission (for a mean of 11–12 months) compared 
with 36% on continued azathioprine.185 Other cohort studies 
with marked heterogeneity in study design and follow-up have 
reported relapse rates ranging from 21% to 100% at 2 years.192 
A prospective study in patients with UC stopping azathioprine 
after a minimum of 3 years of therapy in clinical, biological, 
and endoscopic remission showed a relapse rate of 37% after 
a mean follow-up of 55 months.193 The risks of relapse are 
likely to be much lower in patients with prolonged remission 
(5–10 years) and the benefits of continuing therapy are likely 
to be less than the risk of drug toxicity, including lymphoma. In 
the event of relapse there is a very high likelihood of regaining 
remission; 92% in one observational study.194 Relapse rates are 
lower in those continuing 5-ASA therapy,193 195 so all patients 
stopping thiopurines should be receiving 5-ASA if tolerated. In 
the absence of high-quality data, stopping thiopurines may be 
an option for those in long term (5–10 years or more) clinical, 
endoscopic and histological remission, after appropriate patient 
counselling. Periodic calprotectin monitoring may be a cost-ef-
fective method of monitoring ongoing mucosal healing after 
cessation.
3.12 Acute severe ulcerative colitis
Between 15% and 25% of patients with UC will require hospi-
talisation for an acute severe flare of disease at some stage in 
the natural history of their disease, often as the index presen-
tation.196 Acute severe ulcerative colitis (ASUC) is a potentially 
life-threatening condition, characterised by clinical and labora-
tory assessment using the modified Truelove and Witts criteria102 
or, in the case of adolescent patients, the Paediatric UC activity 
index.197 In current practice C-reactive protein is measured far 
more than ESR, and has the advantage of a less non-specific 
increase with age.198 A retrospective UK study (1950–2007) 
showed that the colectomy rate during first admission with 
ASUC was 19%, but after several admissions rose to 38.2%.199 
In the biologics era, the colectomy rate after admission for ASUC 
in the CONSTRUCT trial was 23% during the inpatient stay,200 
and in another study was 19% at 2 years.201
All patients admitted with ASUC should have baseline bloods 
(FBC, CRP, U&E, LFT and magnesium, stool culture and Clos-
tridium difficile assay, radiological imaging (AXR or CT) and 
flexible sigmoidoscopy, with close monitoring after admission. 
MRI and ultrasound may have a role in determining the extent 
of colitis, but are less sensitive than CT in detecting perfora-
tion. The results of these tests will also assist in determining the 
prognosis for that admission (particularly to predict corticoste-
roid failure and the need for colectomy).196 202 Early flexible 
sigmoidoscopy is important to confirm diagnosis and obtain 
histology including evaluation for cytomegalovirus (CMV) (see 
Section 5.1.4:cytomegalovirus infection in IBD) and prognosis. 
Stool culture and microscopy should be performed routinely, 
as soon as practicable, to exclude pathogenic bacteria including 
testing for C. difficile toxin. An accurate stool chart, recording 
frequency, consistency and the presence of blood should be kept, 
with patients instructed to keep this record if they are able to do 
so. As nearly half are likely to fail intravenous corticosteroids,200 
consideration should be given to pre-biologics screening for all 
ASUC patients on admission.
3.12.1 Corticosteroid therapy for ASUC
Intravenous corticosteroids such as hydrocortisone 100 mg four 
times daily or methylprednisolone 60 mg every 24 hours are 
the cornerstone of treatment of ASUC.106 203–205 Methylpred-
nisolone has less mineralocorticoid effect than hydrocortisone 
at these doses and so causes significantly less hypokalaemia.206 
There is no real advantage from giving higher doses and a bolus 
injection is as effective as a continuous infusion.207 Although a 
meta-regression analysis failed to show a relationship between 
dose and colectomy rate above the equivalent of 60 mg methyl-
prednisolone,106 400 mg hydrocortisone is equivalent to 80 mg 
methylprednisolone. In children and adolescents, a dose of 
1–1.5 mg/kg/day up to a maximum of 60 mg is recommended.208
In the landmark study by Truelove and Witts,102 oral corti-
sone 100 mg daily was given to 213 patients with acute flares 
of varying severity. Clinical remission was achieved in 41% of 
steroid treated patients versus 16% on placebo. In a subsequent 
study, 49 patients with severe UC were treated with intrave-
nous prednisolone 21-phosphate and a clinical remission rate 
of 73% was noted 5 days after treatment.209 Definitions and 
terms differed widely in these studies compared with outcome 
measures in use today. A systematic review of 32 trials of steroid 
therapy for ASUC involving 1991 patients reported an overall 
statement 15. We recommend that adult patients with acute 
severe ulcerative colitis (ASUC) (defined by the modified Truelove 
and Witts criteria as >6 bloody stools per day and systemic 
toxicity with at least one of: temperature >37.8°C, pulse 
>90 bpm, haemoglobin <105 g/L or C-reactive protein >30 mg/L) 
or adolescents with a Paediatric Ulcerative Colitis Activity Index 
(PUCAI) score of 65 or more should be admitted to hospital 
for assessment and intensive management (GRADE: strong 
recommendation, low-quality evidence. Agreement: 100%).
statement 16. We recommend that patients presenting 
with possible acute severe colitis should have urgent 
inpatient assessment and blood tests (FBC, CRP, U&E, LFTs 
and magnesium), stool culture, Clostridium difficile assay, 
radiological imaging (AXR or CT) and flexible sigmoidoscopy 
(GRADE: strong recommendation, very low-quality evidence. 
Agreement: 97.9%).
statement 17. We recommend that patients with ASUC 
should be treated with high-dose intravenous corticosteroids 
such as methylprednisolone 60 mg daily or hydrocortisone 
100 mg 6-hourly (GRADE: strong recommendation, high-quality 
evidence) and should receive prophylactic low-molecular weight 
heparin (GRADE: strong recommendation, moderate-quality 
evidence. Agreement: 97.8%).
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response to steroids of 67%, with 29% (95% CI 28% to 31%) 
having colectomy. Mortality was 1% (n=22/1991; 95% CI 0.7% 
to 1.6%) and none of these outcomes changed between 1974 
and 2006 (R2=0.07, p=0.8).106 In the CONSTRUCT cohort, 
after excluding those with infections or alternative diagnoses, 
response rate to intravenous steroids was 49%.200 Extending 
therapy beyond 7–10 days carries no additional benefit and 
increases toxicity.104 105 Patients should be assessed for a clin-
ical and biochemical response after 3 days of intravenous steroid 
therapy to determine the need for salvage medical or surgical 
therapy.106 210
Risk of venous thromboembolism (VTE) is 2–3 fold higher 
compared with inpatients without IBD, so prophylactic subcu-
taneous low molecular weight heparin is important204 211 212 and 
does not precipitate or exacerbate colonic bleeding.213
ASUC patients should have stool culture and Clostridium 
difficile toxin assay.214 215 C. difficile infection has been associ-
ated with a worse outcome in hospitalised IBD patients.216–218 
If C. difficile is detected (or strongly suspected), treatment with 
corticosteroids should not be withheld, but additional treatment 
with oral vancomycin given219 (see Section 5.1.3: Common 
Disease Considerations, Clostridium difficile infection associ-
ated with IBD). Amoebiasis should be considered in those with 
recent travel to endemic areas, in whom consideration should 
be given to addition of metronidazole pending stool microscopy 
and culture.
3.12.2 Predictors of outcomes of ASUC
Most studies of factors predicting colectomy in ASUC look at 
patients treated with intravenous steroids±salvage therapy and 
do not specifically look at factors after ciclosporin or infliximab 
have been started. Low albumin is predictive of colectomy,220 221 
with one study showing that albumin on day 3 of corticosteroid 
treatment was the only predictor of colectomy on multivariable 
analysis.222 A CRP/albumin ratio of 0.85 on day 3 of intrave-
nous steroids also predicted colectomy with a sensitivity of 70%, 
specificity 76%.223 Flexible sigmoidoscopy performed with care 
is safe in ASUC and gives important information about disease 
severity.224 Severe endoscopic lesions (deep ulcers, extensive loss 
of mucosal layers, well-like ulcers or large erosions) have been 
associated with non-response to corticosteroids225 and colec-
tomy.226 227 A study of 89 ASUC patients treated with intravenous 
corticosteroids and/or infliximab or ciclosporin used the UCEIS 
and showed that almost all patients with a UCEIS score of 7 or 
more on admission required rescue therapy,228 and another study 
shows UCEIS is predictive of need for rescue therapy and for 
surgery.229
3.12.3 Ciclosporin or infliximab rescue therapy for ASUC
Patients who do not respond to corticosteroid therapy after 
3 days should be considered for second-line ‘rescue’ therapy 
or surgery. Early clinical risk stratification tools can be used to 
predict failure of medical therapy (table 5); those at high risk of 
failure should be offered rescue therapy after discussion with the 
colorectal surgeon (figure 2).
3.12.4 Ciclosporin in ASUC
The striking benefits of ciclosporin in ASUC were shown in 
a 1994 paper.230 A randomised controlled trial showed that 
2 mg/kg intravenous ciclosporin was as effective as 4 mg/
kg in ASUC, with response rates at day 8 of 83% and 82%, 
respectively with no difference in colectomy rates.231 Reviews 
have shown short-term colectomy rates in patients receiving 
intravenous ciclosporin vary from 26% to 47%.196 210 The 
initial ciclosporin dose is 2 mg/kg/day intravenously with a 
target trough ciclosporin concentration of 150–250 ng/mL.231 
Responders should be converted to an oral dose twice the 
intravenous dose and administered in divided doses twice daily 
with a target trough concentration of 100–200 ng/mL.200 Oral 
ciclosporin should be continued for several months as bridging 
therapy,230–234 and long-term outcomes are much better if thio-
purine maintenance therapy is given, rising from 40% to 66% 
in one study.235 Those requiring ciclosporin salvage therapy 
who have already failed thiopurine therapy have much worse 
outcomes.233 236
Large case series of ciclosporin therapy in UC have reported 
a significant toxicity profile, with serious infections in 5% of 
patients and mortality in 1–3%.233 237 238 Major adverse events 
related to ciclosporin therapy include nephrotoxicity (6.3%), 
seizures (3.6%), anaphylaxis (0.9%) and death (1.8%).238
3.12.5 Infliximab in ASUC
Infliximab is also effective in ASUC.220 239 240 Long-term 
follow-up data of the original Swedish trial239 which studied a 
single infusion of infliximab showed a significantly lower colec-
tomy rate compared with controls (50% vs 76%; p=0.01) at 
3 years, without use of maintenance infliximab.241 Contrain-
dications to use include latent tuberculosis (TB), active sepsis, 
Good Practice recommendation 1. Corticosteroid treatment 
for patients with suspected ASUC should not be delayed 
pending results of stool cultures and Clostridium difficile assay 
(Agreement: 95.6%).
statement 18. We recommend that patients with ASUC failing 
to respond by day 3, as judged by a suitable scoring system, 
should be treated with rescue therapy in the form of intravenous 
infliximab or ciclosporin for patients who have not previously 
failed thiopurine therapy (GRADE: strong recommendation, high-
quality evidence. Agreement: 97.8%).
table 5 Indices predictive of failure of corticosteroid therapy for 
ASUC
Assessment at day 3 of corticosteroids
Chance of 
treatment 
failure* reference
BO >8/day or BO 3–8/day and CRP 
>45 mg/L
85% Travis et al1281
Mean stool frequency day 1–3 Total: Ho et al1282
  <4 0
  4–6 1 0–1 11%
  7–9 2 2–3 45%
  >9 4 ≥4 85%
Transverse colonic dilatation on 
abdominal X-ray ≥5.5 cm
4
Albumin on admission <30 g/L 1
Number of stools in 24 hours + 
(0.14×CRP (mg/L)) >8
72% Lindgren et al1283
CRP/albumin ratio >0.85 combined plus 
stool frequency >3
74% Gibson et al223
*Variably defined as failure of steroid therapy or risk of inpatient colectomy.
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congestive heart failure and demyelination, and screening is 
required before starting treatment. Combination therapy using 
azathioprine with infliximab has a synergistic effect, with 
evidence of benefit in raising infliximab levels and reducing anti-
body formation against infliximab,242 even in patients who have 
previously failed monotherapy with thiopurines. Azathioprine 
or mercaptopurine should be started during hospitalisation and 
continued after discharge. Once patients have responded well to 
rescue therapy, corticosteroid doses should be tailed. Prophylaxis 
for Pneumocystis jirovecii should be given for those on 20 mg 
Figure 2 Management of acute severe ulcerative colitis.
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prednisolone or more (see Section 5.2.8.6: Common Disease 
Considerations, Prevention of Pneumocystis jirovecii infection).
3.12.6 Comparison of infliximab and ciclosporin in ASUC
Head-to-head comparisons between ciclosporin and infliximab 
have demonstrated equivalent efficacy. In the open label CySIF 
trial, 115 patients previously naïve to infliximab and ciclo-
sporin, who had a Lichtiger score >10 points (range 0–21) and 
colitis refractory to at least 5 days of intravenous steroids, were 
randomised in a 1:1 ratio to receive intravenous ciclosporin 
(2 mg/kg per day for 1 week followed by oral drug until day 98) 
or infliximab (5 mg/kg on days 0, 14 and 42).243 In both groups, 
azathioprine was started at day 7 in patients with a clinical 
response. The primary end-point was treatment failure defined 
by absence of a clinical response at day 7, a relapse between 
day 7 and day 98, absence of steroid-free remission at day 98, 
a severe adverse event leading to treatment interruption, colec-
tomy or death. There was no statistically significant difference 
between treatment failure in patients given ciclosporin (60%) 
and infliximab (54%). Nine (16%) patients in the ciclosporin 
group and 14 (25%) in the infliximab group had severe adverse 
events, which was also not statistically different. Similar mucosal 
healing rates (47% ciclosporin, 45% infliximab) and colectomy 
rates (17% ciclosporin, 21% infliximab) were achieved in both 
groups. There was no difference in colectomy-free survival 
at 1 and 5 years in patients treated with either ciclosporin or 
infliximab.244
The CONSTRUCT trial was an open-label pragmatic 
randomised trial in 270 patients, who were randomly allocated 
(1:1) to receive either infliximab (5 mg/kg intravenous infu-
sion given over 2 hours at baseline and again at 2 weeks and 6 
weeks after the first infusion) or ciclosporin (2 mg/kg per day 
by continuous infusion for up to 7 days followed by twice-daily 
tablets delivering 5.5 mg/kg per day for 12 weeks). The primary 
outcome was quality-adjusted survival; the area under the curve 
of scores from the Crohn’s and Ulcerative Colitis Questionnaire 
completed by participants at baseline, 3 months, and 6 months, 
then every 6 months from 1 year to 3 years.200 There was no 
statistically significant difference between the two groups for 
the primary end-point as well as the secondary end-point of 
colectomy rates, time to colectomy, serious adverse events or 
death. Colectomy rates were 29% for infliximab and 30% for 
ciclosporin at 3 months, and 35% and 45% respectively at 
1 year, with no significant difference between the treatments.200 
However, treatment with infliximab was associated with greater 
cost of treatment compared with ciclosporin.
A meta-analysis of infliximab and ciclosporin randomised 
controlled trials shows no difference in response up to 1 year.245 
In the Spanish ENEIDA registry, where patients with steroid 
unresponsive ASUC were treated with ciclosporin (the majority 
of whom were given azathioprine maintenance therapy), the 
colectomy rate at 5 years was 25.4%. For those treated with 
infliximab, either continuing repeat infusions, combination 
therapy with azathioprine, or azathioprine only, the 5-year 
colectomy rate was similar at 26.2%.234
Mortality from infliximab trials is comparable to data on 
ciclosporin (0–2%).196 210 234 The most significant risk for 
both infliximab and ciclosporin relates to those on either of 
these drugs combined with high-dose corticosteroids who fail 
medical treatment and go on to colectomy with deteriorating 
physical condition (anaemia, hypoalbuminaemia and oedema) 
where surgical complications are a significant concern (see 
Section 3.12.9:Ulcerative Colitis, Surgery for acute severe UC).
Ciclosporin and infliximab are equally effective in ASUC. 
Infliximab, however, is simpler to use and is thus used much 
more widely now. Although infliximab was more expensive, use 
of biosimilars is bringing costs down.
3.12.7 Sequential therapy (infliximab and ciclosporin) in refractory 
ASUC
Sequential therapy with infliximab and ciclosporin can be 
associated with profound immunosuppression and potentially 
risks serious adverse events and infections and is not recom-
mended,246 247 although a recent review suggested that the risks 
were not excessive (on the basis of low-quality data).248 In the 
ENEIDA registry sequential therapy was defined as treatment 
with the second agent (ciclosporin or infliximab) within 3 
months after the steroid-refractory ASUC attack, and was used in 
10% of those with long-term outcomes available.234 The median 
time between treatments was 24 days (95% CI 2.5 to 75.0), and 
showed comparable safety to use of one rescue therapy only. 
The greatest risk of this approach is delaying surgery in a patient 
whose physical condition is deteriorating.
3.12.8 Accelerated infliximab induction regimen in ASUC
Recent studies have demonstrated an association between higher 
serum levels of anti-TNF and better outcomes.249 A post hoc 
analysis of ACT 1 and 2 clinical trials noted that patients in the 
lowest quartile of infliximab serum concentration were less likely 
to achieve clinical response, remission and mucosal healing, 
independent of randomised dose (5 mg/kg or 10 mg/kg).250
Various factors, including a high TNF burden in ASUC, 
proteolytic degradation of anti-TNF associated with increased 
drug clearance and faecal losses from increased gut permeability 
due to severe inflammation, support the need for dose optimisa-
tion of infliximab in the acute phase.251 In a recent study, serum 
and non-inflamed tissue anti-TNF drug levels were shown to 
be related, but serum and tissue drug levels were not associated 
in inflamed tissue.252 This suggests that high mucosal cytokine 
levels during inflammation act as a ‘sink’ for drug, and thus a 
higher serum level of the drug may be required to neutralise 
tissue TNF. In another study, a high baseline CRP (>50 mg/L) 
and a low serum albumin (<35 g/L), as surrogates for severe 
inflammation and extensive colitis, independently correlated 
with lower infliximab concentrations from week 0–6.253
There is further evidence of benefit with accelerated infliximab 
dosing in ASUC. Three doses of accelerated infliximab dosing at 
5 mg/kg, administered over a median 24 days to steroid-refractory 
patients, demonstrated a colectomy rate of 6.7% compared with 
40% in a retrospective cohort (standard 5 mg/kg induction at 0, 
2 and 6 weeks).254 For those completing induction therapy, the 
colectomy rates during follow-up were similar (median follow-up 
of 2.4 years for standard dosing and 1.6 years for accelerated 
dosing regimen). A recent review suggested that dose intensifica-
tion may benefit half of patients with ASUC treated with inflix-
imab, with case control studies showing that 1–2 extra infusions 
in the first 3 weeks can dramatically reduce colectomy rates.251
statement 19. We suggest that patients treated with infliximab 
for ASUC who have not responded sufficiently to a 5 mg/kg dose 
3–5 days after first infusion should be treated with an accelerated 
induction regimen after colorectal surgical review to determine 
whether emergency colectomy is required (GRADE: weak 
recommendation, low-quality evidence. Agreement: 95.7%).
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Patients treated with infliximab who are not responding suffi-
ciently to a 5 mg/kg dose after 3–5 days can be treated with an 
early repeat infusion, particularly in those with a low albumin 
(below 35 g/L). Some clinicians use an initial 10 mg/kg dose as 
salvage therapy but there is as yet insufficient data to demon-
strate the value of this in comparison to a 5 mg/kg dose.255 
Optimal timing and dose (5 mg/kg or 10 mg/kg) are as yet 
unclear. Accelerated dosing should only be given after colorectal 
surgical review, with agreement that colectomy is not required 
imminently (see figure 2). Further studies are required to eval-
uate the use of drug levels and biomarkers to determine person-
alised dosing for patients.
3.12.9 Colectomy for ASUC
Outcomes from ASUC were revolutionised by the use of corti-
costeroids and the introduction of timely surgery in those who 
had not responded. Mortality plummeted from 24% to <1% 
in the landmark studies.102 256 Despite rescue therapy, a signifi-
cant number of patients still go to surgery in the acute situation. 
Although meta-analysis has not shown evidence that infliximab 
increases postoperative complications in UC,257 a recent series has 
shown that outcomes for surgery have been worse since the intro-
duction of biologics.258 One possible explanation for this discrep-
ancy would be that, in the case of ASUC, using biologics as rescue 
therapy after failure of corticosteroids creates a delay in surgery. 
Although thromboembolic complications are a significant risk,259 
a recent study did not show a difference between those going to 
surgery after steroids only and those receiving steroids and ‘rescue 
therapy’ prior to colectomy. Both groups however had been inpa-
tients for a long time before surgery (10 vs 12 days).260
Timely decision-making is therefore important in order to 
prevent delays or prolongation of medical therapy, as those 
failing medical therapy and undergoing colectomy have higher 
postoperative complication rates after delayed surgery.105 
Prolonged admission prior to surgery was the only significant 
predictor of postoperative complications in another study.261 In 
a study from the USA, mortality in those who had colectomy 
within 3 days of admission was used as a comparator.262 For 
those with colectomy up to 6 days, the adjusted ORs for postop-
erative death was 2.12 (95% CI 1.13 to 3.97) and 2.89 (95% CI 
1.41 to 5.91) for colectomy up to 11 days.
Multidisciplinary team involvement with gastroenterologist, 
colorectal surgeon, and stoma therapist enables better manage-
ment.196 263 Surgical input at an early stage helps patients to 
understand that colectomy is an important treatment option and 
is not an outcome to be avoided at any cost. Prompt joint deci-
sion-making is essential to avoid unnecessary delays (figure 2).
3.13 surgical management in uC
3.13.1 Emergency colectomy for UC
Surgery in ASUC is indicated when the disease is medically 
resistant, there are intolerable side effects of medication, or 
when there is life-threatening haemorrhage, toxic megacolon or 
perforation.264 Toxic megacolon is a devastating complication 
of severe colitis, characterised by radiographic distension of the 
colon often with fever, tachycardia, neutrophil leucocytosis and 
anaemia.
In this setting, the operation of choice is a subtotal colec-
tomy and end ileostomy with long rectal stump.259 265 266 This 
could be performed laparoscopically or open according to 
local expertise, although a laparoscopic approach is likely to 
result in shorter length of stay and reduced risk of infectious 
complications.267–269
Care should be taken to avoid leakage from the rectosigmoid 
stump, either by formation of mucous fistula, locating the top of 
the remnant in the subcutaneous tissue of the abdominal wall, or 
closing the stump but leaving a transanal catheter in the initial 
postoperative period to prevent stump 'blow-out', with no clear 
evidence of the preferred technique.269 If the patient wishes to 
consider restoration of intestinal continuity with a proctectomy 
and ileoanal pouch, this should not be undertaken in the acute 
setting, given the significant risk of complications in a patient 
who is likely to be clinically unwell, hypoalbuminaemic and 
on immunosuppressive medication. Timing of pouch surgery 
should be an individualised decision with multidisciplinary 
input, with a minimum of 3 months and preferably 6 months 
from the initial subtotal colectomy in order that adhesions may 
be safely manageable and the patient allowed time to generally 
recover from the initial procedure. A population cohort study 
from Sweden showed that the median time to subsequent recon-
structive surgery is almost 12 months.270 At the time of ileoanal 
pouch surgery, a temporary covering loop ileostomy will reduce 
the clinical anastomotic leak rate as well as the septic sequelae of 
a leak, but may be omitted in optimal circumstances.269 A subse-
quent anastomotic leak from a non-defunctioned ileal pouch-
anal anastomosis would generally require defunctioning.
3.13.2 Outcomes after colectomy for UC
Proctocolectomy followed by ileal pouch anal anastomosis (IPAA) 
is well-established as a management option for UC. Multiple case 
series have demonstrated good outcomes in terms of quality of 
life, with a majority of patients indicating they would undertake 
the same procedure again.271–274 In one of the larger series, 95% 
of patients reported good or excellent functional and quality of 
life outcomes over up to 10 years of follow-up.273 A further study 
showed no deterioration in functional outcome over 10 years or 
more.275 Comparison with medical therapies are difficult since 
there are no published comparative data, and in the absence of 
randomisation there would be selection bias. Comparison of 
IPAA to end ileostomy suggests that both are associated with 
equivalent quality of life, and the decision should be a matter 
of patient choice after detailed explanation and counselling. 
Good Practice recommendation 2. In acute severe ulcerative 
colitis, delay in surgery is associated with an increased risk 
of surgical complications, mandating early referral and direct 
involvement of specialist colorectal surgical and stoma care 
teams (Agreement: 100%).
statement 20. We recommend that patients with ASUC who 
have not responded within 7 days of rescue therapy with 
infliximab or ciclosporin, or those with a deterioration or 
complications before that time (including toxic megacolon, 
severe haemorrhage or perforation) require subtotal colectomy 
and ileostomy, with preservation of the rectum (GRADE: strong 
recommendation, very low-quality evidence. Agreement: 97.4%).
statement 21. We suggest that surgical resection of the colon 
and rectum in ulcerative colitis should be offered to patients 
who have chronic active symptoms despite optimal medical 
therapy. Ileoanal pouch reconstruction or end ileostomy provide 
equivalently good quality of life, and are a matter of patient 
choice (GRADE: weak recommendation, very low-quality 
evidence. Agreement: 94.4%).
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Functional outcomes are just as good after laparoscopic-assisted 
pouch surgery.276
Ileoanal pouch surgery is not currently a centralised service in 
the UK. However, data from the UK suggest that high-volume 
centres (more than 100 procedures between 1996 and 2008) had 
lower pouch failure rates.277 In this study, high-volume centres 
had a pouch failure rate of 5.2%, similar to the rate of 5.3% 
reported from the Cleveland Clinic (5.3%) in the USA.273 A 
further study showed that there is a significant learning curve 
for pouch surgery, with improving outcomes dependent on the 
number of procedures undertaken for both trainees and senior 
staff.278 Likewise, there is evidence that management of leaks 
after IPAA procedure improves with increasing experience, and 
results in better pouch salvage rates.279
3.13.3 Surgery in UC patients with primary sclerosing cholangitis
While the occurrence of complications following IPAA surgery in 
patients with co-existent UC and primary sclerosing cholangitis 
(PSC) is high, the risk of pouch failure is low. The most common 
short- and long-term complication is pouchitis, with acute, 
recurrent acute and chronic pouchitis all occurring frequently. 
The largest published series of 100 patients with co-existent UC 
and PSC with IPAA followed for a median of 5.9 years, reports 
30-day complication rates of 39% and overall pouchitis rates of 
64%.280 Pouch excision was only necessary in 3% of patients in 
this series. Other smaller series present similar data with high 
rates of pouchitis, although whether the rate is higher than in 
the non-PSC UC cohort is unclear, with data conflicting.281–283 
For PSC patients with UC undergoing liver transplantation, graft 
outcomes are better for those who have an end ileostomy after 
colectomy compared with colectomy and IPAA.284 Graft loss 
was mainly associated with hepatic artery thrombosis and biliary 
strictures. The risk associated with IPAA is not dependent on 
the timing of colectomy in relation to the liver transplantation. 
Patients can be offered pouch formation if they have PSC as long 
as they understand the potential implications.
3.13.4 Fertility and delivery after restorative proctocolectomy
Any pelvic surgery incurs a risk to fertility. Whereas there is 
evidence that medical treatment of UC does not impair female 
fertility,285 a retrospective systematic review and meta-analysis of 
fertility rates 1 year after open IPAA surgery showed 63% infer-
tility with a relative risk of 3.91 associated with the surgery,286 
corroborating an earlier meta-analysis showing an infertility rate 
of 15% for medically-treated UC and 48% after IPAA.287 Time 
to conception is longer post-surgery, with a more frequent neces-
sity of in vitro fertilisation and higher incidence of caesarean 
section.288 It is likely that Fallopian tube scarring in relation to 
the procedure is the cause of infertility.286 In selected female 
patients without proctitis, subtotal colectomy with ileorectal 
anastomosis (IRA) may be preferable as this does not impair 
fertility,289 although this procedure is not suitable for all and 
the long-term risk of rectal malignancy remains following IRA. 
There is evidence that pelvic scarring is much reduced when 
IPAA is performed laparoscopically.290 Consistent with this, time 
to first spontaneous pregnancy following IPAA is shorter in those 
undergoing laparoscopic surgery in comparison to open proce-
dures.291 In a retrospective questionnaire-based study comparing 
fertility in 15 women following laparoscopic IPAA to that in 
a control group having appendectomy, infertility was demon-
strated in 27% which was no different to the control group,292 
suggesting that laparoscopic restorative proctocolectomy may be 
the preferred option for female patients of reproductive age.
3.14 Pouches and pouchitis
3.14.1 Assessment of new symptoms after IPAA
Up to 50% of patients will develop pouchitis at some time 
after IPAA (as many as 40% in the first year). Typical symp-
toms of pouchitis include increased bowel frequency, urgency, 
nocturnal seepage or incontinence, pelvic discomfort and 
abdominal cramps (table 6).293 Diagnosis is based on the pres-
ence of symptoms in conjunction with endoscopic appearance 
and histology to rule out other conditions. Patients who develop 
symptoms may not have pouchitis: post-surgical complications 
should be considered particularly within the first year after 
surgery.294 This can be due to fistula development, pelvic sepsis 
and anatomical problems related to pouch construction (for 
instance, long cuffs with flutter valve effects or mechanical 
causes of poor pouch emptying). A study in 68 patients with 
antibiotic-dependent or refractory primary idiopathic pouch-
itis, who had had both pouchoscopy and pelvic MRI, showed 
that 38% had chronic peri-pouch sepsis. Those with sepsis 
more often had inflammation in the upper pouch only, and 
although some had a collection that could be drained radiolog-
ically, outcomes were poor with most remaining on long-term 
antibiotics and nearly a third having a defunctioning stoma or 
pouch excision.293 In patients with chronic pouchitis 20%–30% 
have secondary causes for their symptoms, which include CMV 
infection, Candida, Clostridium difficile,295 ischaemia, autoim-
mune disorder, or damage from radiotherapy, chemotherapy or 
non-steroidal anti-inflammatory drugs.180 296 A proportion may 
have Crohn's disease, with reported frequency ranging from 
3.6%–13%.297
Endoscopy is the main tool in the diagnosis and differential 
diagnosis of pouchitis. The most commonly used clinical scores 
statement 22. We suggest that pouch surgery should be 
performed in specialist high-volume referral centres (GRADE: 
weak recommendation, low-quality evidence. Agreement 
97.4%).
Good Practice recommendation 3. Patients undergoing 
colectomy who have co-existent ulcerative colitis and primary 
sclerosing cholangitis should be advised that there is an increased 
risk of pouchitis, to inform decision-making regarding ileoanal 
pouch formation or permanent ileostomy (Agreement: 100%).
Good Practice recommendation 4. For females requiring 
emergency subtotal colectomy and ileostomy, decisions 
regarding proctectomy and ileoanal pouch reconstruction should 
be discussed because of the potential for impaired fertility. 
Decisions should be personalised, including use of laparoscopic 
techniques and the option of delaying until after completion of 
the family (Agreement: 100%).
Good Practice recommendation 5. Patients with ongoing 
symptoms after pouch surgery should have pelvic MRI scan, 
stool culture and Clostridium difficile assay. Pouchoscopy should 
be performed to assess the pouch, the pre-pouch ileum and the 
mucosa at the anal transition zone (Agreement: 100%).
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for pouchitis evaluation are the Pouchitis Disease Activity Index 
(based on symptoms, endoscopy and histology (table 6) and the 
simpler Modified Pouchitis Disease Activity Index (symptoms 
and endoscopy only).298 299 In both, endoscopy is key. Pouchos-
copy may be best carried out using a gastroscope in view of the 
flexibility and smaller calibre of this compared with a colonos-
cope, and a digital examination adds valuable information. At 
the time of pouchoscopy it is important to assess the pre-pouch 
ileum as well as the pouch itself, the rectal cuff and anal transition 
zone (to look for cuffitis). Morphological changes of oedema, 
loss of vascular pattern, erythema, haemorrhage, erosions/ulcer-
ation should be looked for. Ulcers in the afferent loop may indi-
cate Crohn’s disease or use of NSAIDs. Inflammation in one half 
of the pouch with sharp demarcation along the suture line may 
suggest ischaemia. Staple-line ulcers with normal pouch mucosa 
elsewhere are common and do not suggest pouchitis.296 300 Other 
investigations include pelvic MRI to rule out collections, fistulae 
or anatomical abnormalities; stool cultures and C. difficile toxin 
and celiac serology.
3.14.2 Treatment of acute pouchitis
Antibiotic therapy is the standard treatment for acute pouch-
itis,301 with observational data demonstrating 96% of patients 
have a symptomatic response to antibiotics.302 There is very 
little evidence comparing different antibiotics. However, one 
small study of 16 patients demonstrated that ciprofloxacin was 
superior to metronidazole in the treatment of acute pouchitis.303 
Ciprofloxacin is better tolerated with fewer adverse effects than 
metronidazole and may therefore be considered first line treat-
ment for acute pouchitis.304
There is one trial of probiotics in primary prevention of 
pouchitis. Forty patients were randomised to a specific probi-
otic mixture containing eight bacterial strains, or placebo.305 
Ten percent of the probiotic treated arm developed pouchitis 
in a year compared with 40% of the placebo-treated group. 
An uncontrolled retrospective study reported primary prophy-
laxis with sulphasalazine 2 g. At a median 68 months, pouchitis 
occurred in 15% on sulphasalazine, compared with 64.5% not 
given the drug.306
There are more studies examining secondary prevention of 
pouchitis. Two trials show benefit for a probiotic mixture of 
eight bacterial strains given after a 1 month course of antibiotics 
for patients with chronic relapsing pouchitis.307 308 An open-
label study of a probiotic mixture in 28 patients without symp-
toms, (36% had previous pouchitis but none had symptoms at 
study entry) designed to evaluate immunological changes in the 
pouch, showed progressive improvement in PDAI scores over 
1 year, and expansion of mucosal regulatory T cells, compared 
with patients on no treatment.309 A small study of Lactobacillus 
rhamnosus GG over 3 months (in patients with previous pouch-
itis, and with endoscopic pouch inflammation, but no symp-
toms) showed no benefit.310 Overall trial quality in these studies 
was low, and further trials would be helpful to clarify manage-
ment.304 311 Probiotic therapy can be recommended for preven-
tion of relapsing pouchitis, but there is insufficient evidence to 
recommend primary prophylactic probiotics after pouch surgery, 
or even whether this should be given to those at higher risk of 
pouchitis, such as those with pre-operative extra-intestinal 
manifestations, primary sclerosing cholangitis or high titres of 
p-ANCA.312 313 Recent studies have shown that alterations in 
pre-colectomy bacterial microbiota are predictive of subsequent 
pouchitis, with increases in Ruminococcus gnavus, Bacteroides 
vulgatus, Clostridium perfringens, and absence of Lachnospira-
ceae genera (Blautia and Roseburia) and this may inform future 
treatment strategies.314 A small open-label study of faecal micro-
bial transplantation (FMT), (single treatment via nasogastric 
tube) in 10 patients with chronic pouchitis did not show obvious 
clinical benefit.315
FMT can be used to treat Clostridium difficile infection in the 
context of ulcerative colitis when first line antibiotics are ineffec-
tive.316 There is currently no place for FMT in the management 
of IBD unless complicated by C. difficile infection outside of the 
clinical trial setting.
Anti-diarrhoeal drugs are often used by patients with IPAA 
to reduce bowel frequency. There is no evidence of benefit in 
pouchitis treatment although they are often continued. More 
evidence is required to support this common practice.
3.14.3 Treatment of chronic pouchitis
Chronic pouchitis or chronic refractory pouchitis is defined 
as occurring when patients with pouchitis remain symptom-
atic despite 4 weeks’ treatment with antibiotics. Patients who 
fail to respond to 2 weeks of an antibiotic, or relapse rapidly 
after stopping, can be treated with a combination of antibiotics 
for 4 weeks. Ciprofloxacin plus rifaximin and ciprofloxacin 
plus tinidazole have been shown to be effective in randomised 
table 6 Pouchitis Disease Activity Index1284
variable score
Clinical
  Stool frequency (daily) 0–2 (0=usual post-operative frequency, 1=1–2 stools more than post-operative frequency, 2=>3 stools more than post-
operative frequency)
  Rectal bleeding 0–1 (0=absent/rare, 1=present daily)
  Urgency/abdominal cramps 0–2 (0=absent, 1=occasional, 2=usual)
  Fever (>37.8°C/100.5oF) 0–1 (0=absent, 1=present)
Endoscopic inflammation One point for each of: oedema, granularity, friability, loss of vascular pattern, mucous exudate, ulceration)
Histology
  Polymorphonuclear leucocyte infiltration 1–3 (1=mild, 2=moderate +  crypt abscesses, 3=severe +  crypt abscesses)
  Mean ulceration per low power field 1–3 (1 =<25%, 2=25–50%, 3 =>50% ulceration)
Pouchitis, total score ≥7 points; Remission, score ≤2 with endoscopic subscore ≤1.
statement 23. We recommend that a 2 week course of 
ciprofloxacin or metronidazole is the first-line treatment of 
acute pouchitis (GRADE: strong recommendation, low-quality 
evidence). We suggest that ciprofloxacin is better tolerated 
and may be more effective than metronidazole (GRADE: weak 
recommendation, low-quality evidence. Agreement: 97.2%).
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controlled trials.301 Oral budesonide 9 mg and oral beclometh-
asone dipropionate 10 mg daily given for 8 weeks have also 
been shown to be effective,317 318 and if symptoms worsen on 
stopping, biologics should be considered rather than continuing 
long-term steroids. Some antibiotic-dependent patients may 
require long-term rotating antibiotic therapy, and coliform sensi-
tivity testing may help to choose appropriate agents.319 Patients 
with pre-pouch ileitis (occurring in 6% of patients with pouch-
itis) represent a high-risk group for chronic refractory pouchitis 
and should be considered for early escalation to immunomodu-
latory therapy.320
3.14.4 Treatment with biologics in chronic refractory pouchitis
Patients developing chronic treatment-refractory pouchitis 
should be re-evaluated to exclude other causes (see above). A 
recent systematic review with meta-analysis of the literature 
regarding the use of anti-TNF therapy for patients with chronic 
refractory pouchitis has shown moderate to good benefit in 
eight case series for infliximab and adalimumab therapy with 
a pooled remission rate of 53%.301 A preliminary report of a 
small double-blind randomised trial of adalimumab for chronic 
refractory pouchitis showed that six patients on adalimumab all 
improved, with only two of seven on placebo improving. The 
study was too small for statistical significance.321 A series of 20 
patients with chronic antibiotic-dependent, or refractory pouch-
itis showed benefit with vedolizumab therapy. Assessed at 14 
weeks, PDAI and Oresland scores improved with 17/19 patients 
able to stop antibiotic therapy.322 A small open-label study of 10 
patients using tacrolimus enemas (0.08 mg/kg) showed response 
in nine, and remission in seven.323
3.14.5 Follow-up of pouch patients
Ulcerative colitis patients who have undergone ileoanal pouch 
anastomosis represent a small group of patients, who have 
undergone a specialised procedure with a 5%–10% chance of 
long-term failure and significant risk of complications,324 of 
which pouchitis is the most frequent. A pouch clinic enhances 
patient satisfaction,325 and facilitates data collection for audit 
and research purposes. Participation in a national pouch registry 
is invaluable for this purpose.326
3.14.6 Pouch surveillance
The risk of neoplasia in pouches is extremely small, with a 
risk of cancer less than 0.02% at 20 years.327 328 Cancer may 
arise following pouch surgery within the rectal cuff, within the 
pouch itself or arise from the skin (squamous cell carcinoma).329 
Risk of pouch-associated neoplasia is elevated in patients 
with a diagnosis of IBD-associated cancer,330 family history of 
colorectal cancer, type C ileal changes (severe pouchitis rapidly 
after pouch formation, with moderate to severe villous atrophy), 
long retained rectal cuff, and primary sclerosing cholangitis.331 
Although controversial, annual pouchoscopy is recommended by 
most commentators for these high-risk patient groups.332 333 The 
indications for pouch surveillance in the asymptomatic popu-
lation without the above risk factors is uncertain,328 although 
abnormal endoscopic findings are not uncommon.334 335 A deci-
sion in this low-risk group to either perform no surveillance 
unless symptomatic, or 5-yearly, should be discussed with the 
patient, and documented. Examinations should be performed by 
an experienced endoscopist.
4 Crohn’s dIseAse
4.1 diagnosis, classification and assessment
Crohn’s disease is a complex chronic inflammatory gastrointes-
tinal condition with variable age of onset, disease location and 
behaviour. There is no single unifying definition of Crohn’s 
disease and a combination of investigative modalities is often 
needed to confirm the diagnosis. The most widely accepted 
framework for making a diagnosis dates back nearly 30 years.336 
Factors include an appropriate clinical history and examination, 
ileocolonoscopy, small bowel imaging, blood tests and histology. 
Mucosal biopsies from endoscopic procedures or surgical 
resection specimens show focal or patchy (rather than diffuse) 
inflammation and/or crypt distortion. Discontinuous segments 
of disease (‘skip lesions’), ileal involvement and granulomatous 
inflammation are more suggestive of Crohn’s disease, as is a 
tendency for inflammation to be worse in the proximal colon.14
Distinguishing between Crohn’s disease and UC can sometimes 
be complicated; partially-treated UC can demonstrate patches 
of inflammation, backwash ileitis occurs in UC, and granulomas 
only occur in about half of Crohn’s disease patients. Cryptolytic 
granulomas can occur in UC, diverticular inflammation and all 
forms of colitis and are very non-specific. Pathologists find it 
easier to distinguish between IBD and non-IBD than they do to 
separate Crohn’s from UC, and the diagnosis is helped greatly 
by discussion at a multidisciplinary team meeting with clinicians 
and pathologist present.14 Studies have shown about 3% of UC 
patients will be reclassified as Crohn’s colitis, and conversely a 
small number (0.6–3%) will be reclassified to UC after an initial 
diagnosis of Crohn’s disease.19 21 There is a separate cohort who 
can be neither assigned as Crohn’s disease or UC, so are labelled 
as IBD unclassified.
statement 24. We suggest that chronic pouchitis may be 
treated with a combination of antibiotics (ciprofloxacin, 
metronidazole, tinidazole, rifaximin), oral budesonide or 
oral beclomethasone (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 85.7%).
statement 25. Chronic refractory pouchitis not responding 
to antibiotics or locally-acting corticosteroids should be 
reassessed to consider other factors, and if excluded, we 
suggest that patients may be offered biologics (GRADE: weak 
recommendation, low-quality evidence. Agreement: 90.9%).
Good Practice recommendation 6. Ileoanal pouch patients 
should have long-term specialist follow-up where there is 
sufficient expertise to deal with complications, and collect long-
term outcome data. Rapid access for diagnosis and treatment of 
suspected pouchitis should be available (Agreement: 100%).
statement 26. Restorative proctocolectomy with an IPAA 
does not completely abolish the risk of neoplasia. We suggest 
that patients with high-risk factors may be offered surveillance 
pouchoscopy although it is unclear how frequently this should be 
performed. Low-risk patients do not require surveillance (GRADE: 
weak recommendation, very low-quality evidence. Agreement: 
94.4%)
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4.1.1 Phenotypic classification
The Montreal classification29 is widely used to classify the 
key phenotypic features of patients with Crohn’s disease.22 In 
order to capture the change in disease location and behaviour 
over time, and growth failure in the paediatric IBD pheno-
type, the Paris classification was developed as a modification of 
Montreal (table 7).23 337 338 Using these classification systems in 
clinical practice is useful to ensure appropriate decision-making 
regarding surgery, medical treatment and surveillance. 
Montreal and Paris define disease extent according to endo-
scopic or macroscopic features. With an increasing emphasis 
on mucosal healing as a therapeutic target, it is important to 
note that histological evidence of inflammation may be more 
extensive than macroscopic features. This has been shown in 
paediatric studies, where inclusion of histological inflamma-
tion increases those classified with ileal involvement from 49% 
to 71.3%, those classified with Paris L3 disease increases by 
10%, those with Paris L3+L4a by 24% and those with Paris L4 
disease by 27%.339–341 A further approach to classifying disease 
relates to defining early disease: there is evidence that early 
treatment with biologics is more effective and an international 
consensus has proposed a Paris Definition for Early Crohn’s 
Disease, defined as disease duration of 18 months or less after 
diagnosis without previous exposure to immunomodulators 
and/or biologics.337
4.1.2 Clinical and endoscopic disease activity
The Crohn’s disease activity index (CDAI)342 has in the past 
been used in clinical trials,343 but it has a number of limita-
tions, including the parameters used to define remission (CDAI 
<150), and contemporary trial design no longer favours use of 
CDAI.344 In clinical practice, CDAI is cumbersome to calculate, 
requires diary data from patients, is weighted towards diarrhoea 
(which is often caused by factors other than inflammation), is 
not usable in patients with stomas and is not validated for use 
after surgery. In contrast, the Harvey Bradshaw Index (HBI) 
is both simple to calculate and measure, and less susceptible 
to confounding factors relying on clinical parameters only, 
yet is heavily weighted by diarrhoea.345 An HBI score ≤4 is 
often used to define clinical remission. There is also value in 
monitoring patient-reported outcome measures (PROMs), 
reflecting the overall impact of disease on the individual.346 The 
IBD-Control PROM is an easy to use, reliable 8-item measure 
which correlates well with other quality of life measures347 
and should be used to monitor patients’ perspective of their 
disease. It should be noted that neither HBI nor PROMs 
measures correlate well with objective markers of inflammation 
in Crohn’s disease,348 as subjective factors including psycholog-
ical status impact significantly on patient-reported well-being. 
These measures are thus complementary to objective measures 
of disease activity obtained at endoscopy, imaging and surrogate 
measures including faecal calprotectin. More objective measures 
of disease impact including the Lemann index349 and endo-
scopic inflammation scores are more useful as treatment targets 
in clinical trials,350 and may drive therapeutic decision-making 
in clinical practice.
There are a number of endoscopic scoring systems which 
are used regularly in clinical trials351 352 although the two most 
commonly used are the Crohn’s Disease Endoscopic Index of 
Severity (CDEIS)353 and the Simplified Endoscopic activity Score 
for Crohn’s disease (SES-CD; table 8).354 While the CDEIS is 
complex to calculate, the SES-CD is a simple, reproducible 
and reliable endoscopic score.355 356 Both are used to assess 
for complete mucosal healing as an end-point in clinical trials. 
Although not used extensively in routine clinical practice, the 
SES-CD does systematise recording of features in each segment 
of the colon. Validated MRI activity scores are increasingly used 
as adjunct end-points in clinical trials.357 358 The Rutgeerts score 
(table 9) is used specifically to assess recurrent disease in the 
neo-terminal ileum after surgery.359
table 7 Montreal and Paris classification in Crohn’s disease
Montreal29 Paris23
Age at diagnosis (years) A1 <17 A1a <10
A1b 10–17
A2 17–40 A2 17–40
A3 >40 A3 >40
Location* L1 Terminal ileal±limited caecal disease L1 Distal 1/3 ileum±limited caecal disease
L2 Colonic L2 Colonic
L3 Ileocolonic L3 Ileocolonic
L4 Isolated upper disease† L4a Upper disease proximal to ligament of Treitz†
L4b Upper disease distal to ligament of Treitz and proximal to distal 1/3 ileum†
Behaviour B1 Non-stricturing, non-penetrating B1 Non-stricturing, non-penetrating
B2 Stricturing B2 Stricturing
B3 Penetrating B3 Penetrating
B2B3 Both penetrating and stricturing disease, either at the same or different times
P Perianal disease modifier‡ P Perianal disease modifier‡
Growth G0 No evidence of growth delay
G1 Growth delay
B2: Stricturing defined as the occurrence of constant luminal narrowing demonstrated by radiologic, endoscopic, or surgical examination combined with pre-stenotic dilatation 
and/or obstructive signs or symptoms but without evidence of penetrating disease.
B3: Penetrating disease: defined as the occurrence of bowel perforation, intra-abdominal fistulae, inflammatory masses and/or abscesses at any time in the course of the disease, 
and not secondary to postoperative intra-abdominal complications (excludes isolated perianal or rectovaginal fistulae).
*Defined as endoscopic or macroscopic extent.
†Upper disease in Montreal classification describes disease proximal to the terminal ileum. In both Montreal and Paris: L4 and L4a/b may coexist with L1, L2, L3.
‡Perianal abscesses, ulcers or fistulae (but not skin tags or fissures).
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In clinical practice there is evidence that treatment escalation 
and de-escalation driven by objective markers of inflammation 
that are surrogates for endoscopy (CRP, faecal calprotectin), 
as well as clinical variables, can result in improved endoscopic 
and quality of life outcomes, at least in the short term.360 361 
(The CALM trial is discussed further in the Section on Use of 
faecal calprotectin to inform therapy changes 5.5.1.2). It seems 
likely that this will translate into long-term benefit, but as yet 
there is no widely agreed treatment target in Crohn’s disease. As 
safer and more powerful therapies become available, it may be 
appropriate and feasible to use targets based on these objective 
measures in routine practice, in addition to clinical symptoms, 
to ensure effective control of the disease on a long-term basis. 
The choice of surrogate measure (such as faecal calprotectin), 
endoscopy, cross-sectional imaging or combinations of these at 
intervals may differ between patients, depending on their disease 
distribution, severity and their personal preference.
4.1.3 Diagnostic tests
Ileocolonoscopy with biopsy is established as the first-line inves-
tigation for suspected Crohn’s disease. Ileoscopy with biopsy 
histology is superior in establishing the diagnosis of mild ileal 
Crohn’s disease, however, intubation of the terminal ileum may 
not always be possible, and up to 20% of patients have isolated 
proximal small bowel disease beyond the reach of even complete 
ileocolonoscopy. For example, out of a cohort of 150 Crohn’s 
disease patients, 36 had active small bowel disease diagnosed 
using CT enterography following a normal ileocolonoscopy.362 
Ileoscopy and radiological imaging are complementary in diag-
nosis of ileal Crohn’s disease.363 364 Dedicated small bowel 
imaging should be performed to complement ileocolonoscopy 
in all patients with suspected Crohn’s disease and those with 
an unclassified colitis at ileocolonoscopy. Mucosal biopsy spec-
imens are essential for a complete macroscopic and microscopic 
assessment of the colon and distal ileum.9 365
Crohn’s disease in the upper gastrointestinal tract has a prev-
alence up to 13% in some studies,366 and 16% in a more recent 
study of 119 patients.367 When found, it is usually accompanied 
by ileal or colonic disease.368 It has been suggested that upper 
GI endoscopy can help to differentiate between UC and Crohn’s 
disease in patients with an unclassified colitis. Changes of focal 
gastritis occur, however, in UC as well as Crohn’s disease,369 and 
so gastroscopy may not be helpful. If there is vomiting, dyspepsia 
or other upper GI symptoms then upper GI endoscopy is indi-
cated, but not routinely in adults with suspected or proven 
Crohn’s disease.
4.1.3.1 Cross-sectional imaging: CT, MR and small bowel ultrasound
Luminal barium fluoroscopic techniques have been the main-
stay of radiological imaging for many years and have reasonable 
diagnostic accuracy for Crohn’s disease.370 They have largely 
been replaced by cross-sectional imaging techniques which 
also provide information about the bowel wall and extra-en-
teric soft tissues, and thereby can better classify disease pheno-
type and behaviour. It is necessary to distend the bowel prior 
to CT or MRI using intraluminal contrast agents,371 with little 
data supporting invasive enteroclysis techniques over standard 
enterography,372 which is better tolerated by patients. Ultra-
sound can be performed without or with bowel distension using 
oral contrast agents. Several meta-analyses show no consistent 
difference in accuracy for Crohn’s disease diagnosis between CT 
enterography (CTE), MR enterography (MRE) or small bowel 
table 8 Simple Endoscopic Score for Crohn’s disease (SES-CD)354
Ileum right colon transverse colon left colon rectum total
Size of ulcers (diameter) Absent 0
Aphthous ulcers, 0.1–0.5 cm 1
Large ulcers, 0.5–2 cm 2
Very large ulcers, >2 cm 3
Ulcerated surface None 0
<10% of the segment 1
10–30% of the segment 2
>30% of the segment 3
Affected surface None 0
<50% of the segment 1
50–75% of the segment 2
>75% of the segment 3
Presence of narrowings None 0
Single, passable by scope 1
Multiple, passable by scope 2
Not passable, frank stenosis 3
Total SES-CD=
table 9 Endoscopic evaluation of postoperative Crohn’s disease 
recurrence at ileocolic anastomosis: Rutgeerts score359
Endoscopic 
remission
i0: no lesions in neo-terminal ileum
i1: ≤5 aphthous ulcers
Endoscopic 
recurrence
i2: >5 aphthous ulcers with normal intervening mucosa, skip areas 
of larger lesions confined to ileocolonic anastomosis
i3: Diffuse aphthous ileitis with diffusely inflamed mucosa
i4: Diffuse inflammation with large ulcers, nodules and/or stenosis
Good Practice recommendation 7. Suspected Crohn’s disease 
should be investigated with ileocolonoscopy including segmental 
colonic and ileal biopsies (to look for microscopic disease); 
and with imaging to assess location and extent of small bowel 
disease (Agreement: 97.8%).
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ultrasound (SBUS),373–377 with sensitivity and specificity in the 
region of 85–95%. However, a recent UK multicentre trial of 
284 newly diagnosed or suspected relapse Crohn’s disease 
patients showed that MRE had greater sensitivity for small 
bowel disease extent (presence and location) compared with 
SBUS (80% vs 70% respectively).378 MRE also had greater spec-
ificity than SBUS (95% vs 81% respectively), although SBUS had 
superior sensitivity to MRE for colonic disease presence in newly 
diagnosed patients (67% vs 47% respectively). Diagnostic accu-
racy for abscess, fistulae and stenosis is also largely equivalent 
between techniques.376
4.1.3.2 Detection of active disease
Accuracy for detecting patients with active disease is generally 
reported to be over 85%,376 379 although the data supporting 
SBUS is currently less consistent than for MRE and CT enterog-
raphy380 and multicentre trial data suggest MRE is significantly 
more sensitive than SBUS for detecting active small bowel disease 
(96% vs 90% respectively).378 Radiological signs of disease 
activity include increases in bowel wall thickness and vascularity, 
contrast enhancement, T2 and diffusion weighted imaging signal 
(for MRE), and identification of ulceration and acute extra-
luminal complications.376 Validated and reproducible disease 
activity scores have been developed for MRE.358 381 Intravenous 
contrast-enhanced small bowel ultrasound shows promise382 but 
there is as yet insufficient data to recommend first-line use.
4.1.3.3 Investigation of strictures
Data supporting the use of imaging to quantify fibrosis are 
limited383 and the topic is under active investigation, with novel 
MRI magnetisation transfer sequences,384 delayed contrast 
enhancement,385 contrast enhanced ultrasound386 and ultra-
sound elastography387 all showing promise. Ultrasound detec-
tion of strictures may be improved by oral contrast.377
Compared with an age-matched population, Crohn’s disease 
patients have a 2–3-fold increased incidence of colorectal cancer, 
while the risk of small bowel malignancy is increased between 
18 and 27 times.388 389 Up to 3.5% of Crohn’s disease strictures 
may be complicated by dysplasia or malignancy390 so endoscopic 
biopsy of accessible strictures should be performed to achieve a 
pathological diagnosis.
4.1.3.4 Radiation exposure
Diagnostic imaging, particularly CT scanning, can expose 
Crohn’s disease patients to doses of ionising radiation which 
may significantly increase their lifetime risk of cancer.391–393 This 
risk is particularly important for children and young people.394 
Crohn’s disease patients have more than twice the radiation 
exposure compared with UC patients.395 A study of 409 patients 
from a tertiary hospital showed that 15.5% had a cumulative 
exposure dose in excess of 75 mSv392 (this dose is considered to 
increase the risk of cancer mortality by 7.3%). Factors associ-
ated with excessive diagnostic radiation exposure included age 
under 17 at diagnosis, upper gastrointestinal disease location, 
penetrating disease, need for intravenous corticosteroids and 
more than one Crohn’s disease surgical operation. Although 
significant dose reductions are now possible with emerging CT 
image reconstruction techniques,396 397 MRE and small bowel 
ultrasound are generally preferred over CT to limit patient expo-
sure to ionising radiation.
4.1.3.5 Capsule endoscopy
Capsule endoscopy provides high resolution endoluminal images 
of the small bowel, is less invasive than conventional endoscopic 
techniques and is usually well tolerated by patients.398 Although 
recent randomised trial data suggest a clear fluid preparation 
may be sufficient, marginally outperforming active bowel prepa-
ration,399 patients are commonly given bowel preparation.400 
A recent European expert technical review assessing available 
meta-analysis data recommends the use of PEG bowel prepara-
tion to improve visualisation, but notes inconclusive evidence 
on the impact of preparation on completion rates and diag-
nostic yield.401 The same technical review also recommends use 
of an anti-foaming agent prior to capsule ingestion to improve 
visualisation.401
Evaluating diagnostic accuracy of capsule endoscopy is 
hampered by a lack of reference standard and many studies 
instead report the ‘diagnostic yield’. In this regard, meta-anal-
ysis data suggest the diagnostic yield of capsule endoscopy in 
suspected Crohn’s disease is significantly greater than barium 
fluoroscopy (52% vs 16%), CT enterography (68% vs 21%) 
and ileocolonoscopy (47% vs 25%).381 In established Crohn’s 
disease it was significantly greater than push enteroscopy (66% 
vs 9%), barium fluoroscopy (71% vs 36%) and CT enterography 
(71% vs 39%).402 Data suggest capsule endoscopy is superior to 
statement 30. We suggest that capsule endoscopy has 
greater sensitivity for mucosal small bowel Crohn’s disease 
than radiological imaging techniques and can generally be 
performed where inflammatory small bowel disease is still 
suspected despite normal or equivocal cross-sectional imaging. 
Minor changes found at capsule endoscopy may be insufficient 
in isolation to diagnose Crohn’s disease, particularly with recent 
NSAID use (GRADE: weak recommendation, moderate-quality 
evidence. Agreement 90.9%).
statement 27. We suggest that adult patients with Crohn’s 
disease do not routinely require upper gastrointestinal 
endoscopy as part of the diagnostic evaluation unless 
they have upper gastrointestinal symptoms (GRADE: weak 
recommendation, very low-quality evidence. Agreement: 91.1%).
statement 28. We suggest that cross-sectional imaging, 
specifically MRI, CT and ultrasound, have largely replaced 
conventional barium fluoroscopic and nuclear medicine 
techniques and have the advantage of evaluating both luminal 
and extraluminal disease. Emphasis should be placed on MR 
enterography and ultrasound as they do not expose patients to 
ionising radiation (GRADE: weak recommendation, moderate-
quality evidence. Agreement: 97.9%).
statement 29. We suggest that, while there is no clear evidence 
of diagnostic superiority for one cross-sectional imaging 
modality over another for stricture diagnosis, emphasis should 
be placed on techniques that do not expose patients to ionising 
radiation. For colonic or anastomotic strictures, endoscopy 
and biopsy should be performed to assess and exclude cancer, 
provided the stricture is accessible and endoscopy deemed safe 
(GRADE: weak recommendation, very low-quality evidence. 
Agreement: 100%).
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MRE at detecting small bowel inflammation in Crohn’s disease, 
particularly for proximal or superficial small bowel lesions,370 
although a recent meta-analysis did not find any statistically 
significant difference in diagnostic yield between MRE and 
capsule endoscopy.370
The utility of diagnostic yield as a surrogate for diagnostic 
accuracy has been criticised403 with specificity for capsule endos-
copy reported as 53% in one study, using a consensus reference 
standard paradigm.404 Minor mucosal abnormalities found at 
capsule endoscopy can be seen in normal individuals, particu-
larly those who have been using NSAIDs,398 405 and while vali-
dated diagnostic criteria for capsule endoscopy diagnosis of 
Crohn’s disease are in development, they are not currently in 
widespread clinical use.398 405
Use of capsule endoscopy should therefore be restricted to 
those with a high clinical suspicion of Crohn’s disease (sugges-
tive clinical picture and raised faecal calprotectin) and abstinence 
from NSAID ingestion for at least 1 month,405 where cross-sec-
tional imaging has been normal or equivocal.
The size and rigidity of capsules used for capsule endoscopy 
mean they can be retained within the small bowel, usually in 
stricturing disease. The risk of capsule retention is lower in 
patients with suspected Crohn’s disease than in those with 
established disease. In a 2017 meta-analysis the risk of capsule 
retention in suspected Crohn’s disease (nine studies, 968 
patients) was 3.6% (95% CI 1.7% to 8.6%), although there 
was considerable heterogeneity between included studies.406 
In established Crohn’s disease (11 studies, 558 patients), the 
risk of capsule retention was 8.2% (95% CI 6% to 11%).406 
Retention after successful patency capsule passage or exclusion 
of strictures by cross-sectional imaging was 2.7% (95% CI 1.1 
to 6.4). Comparative data regarding cross-sectional imaging 
and patency capsule is limited.401 When capsule endoscopy is 
indicated in patients with known stricturing Crohn’s disease or 
those with suspected strictures, including patients presenting 
with abdominal pain or distention, nausea or vomiting, or a 
history of small bowel resection, abdominal/pelvic radiation 
exposure or chronic NSAID use, the use of preceding patency 
capsule is suggested.401 405 407
4.1.3.6 Balloon-assisted enteroscopy
Device-assisted endoscopy such as balloon-assisted enteroscopy 
can visualise the small bowel mucosa beyond the reach of ileo-
colonoscopy, allowing tissue biopsy for histological assessment. 
The diagnostic yield may be similar to capsule endoscopy, with 
a recent systematic review reporting a yield of 63.4% (95% 
CI 42% to 82.3%) in known or suspected Crohn’s disease,408 
with likely greater sensitivity than MRE.409 The procedures are 
however costly, invasive, requiring deep sedation or general 
anaesthesia, and not without risk. A recent meta-analysis410 
reported a perforation rate of 0.15% (95% CI 0.05% to 0.45%) 
for diagnostic balloon-assisted enteroscopy, and an overall 
major complication rate (including perforation and bleeding) 
of 0.72% (95% CI 0.56% to 0.90%) has been reported.408 
Given the high diagnostic accuracy of alternative less invasive 
tests, notably cross-sectional imaging and capsule endoscopy, 
diagnostic device-assisted techniques should be reserved for 
patients with high clinical suspicion of Crohn’s disease despite 
negative ileocolonoscopy, who have suspicious but not diag-
nostic cross-sectional imaging or capsule endoscopy, particu-
larly if findings would alter therapeutic strategy, or in patients 
where a firm histological diagnosis would alter management.405 
Device-assisted enteroscopy does have a role in established 
Crohn’s disease where therapeutic intervention, such as stric-
ture dilatation, is needed.411
4.2 Induction of remission in mild to moderate disease 
ileocolonic disease
4.2.1 Budesonide in ileocaecal Crohn’s disease
In a randomised double-blind trial, ileal-release budesonide 
9 mg once daily for 8 weeks was as effective as prednisolone 
(40 mg daily tapering to 5 mg at 8 weeks) at inducing remis-
sion in patients with mild-to-moderate ileocaecal Crohn's 
disease with treatment efficacy (CDAI score <150) of 51% 
on budesonide at 8 weeks compared with 52.5% for predniso-
lone,412 and significantly fewer side effects. Multiple meta-anal-
yses have also demonstrated the efficacy of budesonide 9 mg/
day over placebo in inducing remission.413–415 A once-daily 
9 mg dose is as effective as 3 mg three times daily.416 In the 
context of more severe disease (CDAI >300) budesonide is 
inferior to prednisolone (RR 0.52, 95% CI 0.28 to 0.95).414 
When remission has been achieved, budesonide should be 
tapered over 1–2 weeks.
4.2.2 Corticosteroids in colonic Crohn’s disease
In mild, moderate and severe colonic Crohn’s disease, systemic 
corticosteroids such as prednisolone are effective in inducing 
remission.417–419 A starting dose of 40 mg tapering by 5 mg 
weekly is often used, but should be tailored to disease severity 
and patient tolerance. Ileal-release budesonide does have benefit 
in Crohn’s disease affecting the proximal colon,412 but there 
is no evidence of benefit in more distal colonic inflammation. 
There are no trials of colonic-release budesonide-MMX in 
Crohn’s disease at present.
4.2.3 Nutritional therapy
4.2.3.1 Exclusive Enteral Nutrition (EEN)
Meta-analysis has shown that EEN is as effective as corticoste-
roids at inducing remission in 73% of paediatric patients on an 
intention to treat basis420 but not in adults.421 In paediatrics, it 
is considered the primary treatment option to induce disease 
remission,420 and has added value in that it not only improves 
nutritional status but also benefits growth. In adults, although 
statement 31. The risk of capsule retention is low in suspected 
Crohn’s disease patients without symptoms suggestive of 
stricture. However, when obstructive symptoms are present, or 
in known stricturing Crohn’s disease where capsule endoscopy 
is indicated, we suggest that patency capsule should precede 
capsule endoscopy (GRADE: weak recommendation, low-quality 
evidence. Agreement: 93.5%).
statement 32. We recommend that mild to moderate ileocaecal 
Crohn’s disease can be treated with ileal-release budesonide 
9 mg once daily for 8 weeks to induce remission (GRADE: strong 
recommendation, high-quality evidence. Agreement: 100%).
statement 33. We recommend that active Crohn’s colitis can 
be treated with an 8-week course of systemic corticosteroids to 
induce remission (GRADE: strong recommendation, high-quality 
evidence. Agreement: 100%).
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studies have been small and underpowered, there does seem to 
be a consistent message that, where tolerated, EEN can be effec-
tive at inducing remission422–425 even in the presence of compli-
cations.426 There is increasing evidence that EEN can alter the 
microbiome, with differences in those who have a long-term 
response.427
Tips on the use of EEN are shown in box 3. In practice, EEN 
is not frequently used in adult populations. This is reportedly 
due to a lack of high-quality evidence for its use428 and limited 
access to dietetic expertise within an IBD multidisciplinary team 
(MDT).429 Where avoidance of corticosteroids is considered 
appropriate and patients are motivated to try dietary alterna-
tives, EEN should be considered with appropriate dietetic 
support.421 429 430
Ten days of EEN can achieve symptomatic relief; however 
mucosal healing takes longer, up to 8 weeks.431–433 Further 
research is needed to identify the optimum duration, but 
4–6 weeks of EEN is considered the minimum.429 434
EEN given as elemental diets are not palatable, therefore poly-
meric (whole protein) and semi-elemental (peptide) based feeds 
were created to overcome this barrier and have been shown to 
be as effective as elemental diets.435 EEN can be taken orally in 
the majority of patients, however the nasogastric route can be 
considered as an alternative where appropriate.436 A Cochrane 
review showed no difference in outcomes between elemental 
and non-elemental feeds, but evidence quality was very low.421
4.2.3.2 Elimination diets
There is much interest in elimination diets being used to induce 
or maintain disease remission. Following a course of EEN, 
patients can be unsure what foods to add back into their diet 
first. A low fat, low fibre, exclusion (LOFFLEX) diet was devel-
oped to provide a dietary intervention for 2–4 weeks based 
on a small number of foods unlikely to trigger symptoms (an 
exclusion diet) followed by gradual food reintroduction with a 
new food every few days. The LOFFLEX diet has been shown 
to maintain disease remission in 56% of patients at 2 years,437 
but is not used widely. Another study in paediatrics used a 
3-day rapid food reintroduction diet compared with a 5-week 
food reintroduction plan and showed similar relapse rates of 
almost 50% of patients at 12 months indicating that food can 
be reintroduced more quickly than traditionally thought.438 A 
variety of other diets have been proposed in this context, but 
they lack the backing of high-quality evidence.428 The recently 
reported Crohn’s disease treatment with eating (CD-TREAT) 
study explored the possibility of replicating EEN with solid 
foods.439 Both EEN and the experimental diet achieved similar 
microbiome effects in healthy volunteers and rats, as well as 
improved HLA-B27 rat ileitis histopathology scores. In addition, 
the same paper reported a non-blinded study of five children 
with relapsing Crohn’s disease in which the experimental diet 
achieved 3/5 remission and 4/5 response by weighted paedi-
atric CDAI.439 This is an area that requires further investigation 
before it can be considered a standard therapy.
4.2.4 Antibiotic therapy
Trials of antibiotic therapy in Crohn's disease have studied 
a wide range of antimicrobial agents. While a meta-analysis 
demonstrated efficacy for these pooled trials over placebo (RR 
for continued disease activity 0.85 (95% CI 0.73 to 0.99), 
statement 34. We suggest that Exclusive Enteral Nutrition 
(EEN) may be used to induce remission in mild to moderate 
Crohn’s disease patients where avoidance of corticosteroid is 
desired, and in those who are motivated to adhere strictly to 
EEN for up to 8 weeks (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 86.4%).
statement 35. We recommend that polymeric feeds are as 
effective as elemental or semi-elemental feeds in treatment 
of Crohn’s disease, and improve adherence (GRADE: strong 
recommendation, very low-quality evidence. Agreement: 86.7%).
box 3 Practical guide for exclusive enteral nutrition 
(een) to induce remission in Crohn’s disease
 ► Counsel patients on the risks and benefits of all available 
treatment options including EEN.
 ► EEN is provided as a prescribed liquid diet excluding all food 
and drink except still water. Some units allow limited optional 
intake beyond this, but there is little evidence supporting 
what foods or drinks can be added without impacting 
efficacy. Permit Crusha flavouring (now sugar-free), Fox’s 
Glacier Mints, sugar-containing 7-Up and black coffee.
 ► Whole protein, peptide or elemental diets are equally 
efficacious but whole protein feeds are more palatable and 
are more likely to be tolerated.
 ► EEN is nutritionally complete with all relevant micronutrients 
and trace elements.
 ► Limited palatability and tolerance are often reasons for 
failure, so encouragement from the whole MDT is important 
for success. This is best achieved with a formalised MDT 
pathway for EEN management and specific points of contact 
to assess progress.
 ► A starter regimen, increasing the prescribed daily volume 
gradually over a few days while reducing food intake, is 
important to build up tolerance and prevent the risk of 
refeeding, especially in patients where dietary intake has 
been suboptimal beforehand or weight loss has been 
significant.
 ► Bloods for refeeding syndrome include urea and electrolytes 
(for potassium), phosphate and magnesium, and should be 
monitored daily while calorie intake is increased to maximum 
in at-risk patients.
 ► A standard target regimen should be based on requirements 
for energy: 25–30 kcal/kg/day and protein: 1 g/kg/day. Non-
standard regimens may be used where refeeding syndrome 
is a risk (with lower calories), or where catch-up nutrition is 
required.
 ► Once the target regimen is met, EEN should be continued for 
6–8 weeks to induce mucosal healing.
 ► Once EEN is established, the vast majority of patients can 
continue with their usual daily activities.
 ► Most adult patients can tolerate EEN orally, however 
nasogastric feeding may be required if target volumes 
cannot be met orally or where feed tolerance is limited with 
boluses.
 ► Regular monitoring via email or telephone will help to 
maintain adherence.
MDT, Multidisciplinary team.
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p=0.03),440 there was such heterogeneity in the agents and 
dosing regimens used that it makes it difficult to draw mean-
ingful conclusions.
The risk of adverse effects, particularly with prolonged or 
repeated courses, should also be taken into consideration. In 
this regard, rifaximin (a non-absorbed oral antibiotic), in an 
extended-intestinal release formulation has been shown in a 
large dose-ranging study to be effective, although at a higher 
dose than usually employed (800 mg BD). However, there was 
no dose-response, with numerical but not statistical difference to 
placebo for the 400 mg BD and 1200 mg BD dose.441 442 Rifax-
imin is unlicensed for this indication.
In a blinded randomised trial in 73 patients with paediatric 
Crohn’s disease, azithromycin 75 mg/kg 5 days per week for 
4 weeks, then metronidazole 20 mg/kg/day for another 4 weeks, 
compared with metronidazole only for 8 weeks, showed a remis-
sion rate of 66% for azithromycin/metronidazole and 39% for 
metronidazole (p=0.025), although response rates were similar. 
In 12 patients failing metronidazole, 83% achieved remission on 
open-label azithromycin.443 There is continuing research interest 
in antibiotic therapy in Crohn’s disease treatment, but at present 
antibiotics should only be used in patients with disease compli-
cated by infection (abscesses, bacterial overgrowth, Clostridium 
difficile) or perianal fistulising disease. Overall the efficacy 
for antibiotics as induction therapy in mild-moderate Crohn’s 
disease remains unproven.
The role of Mycobacterium avium subspecies paratubercu-
losis (MAP) has been debated for many years. A randomised 
placebo-controlled trial of 2 years therapy with clarithromycin, 
rifabutin and clofazimine in 213 patients with active Crohn’s 
disease, with a further year of follow-up, showed early benefit 
of antibiotics, but overall there was no significant difference in 
relapse rate during follow-up.444 There was debate about the 
dosage and formulation chosen, and the study design (with with-
drawal of non-responders at week 16). A further phase 3 trial 
using higher doses was reported in October 2018.445 A total of 
331 patients with moderate to severely active Crohn’s disease 
were randomised to RHB-104 (clarithromycin 95 mg, rifab-
utin 45 mg and clofazimine 10 mg) five capsules twice daily or 
placebo for 52 weeks, in addition to their pre-study therapy. At 
week 26, remission was achieved in 37% versus 23% on placebo 
(p=0.007), and durable remission (from week 16 to 52) was 
achieved in 18% versus 9% on placebo (p=0.019). No data are 
available on endoscopic healing or on persistence of benefit after 
stopping treatment.
4.2.5 Surgery in localised ileocaecal Crohn’s disease
The LIR!C study compared laparoscopic ileocaecal resection 
(n=73) to infliximab (n=70) for patients with terminal ileal 
disease in whom conventional therapy had failed.446 Across a 
number of comparators there was equivalence between the two 
approaches, suggesting that resection is a reasonable alternative 
to medical therapy in this scenario. The LIR!C trial excluded 
those who had previous resection, a small bowel segment longer 
than 40 cm, abscesses or where surgery was deemed likely due 
to pre-stenotic dilatation. During the median follow-up period 
of 4 years (range 2–6), approximately a third of patients (n=26, 
39%) in the infliximab group required surgery while a quarter 
of patients in the surgery group (n=19, 26%) required inflix-
imab. Taken together, these data suggest resection is a cost-effec-
tive intervention based on the cost of originator infliximab.447 
Present day medical costs should be lower with the widespread 
availability of biosimilar infliximab.
4.3 Initial treatment of moderate to severe ileocolonic 
Crohn’s disease
4.3.1 Corticosteroids
Systemic corticosteroids are still an effective initial therapy for 
moderate to severely active Crohn’s disease,418 419 regardless of 
disease location, but every effort should be made to limit expo-
sure.448 For less severe symptoms in those with ileocaecal disease 
location, ileal-release budesonide may be tried initially, but if 
ineffective, prednisolone may be required. For teenagers, partic-
ularly where growth has not completed, and for patients with 
diabetes or steroid intolerance, alternatives can be considered, 
including EEN.
4.3.2 Early use of biological therapy
In patients with an aggressive disease course or ‘high-risk’ poor 
prognostic factors, the early introduction of biologics may be 
considered. High-risk features include: complex (stricturing or 
penetrating) disease at presentation; perianal fistulising disease; 
age under 40 years at diagnosis; and need for steroids to control 
the index flare.449 450 The predictive power of these features 
is limited. There is great interest in biomarkers that identify a 
Crohn’s disease subgroup at high risk of an aggressive disease 
course. A gene expression signature from peripheral CD8 T cells 
in active untreated IBD has been identified,451 and is now being 
tested using a whole blood assay in randomised controlled trials 
of a ‘top-down’ versus accelerated ‘step-up’ therapy.
The decision to start biological therapy should also consider 
factors such as stage of life, work absence and availability of 
other treatment options. Discussion in a multidisciplinary 
team meeting can be helpful. As well as anti-TNF therapy, 
vedolizumab and ustekinumab can be considered as first-line 
biologics.
4.4 Maintenance treatment in ileocolonic Crohn’s disease
Irrespective of whether remission is induced surgically or medi-
cally, corticosteroids are not effective in maintaining remission 
in Crohn’s disease compared with placebo (see Section 5.2.8.1: 
Overuse of corticosteroids). Systematic reviews and pooled trial 
data show that budesonide does not reduce relapse rates over 
a 12-month period.452–454 One systematic review did show a 
modest reduction in CDAI scores, but this was outweighed by a 
significant increase in adverse events and adrenocortical suppres-
sion compared with the placebo groups.454
statement 36. We suggest that laparoscopic resection should 
be considered in localised ileocaecal Crohn’s disease for those 
failing or relapsing after initial medical therapy, or in those 
preferring surgery to continuation of drug therapy (GRADE: 
weak recommendation, moderate-quality evidence. Agreement: 
93.5%).
statement 37. We recommend that moderate to severely active 
uncomplicated luminal Crohn’s disease should be treated initially 
with systemic corticosteroids (GRADE: strong recommendation, 
high-quality evidence), but we suggest that those with extensive 
disease or other poor prognostic features should be considered 
for early introduction of biological therapy (GRADE: weak 
recommendation, moderate-quality evidence. Agreement: 
86.7%).
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4.4.1 Immunomodulator therapy
Relapse of Crohn’s disease is common on corticosteroid with-
drawal, particularly in moderate to severe disease, and early 
initiation of corticosteroid-sparing therapy is appropriate. 
Immunomodulators such as azathioprine, mercaptopurine or 
methotrexate are effective in the maintenance of remission of 
Crohn’s disease.
4.4.1.1 Thiopurine therapy
Thiopurines should not be used for induction of remission in 
active Crohn’s disease. Thiopurines are more effective than 
placebo in maintenance of remission in Crohn’s disease but the 
Cochrane analysis reports low quality evidence (NNT=9).455 
A systematic review and network meta-analysis also showed 
the benefit of azathioprine/mercaptopurine compared with 
placebo in remission maintenance (OR 1.7 (95% CI 1.3 to 2.6)), 
although anti-TNF therapy was significantly more effective than 
thiopurines.456
4.4.1.2 Methotrexate
Methotrexate should not be used as monotherapy for induction 
of remission, but may be used in Crohn’s disease patients failing 
to respond to corticosteroids. The landmark trial evaluated 
intramuscular methotrexate 25 mg weekly given to patients with 
chronic active Crohn’s disease despite at least 3 months of pred-
nisolone. It showed increased clinical remission rates compared 
with placebo at 16 weeks, with reduced prednisolone require-
ments.457 458
A follow-on study also showed efficacy of methotrexate as a 
maintenance therapy,459 a finding which has been confirmed in a 
recent Cochrane review.460 A network meta-analysis and system-
atic review showed the benefit of methotrexate with ORs of 2.4 
(95% CI 1.1 to 4.8).456
In other disease areas there is convincing evidence of the supe-
riority of parenteral administration of methotrexate over the 
oral route.461 462 As a result, a variety of studies have attempted 
to compare the efficacy of different routes of administration for 
methotrexate in Crohn’s disease. A retrospective cohort study of 
118 patients showed benefit of methotrexate in both induction 
and maintenance treatment for Crohn’s disease, with steroid-
free remission being achieved in 37.2% of patients, and main-
tained relapse-free in 63.6% for a median of 12 months.463 A 
multicentre retrospective study in 226 children showed numer-
ical, but not statistical superiority of subcutaneous methotrexate 
over the oral route, with sustained corticosteroid-free remission 
in 32% for subcutaneous versus 26% for oral (OR 1.7, 95% CI 
0.5 to 5.9).464 There was no difference in nausea or abnormal 
liver enzymes between the two routes of administration.
Oral methotrexate has reduced and extremely variable 
bioavailability (not corrected by use of folic acid) compared 
with parenteral administration, particularly at doses above 
15 mg.465 466 Because bioavailability and pharmacokinetics are 
very similar for subcutaneous and intramuscular methotrexate, 
the subcutaneous route should be preferred to intramuscular as 
it is easier and less painful.467
Induction therapy should be given by the subcutaneous route. 
If patients prefer, this can be switched to oral during the mainte-
nance phase, with the option to switch back to subcutaneous if 
effectiveness is lost. Whatever the route of administration, meth-
otrexate should be given with folic acid to reduce gastrointes-
tinal and liver toxicity, 5 mg weekly (traditionally 1–2 days after 
the methotrexate dose) or 1 mg daily.
4.4.2 Mesalazine
UK data from 1990 to 2010 show over half of patients with 
Crohn’s disease were prescribed 5-ASA,468 and Swiss data show 
it is more often given for Crohn’s colitis.469 A Cochrane system-
atic literature review showed that oral 5-ASA has no efficacy 
in maintaining clinical remission in Crohn’s disease,470 with 
similar negative findings in meta-analyses for induction or 
maintenance.413 414 471 472 A recent review of colonic Crohn’s 
disease473 showed that there was no benefit for 5-ASA in colonic 
Crohn’s disease, but two studies have shown possible benefit for 
sulphasalazine in remission induction.418 419 Thus, 5-ASAs are 
not recommended for induction or maintenance treatment of 
Crohn’s disease.
4.4.3 Biological therapy with anti-TNF drugs, vedolizumab or 
ustekinumab
4.4.3.1 Infliximab
Infliximab is a monoclonal antibody to tumour necrosis factor 
alpha (TNF) and was the first in class to be used in IBD, 
demonstrating definitive benefit in luminal Crohn’s disease in 
the ACCENT I study. 573 patients with active luminal disease 
received a single 5 mg/kg intravenous dose, and after assessment 
of response at week 2, were randomly assigned to infusions of 
placebo at weeks 2, 6 and then 8-weekly (group 1), or infliximab 
5 mg/kg at the same time points, or 5 mg/kg at weeks 2 and 6, 
then 10 mg/kg 8-weekly. At week 2, 58% responded to the initial 
infusion, and of these responders: at week 30, 39% treated with 
5 mg/kg maintenance and 45% on 10 mg/kg were in clinical 
statement 40. We recommend that azathioprine or 
mercaptopurine can be used as monotherapy in the maintenance 
of remission in Crohn’s disease (GRADE: strong recommendation, 
low-quality evidence. Agreement: 100%).
statement 41. We suggest that methotrexate may be used for 
the maintenance of remission of Crohn’s disease, and the dose 
should be at least 15 mg weekly. Subcutaneous administration 
has better bioavailability than oral, particularly at higher doses 
(GRADE: weak recommendation, moderate-quality evidence. 
Agreement: 88.4%).
statement 38. We recommend that systemic or locally acting 
corticosteroids should be avoided as maintenance therapy in 
Crohn’s disease due to toxicity and lack of efficacy (GRADE: 
strong recommendation, high-quality evidence. Agreement: 
100%).
statement 39. We recommend that for patients with moderate 
to severe Crohn’s disease responding to prednisolone, early 
introduction of maintenance therapy with thiopurines (GRADE: 
strong recommendation, low-quality evidence) or methotrexate 
(GRADE: strong recommendation, moderate-quality evidence) 
should be considered to minimise risk of flare as prednisolone is 
withdrawn (Agreement: 93.3%).
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remission, with similar remission rates observed at week 54.474 
In routine clinical practice reported results are significantly 
better, with a large single-centre cohort of 614 Crohn’s disease 
patients (treated for luminal, perianal or extraintestinal mani-
festations) showing that 89.1% had clinical improvement after 
initial treatment and 63.4% showing sustained clinical benefit.475 
This study included a significant proportion of patients receiving 
episodic therapy, whereas regular scheduled therapy is of proven 
superiority.476
4.4.3.1.1 Combination therapy of infliximab with an 
immunomodulator
The SONIC study showed that combined infliximab and 
azathioprine was superior to infliximab in achieving clinical 
remission and mucosal healing.477 A network meta-analysis of 
published data shows that combination therapy was more effec-
tive than azathioprine monotherapy, as was adalimumab mono-
therapy.456 Similar benefits of combination therapy are seen in 
children.478 479 Addition of an immunosuppressant has also been 
shown to reduce the need for dose escalation of infliximab and 
also reduces the rate of drug switching.480
In the PANTS 3-year observational cohort of 1601 Crohn’s 
patients treated with infliximab or adalimumab, 751 patients 
were treated with infliximab.481 At week 54 the immunoge-
nicity rates for Remicade and biosimilar infliximab (Inflectra/
Remsima) were 26% and 28%, respectively. Immunomodulator 
use reduced the risk of immunogenicity in infliximab therapy 
(HR=0.37, p<0.0001).
A study of patients who had recently started prednisolone 
treatment for active disease showed that combination therapy 
with infliximab and methotrexate was no more effective 
that infliximab monotherapy in maintaining remission up to 
50 weeks, although equally safe.482 A recent Cochrane system-
atic literature review evaluating this460 and a further small open-
label study483 reached the same conclusion. Immunogenicity to 
infliximab may, however, be reduced by the addition of metho-
trexate,480 suggesting that some clinical benefit might have been 
observed beyond the 1 year timeframe of the study. A paediatric 
registry study of 502 Crohn’s disease patients studied the impact 
of concomitant immunomodulator therapy on the duration of 
infliximab therapy.484 Concomitant methotrexate, taken for 
more than 6 months, increased likelihood of remaining on inflix-
imab, both compared with non-use of immunomodulators and 
compared with thiopurine use. Due to the small number of girls 
given methotrexate, only boys were included in this analysis.
In order to maximise the benefit of infliximab therapy 
and reduce treatment failure, combination therapy with 
immunomodulator should always be preferred (with stronger 
evidence for azathioprine than methotrexate). For those intol-
erant to thiopurines and methotrexate, alternatives to infliximab 
should be used unless there are other compelling reasons (such 
as the presence of perianal disease).
4.4.3.2 Adalimumab
Adalimumab is a monoclonal antibody to TNF administered 
subcutaneously. The CLASSIC I study in moderate to severe 
Crohn’s disease naïve to anti-TNF therapy showed that the 
optimum dose for induction therapy was 160 mg followed by 
80 mg at week 2, with remission (CDAI <150) achieved in 36% 
(p=0.001 against placebo) compared with 24% (80 mg/40 mg), 
18% (40 mg/20 mg) and 12% on placebo.485 In the CHARM 
study of maintenance therapy, responders to induction therapy 
with 80 mg subcutaneously and 40 mg at 2 weeks were given 
placebo, 40 mg every 2 weeks or 40 mg weekly, with 12%, 36% 
and 41%, respectively, in clinical remission at week 56.486 The 
GAIN trial showed efficacy of adalimumab in patients with 
active Crohn’s disease and loss of response or intolerance to 
infliximab (secondary infliximab failures).487 Data from the 
EXTEND trial demonstrated adalimumab to be effective in 
inducing and maintaining endoscopic mucosal healing over 
the longer term,488 and with improved outcomes in those who 
achieved deep remission.489
The signal for the importance of combination therapy with 
an immunomodulator is not as strong in studies of adalimumab 
as it is for infliximab. A meta-analysis suggested that combina-
tion therapy with an immunomodulator was slightly better than 
adalimumab monotherapy for induction of remission, but remis-
sion rates at 1 year were no different, and there was no reduction 
in rates of dose escalation compared with monotherapy.490 Like-
wise, the DIAMOND trial comparing adalimumab monotherapy 
to combination therapy with azathioprine in 176 Japanese 
Crohn’s disease patients naïve to biologics and immunomodula-
tors showed similar remission rates at weeks 26 and 52,491 and 
another study has shown efficacy of monotherapy with adalim-
umab in maintaining clinical remission for up to 4 years.492
A variety of studies on drug levels and immunogenicity have 
shown a difference between adalimumab monotherapy and 
combination treatment, with higher trough levels in patients on 
combination therapy with an immunomodulator,493 although 
clinical benefit was not shown. In the DIAMOND study there 
was a trend to higher trough drug levels and fewer antibodies 
against adalimumab with an improvement in endoscopic 
response at week 26, but not at 1 year.491 In another study 
higher trough levels were associated with endoscopic response 
statement 42. We recommend that mesalazine is not used 
for induction or maintenance of remission in Crohn’s disease 
(GRADE: strong recommendation, moderate-quality evidence. 
Agreement: 97.7%).
statement 43. We recommend that patients refractory to 
immunomodulator therapy despite dose optimisation should 
be considered for biological therapy. Choice between anti-TNF 
therapy, ustekinumab and vedolizumab should be made on 
an individual basis, considering patient preference, cost, likely 
adherence, safety data and speed of response to the drug 
(GRADE: strong recommendation, very low-quality evidence. 
Agreement: 95.7%).
statement 44. We recommend that combination therapy 
of infliximab with a thiopurine should be used as it is more 
effective than monotherapy infliximab in induction and 
maintenance of remission in active Crohn’s disease (GRADE: 
strong recommendation, high-quality evidence. Agreement: 
97.7%).
statement 45. We suggest that combination therapy 
of infliximab with methotrexate therapy may be used in 
Crohn’s disease to reduce immunogenicity (GRADE: weak 
recommendation, moderate-quality evidence. Agreement: 
90.5%).
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and mucosal healing at 6 and 12 months.494 In the PANTS 3-year 
observational cohort of 1601 Crohn’s disease patients treated 
with infliximab or adalimumab, immunogenicity to adalimumab 
was present in 11% at 1 year and 23% at 3 years, and was asso-
ciated with non-remission at week 5.481 Concomitant immuno-
modulator therapy reduced immunogenicity (HR 0.34, 95% CI 
0.21 to 0.56, p=0.0001). Combination therapy was particu-
larly beneficial in those patients with HLA-DQA1*05 who are 
more likely to develop antibodies against both adalimumab and 
infliximab.495 A study of UC and Crohn’s disease patients losing 
response to infliximab and adalimumab monotherapy showed 
anti-drug antibodies present in 61 (27%) of those on adalim-
umab. Of these, nine patients were given a thiopurine or meth-
otrexate, with six responding with restored clinical response, 
improved drug levels and loss of antidrug antibodies.496 Although 
it has not been possible to demonstrate the clinical benefits of 
combination therapy for adalimumab in the way it has been for 
infliximab combination therapy, there is evidence that concom-
itant immunomodulator therapy reduces immunogenicity and 
increases trough levels, which may be clinically beneficial for 
longer-term adalimumab maintenance therapy.
4.4.3.3 Choice of anti-TNF agent in Crohn’s disease
There is little to choose between adalimumab and infliximab 
in efficacy in luminal Crohn’s disease, and practical consid-
erations regarding mode and frequency of administration 
are the main factors as well as consideration of the relative 
need for combination therapy with an immunomodulator (see 
Section 5.2.4.1: Choice of anti-TNF agent). Certolizumab is 
not licensed for treatment of IBD in the UK and will not be 
discussed here.
4.4.3.4 Vedolizumab
Vedolizumab is a monoclonal antibody to the α4β7 integrin 
and blocks lymphocyte trafficking to the gut by blocking the 
binding of α4β7 to the mucosal addressin cell adhesion mole-
cule-1 (MAdCAM-1). It has been demonstrated as effective in 
inducing remission in the GEMINI-2 trial.497 Of 967 patients 
entering the randomised induction (Cohort 1) and open-label 
induction (Cohort 2), 461 (47.7%) had a CDAI fall of 70 points 
and entered the randomised maintenance phase. Pooled data 
from the ITT population of the GEMINI-2 and the GEMINI-3 
population (a 10-week induction study with dosing at weeks 0, 
2 and 6) presents induction outcomes at weeks 6 and 10, split 
into 277 TNF-naïve and 490 TNF-failure patients.498 Response 
rates (CDAI fall of 100 points) were better at week 10 on vedol-
izumab, with TNF-naïve patients responding better (48.4% on 
vedolizumab vs 30.1% on placebo) compared with TNF-failure 
(39.7% on vedolizumab vs 22.5% on placebo). Remission rates 
at week 10 were also better for TNF-naïve patients (26.6% on 
vedolizumab vs 15.4% on placebo) compared with TNF-failure 
(21.8% on vedolizumab vs 11.0% on placebo). Among induction 
responders who were re-randomised to placebo or two different 
maintenance vedolizumab dosing strategies, at week 52 clinical 
remission was achieved in 39% of patients receiving 8-weekly 
infusions and 36.4% of patients receiving 4-weekly infusions 
compared with 21.6% of patients in the placebo group.
A systematic review has also demonstrated that vedoli-
zumab was superior to placebo in induction and maintenance 
of remission in IBD and has an acceptable safety profile over 
the short term.499 Vedolizumab responders also appear to have 
persistence of benefit, with long-term follow-up data from 
the GEMINI-2 study showing that, of responders at week 6 
for whom data were available, 83% were in remission after 
2 years and 89% after 3 years.500 Observational studies have 
shown consistent findings—for example, a Scottish retrospec-
tive study of 153 patients had 1 year steroid-free remission of 
28.6%.501 The Swedish SWIBREG study reported 147 patients 
with active Crohn’s disease (86% of whom had previously 
failed anti-TNF therapy) showed 1 year clinical remission of 
54%.502 Recently reported real-world data suggest that higher 
rates of response with vedolizumab are more likely in patients 
with Crohn’s disease of ≤2 years duration in comparison to 
those with later stage disease >2 years.503 This study did not 
identify an association of response to vedolizumab with disease 
duration in UC.
In case of slow response to vedolizumab, prednisolone treat-
ment can be maintained initially, or other immunomodulator 
therapy used or continued for 6–8 weeks, but as yet there are 
few data to support this practice.
There are currently no head-to-head comparative trials 
published of anti-TNF therapy versus anti-integrin therapy. 
Due to heterogeneity in trial design and patient characteristics, 
results of network meta-analyses comparing different agents 
should be treated with some caution, and are no substitute for 
head-to-head comparisons.504 Using propensity score matching, 
269 patients with active Crohn’s disease in the VICTORY 
consortium were matched 1:1 with anti-TNF treated patients. 
At 1 year remission was observed in vedolizumab and anti-TNF 
treated patients in 38% and 34% respectively, HR 1.27 (95% 
CI 0.91 to 1.27), steroid-free remission in 26% and 18%, HR 
1.75 (95% CI 0.90 to 3.43), endoscopic healing in 50% and 
41% respectively, HR 1.67 (95% CI 1.13 to 2.47).505 Side 
effects of vedolizumab are discussed in the Section 5.2.5 Drug 
management: vedolizumab and ustekinumab. In biologics-naïve 
patients, anti-TNF therapy is currently likely to be an initial 
biologic choice, but there are situations where vedolizumab may 
be preferred (such as where there is an advantage of gut-spe-
cific immunosuppression, or use in older patients where infec-
tion and malignancy are a concern), but there are few data to 
support a clear benefit of anti-integrin therapy in any particular 
subgroup in Crohn’s disease as yet.
4.4.3.5 Ustekinumab
Ustekinumab is an anti-IL12/23 p40 antibody and has been 
evaluated in the UNITI and IM-UNITI studies in patients with 
Crohn’s disease. UNITI-1 enrolled patients who had prior 
anti-TNF failure (primary or secondary loss of response or 
intolerance). Clinical response at week 8 was 37.8% in those 
receiving ustekinumab 6 mg/kg (p<0.001 vs placebo), 33.5% 
with 130 mg (p=0.001 vs placebo) and 20.2% with placebo.506 
UNITI-2 enrolled patients who had no previous failure with 
anti-TNF drugs (mostly anti-TNF naïve, but a small number with 
previous successful use of anti-TNF therapy). Clinical response 
at week 8 was 57.9% for 6 mg/kg, 47.4% for 130 mg and 32.1% 
for placebo (p<0.001 vs both doses). Responders from both 
studies at week 8 were randomised to the IM-UNITI mainte-
nance arm. Of these randomised responders, 53.1% treated 
statement 46. We recommend that in Crohn’s disease, 
vedolizumab can be used in both anti-TNF naïve patients and 
in those where anti-TNF treatment fails. Choice of treatment 
in biologics-naïve patients should be individualised (GRADE 
for induction therapy: strong recommendation, moderate-
quality evidence; GRADE for maintenance therapy: strong 
recommendation, high-quality evidence. Agreement: 95.5%).
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with 90 mg subcutaneously every 8 weeks (p=0.005 vs placebo), 
48.8% given 90 mg subcutaneously 12-weekly (p=0.04 vs 
placebo) and 35.9% on placebo were in remission at 44 weeks. 
In total, 45% of those randomised to IM-UNITI were anti-TNF 
refractory. Of these, 41.1% were in remission at week 44 on 
ustekinumab 90 mg subcutaneously 8-weekly compared with 
26.2% on placebo (p=0.10).
Efficacy has been demonstrated in a retrospective observa-
tional GETAID study of 122 Crohn’s disease patients refractory 
to anti-TNF drugs. 65% had clinical benefit within 3 months, 
and in 68% of these, benefit was maintained at 12 months.507 A 
growing real-world experience confirms the benefit of usteki-
numab.508–512 Side effects of ustekinumab are discussed in the 
Section 4.9.5: Vedolizumab and ustekinumab therapy.
4.4.3.6 Choice of biological therapy after anti-TNF failure
To date there are no head-to-head studies comparing usteki-
numab and vedolizumab in patients with IBD who have failed 
anti-TNF therapy, but indirect comparisons suggest no differ-
ence in efficacy in this relatively treatment-refractory group.513
A consistent theme across multiple clinical trials in Crohn’s 
disease is that response rates are generally lower in patients with 
a longer disease duration,514 515 or who have proven refractory 
to other therapies.506 Given the reduced likelihood of response 
to therapies in patients who have medically refractory but surgi-
cally tractable disease (eg, limited ileocaecal inflammation), 
surgical approaches should be actively considered to restore 
quality of life and reduce the risk of complications resulting 
either from prolonged uncontrolled inflammation or from the 
use of multiple drug therapies often interspersed with multiple 
courses of corticosteroid therapy.
4.4.3.7 Corticosteroid use and infection risk while on anti-TNF 
therapy
The observational Crohn’s Therapy, Resource, Evaluation, and 
Assessment Tool registry (TREAT) was established to compare 
infliximab safety with conventional non-biological therapy.516 
Conventional immunomodulator therapies and anti-TNF thera-
pies were associated with an increased risk of infection, including 
serious and opportunistic infections. Nonetheless the greatest risk 
of infection, and with it an associated increase in mortality, was 
seen in patients on corticosteroid therapy (see Section 5.2.1.2: 
Common Disease Considerations, Infection risk in patients on 
anti-TNF therapy). Requirement for continuous corticosteroid 
therapy or repeated short courses in patients on biologics suggests 
that treatment may be failing, and consideration should be given 
to switching to an alternative (see Section 5.2.4.6: Common 
Disease Considerations, Secondary loss of response to anti-TNF 
therapy) or considering other options, including surgery.
4.4.4 Haematopoietic stem cell transplantation
Despite the increasing range of drugs available, there are still a 
number of Crohn’s disease patients with severe resistant disease 
or in whom surgical resection is not appropriate (usually due to 
extensive disease or incipient short bowel syndrome). For this 
group of patients, autologous haematopoietic stem cell trans-
plantation (HSTC) has been used. The ASTIC study, an RCT 
of autologous HSTC published in 2015, set a high bar for its 
primary end point (of sustained therapy-free clinical, endoscopic 
and radiological remission at 1 year) and failed to achieve it.517 
One of the 23 patients undergoing HSTC died and serious 
adverse events (particularly infection) were common, especially 
in individuals with perianal Crohn’s disease. Nonetheless in this 
treatment-refractory population there were, among the compo-
nent parts of the composite primary outcome, suggestions of 
benefit in some patients and further trial data are needed.518
4.4.5 Leucocyte apheresis
Although a number of uncontrolled studies have suggested 
possible efficacy of leucocyte apheresis in IBD, a randomised, 
double-blind controlled trial in 235 patients with moderate to 
severely active Crohn’s disease showed no benefit of granulo-
cyte/monocyte apheresis over sham apheresis.519
4.5 Proximal jejunal or extensive small bowel disease
Crohn’s disease proximal to the terminal ileum (L4) occurs in 
16% of Crohn’s disease patients, and of these about half will 
have jejunal involvement.520 Patients with jejunal involvement 
are more likely to have stricturing disease, and to require 
repeated surgery, compared with those who have oesophageal, 
gastric and/or duodenal disease or those with no disease above 
the terminal ileum.520 In a study of capsule endoscopy, patients 
with jejunal lesions (in addition to disease elsewhere) were more 
likely to have relapses over the next 2 years.521 In patients having 
small bowel surgery, those with jejunal disease have a higher 
recurrence rate, compared with those with ileocaecal disease.522 
As a consequence of poorer prognosis, patients with jejunal or 
extensive small bowel disease should be considered for early 
introduction of biological therapy.
statement 47. We recommend that ustekinumab can be used in 
the induction and maintenance of remission of Crohn’s disease, 
both in anti-TNF naïve patients and in those where anti-TNF 
treatment fails. No direct comparison data are available with 
other biological therapies (GRADE: strong recommendation, 
high-quality evidence. Agreement: 97.7%).
statement 48. We suggest that, where a switch from anti-TNF 
therapy to a different drug class is required in Crohn’s disease, 
the choice to use vedolizumab or ustekinumab may be made on 
an individual basis. Factors to be included in the decision-making 
process should include patient preference, cost, likely adherence, 
safety data and speed of response to the drug. The potential for 
surgery as an alternative to further drug therapy should also be 
considered (GRADE: weak recommendation, very low-quality 
evidence. Agreement: 97.8%).
statement 49. Patients with Crohn's disease treated with a 
biological therapy in optimal dose who remain corticosteroid-
dependent (particularly if on triple immunosuppression 
with immunomodulator therapy) are at significant risk of 
opportunistic infections. We recommend that alternative 
medical treatments or surgery should be explored (GRADE: 
strong recommendation, moderate-quality evidence. Agreement: 
97.8%).
statement 50. We recommend that leucocyte apheresis is not 
used for active Crohn’s disease due to lack of efficacy (GRADE: 
strong recommendation, high-quality evidence. Agreement: 
100%).
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4.6 upper gastrointestinal Crohn’s disease
A multidisciplinary international expert panel (European Panel 
on the Appropriateness of Crohn’s Disease Therapy, EPACT 
II) published guidance on the management of special situations 
in Crohn’s disease in 2009, including upper gastrointestinal 
disease.523 No discrimination was made between oesophageal, 
gastric or duodenal disease, and limited evidence was provided in 
support of recommendations. However, the group split guidance 
into patients with stenosis and those without, with recommen-
dation that Helicobacter pylori be sought and eradicated in all.
In the absence of stenosis, proton pump inhibitors (PPI) were 
recommended as first-line therapy, with steroids second-line, 
and thiopurines and infliximab as third-line. Adalimumab was 
deemed of uncertain benefit. 5-ASA, certolizumab, surgery and 
natalizumab were deemed inappropriate.
In the presence of stenosis, balloon dilatation was recom-
mended as first-line therapy, with PPI second-line, and steroids/
thiopurines/surgery as third-line. Infliximab was deemed of 
uncertain benefit.
Nutritional support is often needed, and may be best delivered 
by gastrostomy tube for severe or stricturing disease. Exclusive 
enteral nutrition is beneficial, especially in children. In isolated 
oesophageal disease, alternative diagnoses should be consid-
ered, including gastro-oesophageal reflux disease, sarcoidosis, 
tuberculosis, disseminated fungal disease, Behçet’s disease and 
malignancy.524
4.6.1 Orofacial granulomatosis
Orofacial granulomatosis (OFG) is a rare disease with similar 
microscopic appearances to intestinal Crohn’s disease. Granulo-
matous inflammation is found in about two-thirds of biopsies in 
OFG but is not needed for a diagnosis.525 The precise relation-
ship between OFG and Crohn’s disease remains uncertain, with 
oral Crohn’s disease and OFG terminology often overlapping.
Gastroenterologists have been reported to miss around half 
of oral lesions compatible with oral Crohn’s disease when 
compared with dentist examination.526
The threshold for luminal assessment should probably be 
lower in younger patients, where positive findings are more 
likely. Sarcoidosis, tuberculosis and chronic infection (partic-
ularly dental-associated infection) should be considered in the 
differential diagnosis. Patients should be referred for assessment 
to an oral medicine clinic.
The current evidence for OFG management relates to case 
series only. Topical steroids and tacrolimus are often used, but 
with limited evidence. An 8-week cinnamon and benzoate-free 
diet was reported in 25 patients with OFG as first-line therapy 
with 72% responding, but with flares on further consumption of 
previously eliminated cinnamon/benzoate-containing foods.527 
The mechanism of this effect remains unclear and the long-term 
continuation of such a diet is challenging. Six weeks of exclu-
sive enteral nutrition (EEN) with Elemental 028 has been used 
successfully to treat 19 of 22 children with OFG, with 10/10 
of isolated OFG cases and 10/12 cases with OFG and Crohn’s 
disease responding.528 Objective criteria for improvement were 
not reported in this study. Such a diet would naturally elimi-
nate cinnamon and benzoate, so may be overly-exclusive in 
some patients who might have responded to a more targeted 
elimination.
In a retrospective cohort of 22 non-Crohn’s disease OFG 
patients treated with intralesional triamcinolone injection, 
63.6% of patients had no disease recurrence after a single course 
of injections.529 The mean disease-free period after therapy was 
28.9 months (95% CI 28.7 to 29.1). Response to azathioprine 
in OFG was significantly greater in those with Crohn’s-associ-
ated disease.530 A small case series of 14 OFG patients, half with 
Crohn’s disease, treated with infliximab suggested 71% short-
term response, but only 33% were still responding at 2 years.531 
Two patients with loss of response subsequently responded to 
adalimumab.
It would seem pragmatic to treat systemic Crohn’s disease with 
standard therapies in the presence of OFG and to add dietary, 
topical or intralesional approaches if there is no response. 
Conversely, systemic treatment of isolated OFG should be 
conserved for disease unresponsive to more limited approaches.
4.7 stricturing disease
For guidance on imaging see the Section 4.1.3.3 Crohn’s disease, 
Diagnostic tests, Investigation of strictures.
4.7.1 Medical therapy for strictures
The CREOLE study evaluated 97 Crohn’s disease patients 
with symptomatic small bowel strictures and assessed response 
to adalimumab treatment. Treatment was successful at week 
24 in 64% of patients, and a prognostic score at baseline was 
constructed. This included clinical features (use of immuno-
suppressive drugs at baseline, obstructive symptoms, severity 
and duration, and MRE features (length of stricture <12 cm, 
an intermediate proximal small bowel dilatation (18–29 mm), 
statement 54. We suggest that patients presenting with 
features of orofacial granulomatosis (OFG) and gastrointestinal 
symptoms, raised inflammatory markers or raised faecal 
calprotectin should have the gastrointestinal tract investigated 
for inflammation (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 100%).
statement 51. Patients with jejunal or extensive small bowel 
disease have a worse prognosis. We suggest that they may 
be considered for early use of biological therapy, and should 
have nutritional assessment and support (GRADE: weak 
recommendation, very low-quality evidence. Agreement: 100%).
statement 52. We suggest that mild gastroduodenal Crohn’s 
disease may be treated with proton pump inhibitors. We suggest 
that moderate or severe disease may also require treatment 
with corticosteroids, and other immunosuppressive or biological 
therapies as for Crohn’s disease elsewhere in the gut (GRADE: 
weak recommendation, very low-quality evidence. Agreement: 
92.7%).
statement 53. We suggest that mild oesophageal Crohn’s 
disease may be treated with proton pump inhibitors. Nutritional 
assessment and support is essential. A short course of 
corticosteroids may be required if symptoms worsen, but early 
anti-TNF therapy should be considered for ongoing moderate 
to severe disease. Oesophageal dilatation should be used for 
strictures, and surgery is a last resort for disease refractory 
to all medical therapy (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 97.6%).
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marked enhancement on delayed T1-weighted sequence and 
absence of fistula). A higher score was associated with greater 
likelihood of response to therapy. The authors emphasised the 
complexity of assessing inflammation and stricturing, which 
nearly always occur together, and the value of both clinical and 
MRI features in deciding the value of using drug therapy rather 
than surgery for small bowel strictures.532
Small bowel bacterial overgrowth is common in small bowel 
Crohn’s disease,533 particularly in areas above strictures, and 
responds to broad-spectrum antibiotics534 535 (for further 
detail see the Section on 4.10.1.2.2 Post-surgical management 
of Crohn’s disease: Small intestinal bacterial overgrowth). For 
nutritional advice for patients with strictures see box 8.
4.7.2 Surgical therapy for strictures
Rates of surgery for Crohn’s disease appear to be declining.536 537 
Patient selection and outcomes in stricturing disease can be opti-
mised by careful assessment of fibrotic burden538 as well as due 
consideration of alternatives including endoscopic therapy,539–542 
and decisions are best taken with joint input from all MDT 
members. As discussed above, a prognostic score based on MRE 
features and clinical factors can help in predicting the likely 
response to anti-TNF therapy. A moderate degree of dilatation 
proximal to the stricture is associated with greater likelihood of 
response than either massive dilatation or, rather surprisingly, no 
dilatation. Having more marked obstructive symptoms, but with 
a shorter duration, is also associated with success of anti-TNF 
therapy.532
4.7.3 Strictureplasty
Strictureplasty, a technique for surgical treatment of small bowel 
strictures without loss of bowel length, is indicated with single 
or multiple strictures, impending short gut or previous extensive 
small bowel resection. The presence of fistulae, fistula-associated 
abscesses or possible carcinoma are contraindications. The pres-
ence of active inflammation at the stricture site does not prevent 
successful strictureplasty.543 Strictureplasty is not associated with 
increased recurrence or re-operation rates.544–546 In fact, there is 
evidence re-operation rates may be lower at strictureplasty than 
resection sites,547 although a meta-analysis of seven studies (688 
patients) from 2006 showed a non-significant trend to lower 
risk of complications if strictureplasty alone was performed, but 
a non-significant trend to increased recurrence after stricture-
plasty and significantly longer recurrence-free survival for those 
having a bowel resection.548 The conventional Heineke–Miku-
licz strictureplasty is generally used for strictures up to 10 cm 
length, with intermediate length (10–25 cm) using a modified 
technique such as the Finney procedure and an enteroenteros-
tomy (Michelassi procedure) for longer strictures.538 549 The 
newer techniques are generally as safe and effective as the 
conventional strictureplasty.550
If multiple small bowel strictures can be dealt with by a single 
resection in a patient with adequate bowel length elsewhere, 
then this is preferable to avoid a complex multiple strictureplasty 
procedure, but such decisions have to be individualised, consid-
ering the patient’s condition at the time of surgery (corticosteroid 
and immunosuppressive drug use, serum albumin, anaemia, 
nutritional status), potential for postoperative complications 
from complex surgery and the risk of future malabsorption and 
malnutrition due to short gut.538 550 551
4.7.4 Endoscopic therapy for strictures
Endoscopic balloon dilatation may prevent or delay the need 
for surgical resection or strictureplasty for Crohn’s disease-re-
lated intestinal strictures, including anastomotic strictures. A 
key concern is the long-term outcome, in particular the need for 
surgical resection. A systematic review identifying 24 published 
studies reported outcomes from 1163 patients, with overall 
surgical intervention rates over a median follow-up period of 
15–70 months of 27%.541 Surgical intervention rates were higher 
after dilatation of primary strictures, but this did not reach statis-
tical significance. Stricture length <4 cm was associated with 
a significant reduction in the need for surgical intervention. 
However, in a different systematic review of largely the same 
primary papers, 25 studies with data on 1089 undergoing a total 
of 2664 dilatations estimated the cumulative rate for surgery 
after 5 years of follow-up as 75%, leading the authors to suggest 
caution around use of the technique.542 However, this figure 
may overestimate the ultimate requirement of surgery as 5-year 
follow-up data were only available in 455 patients, who may 
have remained in follow-up due to a more complicated disease 
course. The authors did not find any association between stric-
ture subtype and outcomes.
A small study has shown benefit of intralesional injection 
of corticosteroids at the time of balloon dilatation of Crohn’s 
disease strictures,552 but further studies have not shown 
benefit.553 554
4.8 non-perianal fistulising Crohn’s disease and abscesses
4.8.1 Intra-abdominal abscesses
4.8.2 Medical therapy
In the first instance, patient optimisation is required when local-
ised perforation in Crohn’s disease has led to abscess forma-
tion. Surgical intervention is mandatory within the context of 
free peritonitis and highly likely to be required at some stage 
in the setting of localised abscess formation. Ideally, surgery 
takes place following treatment of sepsis and treatment of nutri-
tional deficiencies. Exclusive enteral nutrition can be an effec-
tive means of controlling intestinal inflammation without use of 
corticosteroids.
Some observers suggest that surgery may be avoided by percu-
taneous radiological drainage of abscesses and then resumption 
Good Practice recommendation 8. Patients with stricturing 
small bowel Crohn’s disease should have joint medical and 
surgical assessment to optimise medical therapy and plan 
requirement for surgical resection or strictureplasty (Agreement: 
100%).
statement 55. We recommend that strictureplasty is an 
alternative to resection in patients with small bowel Crohn’s 
disease strictures shorter than 10 cm, and is useful where there 
are multiple strictures or a need to preserve gut length. Longer 
strictures can be treated using non-standard strictureplasty 
techniques (GRADE: strong recommendation, very low-quality 
evidence. Agreement: 97.3%).
Good Practice recommendation 9. If there are multiple 
strictures close to each other in a segment of bowel and there 
is adequate remaining healthy bowel, a single resection may be 
preferable to multiple strictureplasties (Agreement: 100%).
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of medical therapy.555 The largest case series to date of 51 
patients identified retrospectively from review of medical charts 
from a single centre over a 10-year period has shown that 
patients undergoing surgical resection were significantly less 
likely to develop abscess recurrence than those treated with anti-
biotics alone or percutaneous drainage over a mean follow-up 
of 3.75 years (12% vs 56%).556 Nevertheless, non-surgical 
approaches were successful in preventing subsequent surgery in 
almost half of the patients treated medically. An almost identical 
proportion of patients avoided surgery over long-term follow-up 
in a different series of 32 patients managed with percutaneous 
drainage for perforating Crohn’s disease.557 This strategy, if 
successful in treating sepsis, is likely to lead to lower morbidity 
and potentially lower stoma rates.
4.8.3 Enterovaginal and enterovesical fistulae
Data on the management of non-perianal fistulae, especially from 
randomised trials, are limited. There are even more limited data 
on the outcomes of patients treated for specifically entero-gy-
naecological or enterovesical fistula. Although these fistulae are 
rare, they are a serious problem to patients with Crohn’s disease. 
A systematic literature review showed that response to medical 
therapy (fistula closure) was complete in 38.3% of rectovaginal 
fistulae and 65.9% of enterovesical fistulae.558 For enteroves-
ical fistulae, risk factors for the need for surgical intervention 
include sigmoid origin and other complications of Crohn’s 
disease including small bowel obstruction, abscess formation, 
other fistulation, ureteric obstruction or urinary tract infec-
tion.559 These authors suggest that enterovesical fistulae should 
be treated medically initially, with surgery reserved for those 
with bowel obstruction or abscess formation, non-responders 
or recurrence after medical therapy. In a series of 47 patients 
with genital fistulae, antibiotics had no lasting benefit, thiopu-
rines resulted in 13% complete and 24% partial response, and 
anti TNF-alpha therapy gave 17% complete and 30% partial 
response. Surgery was undertaken in a third of patients, but only 
22% had complete response after a first operation and 39% after 
reintervention. Overall, fistula closure was only achieved in a 
third of patients.560
These studies highlight that there is still very limited evidence 
on which to base specific management guidance, but medical 
therapy alone or in combination with surgery would appear to 
offer benefit to some patients in the management of enterovag-
inal and enterovesical fistulae. Patients should be discussed in 
multidisciplinary meetings and treatment individualised, consid-
ering patients’ symptoms and situation.
4.8.4 Enteroenteric fistulae
Enteroenteric fistulae are often asymptomatic and expert 
consensus guidelines have recognised that these do not always 
require surgery.561
4.8.5 Enterocutaneous fistulae
Enterocutaneous fistulae usually communicate with segments 
of active Crohn’s inflammation, often in the context of other 
complications including intra-abdominal abscess and luminal 
strictures, or with surgical anastomoses (as a manifestation of 
the poor healing which characterises Crohn’s disease). Histori-
cally, enterocutaneous fistulae were treated surgically but, with 
the advent of anti-TNF therapy, conservative approaches can 
be deployed and may lead to definitive fistula closure in some 
patients. There are no prospective trial data to guide therapy. 
Both the fistulae and any associated complications will need 
to be managed together. For example, in the context of a high 
output fistula with nutritional deficiency and luminal stricture, 
a patient will require a period of nutritional and biochemical 
optimisation, control of sepsis and drainage of collections before 
definitive surgical management.562 563
There is little formal evidence on the role of immunosup-
pressive therapy. If a fistula is associated with active inflam-
mation then medical therapy is worthwhile, but it is unlikely 
to help a postoperative fistula.564 A retrospective series of 48 
patients with enterocutaneous fistula from GETAID included 
21 postoperative fistulae (within 30 days of surgery, most but 
not all of which were intestinal resections).565 One third had 
multiple tracts and one quarter had high output. In addition to 
managing the associated complications, patients were treated 
with anti-TNF therapy. One third had fistula healing, half of 
whom relapsed over a median follow-up of 3 years. One third 
of patients developed an intra-abdominal abscess while on 
anti-TNF therapy. Surgery was required in 54% of patients 
overall. Complexity (multiple tracts) and associated stenosis 
were associated with reduced rates of healing with anti-TNF 
therapy and increased need for surgery. Increasing complexity 
of the fistula is associated with adverse outcomes including 
mortality.566 All patients with enterocutaneous fistulae should 
be managed by a multidisciplinary team.
4.8.6 Anti-TNF therapy for non-perianal fistulae
Higher quality evidence is available for infliximab relative 
to adalimumab for the use of anti-TNF therapy in the setting 
of non-perianal fistulising Crohn’s disease. The ACCENT II 
statement 58. We recommend that enterovaginal and 
enterovesical fistulae should be managed jointly with medical 
control of inflammation and surgical resection (GRADE: strong 
recommendation, very low-quality evidence. Agreement: 100%).
statement 56. We suggest that balloon dilatation is an 
appropriate treatment for ileocolonic anastomotic strictures 
less than 4 cm in length, without sharp angulation and with 
non-penetrating disease, although the majority will require 
repeated dilatation. Endoscopically accessible ileal strictures are 
also amenable to balloon dilation, but complication rates and 
recurrence rates are higher (GRADE: weak recommendation, 
low-quality evidence. Agreement: 94.4%).
statement 57. We suggest that intra-abdominal abscesses 
complicating Crohn’s disease may be treated initially with 
intravenous antibiotics and where possible radiological drainage. 
Surgical drainage may be required but immediate resection 
should be avoided (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 91.9%).
Good Practice recommendation 10. Following treatment of 
an abdominal abscess in the setting of non-perianal fistulising 
Crohn’s disease, joint medical and surgical discussion is 
required, but interval surgical resection is not always necessary 
(Agreement: 100%).
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trial included 25 women with a total of 27 draining rectovag-
inal fistulae at baseline.567 Closure at week 14 after open label 
infliximab induction therapy was achieved for 45% of fistulae. 
Randomisation to infliximab during maintenance therapy was 
associated with a longer duration of fistula closure compared 
with placebo therapy (median 46 weeks vs 33 weeks). Outcomes 
for patients in ACCENT II with enterocutaneous fistulae have 
not been reported separately, but these patients represented 
less than 10% of the total cohort. Adalimumab has never been 
subjected to a randomised control trial of efficacy in fistulising 
Crohn’s disease.
4.9 Perianal Crohn’s disease
4.9.1 Assessment of perianal disease
Multidisciplinary team working in perianal Crohn’s disease 
is widely regarded as best practice according to expert 
consensus.561
Pelvic MRI has a well-recognised role in defining the anatomy 
of perianal fistulae as an adjunct to examination under anaes-
thesia (EUA). Initial reports of sensitivity compared with EUA 
suggested rates of 85–89%.568–570 MRI may also pick up a signif-
icant burden of non-fistulising perianal disease that would other-
wise be missed clinically.570 571 Endoanal ultrasound has also 
shown high sensitivity, although use is limited in patients with 
anal or other luminal stenoses.569 570 Interpretation of fistula 
imaging (MRI or endoanal ultrasound) is dependent on operator 
expertise.
An experienced colorectal surgeon should perform EUA to 
assess perianal disease and identify the anatomy of the fistula 
tracts, as specialist expertise and knowledge are likely to 
improve identification of all tracts.569 572 573 In a comparison 
with endoscopic ultrasound and MRI, an experienced operator 
correctly classified 91% of patients’ perianal fistulae at EUA 
(95% CI 75% to 98%).569 However, a combination of two tests 
from MRI, endoanal ultrasound and EUA is recommended to 
give the optimal assessment.574 Specifically, unless directed by 
the results of MRI or endoanal ultrasound, then small abscesses 
or collections may be missed, particularly if there is significant 
induration or a supralevator collection.574 EUA is more sensi-
tive than MRI in assessment of anal ulceration or anal canal 
stenosis.571
Assessment of rectal mucosa at the time of EUA is 
important.572 575 Largely observational data, but with a large 
effect size, from the pre-biologics era show that outcomes are 
worse for perianal fistulising disease associated with rectal 
inflammation. A study from St Mark’s of perianal fistulising 
Crohn’s disease patients diagnosed in 1993–4 showed that 29% 
of those with rectal involvement had proctectomy compared 
with 4% of those with no rectal involvement.576
4.9.2 Seton insertion
EUA permits drainage of abscesses and placement of setons, 
with evidence that placing setons prior to starting anti-TNF 
therapy improves rates of healing and reduces recurrence 
rates.577–579 A recent meta-analysis confirmed the benefits of 
combined surgical and medical therapy in improving healing and 
makes recurrent abscess less likely.580 The exception to routine 
insertion of setons would be patients with rectovaginal fistulae 
in the absence of an abscess or collection. In this situation, setons 
may make faecal discharge per vagina worse.
Evidence for the timing of seton removal is unclear. Early 
studies removed setons at or shortly after the second infliximab 
infusion.567 577 579 More recent studies suggest later removal, 
either after completing infliximab induction therapy581 or after 
at least five infusions.582 Setons need to be removed to permit 
complete healing of fistula tracks, but if active inflammation is 
ongoing, then seton removal may result in recurrent abscess. 
The optimal timing and assessment method remain unclear, 
and some patients may require long-term setons to avoid or 
delay proctectomy. Further trials are needed to better under-
stand the optimal management of perianal fistulae in Crohn’s 
disease.583 584
4.9.3 Anti-TNF therapy post-surgery for complex perianal fistulae
4.9.3.1 Infliximab for perianal fistulising disease
Higher level evidence is available for infliximab relative to adali-
mumab for complex perianal fistulae following initial surgical 
management, such as draining abscesses and seton placement. 
Use of infliximab has been shown to be effective for the closure 
of perianal fistulae. In a study of 94 patients with Crohn’s disease 
and abdominal or perianal fistulae, induction therapy with 5 mg/
kg or 10 mg/kg was associated with complete fistula closure rates 
of 55% and 38% compared with 13% placebo.585 In the subse-
quent ACCENT II trial, this induction response was confirmed 
in an open-label phase, with fistula closure in 69% of patients at 
14 weeks. Subsequent randomisation to infliximab was associ-
ated with a significantly longer median time to loss of response 
compared with patients randomised to placebo (>40 weeks vs 
14 weeks), with 36% of patients completing this maintenance 
phase showing a complete absence of draining fistulae after 
54 weeks of infliximab treatment compared with 19% of placebo 
patients (p=0.009).567
Higher infliximab doses may be beneficial for perianal fistu-
lising disease, with target levels >10 µg/mL associated with 
better response.586
4.9.3.2 Adalimumab for perianal fistulising disease
Fistula closure or improvement has not been the primary 
outcome of any prospective randomised trials of adalimumab. 
The CHARM trial showed increased efficacy compared with 
placebo for closure of abdominal or perianal fistulae as a 
statement 59. We suggest that low volume enterocutaneous 
fistulae may be controlled with immunomodulator and biological 
therapy. High-volume fistulae usually require surgery to 
achieve symptom control (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 100%).
statement 60. We suggest that anti-TNF therapy may be used 
to control inflammation or maintain remission in the setting 
of non-perianal fistulising Crohn’s disease (GRADE: weak 
recommendation, low-quality evidence. Agreement: 94.6%).
statement 61. We recommend that anti-TNF therapy should 
only be started after abscesses have been treated with 
antibiotics and, where possible, drainage (GRADE: strong 
recommendation, very low-quality evidence. Agreement: 94.9%).
Good Practice recommendation 11. Multidisciplinary 
decision-making should be the standard of care for patients with 
perianal Crohn’s disease (Agreement: 97.4%).
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secondary end-point, but outcomes for fistula subtypes have not 
been reported. At baseline there were 117 patients with draining 
fistulae. All patients received open-label induction therapy with 
adalimumab and were then randomised to maintenance therapy 
with adalimumab or placebo. Complete fistula closure at week 
56 was seen in 33% of subjects on adalimumab versus 13% 
on placebo (p=0.016).486 Of all those with healed fistulae at 
week 56 (including those on placebo), 90% (28/31) maintained 
healing after a year of open-label adalimumab.587
A randomised controlled trial in which 76 patients with 
active perianal fistulising disease received open-label therapy 
with 24 weeks adalimumab in combination with either cipro-
floxacin 500 mg BD for 12 weeks or placebo found that, after 
12 weeks, the primary end-point of 50% reduction in draining 
fistulae was achieved in 71% in the combination adalimumab/
ciprofloxacin group against 47% in the adalimumab/placebo 
group (p=0.047).588 However, by week 24 (ie, 12 weeks after 
cessation of antibiotic therapy) the difference between the two 
groups was no longer significant. This suggests the addition of 
an antibiotic may speed healing but not affect the final outcome. 
Further evidence is required before this can be recommended as 
routine practice.
4.9.4 Combined surgical treatment with anti-TNF therapy
None of these studies included initial surgical interventions for 
the management of fistula tracts. No randomised controlled trial 
has compared these treatments directly or attempted to evaluate 
the additional benefit of combination therapy compared with 
treatment with either surgery or anti-TNF alone. Nevertheless, 
comparison between these approaches has been the subject of 
several retrospective studies which have recently been system-
atically reviewed. Although significant heterogeneity between 
individual studies limits interpretation, there is a consistent 
trend towards improved outcomes with combined surgical and 
anti-TNF treatment.580 583 Careful preparation of the fistula 
track with curettage to destroy all epithelial tissue and ligation 
of the internal opening as standard treatment in both active and 
control arms of one trial of mesenchymal stem cells achieved a 
‘placebo’ (surgical preparation only with no active medical treat-
ment) success rate of 34% at week 24.589 It is highly likely that 
multiple treatment modalities will be needed to control perianal 
fistulae in Crohn’s disease.590
4.9.5 Vedolizumab and ustekinumab therapy
Post hoc analysis of 57 patients with fistulae (site not specified) in 
the GEMINI 2 study showed higher rates of closure of draining 
fistulae at 1 year: 41.2% on 8- weekly vedolizumab (p=0.03 vs 
placebo) and 22.7% on 4- weekly vedolizumab (not significant 
vs placebo).497
Data for outcomes for those patients with fistulae at baseline 
in the CERTIFI phase 2o and UNITI phase 3 studies of usteki-
numab have been reported in abstract form, showing a non-sig-
nificant trend towards improved fistula healing in patients 
randomised to ustekinumab compared with placebo.591 Addi-
tional data suggesting healing with ustekinumab come from 
relatively small case series of TNF refractory patients.507 508 592 
Further controlled trial data are needed to confirm the role of 
ustekinumab in perianal fistula healing.
4.9.6 Surgical treatment of fistulae
In a survey of British surgeons, commonly performed defini-
tive procedures in the context of perianal Crohn’s disease were 
removal of draining seton only (70.7%), fistulotomy (57.1%), 
and less commonly advancement flap (38.9%), fistula plug 
(36.4%) and the ligation of intersphincteric track (LIFT) proce-
dure (31.8%).593 The reported efficacy of curative surgical 
options within the context of perianal Crohn’s disease is vari-
able. Advancement flaps and the LIFT technique are effective 
in selective patients with perianal Crohn’s disease, with healing 
observed in two-thirds of patients at 1 year in a small prospective 
study.594 There is, however, progressive failure over time, related 
to both treatment failure and recurrent disease.595 Video-assisted 
anal fistula treatment (VAAFT) combined with advancement 
flap has been reported in complex fistulising Crohn’s disease 
with an 82% success rate at 9 months.596 Systematic review has 
demonstrated fistula plugs may be effective in 55% of Crohn’s 
disease-related fistulae,597 although variation in reported success 
is wide. A prospective randomised control trial of fibrin glue 
in 36 patients with Crohn’s disease perianal fistulae showed 
effective therapy in 38% after 8 weeks.598 In comparison, just 
16% of those under observation only after removal of seton 
achieved remission (p=0.04). The benefit was greater in patients 
with simple fistulae. Administration of expanded adipose-de-
rived stem cells in addition to fibrin glue appears more effective 
than fibrin glue alone.599 The long-term efficacy of fibrin glue, 
collagen plugs and paste is not clear.
4.9.7 Allogeneic adipose-derived stem cell therapy for perianal 
fistulae
Expanded allogeneic adipose-derived stem cells are simple to 
administer and safe.600 In a recent phase III study, 212 patients 
with treatment-refractory complex perianal fistulising Crohn’s 
statement 62. We recommend that pelvic MRI is used as 
an important adjunct to clinical assessment and examination 
under anaesthesia (by an experienced surgeon) in evaluation 
of fistulising perianal Crohn’s disease. Depending on local 
availability and expertise, endoanal ultrasound may also be 
used (GRADE: strong recommendation, high-quality evidence. 
Agreement: 100%).
statement 63. We recommend that examination under 
anaesthesia should include an assessment of the rectal mucosa 
as the presence of proctitis is associated with lower rates of 
fistula healing in perianal Crohn’s disease (GRADE: strong 
recommendation, high-quality evidence. Agreement: 100%).
statement 64. We recommend that setons should be placed to 
prevent re-accumulation of perianal sepsis in fistulising Crohn’s 
disease (GRADE: strong recommendation, moderate-quality 
evidence). The optimal timing of seton removal is uncertain 
(Agreement: 97.1%).
statement 65. We recommend that infliximab is used as 
the first-line biological therapy for complex perianal fistulae, 
and should be started as soon as adequate drainage of sepsis 
is achieved (GRADE: strong recommendation, high-quality 
evidence. Agreement: 100%).
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disease were randomly assigned to a single intralesional injection 
of 120 million Cx601 cells (darvadstrocel) or placebo.589 Both 
active and control groups had an initial EUA with curettage of 
fistula tracts, and insertion of setons if needed, followed at least 
2 weeks later by a further EUA with ligation of the internal fistula 
opening and injection of the trial treatment into the tissue adja-
cent to all fistula tracts. Week 24 complete remission rate was 
50% for active treatment versus 34% for placebo (p=0.024). 
The high placebo response rate likely reflects the extensive 
surgical interventions received by the placebo group including 
curettage of the fistula tract and closure of the internal opening. 
Of note, failure of anti-TNF therapy was not a requirement for 
study entry, but rather patients had to have failed at least one 
of antibiotics, immunomodulator therapy or anti-TNF therapy. 
In fact, 79% of patients in this trial had been on an anti-TNF in 
the previous 6 months and 61% were on anti-TNF therapy at 
the point of randomisation. One-year outcome data demonstrate 
combined remission (closure of all treated external openings that 
were draining at baseline, and absence of collections >2 cm on 
MRI) of 56.3% in the darvadstrocel group, versus 35.6% in 
the placebo group (p=0.021). Clinical remission at 1 year was 
59.2% and 41.6% respectively (p=0.013).601 Other groups have 
reported promising data with alternative preparations of allo-
genic stem cells, reviewed recently.602 Given the complexity of 
appropriate patient selection, management of luminal disease, 
surgical technique, selection of adjunct therapies and choice of 
stem cell preparation, patients offered these therapies should be 
closely monitored as part of a clinical trial or registry.
4.9.8 Defunctioning stoma formation
Creation of a defunctioning stoma has long been recognised 
to offer rapid improvement of perianal Crohn’s disease, even 
in complex cases. The mechanism likely relates to diversion of 
the faecal stream, which of itself seems to contain factors that 
promote rectal inflammation.603 Evidence is limited to expert 
opinion, supported by several case series.604–607 Although many 
of these series originate from a pre-biologics era, more recent 
data suggest that rates of successful stoma reversal after ileos-
tomy for complex perianal Crohn’s disease are low.608 609 A 
systematic review showed that faecal diversion improves symp-
toms in approximately two-thirds of patients, but bowel resto-
ration is only successful in 17%.610 Rates of successful reversal 
may be particularly low in those with rectal involvement.610 It 
should be noted that, after initial improvement, recurrence of 
inflammation can occur in the pelvis and defunctioned segment 
of bowel, and may present non-specifically with weight loss, 
raised inflammatory markers and fevers. For severe refractory 
disease, proctectomy is an effective treatment, but considered by 
expert consensus to be a last resort.607
4.10 Post-surgical management of Crohn’s disease
4.10.1 Disease recurrence following ileocolonic resection
In a study of factors predictive of recurrent disease after ileo-
caecal resection there was a symptomatic recurrence rate of 20% 
at 1 year and 47% at 5 years. There was a rapid development of 
endoscopic lesions in the neoterminal ileum (73% at 1 year).359 
Risk factors for disease recurrence are discussed in the section 
below on medical prophylaxis (see Section 4.10.3: Reassessment 
and medical prophylaxis following ileocolonic resection).
4.10.1.1 Investigation for symptomatic recurrence following 
ileocolonic resection
After resection for Crohn’s disease of all inflamed tissue, the 
cumulative rate of symptomatic recurrence at 3 years is approx-
imately 50%.359 Patients presenting with new symptoms of pain 
or diarrhoea after resection should be evaluated to confirm 
whether recurrent disease is the cause, as the differential diag-
nosis includes bile salt malabsorption and irritable bowel 
syndrome. Although ileocolonoscopy is the gold standard assess-
ment to determine postoperative recurrence, there are times 
when it is not appropriate or technically possible and cross-sec-
tional imaging may be needed. There is good agreement between 
assessment by MR enteroclysis and endoscopy: mean observer 
agreement was seen in 77.8% (kappa 0.67) in the diagnosis of 
postoperative recurrence.611 In experienced hands, small bowel 
ultrasound is predictive of endoscopic findings,612–614 with 
good correlation to the Rutgeerts score.615 While CT has also 
been shown to be effective in identifying postoperative recur-
rence,616 617 it should be avoided where possible to limit radia-
tion exposure.
Faecal calprotectin and lactoferrin in postoperative Crohn’s 
disease patients correlate well with clinical disease activity as 
measured by the Harvey Bradshaw Index, whereas the correla-
tion with C-reactive protein was weaker.618 There was, however, 
low sensitivity and specificity of the stool tests, particularly in 
those with mild or moderate clinical symptoms. In addition, this 
study did not show that faecal calprotectin was predictive of 
endoscopic (rather than clinical) recurrence. In the POCER trial, 
faecal calprotectin correlated with endoscopic recurrence, with 
a level >100 µg/g stool indicating endoscopic recurrence with 
a sensitivity of 89% and negative predictive value of 91%.619 A 
further multicentre observational cohort study of 86 asymptom-
atic Crohn’s disease patients following ileocaecal resection also 
identified a cut-off of faecal calprotectin of 100 µg/g as best to 
discriminate between endoscopic recurrence versus remission.620 
In this study the sensitivity, specificity, negative predictive value, 
positive predictive value and overall accuracy at 100 µg/g were 
95%, 54%, 69%, 93% and 77%, respectively. The TOPPIC 
Good Practice recommendation 12. Surgical options for 
perianal Crohn’s disease fistulae (advancement flap, LIFT, infill 
procedures) should only be offered in selected patients after 
counselling as long-term results are poor, particularly for those 
with complex disease and ongoing disease activity. (Agreement: 
97.1%).
statement 66. We recommend that faecal stream diversion 
can be used in patients with severe perianal Crohn’s disease 
refractory to medical therapy. Patients should be counselled that 
rates of subsequent successful reversal are low and proctectomy 
may ultimately be required (GRADE: strong recommendation, 
low-quality evidence. Agreement: 100%).
statement 67. We suggest that, in the event of symptomatic 
recurrence following ileocolonic resection for Crohn’s disease, 
an assessment of mucosal inflammation may be performed 
with ileocolonoscopy. Faecal calprotectin and/or cross-sectional 
imaging may be used if ileocolonoscopy is not possible or 
acceptable, but may not be sensitive enough to detect localised 
inflammation (GRADE: weak recommendation, low-quality 
evidence. Agreement: 97.4%).
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trial also showed association of faecal calprotectin with clinical 
recurrence.621 TOPPIC also demonstrated the power of faecal 
calprotectin as a time-dependent variable, in that a 100 µg/g rise 
in calprotectin led to an 18% increase in the HR for clinical 
recurrence. It is suggested therefore that the use of faecal calpro-
tectin is most helpful when there is a comparison value for the 
same patient when in known remission. A rise in the background 
level in the context of clinical symptoms should trigger further 
investigation and treatment.
4.10.1.2 Non-inflammatory causes of diarrhoea after ileocolonic 
resection
Gastrointestinal symptoms in patients with previous surgery 
for Crohn’s disease are not necessarily related to recurrent 
inflammation. Conversely, minor anastomotic Crohn’s disease 
recurrence is often asymptomatic. Other diagnoses should be 
considered.
4.10.1.2.1 Bile salt malabsorption
Bile acid diarrhoea due to malabsorption is common following 
ileal resection, occurring in more than 80% of patients.622–625 
A therapeutic trial of bile acid sequestrants is therefore appro-
priate, particularly if faecal calprotectin is not significantly 
raised. A 75Se-HCAT (SeHCAT) scan should only be requested 
when there is uncertainty, as it is often abnormal after ileal 
resection or with ileal inflammation, and an abnormal scan 
does not prove that symptoms are due to bile salt malabsorp-
tion. Colestyramine is effective623 626 but may be unpalatable, 
and other agents such as colestipol or colesevelam, which are 
more expensive, can be used as alternatives for those who do 
not tolerate it.622 Bile acid sequestrants need to be stopped 
during the SeHCAT test. Loperamide can also be used.627 There 
is increasing interest in bile acid malabsorption as a cause of 
functional diarrhoea.628 Serum markers of bile acid diarrhoea, 
such as reduced fibroblast growth factor-19 levels629 630 and 
raised 7-alpha-hydroxycholestenone (C4),631 are not yet widely 
available; both tests will be abnormal in ileal resection, and also 
with ileal inflammation.
4.10.1.2.2 Small intestinal bacterial overgrowth
Small intestinal bacterial overgrowth occurs more commonly 
after Crohn’s disease resection,533 and can mimic Crohn’s 
disease in causing symptoms of bloating, diarrhoea, nausea or 
vomiting, weight loss or malnutrition.632 The prevalence in one 
study was 30% using a lactulose breath test, measuring hydrogen 
and methane.633 Bacterial overgrowth is more common if there 
are blind loops, dysmotility, diverticulae or strictures. The 
gold standard test for small intestinal bacterial overgrowth is 
jejunal aspirate with quantitative culture for aerobic and anaer-
obic organisms. This test is invasive and usually not available. 
Glucose or lactose hydrogen breath tests are more often used. 
Measurement of methane as well as hydrogen is recommended 
to increase sensitivity, but there is a lack of standardisation and 
poor sensitivity and specificity for these tests.634 Empirical treat-
ment is recommended if the diagnosis is likely, with broad-spec-
trum antibiotics such as metronidazole, ciprofloxacin534 or 
rifaximin.635 Recurrent courses of treatment may be required.
4.10.1.2.3 Other causes of recurrent symptoms following ileo-
colonic surgery
Other co-existing conditions that can cause diagnostic confu-
sion include irritable bowel syndrome,636 coeliac disease and 
short gut syndrome in those with extensive small bowel resec-
tion. Lymphoma and malignancy must also be considered. Post-
operative complications should also be considered, including 
anastomotic strictures, collections and port-site hernia (after 
laparoscopic surgery).
4.10.2 Smoking cessation following surgery
The best described environmental factor affecting the outcome 
of IBD is cigarette smoking, which has a negative impact on 
the clinical course of Crohn’s disease. It has been shown that 
cigarette smokers have quicker and more severe postoperative 
relapse in Crohn’s disease.621 637 Thus, all efforts should be made 
to help patients quit smoking after surgery by offering coun-
selling, pharmacotherapy or nicotine replacement therapy (see 
Section 5.8.1: Smoking and Crohn’s disease).
4.10.3 Reassessment and medical prophylaxis following ileocolonic 
resection
A summary flowchart of postoperative medical prophylaxis 
following ileocolonic resection for Crohn’s disease is shown in 
figure 3.
4.10.3.1 Risk factors for disease recurrence after ileocolonic 
resection
Surgery for the majority of patients with Crohn’s disease is 
not curative, with high rates of disease recurrence by 1 year.638 
Endoscopic recurrence predicts future clinical relapse.359 639 By 
6 months, endoscopic recurrence is apparent in between 39% 
and 84% of patients.640–642 A meta-analysis of the placebo groups 
of postoperative maintenance trials showed an endoscopic recur-
rence rate of 58% (95% CI 51% to 65%) at a median 1 year after 
surgery.643
Clinical factors predictive of symptomatic recurrence in the 
Rutgeerts study were preoperative disease activity, indication 
for surgery (fistulae and abscess being associated with more 
recurrence than strictures) and number of previous resec-
tions.359 Severity of recurrent mucosal lesions in the neoterminal 
ileum at colonoscopy after resection was the main predictor of 
subsequent symptomatic recurrence on multivariable analysis. 
Preoperative disease activity was the main clinical predictive 
factor. Smoking was not evaluated in this study but is the most 
important risk factor, with meta-analysis showing an increased 
Good Practice recommendation 13. Patients with recurrent 
symptoms following resection for Crohn’s disease, who have 
no evidence of active inflammation, should have consideration 
of other diagnoses including bile salt malabsorption, bacterial 
overgrowth, functional bowel disorders, adhesions, fibrostenotic 
or anastomotic strictures (Agreement: 97.3%).
statement 68. We recommend that, following ileal resection, 
Crohn’s disease patients with diarrhoea suggestive of bile acid 
malabsorption should be given a therapeutic trial of a bile acid 
sequestrant such as colestyramine or colesevelam (GRADE: 
strong recommendation, moderate-quality evidence). A SeHCAT 
study can be considered for failed response to therapy or if the 
diagnosis is unclear (Agreement: 97.2%).
statement 69. We recommend that all patients smoking 
after intestinal resection for Crohn’s disease should be actively 
encouraged to stop (GRADE: strong recommendation, moderate-
quality evidence. Agreement: 100%).
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risk of endoscopic recurrence by 2.5-fold and clinical recurrence 
2-fold.637 Other risk factors for postoperative recurrence include 
prior resection, penetrating disease, perianal disease, extensive 
bowel disease (>50 cm), granulomas in the resection specimen 
and myenteric plexitis in the proximal resection margin.643–646
4.10.3.2 Evidence of benefit from medical prophylaxis to prevent 
postoperative recurrence
Postoperative prevention trials have been challenging in this area 
as clinical recurrence is less common than endoscopic recur-
rence, and commonly used end-points for clinical relapse such 
as the CDAI score are not validated in the postoperative setting. 
It has been much easier to demonstrate reduction in endoscopic 
recurrence rates, and endoscopic lesion severity does correlate 
with clinical recurrence risk.359 647
4.10.3.2.1 Thiopurine therapy
For those who are not able to stop smoking, the TOPPIC trial 
provided evidence that thiopurines may improve their chance 
of maintaining remission after surgery. This study did not, 
however, confirm a wider role for thiopurines in the postop-
erative context, with no overall difference in either clinical or 
endoscopic recurrence at 3 years (although a post-hoc analysis 
showed that complete endoscopic healing (Rutgeerts score i0) 
was more likely in the mercaptopurine group).621 A Cochrane 
review of previous trials showed low quality evidence for benefit 
of thiopurines in comparison to placebo.648
4.10.3.2.2 Anti-TNF therapy
Early studies had shown benefit for infliximab in preventing 
postoperative recurrence, but in general it has been easier to 
demonstrate prevention of endoscopic recurrence at 1 year649 650 
or 2 years,651 as clinical relapse rates in these studies were lower 
and differences non-significant. The Yoshida650 study had 
follow-up at 3 years and there was a significantly higher remis-
sion rate of 93.3% on infliximab compared with 56.3% on no 
treatment. A study by Sorrentino et al652 evaluated those who 
remained in clinical and endoscopic remission on infliximab at 
2 years post-surgery, at which time the treatment was stopped. 
Ten of the 12 patients had endoscopic relapse at 4 months and 
all achieved healing on retreatment with lower doses of inflix-
imab (3 mg/kg 8-weekly). A large double-blind placebo-con-
trolled trial of postoperative infliximab in 297 patients did not 
demonstrate significant reduction in clinical relapse at 76 weeks 
(12.9% on infliximab) compared with placebo (20%), but did 
show reduction in endoscopic recurrence (30.6% vs 60%). Clin-
ical relapse rates were low despite patients having to have a risk 
factor for recurrence (previous surgery, resection for penetrating 
disease, recent perianal fistulae or current smoking).653 For 
patients given anti-TNF prophylaxis postoperatively, the use of 
multiple anti-TNF drugs in the past makes relapse much more 
likely.654 A randomised three-arm study compared postopera-
tive adalimumab against azathioprine and 5-ASA with a 2-year 
follow-up. There was significantly reduced endoscopic recur-
rence for those on adalimumab (adalimumab 6.3%, azathioprine 
64.7%, 5-ASA 83.3%) and significantly reduced clinical recur-
rence (12.5%, 64.7% and 50%, respectively).655
statement 70. We suggest that, following ileocolonic resection 
for Crohn’s disease, ileocolonoscopy may be performed at 
6 months to assess the neoterminal ileum in order to consider 
treatment escalation if mucosal inflammation (Rutgeerts i2 or 
above) (GRADE: weak recommendation, low-quality evidence). If 
the anastomosis is not within reach of endoscopic examination, 
then cross-sectional imaging with MR enterogram may be 
performed (Agreement: 89.2%).
statement 71. We suggest that Crohn’s disease patients 
with significant risk factors for disease recurrence following 
ileocolonic resection (particularly smoking) or with recurrent 
disease at 6 months post-surgery colonoscopy may be started 
on thiopurines (GRADE: weak recommendation, low-quality 
evidence) or anti-TNF therapy (GRADE: weak recommendation, 
low-quality evidence. Agreement: 94.4%).
statement 72. We recommend that mesalazine should not be 
given to prevent recurrence after ileocolonic Crohn’s disease 
resection (GRADE: strong recommendation, moderate-quality 
evidence. Agreement: 97.2%).
Figure 3 Medical prophylaxis after ileocolonic resection for Crohn’s 
disease.
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4.10.3.2.3 Postoperative colonoscopy at 6 months
The POCER trial was a pragmatic randomised trial that 
compared an active care model using endoscopic assessment at 
6 months postoperatively with standard care (no colonoscopy 
at 6 months).640 All patients entering the trial received metro-
nidazole for 3 months postoperatively, and those at high risk 
of recurrence received thiopurines (or adalimumab if intol-
erant). In the active care group, treatment was stepped up 
if 6-month endoscopic recurrence was documented: to thio-
purine, fortnightly adalimumab with thiopurine, or weekly 
adalimumab. At 18 months endoscopic recurrence was 49% 
in the active group versus 67% in the standard care group 
(p=0.03) and clinical recurrence was 27% and 40%, respec-
tively (p=0.08).
4.10.3.2.4 Antibiotic therapy
Antibiotic therapy can maintain remission for at least 3 months 
after surgery.656 657 Metronidazole is the most widely used,658 but 
is poorly tolerated (23% dropped out during the 3 months trial 
treatment on metronidazole 20 mg/kg daily), and causes neuro-
pathic complications which relate to total dose and generally 
prohibit longer use. Ornidazole is also effective but still limited 
by significant side effects (32% dropped out during the 1 year 
trial treatment).659 In a small pilot study, ciprofloxacin did not 
show much benefit over placebo.660 In view of its gut specificity 
and reduced side effect profile, there is interest in using rifaximin 
in this context. There is a study of rifaximin for maintenance 
therapy over 3 months after medically-induced remission,661 but 
trials are awaited in the postoperative setting.
4.10.3.2.5 Other treatment
Evidence regarding 5-ASA is conflicting, with small studies 
showing no significant benefit. Meta-analysis has shown a 
modest reduction in clinical recurrence and severe endoscopic 
recurrence,662 but less effectiveness than other therapies.663 
Likewise, steroids have significant toxicity and are ineffective 
in maintaining postoperative remission.656 As yet there are not 
enough data to specifically recommend vedolizumab or usteki-
numab in this context.
5 CoMMon dIseAse ConsIderAtIons
5.1 Infectious diseases and Ibd: differential and concurrent 
diagnoses
5.1.1 Tuberculosis
Differentiating between intestinal tuberculosis (TB) and Crohn’s 
disease may be challenging in those who have lived in endemic 
areas as clinical features may be similar. Features suggestive of 
a diagnosis of intestinal TB include night sweats, concomitant 
pulmonary tuberculosis, positive tuberculin skin test, antibodies 
to TB, abdominal lymphadenopathy, ascites, transverse ulcers and 
a patulous ileocecal valve.664–666 Haematochesia, involvement of 
the sigmoid colon, skip lesions and aphthous ulceration are more 
common in Crohn’s disease, whereas weight loss may be predic-
tive of TB.665 Extraintestinal manifestations are more commonly 
associated with Crohn’s disease.666 A recent study from South 
Korea used 40 Crohn’s patients and 40 with intestinal TB to 
develop a predictive model using colonoscopic, laboratory and 
radiological criteria. Features suggesting Crohn’s at colonoscopy 
were anorectal lesions, longitudinal ulcers, aphthous ulcers and 
cobblestoning. Colonoscopic features suggesting TB were fewer 
than four segments of colon involved, patulous ileocaecal valve, 
transverse ulcers and scars or post-inflammatory polyps. Posi-
tive ASCA serology and proximal small bowel disease suggested 
Crohn’s, and a positive quantiferon gold test and typical pulmo-
nary lesions suggested TB. A score derived from these features 
was able to make an accurate diagnosis in 96.3% of patients.667 
TB PCR performed on intestinal biopsies may be helpful for 
discrimination between the diseases.668
5.1.2 Enteric infections associated with IBD
The risk of enteric infections is higher in IBD than controls.669 
A UK study showed that 10.5% of IBD relapses were associ-
ated with enteric infection (half were Clostridium difficile).670 A 
more recent retrospective study in over 9000 Mayo Clinic IBD 
patients from whom stools were collected showed a low rate of 
bacterial infection of less than 3% by culture and PCR (excluding 
C. difficile infections), with no adverse impact on disease course 
(higher proportions of stool positive patients remained in remis-
sion over the next year compared with those with a non-infec-
tive disease flare or C. difficile infection).671 A recent USA study 
using a multiplex PCR for gastrointestinal pathogens reported 
that 18.1% and 16.1% of samples from Crohn’s disease and 
UC patients respectively were positive. Crohn’s disease patients 
were more likely to have norovirus and Campylobacter, while 
UC patients were more likely to have bacterial infections, 
particularly Campylobacter, Plesiomonas and Escherichia coli 
(compared with non-IBD samples).672 The sensitivity of the 
molecular test used, the breadth of pick-up of the panel covered 
and the likelihood of false-positive infections because of asymp-
tomatic carriage all warrant consideration when assessing the 
literature in this area. Nevertheless, a comprehensive infection 
screen considering clues from the history, and local infectious 
epidemiology, is an essential component of evaluating IBD 
disease flares.
5.1.3 Clostridium difficile infection associated with IBD
Clostridium difficile infection is more common in IBD than 
non-IBD populations, and in contrast to non-IBD populations, is 
less associated with PPI and antibiotic therapy.673 674 C. difficile 
can also be a cause of chronic pouchitis.675
A Canadian population-based case-controlled study of 278 
UC patients hospitalised due to a flare of colitis and tested for C. 
difficile infection identified 6.1% were positive. These patients 
had an increased risk of colectomy (adjusted OR 3.39) and preop-
erative C. difficile infection was associated with a higher risk of 
postoperative infectious complications (OR 4.76).218 Observa-
tional studies have shown approximately 20% of IBD patients 
with C. difficile infection require colectomy.214 676 Outcomes in 
hospitalised IBD patients with C. difficile infection are worse 
with higher colectomy rates and higher mortality.215–218 677 678 A 
statement 73. We recommend that the differential diagnosis 
of tuberculosis should be considered in patients with suspected 
ileocaecal Crohn ’s disease, particularly in patients born in or 
who have lived for extended periods in endemic areas or have 
other risk factors for infection (GRADE: strong recommendation, 
very low-quality evidence. Agreement: 97.8%).
statement 74. We recommend that all patients presenting 
with acute flares of colitis should have stool cultures for entero-
invasive bacterial infections and stool Clostridium difficile 
assay (GRADE: strong recommendation, low-quality evidence). 
Microscopy and culture for amoebic or Shigella dysentery should 
be performed in patients with relevant travel history (Agreement: 
93.5%).
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systematic review and meta-analysis showed that the 3-month 
colectomy risk was not increased by C. difficile infection (OR 
1.35; 95% CI 0.68 to 2.67) either in IBD or non-IBD popula-
tions, but the colectomy risk after 1 year or more was higher for 
IBD overall (OR 2.23; 95% CI 1.18 to 4.21) and UC specifically 
(OR 2.96; 95% CI 1.19 to 7.34).679
In non-IBD populations vancomycin is equally as effective as 
metronidazole for mild C. difficile, but has superior efficacy in 
severe disease.680 As such, Public Health England recommend 
vancomycin therapy in severe infection, as do others.219 681 It 
is not necessary to withhold corticosteroid treatment for acute 
severe colitis in this situation, and a decision regarding continu-
ation of immunomodulator therapy should be taken on an indi-
vidual basis (including the surgical team in the discussion).196 681 
It is prudent not to escalate therapy or introduce rescue therapy 
with infliximab or calcineurin inhibitors in ASUC associated 
with C. difficile infection, as there is little or no data on safety 
in this situation.
5.1.4 Cytomegalovirus infection in IBD
Cytomegalovirus (CMV) in IBD can be diagnosed by the pres-
ence of typical CMV inclusions on H&E stain, immunohis-
tochemistry and/or tissue PCR. A recent systematic review 
suggested that blood-based testing and histology lack sensitivity 
to predict reactivation of CMV in the colon and so immuno-
histochemistry or tissue PCR remain essential in the detection 
of CMV IBD.682 In a retrospective case control study from the 
Mayo Clinic, the risk of CMV disease was independently asso-
ciated with refractory disease, treatment with immunomodula-
tors and age over 30 years.683 Other studies show an association 
of CMV with corticosteroid use, corticosteroid-refractory UC 
and leukopaenia.684–687 CMV viraemia and blood PCR have 
poor sensitivity for diagnosis of CMV colitis, though specificity 
is high.688 Immunohistochemistry or quantitative PCR can be 
used to detect CMV on mucosal tissue, and may allow detec-
tion of CMV in patients who do not have inclusion bodies on 
H&E staining.689–692 A recent systematic review has identified 
wide heterogeneity of the definitions of CMV infection and 
CMV intestinal disease.693 Due to this heterogeneity, the preva-
lence of CMV intestinal disease in IBD varies from 2% to 38%. 
Tissue PCR has a sensitivity of 65% to 100% and a specificity of 
40% to 100% whilst immunohistochemistry had a sensitivity of 
93% and a specificity of 92% to 100%. These are the preferred 
methods of diagnosis.
5.1.4.1 Treatment of CMV in IBD
Reactivation of CMV infection detected by serology is common 
in IBD patients receiving immunosuppression.694 Low-level reac-
tivation may disappear without antiviral therapy. Small observa-
tional studies show benefit for treating colonic CMV disease in 
UC patients, particularly those who are steroid-refractory.695 696 
Hospitalised patients with refractory UC, associated with CMV 
disease, treated with ganciclovir and requiring treatment with 
infliximab or ciclosporin did not have a worse outcome compared 
with those receiving ganciclovir only.697 Antiviral therapy in 
patients with a high density of CMV inclusions (biopsy specimens 
with five or more inclusions) reduces the need for surgery in 
the following year.698 Despite the lack of controlled trial data, 
a recent review concluded that there was sufficient evidence to 
support antiviral therapy in patients with moderate to severe 
colitis, particularly those resistant to steroids and colonic CMV 
reactivation by H&E staining with immunohistochemistry and/
or CMV tissue PCR.699 The treatment recommended by ECCO 
is intravenous ganciclovir (5 mg/kg twice daily) for 3–5 days, 
then oral valganciclovir (900 mg twice daily) for 2–3 weeks, but 
virology/microbiology advice should be taken regarding route 
and duration of therapy.700 Systemic CMV reactivation causing 
meningoencephalitis, pneumonitis, oesophagitis or hepatitis 
carry a poor prognosis and require prompt antiviral therapy and 
cessation of all immunosuppressive therapy.700
5.2 Immunosuppressive therapy
It is important that all patients receive written information prior 
to starting treatment, in addition to counselling regarding the 
risks of treatment and how these are minimised by monitoring. 
Patients have differing perceptions regarding treatment and 
this can significantly influence drug adherence.701 No study has 
addressed the impact of specific patient information, but a recent 
survey of IBD patients showed that patients access a wide variety 
of information sources about IBD and its treatment.702 Of these, 
information from the IBD team and written patient information 
material were the most widely used, and the most trusted by 
patients. Information can be provided by IBD teams in written 
form or by sign posting to official patient support websites that 
provide high-quality drug information for patients.
5.2.1 Prevention of infection related to IBD and immunosuppressive 
therapy
If evidence of active HBV, latent or active TB, HCV or HIV 
infection, seek specialist input prior to commencing immune 
modifying therapy.
All IBD patients should be screened at diagnosis for infection 
risk, as there is both an increased risk of infection as a result 
of the disease and a high likelihood of requiring immunosup-
pressive drug therapy (box 4). Patients without a clear history 
of chickenpox, shingles or receipt of two doses of varicella 
statement 75. We suggest that Clostridium difficile infection 
in acute severe ulcerative colitis is associated with significantly 
increased risk of colectomy and should be treated with oral 
vancomycin (GRADE: weak recommendation, low-quality 
evidence. Agreement: 93.2%).
statement 76. We suggest that patients with moderate 
to severe colitis, particularly those with corticosteroid-
refractory disease, should have colonic biopsies to look for 
cytomegalovirus disease by H&E staining, and preferably also 
immunohistochemistry or quantitative tissue PCR (GRADE: weak 
recommendation, low-quality evidence. Agreement: 93.3%).
statement 77. We suggest that CMV reactivation in the 
colonic mucosa of patients hospitalised with an exacerbation 
of ulcerative colitis or Crohn’s colitis may be treated by 
intravenous ganciclovir 5 mg/kg twice daily while continuing 
conventional therapy with corticosteroids or rescue medication 
with infliximab or ciclosporin (GRADE: strong recommendation, 
very low-quality evidence). In rare cases with systemic disease 
(meningo-encephalitis, pneumonitis, hepatitis or oesophagitis), 
all immunosuppressive therapy should be stopped while CMV 
is treated (GRADE: weak recommendation, very low-quality 
evidence). (Agreement: 88.4%).
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vaccine should be tested for varicella zoster virus (VZV) IgG. 
All patients with IBD should be screened for hepatitis B and C, 
and HIV. The prevalence of hepatitis B and C viral infection in 
IBD was similar to the general population in 315 patients from 
France (hepatitis B virus 2.54%, hepatitis C virus 0.95%).703 
A Dutch study showed that rates of screening for hepatitis B 
remain suboptimal at 36–49%.704 Opportunistic testing for HIV 
should be done at the same time, as the condition is treatable 
and has public health implications. A panel of viral screening at 
diagnosis makes it more likely that patients can receive appro-
priate vaccinations with less delay to receiving immunomod-
ulator therapy, which is now used in at least half of patients 
at some stage in their disease course. For the same reason, 
checking thiopurine methyltransferase (TPMT) status early 
reduces delays in starting thiopurines.
5.2.1.1 Epstein Barr Virus
There is increasing interest in Epstein Barr virus (EBV) infec-
tion in IBD patients because of the risk of severe complications, 
including haemophagocytic syndrome and post-mononucleosis 
type lymphomas after primary infection and haemophagocytic 
syndrome and post-transplant type lymphoma during latent 
infection. A Spanish tertiary care centre studied 1483 patients 
aged over 17 years between 2006 and 2016.705 They assessed 
EBV seroprevalence and seroconversion and documented those 
who developed complications while on azathioprine. EBV had 
a role in tumour development in three out of five patients on 
azathioprine, but only one (in a 66-year-old man) occurred 
during a primary infection. The authors conclude that the risk 
of haemophagocytic syndrome and lymphoma on thiopurine 
therapy is not restricted to young males. This is confirmed in a 
USA paediatric IBD follow-up cohort, where 3/5 patients with 
haemophagocytic syndrome (all on thiopurines) were female. 
There was no association with use of infliximab or methotrexate 
(although numbers on methotrexate were much smaller).706 It 
remains unclear whether screening for EBV status should be 
done routinely in adults.707 In paediatric patients who are partic-
ularly at risk from primary EBV infection, there may be more 
justification for screening in order to avoid thiopurine use in 
those who are seronegative. Routine EBV testing prior to thio-
purine therapy remains controversial.
5.2.1.2 Infection risk in patients on anti-TNF therapy
Meta-analysis of clinical trial data of 4135 patients receiving 
anti-TNF therapy as part of randomised clinical trials found a 
0.9% incidence of opportunistic infection.708 This represented 
a two-fold increased risk of infections including TB, herpes 
simplex, oral or oesophageal candidiasis, herpes zoster, CMV, 
EBV and Nocardia in IBD patients (RR 2.05; 95% CI 1.10 to 
3.85). The relative risk for TB was 2.52 (95% CI 0.62 to 10.21). 
Pooled analysis of 2266 patients receiving adalimumab as part 
of clinical trials found that higher disease activity was associ-
ated with an increased risk of opportunistic infection, with a 
31% (HR 1.31; 95% CI 1.04 to 1.64) increase accompanying 
every 100 point rise in CDAI.709 IBD patients over 50 years of 
age receiving immunosuppression are at highest risk of opportu-
nistic infection.710 711
For patients starting biologics or immunosuppressive drugs, 
the viral screen (as recommended at diagnosis, see box 4) should 
be performed if not done initially, or if new risk factors have 
arisen since that time.
5.2.1.2.1 Tuberculosis
Screening for active or latent TB is essential prior to starting 
anti-TNF or other biologic therapy. A Dutch study suggested that 
screening rates for TB in IBD patients are high at 90–97%, with 
3% latent prevalence.704 Tuberculin skin test is likely to have 
false-negative results due to immunosuppressive therapy, so 
interferon gamma release assays (IGRA) should be used. A high 
rate of anergy to skin-based antigen tests was shown by immu-
nising 82 consecutive IBD patients against tuberculin (TST) or 
control antigens.712 In this study no TST result was positive, but 
71% of patients failed to respond to any antigen. Importantly, 
83% of patients on steroid or immunomodulator therapy were 
anergic versus 43% not on these therapies (p<0.002). A retro-
spective study of TB screening in 340 patients in the USA with 
512 Quantiferon TB Gold (QFT-G) IGRA tests reported 1.5% 
positivity, 2.7% indeterminate and 95.8% negativity.713 Only 
one case of tuberculosis reactivation occurred in 17 months of 
follow-up (0.3%). This patient had an indeterminate test and 
was on immunosuppressive therapy prior to testing. No signif-
icant difference was seen in positivity rates between those on 
box 4 Infection and pretreatment checklist at diagnosis 
and prior to immunomodulator or biological therapy
 ► history of specific infections: HSV (oral, genital), VZV 
(chicken pox, shingles), tuberculosis.
 ► Immunisation status: BCG, diphtheria, tetanus, pertussis, 
Haemophilus influenzae type B, polio, meningococcus, 
measles, mumps, rubella, pneumococcus, HPV, rotavirus, 
influenza, VZV/shingles.1285
 ► Prior exposure to tb: household contacts, prolonged stay 
or origin from endemic area.
 ► tb screening: patients considered for anti-TNF therapy 
should be screened for tuberculosis using a combination of 
clinical risk stratification, chest x-ray and interferon-gamma 
release assays.
 ► tPMt: check in all patients considered for thiopurine therapy.
 ► serology: HBV, HCV, HIV and VZV (in patients without clear 
history of prior infection or prior vaccine).
Good Practice recommendation 14. All IBD patients to be 
initiated on immunosuppressive therapy should receive written 
information regarding the benefits, risks, side effects and 
monitoring of treatment (Agreement: 97.9%).
statement 78. We suggest that blood tests for thiopurine 
methyltransferase status and screen for HBV, HCV and HIV 
(and VZV if no history of chicken pox, shingles or varicella 
vaccination) may be arranged once diagnosis is confirmed for 
all Crohn’s disease and moderate to severe ulcerative colitis 
patients (GRADE: weak recommendation, very low-quality 
evidence. Agreement: 88.9%).
statement 79. We recommend that IBD patients commencing 
immunomodulators or biologics treatment should undergo 
screening for HBV, HCV and HIV (and VZV if no history of chicken 
pox, shingles or varicella vaccination), unless screened already 
at time of diagnosis (GRADE: strong recommendation, very 
low-quality evidence. Agreement: 88.9%).
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immunosuppressive therapy and those not. Only moderate 
concordance was seen between TST and QFT-G in this study 
(kappa=0.4152, p=0.0041). IGRA tests were evaluated in 
125 adult patients with IBD in London, 90 of whom were 
anti-TNF naïve, with 35 on established anti-TNF therapy.714 109 
(87%) were BCG vaccinated. 98% IGRA tests were negative, 
1% indeterminate and 2% positive. This method of screening 
was deemed cost-effective in comparison to the 2005 British 
Thoracic Society guideline.715 No subsequent cases of TB were 
reported with a median follow-up of 24 months. A Korean 
study examined newly developed TB cases in IBD patients on 
established anti-TNF therapy.716 They described 25 cases in 
total (84% pulmonary, 16% extrapulmonary), of whom 76% 
developed TB within 5 years of commencing anti-TNF despite 
previous negative screening for latent infection, and 12% devel-
oped reactivation of latent infection after 3 months of chemo-
prophylaxis. Primary infection with TB on anti-TNF agents is 
therefore a significant risk, particularly in higher incidence areas, 
irrespective of baseline screening.
It has been proposed that extensive screening for TB using 
chest x-ray and IGRA compared with chest x-ray and TST is 
only cost-effective if latent prevalence is >12% or false positivity 
rate of TST is >20%.717 In low prevalence areas, patients should 
have a risk assessment questionnaire and chest x-ray, with IGRA 
test if at increased risk.
5.2.1.2.2 Strongyloides stercoralis
Strongyloides stercoralis is an intestinal parasitic infection 
affecting tens of millions of people globally. It has been estimated 
the infection may be present in up to 10–40% of the population 
in tropical and subtropical countries, rising to 60% in the poorest 
socioeconomic communities where environmental conditions 
favour spread of infection.718 Patients with HIV/AIDS have 
twice the risk of infection compared with non-HIV populations 
(OR 2.17; 95% CI 1.18 to 4.01). Immunocompromised patients, 
particularly those on systemic steroids, are at risk of potentially 
fatal hyperinfection syndrome, characterised by increased para-
site burden leading to GI bleeding, pneumonia, sepsis or menin-
gitis.719 Blood eosinophilia is a common finding in patients with 
S. stercoralis infection though is not present in all patients.720 S. 
stercoralis serology is unreliable in immunocompromised indi-
viduals. Treatment is with ivermectin or albendazole.
Risks and management of other opportunistic infections are 
well-covered in the ECCO guidance.700
5.2.1.3 Vaccination
A vaccination history should be taken both at diagnosis and prior 
to starting immunosuppressive therapy (see box 4). General 
advice regarding vaccination is given in box 5.
5.2.1.3.1 Non-live vaccines
IBD patients have a greater risk of contracting influenza than 
non-IBD populations (incidence rate ratio 1.58; 95% CI 1.49 to 
1.68) and are more likely to require admission to hospital.721 
Annual influenza vaccination is recommended for all immuno-
suppressed patients,1 700 722 although vaccine efficacy may be 
reduced, particularly in those on anti-TNF therapy.723 It should 
be remembered that the nasal influenza vaccine contains live 
virus and so should be avoided, with the injection favoured 
instead.
Assessment of hepatitis B serology and vaccination in all 
seronegative patients at diagnosis is recommended in ECCO 
guidelines, although the value of this in low prevalence coun-
tries has been questioned, and in the UK it may be more appro-
priate to offer this to high-risk groups on the basis of lifestyle, 
occupation or other factors.724 Efficacy of vaccination may be 
impaired in active IBD725 and in those on immunosuppressive 
drugs.726 727 After hepatitis B vaccination, anti-HBs response 
should be measured as higher doses may be required. Acceler-
ated double-dose vaccination in IBD has been shown to improve 
response, with double-dose Engerix-B vaccine at 0, 1 and 2 
months.728
Pneumococcal vaccination is also affected by immunosuppres-
sion and should ideally be administered at least 2 weeks before 
starting immunomodulators. Three pneumococcal vaccines 
are licensed in the UK: pneumococcal polysaccharide vaccine 
(PPV23, containing polysaccharide from 23 capsular types of 
pneumococcus) and two variants of pneumococcal conjugate 
vaccine (PCV13 and PCV10, containing polysaccharide from 13 
and 10 capsular types of pneumococcus).729 The current recom-
mendation for adults on immunosuppression is a single dose of 
PCV13 followed by PPV23 at least 2 months later; however, we 
recommend reviewing the Green Book for further detail. Booster 
pneumococcal vaccination with PPV23 is recommended after 
5 years in patients who are asplenic, who have reduced splenic 
function or chronic renal disease. It seems reasonable to give 
boosters to patients on long-term immunomodulator therapy 
also, although there is little evidence in this group.
5.2.1.3.2 Live vaccines
Following live vaccination, the UK Department of Health 
currently recommends allowing 4 weeks for the immune 
response to be established prior to commencing immuno-
suppressive or biologics therapy.730 Live vaccination should 
be avoided during biologics therapy and for a minimum of 
3 months after stopping.731–733 The evidence base for the 
3-month period is poor, and while drug blood levels will be 
minimal by this time, it is unclear whether alterations to white 
cell populations may have more persistent subtle effects on 
immunity. The USA Centre for Disease Prevention and Control 
states in their IDSA guidelines that zoster live vaccination can 
be considered for patients aged 60 or over while on treatment 
statement 80. We recommend that prior to commencing 
anti-TNF therapy, IBD patients should be screened for 
tuberculosis (TB) using a combination of clinical risk 
stratification, chest x-ray and interferon-gamma release assays 
(IGRAs) (GRADE: strong recommendation, low-quality evidence. 
Agreement: 97.8%).
statement 81. We suggest that IBD patients who have travelled 
for long periods or lived in endemic areas may be at increased 
risk of parasitic infections, and may have Strongyloides serology, 
and eosinophil count checked prior to commencing anti-TNF 
therapy (GRADE: weak recommendation, very low-quality 
evidence. Agreement: 90.9%).
statement 82. We recommend that a vaccination history should 
be obtained and vaccinations updated for all patients with 
Crohn’s disease, those with moderate to severe ulcerative colitis 
at diagnosis, and prior to commencing immunomodulator or 
biologics in all patients. Live vaccinations may be given at least 
4 weeks before starting and at a minimum of 3 months after 
stopping, but not while receiving immunosuppressive therapy 
(GRADE: strong recommendation, very low-quality evidence. 
Agreement: 93%).
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with low-level immunosuppression (defined as prednisolone 
doses <20 mg, methotrexate weekly dose ≤0.4 mg/kg, azathio-
prine ≤3 mg/kg/day or mercaptopurine ≤1.5 mg/kg/day).734 In 
the UK the age recommendation for zoster vaccine is at age 70 
or up to the age of 79 if not given at age 70, and the Green 
Book also advises that shingles vaccination may be administered 
to those on low-level immunosuppression (defined as ≤20 mg 
prednisolone/day for >14 days, either alone or in combination 
with low-dose non-biological oral immunomodulators (metho-
trexate ≤25 mg/week, azathioprine ≤3 mg/kg/day or mercapto-
purine ≤1.5 mg/kg/day)).735
The UK Department of Health Green Book vaccination guide 
Chapter 6730 also suggests that all live vaccines can be considered 
for those on low-dose immunosuppression as defined above, 
including low-dose immunosuppressive drugs in combination 
with prednisolone up to 20 mg. There is evidence from a small 
controlled study that the use of zoster vaccine in IBD patients on 
low-level immunosuppression does not result in adverse effects, 
although antibody titres were somewhat lower than those in 
vaccinated IBD patients not taking immunosuppressive drugs.736 
Live vaccination must not be given to those taking biologics, and 
should only be undertaken for those on low-level immunosup-
pression after careful consideration of the risks and benefits in 
conjunction with the patient.
The Green Book advises that live vaccination should be 
delayed until 6 months of age in children exposed in utero to 
biologics.730
5.2.2 Drug management: thiopurines
A checklist of considerations when commencing thiopurines is 
shown in box 6, and table 10 gives a guide on interpretation 
of thiopurine metabolites during dose optimisation. Practical 
management of thiopurine side effects is described in box 7.
5.2.2.1 Thiopurine methyltransferase and NUDT15
20–30% of IBD patients stop thiopurine treatment because of 
side effects. While overall, thiopurine methyltransferase (TPMT) 
activity does not predict adverse effects, the subset of patients 
with low TPMT activity are at increased risk of discontinuing 
thiopurines due to adverse effects. In a prospective study of 
TPMT-directed versus standard therapy, patients with TPMT 
variants fared significantly better if dosed according to TPMT 
status (2.6% haematological adverse effects in TPMT-directed 
therapy versus 22.9% in undirected group, RR 0.11, 95% CI 
0.01 to 0.85).737 In a prospective evaluation of TPMT activity 
in 207 patients with IBD commenced on azathioprine, patients 
with heterozygous TPMT deficiency were much more likely to 
withdraw due to adverse effects compared with those with wild-
type TPMT status (79% vs 35%, p<0.001).738 There is evidence 
that TPMT measurement in all patients starting thiopurine 
therapy is cost-effective.739 740
The usual dose of azathioprine is 2–2.5 mg/kg daily and for 
mercaptopurine 1–1.25 mg/kg daily for patients with normal 
TPMT activity (box 6). There is a very high risk of thiopurine-in-
duced myelosuppression in patients with absent TPMT activity 
(homozygous or compound heterozygous TPMT deficiency). 
While very low dose (5% of usual target) has been proposed, a 
thiopurine should generally be avoided in this group. In those 
with heterozygous TPMT deficiency, however, 50% of standard 
thiopurine dose is associated with improved tolerance.737
Genetic variation in NUDT15 has now also been described in 
association with myelosuppression. This was originally described 
in East Asians741 but has now also been described in IBD patients 
of European ancestry.742 Recent CPIC guidelines recommend 
NUDT15 testing, particularly for Asian patients, with consider-
ation of dose reduction or thiopurine avoidance.742
5.2.2.2 Starting dose for thiopurines
Azathioprine and mercaptopurine should be started at the full 
dose. There is no evidence that starting at low doses and then 
gradually increasing up to target improves safety or tolerance, 
and low-dose initiation may cause significant delay in achieving 
the correct target dose.743
5.2.2.3 Renal excretion of thiopurines
Thiopurine metabolites are renally excreted. Thiopurines should 
be used with caution in renal impairment with 75% of usual dose 
given if creatinine clearance is 10–50 mL/min, and 50% of usual 
dose if <10 mL/min.744
5.2.2.4 Cervical neoplasia and thiopurines
A number of large studies have found an increased risk of cervical 
dysplasia among women with IBD compared with controls.745 
This risk is mainly confined to those on oral immunosuppressive 
therapy, including corticosteroids, and those who smoke.746–749 
A meta-analysis gives an overall modest increase in risk, with 
statement 83. We recommend that IBD patients receiving 
immunomodulators or biologics should receive influenza 
vaccination each autumn, and pneumococcal vaccination with 
a booster after 5 years (GRADE: strong recommendation, very 
low-quality evidence. Agreement: 95.5%).
box 5 General considerations regarding vaccination
 ► Live vaccines are contraindicated if your patient is on 
immunosuppression or with significant protein calorie 
malnutrition: live vaccines include BCG, attenuated (oral) 
influenza vaccine, measles, mumps and rubella (MMR), 
polio, rotavirus, oral typhoid Ty21a, varicella zoster, yellow 
fever. Immunosuppressive therapies include: glucocorticoids 
(prednisolone ≥20 mg/day or equivalent for 2 weeks or more), 
thiopurines, methotrexate, biological therapy and tofacitinib.
 ► Shingles vaccination (current UK age recommendation is 
at age 70 years or up to the age of 79 years if not given at 
age 70 years) may be administered to those on low-level 
immunosuppression (defined as ≤20 mg prednisolone/
day for >14 days, either alone or in combination with low-
dose non-biological oral immunomodulators (methotrexate 
≤25 mg/week, azathioprine ≤3 mg/kg/day or mercaptopurine 
≤1.5 mg/kg/day).735
 ► Immunomodulators should be withheld for 4 weeks after live 
vaccine administration.
 ► Live vaccines should be avoided for at least 3 months after 
discontinuing treatment with immunosuppressive therapies 
above.
 ► Infants exposed to biologics in utero should not receive live 
vaccines for 6 months after birth.
 ► IBD patients on immunosuppressant therapy should receive 
pneumococcal vaccine and annual influenza vaccination 
(prior to starting treatment if possible) with a single 
pneumococcal booster at 5 years.
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an OR of 1.34 (95% CI 1.23 to 1.46) for IBD patients on 
immunosuppression.750 As a consequence, all women should be 
encouraged to participate in national cervical cancer screening 
programmes; in the UK this is currently 3-yearly from age 25–49 
and 5-yearly from age 50–64 years.
5.2.2.5 Drug monitoring for thiopurines
Measurement of the thiopurine metabolites (thioguanine 
nucleotides (TGN) and methylmercaptopurine (MeMP)) 
offers a benefit over standard haematological and biochem-
ical monitoring by detecting non-adherence to therapy, 
inadequate dosing or an unnecessarily high dose of thiopu-
rine,751 752 as shown in table 10. Furthermore, detection of a 
skewed metabolism towards excessive thiopurine methylation 
determines a group of patients at risk of poor response and 
hepatotoxicity.
Although one study has suggested cost-effectiveness of 
metabolite monitoring in improving sustained response to 
thiopurines,753 it is unclear whether routine measurement in 
all patients on thiopurines is beneficial, owing to wide varia-
tion in levels (as much as fivefold intra-patient variation in one 
study754). Although TGN levels of 230–400 pmol/8×108 eryth-
rocytes have been associated with better response and MeMP 
levels >5000 pmol/8×108 erythrocytes with more liver 
toxicity,755 appropriate thresholds are unclear and small 
prospective studies have not shown clinical benefit.756–758 In 
patients on combination therapy with infliximab and thiopu-
rines, a lower target level of TGN of 125 pmol/8×108 RBCs 
may be adequate to achieve therapeutic levels of inflix-
imab,759 with a further study suggesting a target level of 
>105 pmol/8×108 RBCs.760
5.2.2.6 Low-dose thiopurines with allopurinol
Individuals whose methylation pathways predominate 
(hypermethylators) create less TGN and more methylated 
metabolites (MeMP). They therefore have lower thiopurine 
efficacy and a higher risk of side effects, particularly hepa-
totoxicity.761 This pattern of metabolism can be picked up as 
early as 4 weeks after starting the drug (ie, long before thera-
peutic effect is anticipated) and circumvented by switching to 
a low-dose thiopurine (25–33% of usual dose) with allopu-
rinol 100 mg co-prescription regimen, avoiding toxicity and 
increasing efficacy. Allopurinol achieves this optimisation of 
thiopurines by reducing methylation and increasing levels of 
the target metabolite, TGN.762 763 The accepted ratio of MeMP 
to TGN at which a switch is indicated is MeMP:TGN ≥11.764 
One randomised study comparing low-dose thiopurine with 
allopurinol with thiopurine monotherapy showed a higher 
proportion of patients were able to avoid steroid or biologic 
on combination treatment: 69.6% vs 34.7%, RR 2.1 (95% 
CI 1.07 to 4.11).765 Withdrawal rates due to adverse events 
on combination therapy were 30.4% versus 47.8% in those 
receiving monotherapy (RR 1.47, 95% CI 0.76 to 2.85). Other 
uncontrolled series show consistently that adverse effects 
experienced on monotherapy can frequently be circumvented 
by low-dose thiopurine with allopurinol,766–769 and clinical 
responses improved.766 770–772
5.2.2.7 Thiopurine toxicity
TPMT testing will only predict a proportion of early haemato-
logical toxicity on thiopurines,737 773 and no current pretreatment 
test will rule out future biochemical toxicity on a thiopurine. 
Hence, early intensive monitoring for haematological and 
biochemical toxicity is recommended in all patients with blood 
tests for full blood count, renal and liver biochemistry at 2, 4, 8 
box 6 Initiation of thiopurines
before starting:
 ► All patients should receive verbal and written information 
about their medication
 ► Baseline FBC, U&E and LFT measurement
 ► If available test NUDT15 genotype
 ► Screen for HCV, HBV, HIV, refer if positive, consider HBV 
vaccination if naïve
 ► Check VZV immunity and vaccinate if low
 ► Vaccinate for influenza and pneumococcal vaccine
 ► Check cervical screening up to date
 ► Check TPMT and start at target dose once result 
available. Normal TPMT: 2 mg/kg azathioprine or 1 mg/kg 
mercaptopurine. Low: 1 mg/kg azathioprine or 0.5 mg/kg 
mercaptopurine. Very low: avoid thiopurine
Monitoring:
 ► FBC, U&E and LFT at least at weeks 2, 4, 8, and 12, and then 
at least 3-monthly
table 10 Use and interpretation of thiopurine metabolites
tGn (pmol/8×108 rbCs) MeMP (pmol/8×108 rbCs) Interpretation treatment change to consider
Undetectable Undetectable Poor/variable compliance Patient education
Rarely poor absorption
Low (<235) Low/normal (<5700) Subtherapeutic dosing Uptitrate dose then repeat metabolites
Low (<235) High (>5700 or
MeMP: TGN >11)
Thiopurine hypermethylator
(occurs in up to 20% of patients with normal 
TPMT)
Reduce dose to 25–33% + start allopurinol 100 mg/day, then 
repeat metabolites
Therapeutic (235–450) Normal (<5700) Therapeutic (if responding)
Thiopurine resistant (if not responding)
If responding, continue current dose
If not responding, change drug category
Therapeutic (235–450) High (>5700) Possible supratherapeutic dosing Attempt dose reduction and repeat in 4 weeks. If non-responding 
and TGN low end of normal range, consider low dose azathioprine 
with allopurinol as above
High (>450) High (>5700) Supratherapeutic dosing Reduce dose then repeat metabolites
Adapted from Goel et al.1286
MeMP, methylmercaptopurine nucleotides; RBC, red blood cells; TGN, 6-thioguanine nucleotides; TPMT, thiopurine methyltransferase.
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and 12 weeks of therapy,774 with ongoing 12-weekly blood moni-
toring as toxicity can occur at any stage during therapy.774 775 
Bloods should be repeated 2 weeks after all dose increases. In a 
Spanish nationwide database study of nearly 4000 patients, the 
cumulative incidence of thiopurine side effects was 26%. Nausea 
was seen in 8%, hepatotoxicity in 4%, myelotoxicity in 4% and 
pancreatitis in 4% (pancreatitis occurring more often in Crohn's 
than UC, and more likely if also taking prednisolone).776 While a 
genetic predictor of thiopurine-induced pancreatitis has recently 
been discovered (the HLA-DQA1*02:01-HLA-DRB1*07:01 
haplotype), routine screening is not considered cost-effective at 
present.777
In patients with side effects to azathioprine, potential strate-
gies include split dosing, a switch to mercaptopurine778 and use 
of low-dose thiopurine/allopurinol (as detailed in Section on 
Low-dose thiopurines with allopurinol 5.2.2.6). The success of 
such strategies varies between type of adverse reaction, and more 
details are provided in box 7.
5.2.3 Drug use: methotrexate
Gastrointestinal and liver toxicity of methotrexate is reduced 
by administration of folic acid, either 1 mg daily or 5 mg 
weekly, traditionally taken 1 or 2 days after the methotrexate 
dose.779 780 Methotrexate has comparable safety to thiopu-
rines.781 782 Risk of cirrhosis is much lower than previously 
thought and routine liver biopsy after prolonged use is not 
necessary. Abnormalities of liver function can be transitory; in 
one study of 87 IBD patients (with a cumulative methotrexate 
dose of 1813 mg) this occurred in 24% of patients treated, but 
many normalised without stopping methotrexate and only 5% 
had to stop the drug.783 In this study 17 liver biopsies were 
performed, none showing advanced liver fibrosis or cirrhosis. 
Another study of 518 patients on methotrexate for inflamma-
tory disease (24% with Crohn’s) assessed liver fibrosis by tran-
sient elastography.784 Six percent (31 patients) had FibroScan 
results suggesting severe liver fibrosis (4% of the Crohn’s disease 
patients). Only 13 went on to liver biopsy, with just under half 
having severe fibrosis confirmed histologically. On multivari-
able analysis, BMI >28 kg/m2 and alcohol intake >14 drinks 
per week were independent predictors of FibroScan values 
>7.9 kPa. Patients with these additional risk factors should be 
screened using transient elastography. For all patients, meth-
otrexate should be stopped if transaminases exceed twice the 
upper limit of normal. Pulmonary toxicity in the form of acute 
interstitial pneumonitis presents with dyspnoea, dry cough and 
fever, and is rare. Most cases are reversible on withdrawal of 
methotrexate.781 All patients commencing methotrexate should 
have a baseline chest x-ray.
5.2.3.1 Methotrexate and pregnancy
Methotrexate is teratogenic and should not be given to women 
of childbearing age without detailed discussion and agreement 
about the importance of assured contraception during therapy, 
and for 6 months after stopping the drug. If there are concerns 
about reliability of adherence to effective contraception, then 
alternative therapy should be used. Information on 63 preg-
nancy outcomes of women exposed to low-dose methotrexate 
in the first trimester reported that 30% underwent termination 
box 7 Managing side effects of thiopurines
Pancreatitis:
 ► Do not give AZA or MP again, even at low dose. High chance 
of recurrence
nausea and vomiting:
 ► Try switching from AZA to MP; or continue drug with split 
dosing
 ► If recurs then consider low dose (25–33% of standard dose) 
AZA or MP+allopurinol 100 mg
Flu-like symptoms:
 ► Unlikely to resolve on switching from AZA to MP; some 
evidence for AZA/MP+allopurinol 100 mg
 ► If convincing early hypersensitivity reaction, there is high risk 
of recurrence and so consider switch to alternative class of 
drug
newly abnormal lFts:
 ► Stop and check thiopurine metabolites
 ► Withhold until LFTs abnormality resolves
 ► If not resolving, investigate as usual
 ► Once resolved, re-challenge with low dose AZA/
MP+allopurinol 100 mg. This is particularly likely to work 
if the original metabolites showed hypermethylation (High 
MeMP levels)
Myelotoxicity:
 ► Check thiopurine metabolites and alter dosage according to 
table 10
 ► Monitor white cell counts closely
 ► If total white cells <3.5×109/L or neutrophils <2×109/L, 
withhold thiopurine until counts correct above this level
 ► If neutrophils <1 ×109/L, patients should be warned to 
present for antibiotics±GCSF if febrile
 ► If TGN high, then restart at lower dose once abnormality 
has resolved and monitor haematology and thiopurine 
metabolites carefully
 ► If MeMP high then consider restarting low-dose thiopurine 
with allopurinol 100 mg
 ► If TGN low or normal then likely to reoccur. Advise to stop 
thiopurine in this circumstance
AZA, azathioprine; MP, mercaptopurine; AZA/MP, azathioprine or 
mercaptopurine; GCSF, granulocyte colony stimulating factor; MeMP, 
methylmercaptopurine nucleotides; TGN, 6-thioguanine nucleotides.
statement 84. We recommend that all IBD patients 
considered for thiopurine therapy should have assessment of 
thiopurine methyltransferase (TPMT) status (GRADE: strong 
recommendation, moderate-quality evidence. Agreement: 100%).
statement 85. We recommend that thiopurines should 
be avoided in patients with low TPMT activity. The dose of 
thiopurine should be reduced to 50% in those with intermediate 
thiopurine activity. Daily dosage should also be reduced in 
patients with significant renal impairment (GRADE: strong 
recommendation, moderate-quality evidence. Agreement: 100%).
statement 86. We recommend that women with IBD 
commencing thiopurine therapy should be advised to participate 
in a national cervical screening programme (GRADE: strong 
recommendation, very low-quality evidence. Agreement: 95.7%).
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of pregnancy, and of the remaining women, 25% had miscar-
riage and 12% of those going to term had a baby with congen-
ital abnormality (including one child with multiple skeletal 
abnormalities).785
There is no firm evidence to support the recommendation 
that men should discontinue methotrexate pre-conception. 
Two cohort studies of men receiving the drug for rheumatoid 
arthritis are reassuring regarding risk of preterm birth and 
fetal malformation. In a study of men with immunosuppressive 
and biological drug therapy for rheumatic diseases (of whom 
100 were taking methotrexate), there was no evidence of an 
increase in adverse pregnancy outcomes.786 A further study of 
113 pregnancies where the male partner had taken low-dose 
methotrexate for rheumatological disorders also showed no 
increase in risk.787 A Danish nationwide cohort study showed 
no adverse birth outcomes in children born to 193 men taking 
methotrexate.788
5.2.4 Drug management: anti-TNF including biosimilars
5.2.4.1 Choice of anti-TNF agent
Data regarding differences in efficacy between available anti-TNF 
drugs are not available from direct head-to-head trials. Existing 
trial data are difficult to compare indirectly owing to differences 
in study design and patient populations. Nevertheless, several 
systematic reviews and meta-analyses have reported minimal or 
inconsistent efficacy differences in Crohn’s disease, with possible 
superiority of infliximab compared with other anti-TNF agents 
in the induction phase of treatment of UC.161 789–791 No signifi-
cant differences in safety profile have been reported,792 although 
the increased immunogenicity of infliximab potentially increases 
the need for co-prescription of an immunomodulator, with 
resulting effects on safety.
A retrospective study using USA Medicare data showed no 
difference between adalimumab and infliximab treatment for 
Crohn’s disease in the proportion of patients continuing treat-
ment at 6 months, nor in rates of surgery or hospitalisation.793 
In a retrospective study of 3205 biologic-naïve patients with 
Crohn’s disease from a USA national administrative claims 
database, those who received infliximab had a small but signifi-
cantly lower risk of Crohn’s disease-related hospitalisation, 
surgery or need for steroids compared with those started on 
adalimumab (adjusted HRs of 0.8 (95% CI 0.66 to 0.98), 0.76 
(95% CI 0.58 to 0.99) and 0.85 (95% CI 0.75 to 0.96), respec-
tively). The study used propensity scores to match the cases 
as there were significant differences at baseline between the 
groups.794
In a nationwide Danish IBD registry-based propensity 
score-matched cohort study, when used as a first anti-TNF in 
Crohn’s disease, adalimumab-treated patients had a higher rate 
of all-cause hospitalisations (HR 1.84, 95% CI 1.18 to 2.85), 
a trend towards higher UC-related hospitalisation and a higher 
rate of serious infection requiring hospitalisation (HR 5.11, 95% 
CI 1.20 to 21.80) relative to infliximab. The risk of abdominal 
surgery was not different between the two treatment groups.795 
In the prospective randomised SWITCH trial 47% of Crohn’s 
disease patients in remission on standard dose infliximab who 
were switched to adalimumab 40 mg every other week either 
required dose escalation or switch back to infliximab to main-
tain remission.796 Combination infliximab plus azathioprine and 
adalimumab also seemed to be more effective than certolizumab 
in inducing remission in a recent network meta-analysis (OR 3.1 
(95% CI 1.4 to 7.7) and 2.1 (95% CI 1.0 to 4.6) respectively), 
although both appeared equivalent in maintaining remission 
(and both were superior to thiopurine alone).456
In a Swiss study, patients offered a choice between treatments 
stated that ease of use was the most important consideration with 
a majority favouring adalimumab, but also cited time required 
for treatment, time interval between doses, evidence of efficacy 
and fear of injections as reasons for expressing preference.797 A 
Korean study cited the presence of a doctor as the reason why a 
majority favoured infliximab.798 Relative costs and infusion unit 
availability issues/access should also be considered (see box 2).
5.2.4.2 Biosimilar anti-TNF drugs
The introduction of biosimilar medicines has introduced compe-
tition into the market for biological medicines with significant 
cost reductions. Biosimilar medicines are approved for use in the 
EU by the European Medicines Agency on the basis of high simi-
larity of structure, purity and biological activity to the originator 
biological medicine, with clinical evidence of comparable safety 
and efficacy for at least one therapeutic indication.799 Based on 
all the scientific data (comparability studies in quality, non-clin-
ical and clinical areas), extrapolation to other indications (where 
the drug is believed to have a similar mechanism of action) 
can then be made for the biosimilar. The European Medicines 
Agency does not regulate interchangeability, switching or substi-
tution, which is the remit of national bodies. It is recommended 
that biosimilars are prescribed by brand name to ensure full 
traceability and accountability. Patients should be fully informed 
statement 90. We recommend that, due to teratogenic and 
embryotoxic effects of methotrexate, prior to conception women 
should discontinue methotrexate for 6 months (GRADE: strong 
recommendation, low-quality evidence). If patients become 
pregnant on methotrexate then the drug should be discontinued 
and high dose folic acid (15 mg daily) provided for at least 
6 weeks. We suggest that men taking methotrexate may not 
need to discontinue treatment prior to conception (GRADE: weak 
recommendation, low-quality evidence. Agreement: 92.7%).
statement 87. Thiopurine metabolites (TGN and MeMP) can 
be used to optimise drug dosing. We suggest that metabolite 
monitoring may be used for those with inadequate response to 
therapy or toxicity, but should not be a substitute for routine 
monitoring blood tests (GRADE: weak recommendation, 
low-quality evidence. Agreement: 92.9%).
statement 88. We suggest that low-dose thiopurines (25–33% 
of usual dose) used in combination with allopurinol 100 mg 
may be considered in patients with thiopurine hepatotoxicity, 
nausea or flu-like symptoms, or those who are hypermethylators 
(GRADE: weak recommendation, low-quality evidence. 
Agreement: 81.4%).
statement 89. We recommend that IBD patients initiating 
thiopurine or methotrexate therapy should have baseline FBC, 
U&E and LFT measurement, with monitoring of these bloods at 
least at weeks 2, 4, 8 and 12, and then at least 3-monthly with 
monitoring for side effects (GRADE: strong recommendation, 
low-quality evidence. Agreement: 100%).
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about the biological medicine they are using, particularly if there 
is a change to a biosimilar from the originator molecule. Auto-
matic substitution is inappropriate, as all changes should be made 
with the full agreement and supervision of the prescribing physi-
cian.800 Extrapolation by indication is likely to be required for 
biosimilar use in IBD (comparative trials for regulatory purpose 
have not, to date, been performed in IBD) and should be eval-
uated by regulators on a case-by-case basis. Switching from 
originator biological medicine to biosimilar should also remain 
a clinical decision to be made by the physician and patient on 
an individual basis supported by the scientific evidence and 
by national recommendation.801 Currently, scientific evidence 
is lacking for reverse switching (back from biosimilar to origi-
nator), multiple switching and cross-switching.802 The effect on 
safety, efficacy and immunogenicity is not known and these prac-
tices should be avoided unless there is a specific need identified 
by the treating physician for an individual patient.
Biosimilar infliximab is already in use in IBD, and there is 
evidence available to support its safety and effectiveness. The 
NOR-SWITCH investigators studied 482 patients with Crohn’s 
disease, UC, spondyloarthritis, rheumatoid arthritis, psoriatic 
arthritis or plaque psoriasis who were randomised to continue 
originator infliximab or switch to CT-P13 biosimilar inflix-
imab.803 Switching to biosimilar infliximab was non-inferior over 
52 weeks with 26% experiencing disease worsening with contin-
uation of originator infliximab versus 30% of those switched 
to CT-P13. A potential limitation of this study was a selected 
15% non-inferiority margin. NOR-SWITCH was not powered 
to examine non-inferiority in individual disease groups, though 
the CI was close to inferiority for CT-P13 in Crohn’s disease. 
Excluding patients who had detectable anti-drug antibodies 
(ADAs) at baseline, the incidence of ADAs was 7% for inflix-
imab originator and 8% for CT-P13, with no significant differ-
ence in immunogenicity. Two single-centre observational studies 
of switching from Remicade to CT-P13 in Crohn’s disease and 
UC have also shown good short-term outcomes.804 805 Cohort 
studies of switching to biosimilar infliximab for psoriasis, anky-
losing spondylitis and rheumatoid arthritis have all confirmed 
comparable efficacy and tolerability following switching.806–809
Biosimilar versions of adalimumab became available in the UK 
in late 2018. Comparative clinical effectiveness and safety trials 
against originator adalimumab have been conducted in rheuma-
toid arthritis and psoriasis. Principles as discussed above should 
be used in decision-making about the use of all biosimilar adali-
mumab drugs in IBD. Post-marketing surveillance and outcomes 
data collected in national registries are essential to look for safety 
evidence, including immunogenicity, with biosimilar medicines.
5.2.4.3 Assessment after anti-TNF induction therapy
Clinical response to anti-TNF agents is seen early in Crohn’s 
disease and UC. Non-responders to induction therapy seem 
to have little benefit from sustained treatment, as shown in 
the ACCENT and CHARM studies.476 486 A clinical assess-
ment should be made 2–4 weeks after loading doses have been 
given. For those who have responded, dose optimisation is 
recommended. If a response is unclear, then measurement of 
biomarkers, serum C-reactive protein and faecal calprotectin, or 
comparison of disease activity scores or PROMs with baseline 
values, may be helpful. For those with complete lack of response, 
treatment should be discontinued and alternatives considered 
(choosing a different class of therapy). Further data are needed 
on the use of drug level monitoring during induction to guide 
therapy. Much of the data on drug levels after induction is at 
a later time point, such as 14 weeks after starting infliximab in 
the TAILORIX study (see below).810 Observational data in UC 
show that higher infliximab drug levels at weeks 2 and 6 during 
induction therapy are associated with early mucosal healing, but 
there are no prospective studies using drug levels at these early 
time points to guide dose adjustment.811
5.2.4.4 Drug levels of infliximab and adalimumab
Trough concentrations during and following induction therapy 
have been shown to correlate with response to therapy for both 
infliximab and adalimumab.812 In an analysis of infliximab data 
from the ACT 1 and ACT 2 UC studies, serum levels at week 8 
correlated with clinical response, remission and mucosal healing.250 
This is confirmed in many studies, also showing that undetectable 
serum levels are often associated with anti-drug antibodies and 
worse clinical outcomes.813–815 The randomised TAILORIX trial 
assessed use of drug levels in 122 luminal Crohn’s disease patients 
starting infliximab with an immunomodulator, and did not show 
benefit for treatment intensification starting at week 14 based 
on regular clinical assessment combined with drug levels and 
biomarker measurement when compared with clinical assessment 
only.810 The TAXIT study recruited IBD patients on stable main-
tenance infliximab therapy to evaluate trough infliximab levels 
to guide dosing.816 In the initial phase, all had their dose opti-
mised with a target level of 3–7 µg/mL. Patients with low trough 
levels had their dose increased. For Crohn’s disease patients there 
was a corresponding increase in clinical remission. Patients with 
high trough levels had their dose reduced. Overall this optimis-
ation strategy was shown to be cost-effective. Patients were then 
randomised to dosing over the following year based on clinical 
features alone or based on trough levels. There was no difference 
in remission between the two groups, but there was a lower rate of 
flare in those randomised to the trough level-based dosing.
As discussed in the Section 4.9.3.1: Infliximab for perianal 
fistulising disease, higher levels may be required for patients with 
perianal fistulae.586 Drug levels vary according to the assay used, 
and consensus has not yet been achieved on the optimal thera-
peutic ranges. A flow chart for the use of anti-TNF therapeutic 
drug monitoring is presented in figure 4.
5.2.4.5 Primary non-response to anti-TNF therapy
Treatment failure to anti-TNF therapy should be divided into 
primary non-response (failure to respond to induction therapy) 
and secondary loss of response. For patients with primary 
non-response to one anti-TNF, the likelihood that they will 
respond to a second is small but is dependent on the clinical 
Good Practice recommendation 15. All IBD patients should 
be reviewed 2–4 weeks after completing loading doses of 
anti-TNF therapy to assess response and optimise maintenance 
dosing based on clinical response and measures such as serum 
drug and anti-drug antibody concentrations, blood inflammatory 
markers, faecal biomarkers or endoscopy (Agreement: 82.5%).
statement 91. We recommend that biosimilar infliximab may 
be used for IBD patients starting treatment (GRADE: strong 
recommendation, low-quality evidence). We recommend that 
patients already on originator infliximab can be switched to 
biosimilar infliximab if in stable response or remission (GRADE: 
strong recommendation, moderate-quality evidence. Agreement: 
97.7%).
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context. Switching to a drug that acts through a different mech-
anism is more likely to be successful. Measuring drug and anti-
body levels may have a role, with recent evidence suggesting that 
drug levels in primary non-responders are often lower than in 
responders,817 and antibody formation can be a significant factor 
within a few weeks of treatment initiation.
5.2.4.6 Secondary loss of response to anti-TNF therapy
Secondary loss of response to anti-TNF therapy can occur as 
a consequence of immune-mediated neutralising antibodies 
to the drug (although there are likely to be other mechanisms 
including non-neutralising, drug-clearing antibodies or non-im-
mune-mediated mechanisms). Measurements of drug and anti-
body levels are helpful in guiding next steps.818 A retrospective 
analysis of 247 IBD patients with 330 loss of response events 
(188 to infliximab and 142 to adalimumab) showed that, 
following loss of response, trough concentration measurements 
and anti-drug antibodies could inform the likely outcome of 
interventions. Patients with either adequate drug concentra-
tions (adalimumab >4.5 µg/mL or infliximab >3.8 µg/mL) or 
positive anti-drug antibodies (adalimumab >4 µg/mL equivalent 
or infliximab >9 µg/mL equivalent) did better by switching to 
an alternative anti-TNF or an alternative class of drug, whereas 
patients with low drug concentration and negative antibodies 
improved with dose increase.819 A decision analytic model in 
Crohn’s patients losing responsiveness to infliximab showed 
that a testing strategy was likely to be cost-effective compared 
with empiric changes in treatment.820 In a prospective study of 
IBD patients with secondary loss of response to infliximab, all 
of whom had a dose increase, mucosal healing occurred in half 
of patients and was associated with a rise in trough levels.821 
In patients losing response to infliximab and manifesting with 
‘end of dose’ recurrence of Crohn’s symptoms, drug levels and 
anti-drug antibody levels should be checked and consideration 
given to starting concomitant immunomodulator therapy where 
this is not already being used. To increase the drug levels of 
infliximab by shortening the infusion interval to 6 weeks may 
be as effective as shortening to 4 weeks or giving a 10 mg/kg 
dose.822 Once remission has been recaptured over a period of 
3–4 months, it may be possible to reduce the dose or stretch the 
intervals back out again without losing response. In a further 
retrospective study in 168 Crohn’s patients losing response, 
112 patients were treated with 10 mg/kg 8-weekly and 56 with 
5 mg/kg at 4-week intervals. Sustained response was achieved in 
50% who received double dose and 39% of those with interval 
shortening, OR 1.5 (95% CI 0.8 to 2.9).823 Doubling the dose 
is generally more convenient and cost-effective than interval 
shortening.
A significant proportion of patients have detectable drug 
levels and a low titre of anti-drug antibodies. Management in 
this situation is not clear as antibodies may be transient824 and, 
as shown in a post-hoc analysis of the TAXIT trial,825 infliximab 
dose escalation can facilitate an adequate trough drug level and 
can result in clinical response despite the presence of anti-drug 
antibodies. Starting the patient on immunomodulator therapy (if 
they are not already on this) can abolish the antibody response 
and restore efficacy, particularly if combined with an increase in 
anti-TNF dose.826
The presence of low drug levels in the presence of high titre 
antibodies (and perhaps even low titre antibodies in the context 
of adalimumab) mandates a switch, ideally within class to an 
alternative anti-TNF therapy, particularly if the patient has 
previously shown themselves to be anti-TNF responsive over a 
Figure 4 Anti-TNF therapeutic drug monitoring.
statement 92. We suggest that treatment options for failure of 
initial anti-TNF therapy (increase dose, shorten dosage interval, 
switch to alternative anti-TNF, or switch to different drug class) 
may be informed by the clinical context and by measurement of 
serum drug and anti-drug antibody concentrations (GRADE: weak 
recommendation, low-quality evidence. Agreement: 97.7%).
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prolonged period. Of note, individuals who form antibodies to 
one biological therapy may be more prone to forming them to a 
second.827 In this context, having a low threshold for combining 
the second biologic with immunomodulator therapy is logical 
to reduce the risk of future antibody-mediated loss of response.
Many of the published studies on switching from originator 
to biosimilar infliximab have measured drug and anti-drug anti-
body concentrations before switching.803 828 This may identify 
patients with low drug levels and/or antibodies, who probably 
should not switch, with a more appropriate action either to 
withdraw therapy (if in deep remission) or switch to a different 
drug class.
5.2.4.7 Annual review of patients on biologics therapy
National Institute for Health and Care Excellence (NICE) 
technology appraisals for biological therapies in IBD (inflix-
imab, adalimumab, golimumab, vedolizumab and ustekinumab) 
recommend annual review.137 829–832 Although there is little 
evidence to support this, it is sensible to assess the safety and effi-
cacy of long-term treatment with both immunosuppressive and 
biological drug therapy. Patients may be having their treatment 
in infusion facilities or at home, and a formal clinical review is 
necessary to ensure that changing circumstances, adverse effects 
of treatment, long-term clinical remission or other factors do not 
make it more appropriate to withdraw treatment or substitute 
alternative therapy.816
5.2.5 Drug management: vedolizumab and ustekinumab
Vedolizumab and ustekinumab are contraindicated in patients 
with active TB, sepsis or opportunistic infections, including gut 
infections such as Clostridium difficile. Pretreatment screening 
should be undertaken as for anti-TNF treatment. Latent TB 
should be treated prior to commencing either drug. Patients 
should be up to date with vaccination prior to starting treatment 
where possible. Non-live vaccines may be administered during 
either drug treatment, but not live vaccines. Both drugs should 
be stopped if severe infection develops.
5.2.5.1 Vedolizumab
Close monitoring for evidence of progressive multifocal leuco-
encephalopathy (PML) in patients treated with vedolizumab 
has shown no cause for concern. However, patients should be 
monitored for and advised to report any neurological symptoms 
that develop because of the rare occurrence of PML in patients 
treated with other integrin receptor antagonists in conjunction 
with systemic immunosuppressive drugs.
Integrated long-term safety data (May 2009 to June 
2013) showed that serious C. difficile infections, sepsis or 
TB occurred in 0.6% of patients and there were no cases 
of PML.165 833 Other studies show no increase in infection 
risk.834–836 A meta-analysis of 49 studies of biologics with 
safety data in IBD did show that there is an increase in risk of 
opportunistic infections that is no different between anti-TNF 
and anti-integrin agents. Long-term safety data for vedoli-
zumab over 9 years are reassuring.163 The same study showed 
very small numbers of malignancies.837 An advantage of the 
gut-specific immunosuppression of vedolizumab, however, 
is that it does not alter the immune response to parenterally 
administered antigens, although it does affect the response 
to orally administered vaccines.838 There is still uncertainty 
about the mechanism of action of vedolizumab, with recent 
data showing that modulation of innate immunity contributes 
to its therapeutic efficacy.839 Subanalysis and data from the 
GEMINI studies have shown that the frequency of infusion 
related reaction (IRR) with vedolizumab is around 5%.840
5.2.5.2 Ustekinumab
Ustekinumab, through inhibition of IL-12 and IL-23, inhibits 
key molecules in cellular immunity. Although there are no 
head-to-head data with anti-TNF therapy, safety appears to be 
very good. Data from dermatological studies (where the drug 
has been NICE-approved for treatment of psoriasis since 2009) 
are also reassuring. Analyses of psoriasis registry data show that 
anti-TNF therapies are associated with a greater risk of serious 
infection (1.9–2.9/100 patient-years) compared with usteki-
numab (0.93/100 patient-years),841although at a lower dose 
of ustekinumab than used in Crohn’s disease. A further safety 
review in psoriatic arthritis treatment concluded that the most 
common events were respiratory tract infections, nasopharyn-
gitis, headache and injection site reactions.842 In 167 Crohn’s 
patients failing anti-TNF therapy, treated with ustekinumab, 
a very similar side effect profile occurred, with no malig-
nancy, TB or deaths attributed to the drug. It was noted that 
11.4% developed arthralgia,512 but arthralgia was not noted 
to be more common on active treatment than placebo in the 
IM-UNITI maintenance trial. Adverse events associated with 
infusions in the UNITI and IM-UNITI trials occurred in 3.4% 
of patients.506
5.2.5.3 Extraintestinal manifestations (EIM) of IBD and vedolizumab 
therapy
There has been interest in the impact of vedolizumab on 
patients with extraintestinal manifestations (EIMs). The 
OBSERVIBD GETAID cohort followed 294 patients treated 
with vedolizumab (173 Crohn’s disease, 121 UC) of whom 49 
(16.7%) had EIMs at baseline (47 arthropathy, four skin, and 
two both joints and skin). At week 54, 44.7% had complete 
remission of their arthropathy and 75% of their skin EIMs. 
On multivariable analysis, remission of arthropathy was asso-
ciated with clinical remission of their luminal disease and with 
recent onset of arthropathy. However, during follow-up 13.8% 
statement 94. We suggest that pretreatment screening 
and blood monitoring of therapy on vedolizumab and 
ustekinumab should at present follow recommendations for 
anti-TNF drugs due to insufficient long-term safety data at 
this time to recommend an alternative algorithm (GRADE: 
weak recommendation, very low-quality evidence. Agreement: 
95.3%).
statement 93. We suggest that patients with secondary loss 
of response to anti-TNF therapy may have serum drug and anti-
drug antibody concentrations measured to inform appropriate 
changes in treatment (GRADE: weak recommendation, 
moderate-quality evidence. Agreement: 97.6%).
Good Practice recommendation 16. IBD patients receiving 
immunomodulators or biologics should have an annual review 
of treatment, including consideration of response and treatment 
continuation, optimisation or cessation (Agreement: 97.7%).
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developed de novo arthropathy and 4.8% paradoxical skin 
inflammation.843
5.2.6 Cancer and treatment with biologics
Biologics in the treatment of IBD are not completely contrain-
dicated in patients with prior malignancy, and decisions should 
be individualised. A delay of at least 2 years after successful 
cancer eradication is appropriate, and this should be extended 
to 5 years for those cancers with a high risk of late metastatic 
spread (including breast, malignant melanoma and renal cell carci-
noma).844 Data from the New York Crohn’s and Colitis Organi-
sation for 333 IBD patients with a history of cancer followed up 
for 5 years did not show any differences in the rate of cancer-free 
survival between patients treated with anti-TNF therapy, immu-
nomodulators, anti-TNF/thiopurine combination therapy or no 
immunosuppression.845 Evidence related to malignancy in relation 
to IBD and its treatment is reviewed in recent ECCO guidance.846
5.2.7 Withdrawal of immunosuppression for patients in sustained 
remission
5.2.7.1 Stopping thiopurines
A recent systematic review summarised the published data 
on thiopurine withdrawal in patients in clinical remission.192 
Relapse rates were higher among patients randomised to with-
drawal, and at 12 months ranged from 16.5% to 53% in Crohn’s 
disease and from 11% to 77% in UC. Fewer studies reported 
longer term rates: at 5 years ranging from 63% to 85% in 
Crohn’s disease and 43% to 65% in UC. Two studies reported 
on the rate of success at reintroducing thiopurines in Crohn’s 
disease, with rates of 74%194 and 96%,847 with only a single 
study reporting this outcome in UC with successful reintroduc-
tion in 92% of cases.194 The risk of relapse should be weighed 
against the emerging risks of longer term thiopurine therapy, 
including infections and cancer. In particular, the absolute risk 
increase of lymphoma rises markedly with increasing age.848
5.2.7.2 Stopping anti-TNF therapy
From studies assessing outcomes of stopping therapy after 
at least 12 months of anti-TNF therapy, the estimated relapse 
rate at 1 year was 39% for Crohn’s and 35% for UC/IBD-U.849 
The estimated relapse rates at 2 years were 54% for Crohn’s 
disease and 42% for UC/IBD-U. Among patients relapsing 
and retreated with anti-TNF, the estimated chances of success 
were 88% for Crohn’s disease and 76% for UC/IBD-U. Various 
models to predict chance of relapse have been proposed.192 The 
clinical factors associated with relapse, however, vary between 
studies.850 Younger age, smoking, longer disease duration, fistu-
lising perianal Crohn’s disease, anaemia, raised CRP and raised 
faecal calprotectin are linked with increased risk of relapse. 
Mucosal healing (and in some studies low serum drug levels) are 
associated with a lower risk of relapse. Patients receiving esca-
lated dosages of anti-TNFs or for the indication of postopera-
tive recurrence in Crohn’s disease had a >75% risk of relapse on 
drug withdrawal. Persistent abnormalities on MRE in Crohn’s 
disease patients in endoscopic remission also makes relapse more 
likely.851 Decisions regarding withdrawal should be taken in the 
context of the individual patient, their disease history and the 
consequences of relapse.852 Patient profiles favouring treatment 
withdrawal include: older patients without previous complica-
tions, surgery and with no evidence of active inflammation, those 
with comorbidities increasing their infection risk, those with 
undetectable trough drug levels and other practical reasons miti-
gating against continuing injections or infusions.853 There is no 
safe minimum period of corticosteroid-free remission, but at least 
1–2 years seems reasonable. The concept of cyclical biologics use 
(stopping when deep remission is established and restarting in 
the event of pre-clinical relapse) has been introduced, but there 
is no evidence as yet that this is safe or cost-effective.853 All the 
published data so far come from prospective and retrospective 
cohort studies such as the STORI study.854 Data on outcomes 
after withdrawal of newer biologics are awaited.
5.2.7.3 Monitoring following immunosuppressive and biological 
therapy withdrawal
As with stopping thiopurines, faecal calprotectin rises prior to clin-
ical relapse.855 856 A study of serial faecal calprotectin, C-reactive 
protein, full blood count and protein electrophoresis at 3-month 
intervals after stopping azathioprine showed that calprotectin was 
the only predictor of clinical relapse in both Crohn’s disease and 
UC.857 Serial measurement of faecal calprotectin offers a potential 
opportunity to escalate therapy prior to the development of symp-
toms, although prospective evidence to validate increasing therapy 
in this context is lacking. It should not be measured routinely in all 
patients, but targeted to those where there are significant anxiety 
or concerns related to stopping anti-TNF therapy.
5.2.8 Drug management: corticosteroids
5.2.8.1 Overuse of corticosteroids
Corticosteroids are effective agents at inducing clinical remis-
sion, but do not have a role in preventing relapse.99 858 Steroid 
dependency is generally defined as an inability to wean below 
10 mg of prednisolone or 3 mg of budesonide within 3 months 
of starting, or disease flare within 3 months of stopping steroids; 
steroid refractory disease is active disease despite taking up 
to 1 mg/kg/day of prednisolone for 4 weeks. Steroid excess is 
considered to be two or more courses of steroid over 1 year. A 
recent audit found that 14.9% of IBD patients had steroid depen-
dency or excess in the UK, more commonly in UC than Crohn’s 
disease.448 Prolonged steroid use (often defined as continuous 
therapy for more than 3 months) is associated with numerous 
side effects including increased infection risk, osteoporosis, 
suppression of the hypothalamic-pituitary-adrenal axis, diabetes, 
weight gain and cardiovascular disease. There is evidence of 
increased mortality in IBD patients on long-term steroids, with 
a study in USA Medicare and Medicaid patients showing that 
prolonged steroid use (more than 3000 mg prednisolone equiv-
alent in 1 year) carries greater mortality (significant for Crohn’s, 
non-significant for UC) compared with patients starting anti-TNF 
therapy,859 with data from the TREAT registry also showing that 
statement 95. We suggest that IBD patients in prolonged 
remission on thiopurines, and who have mucosal healing, 
may stop the drug after discussion of risks and benefits and 
considering patient preference. Reintroduction if relapse occurs 
is usually successful (GRADE: weak recommendation, low-quality 
evidence. Agreement: 95.3%).
statement 96. We suggest that anti-TNF therapy may be 
withdrawn in patients with prolonged corticosteroid-free 
remission and mucosal healing. Retreatment in the event of 
relapse is usually successful, but there is insufficient evidence 
about which clinical factors predict relapse after withdrawal 
and decisions should be individualised (GRADE: weak 
recommendation, very low-quality evidence. Agreement: 93.2%).
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prednisolone use was an independent risk factor for mortality.516 
In an audit excessive steroid use was avoidable in nearly half of 
patients,448 was more likely to be avoided if patients attended a 
dedicated IBD clinic, and if there was a local multidisciplinary 
IBD team. Steroid use in the previous year is an important disut-
ility included in the ICHOM dataset,346 and documenting assess-
ment of alternative therapies and discussion with the patient is 
important for all patients on long-term steroids.
5.2.8.2 Corticosteroid-related bone disease
Approximately 35–40% of patients with IBD suffer from osteo-
penia and 15% from osteoporosis, and both Crohn’s disease 
and UC patients have increased risk.860–862 Risk factors include 
uncontrolled inflammation, malabsorption (particularly in 
Crohn’s disease), weight loss, prolonged or high-dose oral 
steroid use or lack of physical activity.863–866
5.2.8.3 Calcium and vitamin D supplementation
For patients who have to receive corticosteroids, other factors 
should be addressed that have a negative impact on bone 
mineral density. This includes advice to stop smoking, reduce 
excess alcohol intake and partake in regular muscle-building and 
weight-bearing exercise such as weight training or running.860 
Vitamin D deficiency is common, and occurs in more than 
half of patients with UC and Crohn’s disease in the UK and 
northern Europe.867 868 In older people, there is evidence from 
a systematic review that vitamin D supplementation with daily 
dose of 700–800 IU reduces the risk of hip and non-vertebral 
fractures.869 A study of patients with Crohn’s disease showed 
that treating their active disease, and supplementing vitamin D 
with 800 IU and 500–1000 mg calcium daily, resulted in a small 
increase in bone density over the next 4 years.870 Steroids reduce 
calcium absorption from the gut and increase urinary losses, 
leading to secondary hyperparathyroidism which results in bone 
resorption. A Cochrane review of five trials confirmed that 
calcium and vitamin D supplementation for all patients treated 
with steroids prevented bone loss from the lumbar spine and 
forearm.871 Calcium supplementation may increase cardiovas-
cular risk (particularly if not accompanied by vitamin D supple-
mentation). A Swedish long-term cohort study showed that a 
total (dietary and supplements) calcium intake greater than 
1400 mg daily was associated with increased all-cause mortality 
(HR 1.4; 95% CI 1.17 to 1.67).872 Calcium supplements should 
not be given without vitamin D, and treatment with calcium and 
vitamin D should not therefore continue long term unless dietary 
calcium intake is less than 800 mg daily. An online calcium calcu-
lator can be used to estimate dietary calcium intake (http://www. 
cgem. ed. ac. uk/ research/ rheumatological/ calcium- calculator/). 
Vitamin D should be measured and supplemented if deficient, 
with a high loading dose followed by maintenance.
Reduction in bone mineral density and fracture risk are wors-
ened by oral corticosteroid use, and the greatest bone loss occurs 
in the first 6 months of treatment.873 874 Before starting oral 
steroids, patients should have their fracture risk assessed as shown 
in figure 5. For patients aged over 40, the Fracture Risk Assess-
ment Tool (FRAX) can be used to assess the 10 year probability 
of a major osteoporotic fracture (http://www. shef. ac. uk/ FRAX/). 
Patients with a high FRAX score (score ≥20% major fracture and 
≥3% hip fracture), those aged under 40 with risk factors or those 
receiving prolonged (more than 3 months) or repeated courses 
of oral corticosteroids should have their bone mineral density 
assessed by bone densitometry.861 875 Note that FRAX does not 
discriminate past versus current corticosteroid use, nor does it 
stratify risk according to doses beyond 7.5 mg, and risk should 
be adjusted accordingly.876 877 Patients on long-term steroids 
should have a repeat bone densitometry at 1 year, and if stable, 
repeated at 2–3-year intervals, but if declining, repeated annually. 
Women and men aged 70 or more, with past fragility fracture, 
taking high-dose steroids (7.5 mg or more prednisolone-equiva-
lent), or at high risk based on FRAX score, should be considered 
for bone-protective therapy at the start of steroid treatment.878 
Alendronate or risedronate should be used, unless contra-indi-
cated or not tolerated, in which case intravenous zoledronate 
or teriparatide should be given. For women of childbearing age 
requiring bone-protective therapy, if they are taking effective 
contraception (or not sexually active), oral bisphosphonates are 
the first-line therapy followed by teriparatide if oral bisphospho-
nates cannot be used.878 Denusomab and high-dose intravenous 
bisphosphonates should not be used in this situation due to lack 
of data on the risk of fetal harm should an unplanned pregnancy 
occur. There is a lack of safety data on use of denosumab with 
immunosuppressive therapy, and on all osteoporosis therapies 
during pregnancy, other than calcium and vitamin D.878
Bisphosphonate or denosumab therapy are associated with the 
rare adverse effects of osteonecrosis of the jaw or atypical femoral 
fractures. Current UK guidance for the prevention and treatment 
of osteoporosis recommends dental examination with preventative 
dentistry in those with dental disease or other risk factors (eg, use 
of corticosteroids or smoking).877 These guidelines also encourage 
patients to maintain good oral hygiene and regular check-ups 
with reporting of new oral symptoms (eg, dental mobility, pain or 
Good Practice recommendation 17. Risk factors for 
osteoporosis in IBD include prolonged corticosteroid use, but 
general risk factors should also be screened for and corrected, 
including malnutrition, inflammation, smoking and lack of 
weight-bearing exercise (Agreement: 100%).
statement 99. We recommend that all patients receiving a 
course of corticosteroids for a disease flare should receive an 
intake of 800–1000 mg/day calcium and 800 IU/day vitamin D 
(GRADE: strong recommendation, very low-quality evidence). 
This can be achieved by administration of oral calcium and 
vitamin D supplements while on corticosteroids, or vitamin D 
only if dietary calcium intake is adequate. Lifestyle modification 
advice including regular physical exercise and smoking cessation 
should also be provided (Agreement: 90.9%).
statement 97. We suggest that patients in whom anti-TNF 
therapy is withdrawn should be observed for evidence of relapse. 
Monitoring of faecal calprotectin may be helpful in this context 
as levels may rise before clinical relapse occurs (GRADE: weak 
recommendation, low-quality evidence. Agreement: 97.9%).
statement 98. We recommend that prolonged corticosteroid 
therapy is harmful and should be minimised by specialist 
intervention and involvement with the multidisciplinary 
team to explore other treatment options (GRADE: strong 
recommendation, moderate-quality evidence. Agreement: 
97.8%).
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swelling) while on therapy.877 Treatment review is recommended 
to consider stopping bisphosphonate after 5 years (after 3 years 
for zolendronate) unless patients are aged over 70, have previous 
hip/vertebral fracture, sustain a fracture during treatment or are 
continuing ≥7.5 mg prednisolone, in which case treatment may 
be continued.877 If treatment is discontinued fracture risk should 
be assessed after a new fracture, or if no new fracture should be 
assessed after 18 months to 3 years.877
5.2.8.4 Corticosteroid-related adrenal suppression
Corticosteroid withdrawal syndrome can present with weak-
ness, fatigue, loss of appetite, weight loss, nausea and vomiting, 
diarrhoea and abdominal pain, and so can mimic the underlying 
disease. It is under-recognised, occurring in about half of patients 
tested immediately after withdrawal of medium- or high-dose 
prednisolone used for long periods.879 Symptoms may be mild, 
statement 100. We recommend that patients starting 
corticosteroids should be assessed for risk of osteoporosis. Those 
at high risk should be started on bisphosphonate therapy at the 
onset of corticosteroid therapy (GRADE: strong recommendation, 
high-quality evidence), after ensuring adequate calcium intake 
and supplementing vitamin D (Agreement: 90.7%).
Figure 5 Osteoporosis prevention and management in IBD.
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with decompensation only when exposed to stressful situations, 
or can be severe. Stimulation tests (such as the ACTH test or 
short synacthen test) are abnormal in 46–100% immediately 
after stopping, but still abnormal in 26–49% after 1 week, and 
in a few patients remain abnormal 6–22 months later.880 Neither 
previous prednisolone dose nor duration are good predictors of 
the problem, which will occur with rectal-administered as well 
as oral steroids, and can occur after as little as 4 weeks of treat-
ment. Steroid tapering does not completely prevent its occur-
rence. There is no optimal test to confirm adrenal suppression 
in this situation. Steroid dose and duration should be minimised 
where possible, with slow taper, and awareness when suggestive 
symptoms occur. Slow tapering of budesonide is not required as 
there is little or no suppression of the HPA axis.
5.2.8.5 Other metabolic complications of corticosteroids
Before starting oral corticosteroid therapy for 3 months or longer 
or repeating oral steroids within 6 months of a previous course, 
record height, weight, blood pressure, full blood count, fasting 
plasma glucose or HbA1c and lipids. Blood pressure and BMI 
should be measured at every clinic visit. For patients with dyslip-
idaemia or a raised cardiovascular risk at initiation, repeat a 
lipid profile 1 month after initiation and then every 3–6 months. 
Monitor fasting glucose or HbA1c every 3 months. An annual 
examination by an ophthalmologist is required for patients with 
symptoms of cataracts, a personal or family history of open angle 
glaucoma, diabetes mellitus, high myopia or connective tissue 
disease (particularly rheumatoid arthritis). Mood disturbance 
such as depression or sleep disturbance should be questioned at 
every clinic visit. Steroids may exacerbate the potassium-low-
ering effects of thiazide or loop diuretics, and potassium should 
be monitored.875 Avascular necrosis of the femoral head is a 
serious complication of prolonged steroid use, and if hip pain 
develops should be considered, and if suspected urgent MRI 
is recommended along with cessation of steroids. Patients on 
long-term steroids should be vaccinated as for those on immu-
nosuppressive therapy (see Section 5.2.1.3: Common Disease 
Considerations, Immunosuppressive therapy, Vaccination).
5.2.8.6 Prevention of Pneumocystis jirovecii infection
Prophylaxis for Pneumocystis jirovecii using co-trimoxazole has 
been shown to reduce incidence by 91% in a meta-analysis of 
studies in transplant recipients and haematological malignancy.881 
In the Spanish registry ENEIDA study of 571 patients treated 
with rescue therapy, two developed P. jirovecii pneumonia (PJP) 
and one died. Both had received double immunosuppression 
(corticosteroids and azathioprine) and had not received prophy-
laxis, which was given to all receiving triple immunosuppression. 
The risk relates as much to use of corticosteroids as to other 
immunosuppressive drugs.234 A study from the USA showed a 
low incidence of PJP in IBD patients despite low use of prophy-
laxis. There were three cases identified among 937 patients with 
6066 patient-years follow-up with wide confidence intervals 
around the risk related to each class of immunosuppressant.882 
Overall risk is low. PJP prophylaxis should perhaps be restricted 
to those on triple therapy taking ≥20 mg prednisolone, particu-
larly those with other risk factors (age, frailty, comorbidity). The 
optimal dose regimen is unclear, but in adults co-trimoxazole 
960 mg three times per week or 480 mg daily are widely used. 
Stevens–Johnson syndrome is a rare but devastating complica-
tion of co-trimoxazole and should be discussed with patients 
when offering co-trimoxazole therapy.
5.3 diet and Ibd
Dietary patterns and food consumption vary hugely across the 
world and the diet is very different in countries with a high prev-
alence of IBD compared with countries with a low prevalence. 
From epidemiological evidence, when people migrate from a 
country with a low prevalence of IBD to a country with a high 
prevalence they are at increased risk of developing IBD, thus 
incriminating environmental changes. Dietary components that 
have been associated with an increase in the risk of or relapse of 
IBD include cereals, dietary fibre, sugar, fat, fruit, vegetables and 
protein.883–887 However, no one dietary component is consis-
tently blamed. Thus, until strong scientific evidence supports a 
defined diet, patients with IBD should be advised to eat a varied 
diet to meet their energy and nutrient requirements, including 
dietary fibre. The diet (box 8) should be based on local healthy 
eating guidelines and include a wide variety of fruit and vege-
tables, cereals, grains, nuts and seeds, protein-rich foods with a 
moderation/reduction of high fat, particularly animal fat, high 
sugar and processed (cured, salted or smoked) meats. Patients 
with stricturing Crohn’s disease may need to alter their intake of 
dietary fibre and fibrous foods for symptomatic management of 
strictures and may need supplementation with enteral or paren-
teral nutrition to achieve their energy and nutritional require-
ments.424 436 Management of short gut or intestinal failure due 
to Crohn’s disease is covered well elsewhere.888
5.3.1 Nutritional assessment and monitoring
Malnutrition is common in IBD and comprises undernutrition 
and overnutrition. Up to 85% of patients with IBD have under-
nutrition.889 Unintentional weight loss and low BMI are common 
in patients with newly diagnosed IBD and during disease relapse. 
The causes are multifactorial and include suboptimal nutritional 
intake, alterations in energy/nutrient requirements and metabo-
lism, malabsorption, excessive gastrointestinal losses and medi-
cation. Overnutrition occurs in 15–40% of patients with IBD 
and may in part be due to improved management of IBD and the 
obesity epidemic.890 891 Thus, nutritional assessment in patients 
with IBD is crucial to identify and appropriately manage patients 
with or at risk of malnutrition.
Good Practice recommendation 18. Patients receiving 
prolonged courses of corticosteroids are at risk of adrenal 
suppression and should have a tapering course if stopping. They 
should be warned about possible steroid withdrawal syndrome, 
including non-specific symptoms such as weakness, nausea and 
arthralgia (Agreement: 97.8%).
Good Practice recommendation 19. Patients on prolonged 
corticosteroids should have blood pressure, glycaemic 
control and serum potassium monitored. They should receive 
vaccinations as for those on immunomodulatory therapy 
(Agreement: 82.6%).
statement 101. We suggest that adult IBD patients on triple 
immunosuppression and using more than 20 mg prednisolone 
may be offered prophylactic antibiotics for Pneumocystis jirovecii 
(co-trimoxazole oral 960 mg three times weekly or 480 mg daily) 
(GRADE: weak recommendation, very low-quality evidence. 
Agreement: 85.7%).
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There are limited data on the frequency of routine nutritional 
assessment in IBD, although inpatients seem to be much more 
frequently assessed892 than outpatients.436 893
Standard nutritional assessments should assess BMI, 
recent unintentional weight loss and the nature of disease. 
However, deficits in body composition, muscle strength and 
serum micronutrients are common in IBD, and BMI alone 
cannot detect these. An increase in fat mass and decrease in 
fat-free mass are often reported and increased intra-abdom-
inal fat (visceral fat) is linked to increased cardiovascular 
risk, increased surgical complications and hospitalisation.890 
A more detailed assessment of nutritional status should also 
include measurements of body composition (waist circumfer-
ence (a proxy for visceral adiposity894), tricep skinfold thick-
ness, mid arm muscle circumference), muscle (hand-grip) 
strength and micronutrient status (dietary intake and serum 
measurements).895
5.3.2 Blood tests for specific nutritional deficiencies
Measurement of macronutrient and micronutrient status in IBD 
is important for ongoing monitoring in patients who have or are 
at risk of malnutrition; however, interpretation of results can 
be challenging. Some micronutrients are influenced by disease 
activity so serum levels should consider C-reactive protein (CRP) 
when interpreting these micronutrients. A reliable clinical inter-
pretation can be made only if the CRP is <20 mg/L (plasma 
zinc), <10 mg/L (plasma selenium, vitamin A and vitamin D) or 
<5 mg/L (vitamin B6 and vitamin C).896 Magnesium deficiency 
has been reported to occur in 13–88% of patients with IBD,897 
but serum magnesium is not an accurate measurement of magne-
sium status because less than 1% of magnesium stores are in 
the blood. The remainder is in bone, soft tissue and muscle.898 
Magnesium deficiency in IBD is likely to be caused by increased 
gastrointestinal losses. Symptoms of magnesium deficiency 
include abdominal cramps, impaired healing, fatigue and bone 
pain. Magnesium supplementation can be given orally or intra-
venously, although oral supplementation can worsen diarrhoea. 
Up to a third of patients with IBD fail to meet the recommended 
dietary intake for calcium and calcium supplementation should 
be considered alongside vitamin D supplementation (see Section 
5.2.8.3: Common Disease Considerations, Calcium and vitamin 
D supplementation). Plasma potassium levels should be moni-
tored and supplemented as required. There are existing ECCO 
guidelines for monitoring and management of iron, vitamin B12 
and folate deficiency.899 General advice about iron replacement 
is shown in box 9.
5.3.3 Vitamin D
In a multicultural UK IBD cohort, the prevalence of vitamin D 
deficiency (<50 nmol/L) was 66% in Crohn’s disease and 69% 
in UC, and severe vitamin D deficiency was 27% in Crohn’s 
disease and 36% in UC.867 Median vitamin D levels were lower 
in black and Asian ethnic groups relative to white subjects, and 
box 8 Practical dietary advice in Ibd
In general:
 ► Some dietary components (ie, cereals, dietary fibre, sugar, 
fat, fruit, vegetables and protein) have been associated with 
IBD; however, a relapse or ongoing symptoms cannot be 
attributed to one dietary component
 ► Non-evidence based self-directed exclusion diets are to be 
discouraged as they can lead to limited diet quality and 
nutrient deficiency
 ► All Ibd patients should be advised to eat a varied diet to 
meet energy and nutrient requirements, including dietary 
fibre. The diet should be based on local healthy eating 
guidelines and include a wide variety of fruit and vegetables, 
cereals, grains, nuts and seeds, protein-rich foods with a 
moderation/reduction of high fat, particularly animal fat, high 
sugar and processed meats
 ► Patients with stricturing Crohn’s disease: consider 
limiting dietary fibre and fibrous foods. Supplementation with 
enteral or parenteral nutrition may be required to achieve 
energy and nutritional requirements
 ► Patients with functional bowel symptoms (in remission/
mildly active disease): consider giving dietary advice as for 
irritable bowel syndrome (eg, low FODMAP diet)
diet with an ileostomy*
 ► Initial dietary advice: small frequent, nutrient dense meals/
snacks and oral nutritional supplements where necessary
 ► Sodium: to prevent dehydration, sprinkle extra salt onto 
meals; add 0.5−1 teaspoon per day
 ► Potassium: increase intake if serum potassium is low 
(potassium-rich foods suitable for an ileostomy include 
bananas, potatoes and potato crisps, spinach, fish, poultry, 
lean red meat, sweet potato, avocado)
 ► Fibre: a high fibre intake can increase loose stools, flatulence 
and bloating
 ► Thickening output: bananas, pasta, rice, white bread, mashed 
potato, marshmallows or jelly
 ► Fluids: avoid chronic dehydration and advise 2–2.5 litres of 
fluids per day, more during hot weather or exercise. Check 
urinary sodium to detect dehydration. Be cautious with high 
intakes of hypotonic (eg, tea, water) and hypertonic (eg, fruit 
juice) drinks as these can increase stoma output and increase 
dehydration. Encourage isotonic drinks (eg, Dioralyte, sports 
drinks) and if ileostomy output exceeds one litre per day 
recommend oral rehydration solution: 1 litre tap water with 
six level teaspoons glucose, one level teaspoon salt, half 
teaspoon sodium bicarbonate or sodium citrate with or 
without flavouring
 ► 1–2 tablets (2–4 mg) loperamide half hr before meals.
 ► Avoid stoma blockages: recommend chewing food 
thoroughly and advise caution with fruit and vegetable skins, 
sweetcorn and celery and avoid nuts (smooth nut butters are 
fine).
 ► Vitamin B12 monitoring.
 ► An ileostomy pathway based on patient education for 
monitoring fluid balance post discharge reduces readmission 
rates for dehydration.1287
*Ileostomy diet advice does not apply to patients with short gut, 
jejunostomy or high-output ileostomy.
Good Practice recommendation 20. IBD patients should 
be encouraged to eat a varied diet that meets their energy, 
macro- and micronutrient requirements. All who are at risk of 
malnutrition should have dietitian or nutrition team review, and 
where nutritional requirements cannot be met, supplementation 
with enteral or parenteral nutrition are indicated (Agreement: 
100%).
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IBD-related surgery was associated with vitamin D deficiency in 
the Crohn’s disease group (OR 2.9). A recent Norwegian study 
reported the prevalence of vitamin D deficiency (25-OH-D 
concentrations <50 nmol/L) to be 53% in Crohn’s disease and 
44% in UC.868 Vitamin D levels in IBD patients are lower than 
in the general population.900 901 Latitude did not influence the 
association between IBD and vitamin D.901
In Crohn’s disease patients, vitamin D concentrations were 
inversely associated with disease activity measured by the 
Harvey Bradshaw index, and in UC vitamin D deficiency was 
associated with elevated calprotectin >100 mg/kg. Vitamin 
D deficiency is associated with low bone mineral density.902 
Vitamin D is important in some immune-mediated diseases 
although its role in IBD inflammation is not fully elucidated.903 
Retrospective studies have shown an association between 
higher levels of vitamin D and remission rates,904 and durability 
of response to anti-TNF therapy.905 906 It is unclear whether this 
association is due to confounding by increased disease activity 
associated with lower vitamin D (although controlled for in 
these studies).
Limited data exist on the impact of vitamin D supplemen-
tation on clinical disease course in IBD. A small double-blind 
randomised controlled trial of 108 patients with Crohn’s disease 
treated with 1200 IU daily of oral vitamin D3 or placebo for 
1 year just failed to reach significance with 13% in the inter-
vention group versus 29% in the placebo group experiencing 
a clinical relapse (p=0.06).907 Small uncontrolled studies show 
that high-dose vitamin D improves clinical indices in Crohn’s 
disease.908 909 Vitamin D status should be routinely measured in 
IBD and deficiency should be corrected using oral supplemen-
tation, with evidence that this reduces risk of bone disease; but 
as yet the impact of vitamin D on inflammation in IBD and its 
impact on disease course, and the optimal vitamin D level as a 
goal of treatment is poorly understood.
5.3.4 Dietary treatment of functional symptoms in IBD
At least a third of patients with inactive IBD have coexisting 
functional bowel symptoms (eg, abdominal pain, bloating, 
increased flatulence, diarrhoea and/or constipation) and 
these symptoms may be mistaken for active IBD.910 Objec-
tive markers of disease activity (histological and inflamma-
tory markers (eg, faecal calprotectin, CRP)) alongside clinical 
symptom assessment help to distinguish between functional 
bowel symptoms and active IBD. Identification of func-
tional bowel symptoms in inactive IBD is important to avoid 
unnecessary and potentially harmful treatment strategies. 
In contrast, active disease should be excluded before estab-
lishing that symptoms are functional in nature. From a dietary 
perspective, identification of dietary triggers is useful but it is 
often difficult due to diet complexity and a delay in symptom 
generation following food ingestion. Many patients with IBD 
alter their diet in an effort to control their symptoms, whether 
during periods of active disease or during remission.911 Indeed, 
these self-induced dietary restrictions may be detrimental to 
patients’ nutritional status, therefore supervision by a dieti-
tian may be required. A diet low in fermentable oligosaccha-
ride, disaccharide, monosaccharide and polyols (FODMAP) 
has become a recognised successful management strategy for 
functional bowel disorders like IBS. In IBD, 56% of patients 
who had previously received low FODMAP dietary advice 
reported overall symptom improvement.912 Furthermore, in 
a dietary re-challenge study, FODMAPs (specifically fructans) 
increased functional bowel symptoms in patients with quies-
cent IBD.913 In a prospective study of a low FODMAP diet in 
88 IBD patients, 78% of patients reported satisfactory relief 
from their functional bowel symptoms at follow-up compared 
with only 16% at baseline.914 Mechanisms by which food-re-
lated functional symptoms in IBD develop, and which dietary 
interventions are effective and safe for the management of 
functional symptoms in inactive IBD, remain unclear.
5.4 Preoperative optimisation
Despite improvements in medical therapy, the rate of surgery 
in Crohn’s disease after 5–10 years ranges from approximately 
20%–30%.536 915 Postoperative complications are also more 
common in patients undergoing IBD surgery than operations 
Good Practice recommendation 21. Patients with IBD should 
have an assessment of their general nutritional status and 
screening for evidence of recent weight loss and/or assessment 
of malnutrition risk at each clinic appointment and on hospital 
admissions (Agreement: 95.7%).
statement 102. We recommend that IBD patients who are 
malnourished or at risk of malnutrition should have relevant 
screening blood tests to assess for macronutrient and 
micronutrient deficiencies. This may include measurement of iron 
stores, vitamin B12, folate, vitamins A, C, D and E, potassium, 
calcium, magnesium, phosphate, zinc and selenium (GRADE: 
strong recommendation, very low-quality evidence. Agreement: 
93.6%).
box 9 Iron deficiency anaemia in Ibd
 ► A third of patients with active IBD have iron deficiency 
anaemia
 ► Anaemia causes fatigue, affects quality of life and delays 
recovery
 ► As systemic inflammation inhibits absorption of iron, iron 
tablets should not be used in those with active disease 
and, in patients with inactive disease, no more than 100 mg 
elemental iron should be taken daily899
 ► Ferritin levels up to 100 µg/L in the presence of inflammation 
may still reflect iron deficiency.899 Measurement of transferrin 
saturation may therefore be helpful
 ► Consider other causes of anaemia (eg, folate deficiency, 
B12 deficiency or bone marrow depression) in patients  
with IBD
 ► Intravenous iron should be used first line in patients 
intolerant of oral iron who have active IBD and moderate 
to severe anaemia (Hb <100 g/L), or those who need 
erythropoietin899
 ► Iron absorption may be improved by once daily or alternate 
daily oral dosing1288
statement 103. We suggest that vitamin D levels should 
be measured and deficiency corrected in Crohn’s disease 
and ulcerative colitis (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 86.7%).
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for other conditions due to the active inflammation, emergency 
setting, complications and drug treatment.916
5.4.1 Preoperative nutritional status
Malnutrition and nutrient deficiencies are common in 
IBD.917 918 Severe malnutrition (BMI <18.5 kg/m2 and recent 
weight loss >10% body weight) is associated with a higher risk 
of postoperative complications, particularly intra-abdominal 
sepsis919 and increased mortality.920 Poor preoperative nutri-
tional status has been identified as an independent risk factor 
for postoperative intra-abdominal septic complications (OR 
6.23, 95% CI 1.75 to 22.52) in multivariate analysis.921 Thus, 
all IBD patients undergoing surgery should be assessed for 
risk of malnutrition. Elective surgery should ideally be post-
poned until malnutrition is treated. However, in an emergency 
situation this may not be feasible, and should be considered 
in the nature of operation undertaken to minimise risk of 
complications.
5.4.1.1 Evidence for preoperative nutritional support
There are few prospective studies of preoperative nutrition and 
no prospective randomised trials with a non-nutrition control 
group. A meta-analysis of pre-surgical nutritional support in 
gastrointestinal surgery patients found that the provision of 
500–1000 kcal of an immune enhancing oral nutritional supple-
ment plus usual food significantly reduced post-surgical compli-
cations.922 A more recent systematic review of preoperative 
nutrition in Crohn’s disease included 14 original studies, but 
only five prospective studies including one randomised trial.923 
Five studies showed significantly reduced complications and 
infectious episodes in patients receiving preoperative nutritional 
therapy. Significant heterogeneity was reported between studies 
in terms of the nutritional supplement used and timing of nutri-
tion. There is sufficient evidence to propose delaying surgery 
when possible to allow a multimodal approach to management 
including nutrition, steroid weaning and management of any 
abscesses.
The European Society of Parenteral and Enteral Nutrition 
(ESPEN) recommends preoperative nutritional support for 
7–10 days in patients who are undergoing major gastrointes-
tinal surgery and are mildly malnourished.924 A longer duration 
is recommended for severely malnourished patients even if it 
delays surgery.924 If oral nutritional supplements are not toler-
ated, then enteral nutrition should be considered and parenteral 
nutrition should only be used when nutritional targets cannot be 
delivered by the enteral route.436 924
5.4.2 Preoperative serum albumin
Hypoalbuminaemia (albumin <30 g/L), as a reflection of signif-
icant inflammation or secondary to malabsorption, is frequently 
associated with severe malnutrition although is not in itself a 
marker of nutritional status.919 This level of hypoalbuminaemia 
is associated with a higher risk of postoperative intra-abdominal 
sepsis.925 The evidence to support the use of intravenous albumin 
is weak919 925 and correction of hypoalbuminaemia hinges on 
treatment of underlying sepsis and control of inflammation. 
Nutritional support alone is very unlikely to restore low albumin 
levels to normal while sepsis and uncontrolled inflammation 
persist, but feeding is an important supportive measure.926 927
5.4.3 Preoperative anaemia
Preoperative anaemia (Hb <130 g/L in men and <120 g/L in 
women) increases the risk of postoperative intra-abdominal 
sepsis, correction of which is associated with improvement in 
outcomes including risk of intestinal obstruction and haemor-
rhage, anastomotic leak, postoperative perforation, pulmo-
nary oedema and septic complications such as pneumonia and 
wound infection.925 928 Perioperative red cell transfusion in 
patients undergoing ileocaecal resection has been shown to be 
associated with an increased risk of postoperative complications 
including an anastomotic leak, ileus, intra-abdominal abscess, 
wound dehiscence and thrombotic events.929 Anaemia should be 
recognised and treated early, preferably with oral or intravenous 
iron and other haematinics as needed, and avoiding blood trans-
fusion where possible.
5.4.4 Preoperative corticosteroids
Patients undergoing IBD surgery while on corticosteroids have 
an increased risk of postoperative infectious complications and 
anastomotic leaks.930–932 There is some evidence that risks are 
greater for those taking high-dose steroids (40 mg prednisolone 
or more).932 933 A comparison of prednisolone doses greater than 
20 mg versus 20 mg or less did not show a significant difference 
in risk of infections.931 Use of more than ≥15 mg oral corti-
costeroid in UC patients within 30 days of IPAA surgery, or 
more than ≥20 mg in the setting of proctocolectomy, is asso-
ciated with increased risk of complications.934 935 IBD patients 
having elective surgery should have their corticosteroids stopped 
if possible, or brought to as low a dose that can be managed 
without deterioration.
Patients who are on corticosteroids at the time of their 
IBD surgery should be given intravenous hydrocortisone in 
equivalent dosage until they can resume oral prednisolone.930 
Prednisolone 5 mg is equivalent to hydrocortisone 20 mg or 
statement 104. We suggest that a low FODMAP diet may 
be used to treat functional bowel symptoms in IBD patients 
(GRADE: weak recommendation, low-quality evidence. 
Agreement: 84.4%).
statement 105. We recommend that IBD patients should have 
assessment and optimisation of their physical condition prior 
to elective surgery. This should include appropriate imaging 
to determine disease extent and complications; radiological 
drainage of abscesses and treatment of sepsis; correction of 
anaemia; treatment of malnutrition and physical mobilisation 
(GRADE: strong recommendation, very low-quality evidence. 
Agreement: 97.3%).
statement 106. We recommend that prior to surgery all IBD 
patients should have their nutritional status assessed and if 
at risk of malnutrition should receive nutritional support (oral 
nutritional supplements or enteral or parenteral nutrition if 
required) (GRADE: strong recommendation, very low-quality 
evidence. Agreement: 97.3%).
statement 107. We suggest that patients with penetrating or 
stricturing Crohn’s disease, or those who are malnourished, may 
benefit from exclusive or partial enteral nutrition for at least 
6 weeks preoperatively (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 97.2%).
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methylprednisolone 4 mg. There is no value increasing steroid 
dosage to cover stress in the perioperative period, as shown in a 
randomised trial in IBD surgery936 and case series.937 Anaesthe-
tists will generally give a single steroid dose prior to induction 
(such as dexamethasone 4 mg intravenous or intramuscular) for 
those taking more than 5 mg prednisolone.938 Patients who are 
on physiological corticosteroid replacement because of disor-
ders of the hypothalamic pituitary axis (such as oral hydrocor-
tisone 20 mg mane, 10 mg nocte) should receive supplementary 
doses in the perioperative period.939 For patients who have had 
complete resection of active disease, it is important to avoid 
inappropriate prolongation of steroids after surgery, and there 
is virtue in standardised steroid-taper protocols in the postop-
erative period, dependent on the dose and duration of steroids 
preoperatively (table 11).
5.4.5 Preoperative thiopurines
With one exception,940 the literature on the use of immunosup-
pressive therapy (thiopurines and methotrexate) leading up to 
surgery does not describe an association with an increased risk 
of postoperative complications.932 933 941
5.4.6 Preoperative anti-TNF therapy
The risk of surgical complications for Crohn’s patients taking 
anti-TNF therapy during the perioperative period has been 
assessed in many small observational studies. The majority of 
systematic reviews and meta-analyses conclude that there is a 
small increase in risk of infectious complications,257 932 942–945 
although one systematic review found no difference.946 This risk 
is less than that for corticosteroid use,947 and anti-TNF therapy 
alone does not justify the formation of a diverting stoma. Opera-
tive risk should be based on other risk factors including presence 
of fistulae, abscess, low albumin, anaemia and corticosteroid use 
in addition to anti-TNF therapy.930 There is evidence in Crohn’s 
disease that risk is related to anti-TNF drug levels.948 If clinically 
appropriate, cessation should be 6–8 weeks before surgery for 
infliximab and 4 weeks for adalimumab, but evidence to support 
this is lacking. If necessary, treatment should be restarted soon 
after the patient is well enough to be discharged from hospital. 
For UC, compared with Crohn’s disease there are fewer data 
on which to assess risk of anti-TNF therapy and studies have 
methodological limitations, but two meta-analyses conclude that 
the postoperative risk is not increased overall.944 949 Anti-TNF 
therapy for Crohn’s patients should therefore be discontinued 
where possible prior to elective surgery. If not appropriate to 
stop, then timing of injections should be arranged to have as 
long a gap as possible prior to the operation. Stopping anti-TNF 
therapy prior to UC surgery is less critical.
In patients having proctocolectomy, corticosteroids are associ-
ated with an increased risk of impaired wound healing and need 
for re-operation.935 There is no evidence of increased compli-
cation risk for patients taking immunomodulators (mercapto-
purine, ciclosporin) who have ileoanal pouch surgery950 or IBD 
surgery generally.941 A two-stage IPAA procedure carries more 
risk than a three-stage procedure if patients are on anti-TNF 
therapy.951 Pouch surgery is complex with inherent risks, and 
it is prudent to conduct a controlled withdrawal of both corti-
costeroids and anti-TNF as part of a staged approach to pouch 
formation, which should always be done in an elective setting.
5.4.7 Summary of recommendations for operative optimisation
In elective surgery IBD patients should have their physical 
condition assessed and optimised prior to surgery. This should 
include assessment of comorbidities; imaging or endoscopy to 
document disease extent; drainage of abscesses and treatment of 
sepsis; assessment and correction of nutritional deficiencies; and 
stopping corticosteroids and biologics where possible. All IBD 
patients undergoing surgery should follow an enhanced recovery 
(ERAS) protocol.436 924 A checklist is shown in box 10.
5.5 Faecal calprotectin
5.5.1 Faecal calprotectin in the differential diagnosis of IBD versus 
IBS
Faecal calprotectin is a sensitive and specific marker of intes-
tinal inflammation and is a useful non-invasive method to 
investigate patients with chronic gastrointestinal symptoms in 
low-risk groups for malignancy, when infection and coeliac 
disease have been excluded as the cause and symptoms are 
suspected to be either due to IBD or IBS (figure 6). A normal 
level has a very high negative predictive value for IBD.952–954 
By contrast, the positive predictive value of levels above the 
assay reference level (normal defined as <50 µg/g stool) is low, 
and it is recommended that a higher threshold is used to trigger 
colonoscopy, which improves the positive predictive value with 
little reduction in the negative predictive value.955 956 Due to 
the variety of calprotectin assays in commercial use, the exact 
cut-off prompting colonoscopy should be determined locally, 
but it is generally between 100 and 250 µg/g stool and should be 
monitored to ensure appropriate specificity and sensitivity. Used 
in this way, faecal calprotectin can be used as a cost-effective 
measure957 to prevent unnecessary colonoscopy in those where 
IBD is extremely unlikely.958
Faecal calprotectin is generally raised in patients with bloody 
diarrhoea and patients with this presenting feature will need 
flexible sigmoidoscopy regardless of the calprotectin result. In 
acute diarrhoea due to infection, calprotectin is also likely to be 
raised and will not discriminate between IBD and gastroenteritis, 
thus stool culture and/or flexible sigmoidoscopy or colonoscopy 
are the appropriate diagnostic investigations. While there is 
limited evidence to support routine repeat testing, an evalua-
tion of the York Faecal Calprotectin Care Pathway found that, in 
243 patients with a faecal calprotectin ≥100 µg/g after a median 
of 18 (IQR 14–29) days, repeat testing identified a reduction in 
53% of patients, either to <100 µg/g or, if initially >250 µg/g, 
into the 100–250 µg/g range.959
Faecal calprotectin is not sensitive enough in the exclusion of 
advanced colorectal adenoma or colorectal carcinoma,960 961 and 
so in patients with rectal bleeding and abdominal pain, change 
in bowel habit, weight loss, or iron-deficiency anaemia, cancer 
pathway referral should be strongly considered962 and calpro-
tectin is not appropriate. In primary care, symptoms of change 
statement 108. We recommend that prior to elective surgery 
for Crohn’s disease or ulcerative colitis, corticosteroids should be 
stopped or dose minimised wherever possible to reduce risk of 
postoperative complications (GRADE: strong recommendation, 
low-quality evidence. Agreement: 94.6%).
statement 109. We recommend that IBD patients who have 
been on oral corticosteroids for more than 4 weeks prior to 
surgery should receive an equivalent intravenous dose of 
hydrocortisone while nil by mouth in the perioperative period 
(GRADE: strong recommendation, moderate-quality evidence. 
Agreement: 100%).
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in bowel habit with rectal bleeding and abnormal haematology 
in patients under 50 years are strongly predictive of IBD or 
colorectal cancer, but generally do not discriminate between 
the two.963 IBD is significantly more common in younger age 
groups, so referral will generally be to medical gastroenterol-
ogists. However, if there are reasons to suspect malignancy, 
patients should be referred via a suspected cancer pathway, 
although both need rapid colonoscopy (figure 6).962
5.5.1.1 Faecal calprotectin in the assessment of disease activity in 
known IBD
Faecal calprotectin is a useful surrogate marker of inflammatory 
activity in IBD.964 It correlates well with endoscopic inflamma-
tion in UC965 and in Crohn’s disease.966 If it is unclear whether 
new symptoms represent a relapse or other causes, particularly 
in Crohn’s disease, then calprotectin is useful to confirm active 
inflammation and can be a non-invasive alternative to flexible 
sigmoidoscopy or colonoscopy and cross-sectional imaging. If 
relapsing disease is clinically obvious, then measurement is not 
necessary.
A recent meta-analysis including data for 2822 IBD patients 
and 298 controls found that a calprotectin cut-off of 50 µg/g 
had the best sensitivity (90.6%) to detect endoscopically 
active disease, with specificity performing best (78.2%) at 
levels >100 µg/g.967 A separate meta-analysis has shown that a 
threshold of 250 µg/g provides better specificity of 82% than 
thresholds of 100 µg/g and 50 µg/g (specificity of 66% and 60%, 
respectively) in differentiating active IBD from remission.968 
However, a faecal calprotectin of 250 µg/g had a relatively lower 
sensitivity of 80% compared with a sensitivity of 84% and 92% 
at cut-offs of 100 µg/g and 50 µg/g, respectively.
5.5.1.2 use of faecal calprotectin to inform therapy changes
There is increasing evidence of the benefits of mucosal healing in 
reducing future relapse rate.50 52 969 970 Meta-analyses have shown 
that faecal calprotectin can discriminate between active and 
inactive IBD, although accuracy is greater for UC than Crohn’s 
disease.968 971 Studies in UC patients in clinical remission show 
that calprotectin correlates with endoscopic inflammation,972 and 
for those with both clinical and endoscopic remission, correlates 
with histological inflammation.973 A further study showed that 
calprotectin levels were a better predictor of relapse over the 
next year than the presence of histological inflammation.974
The information about mucosal inflammation provided by 
faecal calprotectin levels is a practical means to target increases in 
drug dosage, and studies are now starting to investigate the value 
this has in improving long-term outcomes. In UC, patients with 
clinically inactive disease but raised calprotectin can have levels 
reduced to those associated with lower risk of relapse by increases 
in dose.67 In Crohn’s disease the open-label randomised CALM 
study has shown that calprotectin levels below 250 µg/g stool, 
CDAI <150, CRP <5 mg/L and no prednisolone can be used as 
a target, with dose escalation of adalimumab and azathioprine at 
intervals until these levels are reached.360 At 1 year the ‘treat to 
target’ group achieved the primary end-point of a colonoscopic 
CDEIS score <4 without deep ulcers in 45.9%, with only 30.3% 
of the control group achieving this (p=0.010). Calprotectin may 
also be useful in predicting the likelihood of future relapse in 
order to decide who can withdraw therapies. In the STORI study, 
patients stopping anti-TNF with mucosal healing and a calpro-
tectin ≥300 µg/g had a relapse rate of 30%, but those with both 
mucosal healing and a lower calprotectin had a relapse rate of 
between 10% and 20%.854 975 Serial measurement over time can 
give a more accurate prediction of the likelihood of relapse.976
5.5.2 Collection of faecal calprotectin samples
There remain practical issues around the use of faecal calpro-
tectin. These include variability between different assays, vari-
ability in levels in different stool samples from one patient during 
1 day, lack of stability for samples kept at room temperature for 
more than a few days, and variation in calprotectin levels related 
to the interval between stools being passed.977 978 It is there-
fore recommended that the first stool passed in the morning is 
routinely used for sampling, and that this is stored for no more 
than 3 days at room temperature before analysis.
5.6 lower GI endoscopy in Ibd patients
5.6.1 Flexible sigmoidoscopy and colonoscopy in acute colitis
In the 1970s and 1980s it was recommended that colonoscopy 
be avoided in severe colitis because of the risk of toxic megacolon 
or perforation,979–981 or be limited to a flexible sigmoidoscopy 
table 11 Postoperative prednisolone tapering
Preoperative prednisolone dosage Initial dose after surgery taper regimen
5–20 mg daily Same dose as before surgery Reduce by 5 mg every 3 days and stop
>20 mg daily for <3 weeks Same dose as before surgery Reduce by 5 mg every 3 days and stop
>20 mg daily for >3 weeks at any time during the past 6 months Same dose as before surgery Reduce by 10 mg weekly until 20 mg, then reduce by 5 mg weekly until 
5 mg, then after 2 weeks give 2.5 mg for 2 weeks then stop
Adapted from Lightner et al.938
statement 110. We recommend that patients with ulcerative 
colitis should not be considered for pouch surgery while 
taking corticosteroids (GRADE: strong recommendation, very 
low-quality evidence. Agreement: 94.1%).
box 10 Ibd operative checklist
before admission:
 ► Notify physicians of planned admission date if elective 
surgery or notify of emergency admission
 ► Optimise nutrition in weeks prior to elective surgery
 ► Smoking cessation education and support including from 
general practitioner and community support services
 ► Stoma nurse counselling (where relevant) and appropriate 
psychological support including peer support
 ► Agree and implement plan regarding medical therapy: 
minimisation of steroid use; dose optimisation of 
immunomodulators and biologics prior to and after surgery
Postoperative during inpatient stay:
 ► Dietary assessment and nutritional plan
 ► Tail prednisolone as per table 11.
 ► Consider medical prophylaxis
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without bowel preparation.982 Colonoscopy equipment and 
technique has changed radically since then, and more recent data 
suggest that it can be performed safely and provide useful infor-
mation in acute severe colitis.983 Endoscopic assessment with a 
limited unprepared sigmoidoscopy and biopsies with minimal air 
insufflation can be performed safely by an experienced endos-
copist.224 In a study of colonoscopy in IBD, complications were 
no more likely in severe colitis than less active disease, nor did 
statement 111. We recommend that, for patients aged 16–40 
presenting in primary care with chronic diarrhoea and symptoms 
that may be consistent with either IBD or IBS, faecal calprotectin 
is a useful screening tool with a high negative predictive value. 
If significantly elevated, patients should have an infective cause 
excluded and be referred for further investigation (GRADE: strong 
recommendation, moderate-quality evidence. Agreement: 97.9%).
Figure 6 Use of faecal calprotectin in primary care.
statement 112. We suggest that, in IBD patients where it is 
unclear if symptoms are due to ongoing inflammation or other 
non-inflammatory causes (such as bile acid malabsorption, 
functional bowel disorder or short bowel), faecal calprotectin 
measurement may be used to provide evidence of mucosal 
inflammation (GRADE: weak recommendation, low-quality 
evidence. Agreement: 97.8%).
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tolerance of the procedure relate to disease activity.984 Retro-
flexion in the rectum is not recommended in the presence of 
active colitis due to risk of perforation. In acute severe colitis the 
inflamed area of rectum and colon are generally free of stool, so 
it is reasonable to avoid bowel preparation.
5.6.2 Bowel preparation for colonoscopy
High-quality preparation is desirable to allow optimal colonic 
mucosal visualisation and to facilitate chromo-endoscopy. There 
are limited studies examining the effectiveness of bowel cleansing 
in IBD. A prospective observational study in 429 IBD patients 
showed poorer bowel cleansing quality in comparison to patients 
attending for investigation of abdominal pain.985 In a study of 
100 IBD patients with age- and sex-matched controls, disease 
activity was not associated with poorer quality bowel preparation 
according to the Boston Bowel Preparation Scale.986 However, 
questionnaire assessment during bowel preparation demonstrated 
that a higher visceral sensitivity index, anxiety and a higher 
Harvey Bradshaw index was associated with increased abdominal 
pain and nausea, which in turn led to greater anxiety immedi-
ately prior to colonoscopy.986 IBD patients also experience high 
embarrassment and burden from the bowel cleansing process, 
and are more likely to find colonoscopy painful.987 Patients may 
experience an increase in abdominal symptoms suggestive of a 
flare within 1 month following colonoscopy,983 but no definite 
correlation to bowel preparation has been reported. As aphthous 
ulceration has been associated with use of sodium phosphate,988 
PEG-based bowel cleansing agents are commonly used in IBD. 
Low-volume regimens are better tolerated and bowel cleansing is 
non-inferior to high-volume PEG regimens.989
5.7 drug treatment adherence
There is no gold standard definition of treatment non-adher-
ence, but patient self-reporting is simple and reasonably accu-
rate.990 Non-adherence is common, occurring in at least a third 
of IBD patients,991 most frequently for those on 5-ASA drugs.992 
Although lower rates are reported with immunosuppressive drug 
use,993 994 even patients on infliximab have non-adherence rates 
of 17% and for adalimumab this could be as high as 29%.995
The impact of non-adherence is significant, with increased 
relapse rates996 and generally worse clinical outcomes.997
Studies have identified numerous factors associated with IBD 
medication non-adherence. Although there is some heteroge-
neity across studies, the factors that are most consistently associ-
ated with non-adherence include psychological distress, patient 
beliefs (particularly about the efficacy of the drug or necessity 
of taking it) and discordance between the health professional 
and patient.991 995 998 999 Practical barriers to adherence (eg, cost, 
complex treatment regimens, inconvenience, busy lifestyle, 
forgetfulness) constitute a major issue for adherence, although 
patient perception greatly affects what is perceived as a barrier.998
5.7.1 Strategies to improve adherence
There are few intervention studies evaluating methods of improving 
non-adherence in IBD. One study evaluated education sessions1000 
with a non-significant improvement in adherence. Trials using multi-
component intervention1001 1002 are more successful in improving 
adherence, with techniques combining education sessions with 
practical aids. These include regimen simplification, medication 
reminder charts, weekly or daily electronic pill-box organisers 
with alarms, or mobile phone alarms.1003 Web-based interventions 
are also valuable including education about disease and how to 
manage flares, monitoring using a traffic-light system and access to 
advice from a health professional by email or phone.1004 Although 
psychological factors are a significant influence on adherence,1005 
there are no intervention studies to date.
5.8 smoking
All IBD patients should be asked about cigarette smoking. 
Those who smoke should be advised of the widespread harm to 
health, and should be advised to stop. They should be offered 
referral to a smoking cessation service, where they should be 
offered behavioural therapy (eg, cognitive behavioural therapy) 
in combination with pharmacotherapy (nicotine replacement, 
bupropion or varenicline).1006 Bupropion and varenicline should 
not be given to those under 18 and pregnant women should be 
advised about risks and benefits of nicotine replacement therapy. 
Without support, there is a less than 10% likelihood of long-
term abstinence in smokers attempting to stop, but these inter-
ventions increase success rates substantially.1007 1008
5.8.1 Smoking and Crohn’s disease
Cigarette smoking is more common in patients diagnosed 
with Crohn’s disease.1009 The increase in smoking is more 
pronounced in those diagnosed at an older age, with one USA 
study showing a prevalence of smoking of 47% in those diag-
nosed over age 40 compared with 27% in the background popu-
lation.1010 Continued smoking results in a worse disease course 
compared with those who quit or never smokers,1009 1011 a higher 
risk of surgery and worse outcomes after surgery. A meta-anal-
ysis showed a 2.5-fold increase in risk of repeat surgery and 
a twofold increased risk of clinical recurrence.637 It is of note 
that smoking makes surgical complications more common after 
colorectal surgery for any indication.1012 1013 Passive smoking1014 
and light smoking (less than 10 per day) are just as bad as 
heavy smoking.1015 The adverse effects of smoking are more 
pronounced in women than in men with Crohn’s disease.1016
Efforts to help Crohn’s disease patients quit smoking are there-
fore important, with evidence that setting up a smoking cessation 
service is cost-effective with costs paid for by reduced disease 
management costs.1017 Despite this, there is poor awareness 
among patients of the benefits of quitting1018 1019 and measures to 
statement 114. We recommend that IBD patients should 
be routinely asked about medication adherence because 
non-adherence is common and results in worse outcomes. 
Risk factors include young age, psychological distress, patient 
beliefs and discordance between patient and health professional 
GRADE: strong recommendation, moderate-quality evidence. 
Agreement: 100%).
statement 115. We recommend that IBD patients at risk 
of non-adherence should be offered a variety of means to 
improve adherence, such as regimen simplification, reminder 
aids and additional support and education (GRADE: strong 
recommendation, low-quality evidence. Agreement: 97.8%).
statement 113. We suggest that faecal calprotectin is a 
validated biomarker for endoscopic and histological disease 
activity. It may therefore be a useful non-invasive parameter 
to inform decisions on treatment escalation or de-escalation 
(GRADE: weak recommendation, moderate-quality evidence. 
Agreement: 100%).
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help patients quit are underused.1020 Benefits of quitting accrue 
at any stage in the course of Crohn’s disease.1021 When active 
measures are employed, significant numbers can be helped to 
stop. The TABACROHN study showed 31% of 408 patients quit 
initially, with 23% still abstinent after 18 months follow-up.1022
5.8.2 Smoking and UC
UC is more common in non-smokers and is more likely to arise 
in those who have recently quit smoking.1011 1023 The highest risk 
period for disease onset is in the first 2–5 years after stopping.1024 
Ex-smokers present later in life than never-smokers.1025 1026 UC 
patients who smoke have reduced colectomy rates, less primary 
sclerosing cholangitis and less back-wash ileitis than never-
smokers.1014 The same study showed higher cigarette consump-
tion was associated with less extensive disease and reduced need 
for therapy. UC patients who quit smoking have a significantly 
worse disease course than those who continue, with more corti-
costeroid and azathioprine use and increased hospitalisation 
rates.1014 1027 Interestingly, a large study showed that smoking 
does not reduce the risk of pouchitis after ileal pouch-anal anas-
tomosis for UC, neither smoking at the time of operation nor 
later.1028 Ex-smokers with refractory UC who resumed smoking 
(mean 8.6 cigarettes daily) subsequently had high rates of corti-
costeroid-free remission.1029 In spite of the benefits of smoking 
in UC, every effort should be made to encourage patients to 
stop. For patients who do plan to stop, a plan to mitigate the risk 
of worsening disease by an increase in their treatment should be 
discussed. Trials of transdermal nicotine therapy in the 1990s 
showed at best modest benefit in active UC,1030 1031 but mainte-
nance trials were negative,1032 and small trials of enema therapy 
were shown to be associated with inability to retain the enema in 
30%, and side effects of nausea, light-headedness and tremor.1033 
There are no trials of nicotine gum use in UC, but case reports 
show effectiveness in ex-smokers with refractory UC.1034 1035 
Electronic cigarettes are now widely used as a cigarette substitute 
and, by means of a small vaporiser, provide a similar experience 
to smoking, with nicotine and taste and throat sensations akin 
to tobacco smoke. There is very little evidence of the effect of 
e-cigarettes on UC, although a case report surprisingly shows 
no benefit despite comparable amounts of nicotine.1036 The use 
of nicotine gum to control UC should only be recommended 
in refractory disease and as an alternative to resumption of 
smoking, with full discussion of its addictive nature.
5.9 Psychology and stress
A study using the UK Health Improvement Network (THIN) 
showed that patients with depression had a significantly 
greater risk of developing Crohn’s disease (adjusted HR 2.11, 
95% CI 1.65 to 2.70) and UC (adjusted HR 2.23, 95% CI 1.92 
to 2.60).1037 In this study treatment with selective serotonin 
reuptake inhibitors (SSRI) and tricyclic antidepressants (TCA) 
were protective against Crohn’s disease, whereas mirtazapine, 
serotonin and norepinephrine reuptake inhibitors, SSRI, sero-
tonin modulators and TCA were protective for UC.
5.9.1 Treatment of anxiety and depression in IBD
Anxiety and depression are common in IBD and are associated with 
poorer outcomes including the need for hospitalisation.1038–1040 A 
high proportion of patients with IBD have co-existent symptoms 
of IBS.1041 1042 Stress can promote a flare of IBD.1043 High quality 
studies of pharmacological intervention for anxiety or depres-
sion are limited and this is an area of research need. Reports of 
psychological intervention (psychotherapy, patient education and 
relaxation techniques) have demonstrated a reduction in health-
care utilisation with psychotherapy,1044 and relaxation techniques 
can reduce anxiety, pain and stress levels while improving quality 
of life and mood.1045 However, a Cochrane Systematic Review in 
2011 revealed high levels of bias within studies and no benefit in 
health-related quality of life, emotional status or disease remission 
in adults, with limited benefit noted in adolescents.1046 Conflicting 
outcomes have been published from studies of small patient 
numbers regarding the impact of cognitive behavioural therapy 
on psychological symptoms in IBD.1047–1050 Limited studies on 
the therapeutic benefit of mindfulness suggest it may be a useful 
adjunct to pharmacological therapy to improve psychological 
symptoms in IBD, improve quality of life and to facilitate coping 
with symptoms during a disease flare.1051–1053 Gut directed hypno-
therapy has an established evidence base in IBS, and though it may 
be useful in symptomatic control in IBD and delay flares in UC, 
further research is necessary in this area.1054 1055
5.10 Pain and fatigue in Ibd
Pain is a common symptom in IBD and may be present in patients 
with and without evidence of clinical disease activity.1056 1057 
Pain in IBD adversely affects quality of life.1058–1060 It is more 
common in females and in those experiencing stress, anxiety and 
depression.1061 1062 In Crohn’s disease, pain is more common in 
smokers and those receiving steroids and antidepressants1063 and 
narcotics.1064 When inflammation, stricturing disease, abscesses, 
uncontrolled inflammation or adhesional causes of pain have 
been excluded, other factors should be considered. In addition to 
psychosocial factors, causes of pain may include co-existing irritable 
bowel syndrome,910 1065 1066 visceral hypersensitivity (which may be 
mediated by microscopic inflammation, including the presence of 
mast cells),1067 1068 fibromyalgia1069 and bacterial overgrowth.632
5.10.1 Psychological therapy for unexplained pain in IBD
Psychological interventions, especially cognitive behavioural 
therapy, may have a positive impact on depression and improve 
quality of life in IBD.1070 Due to overlap between diagnoses of IBD 
and IBS with visceral hypersensitivity, psychological interventions 
statement 117. Ulcerative colitis patients who continue to 
smoke cigarettes should be encouraged to stop. There is an 
increased risk of flare after stopping, and patients should be 
made aware of this. We suggest that they are informed that an 
increase in medication may be required to control their disease 
(GRADE: weak recommendation, very low-quality evidence. 
Agreement: 95.7%).
statement 118. We suggest that in patients with IBD, 
psychological therapies including cognitive behavioural therapy, 
hypnotherapy and mindfulness meditation may be offered 
to interested patients, particularly those with psychological 
symptoms, as an adjunctive therapy to improve symptom 
control and quality of life (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 91.1%).
statement 116. We recommend that smokers with Crohn’s 
disease should be encouraged to stop, as smokers have a 
higher risk of disease flare, a higher incidence of surgery and a 
higher risk of postoperative recurrent disease (GRADE: strong 
recommendation, low-quality evidence. Agreement: 100%).
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for pain in these conditions may also be efficacious in IBD patients. 
Relaxation training may improve chronic pain in UC.1045 1071
5.10.2 Opioid medication use in IBD
Opioid medications have analgesic and anti-motility properties. 
They are more likely to be prescribed to IBD patients than to 
matched controls.1072 Risk factors for use include female gender, 
multiple surgeries, severity of pain, higher clinical disease 
activity, a history of depression or anxiety and polypharmacy, 
particularly with neuropsychiatric drugs.1073 1074 Patients with 
sustained poor quality of life have a higher risk of subsequent 
opioid use and a decreased time to first opioid prescription.1075 
Use of narcotics correlates with corticosteroid use in IBD.1076 A 
Canadian point prevalence study showed that opioid prescribing 
was highest in the first month following IBD diagnosis where 
11% of patients received this class of drug.1077 Prescription 
was more common in females and in Crohn’s disease relative 
to UC. Patients with IBD were more likely to become heavy 
opioid users (defined as a dose exceeding 50 mg of morphine 
or equivalent per day for at least 30 consecutive days) than 
age-matched controls. Use of narcotics in both Crohn’s disease 
and UC is associated with increased prevalence of depressive 
symptoms,1078 a higher risk of serious infection in IBD516 and 
increased mortality.516 1077 Historical studies show an association 
of opioid prescription with development of toxic megacolon in 
fulminant colitis.1079 1080
5.10.3 Fatigue in IBD
Fatigue is an increasingly recognised symptom affecting 
patients with IBD and many other chronic inflammatory 
disorders. Research into IBD-related fatigue has increased in 
recent years.1081 IBD patients describe a spectrum of symptoms 
including tiredness, lethargy and lack of energy that do not 
subside with rest.1082 Due to a lack of understanding regarding 
the aetiology and complexity of individual experience of 
fatigue, many healthcare professionals identify the symptom as 
of importance but describe difficulty understanding or concep-
tualising fatigue, thus struggle to assess the severity of fatigue 
and describe frustration at not being able to adequately improve 
the symptom for patients.1082 Approximately 50% of patients 
with IBD report fatigue at the time of diagnosis,1083 and in 
cohort studies the prevalence of fatigue is between 40% and 
72% of IBD patients.1084–1088 Fatigue is associated with poor 
health-related quality of life,1089 and related factors include 
poor sleep quality and mental illness.1084 Disability and depres-
sion associated with fatigue is equally prevalent between UC 
and Crohn’s disease.1089 Patients describe a negative impact on 
social and emotional well-being and a limiting effect on the 
ability to gain employment.1090 Studies identify active disease 
or history of surgical resection in Crohn’s disease as a predictor 
of fatigue.1089 1091 However, fatigue remains very common 
in patients with inactive disease with a prevalence around 
30–50%.1084 1086–1088 1091–1093
5.10.3.1 Investigations and treatment in IBD patients with fatigue
A questionnaire study of 631 patients in Europe, North 
America and Asia Pacific showed that daily fatigue was 
reported by 53% of IBD patients with anaemia.1094 Anaemia 
in IBD can be multifactorial including poor oral intake, malab-
sorption, chronic blood loss or due to chronic inflammation. 
Vitamin B12 and iron therapy are easily administered treat-
ments that may correct anaemia in IBD patients. A Canadian 
population-based study found iron deficiency in the absence of 
anaemia did not contribute to fatigue.1095 However, a recent 
European study identified iron deficiency as a risk factor for 
fatigue (OR 2.5, 95% CI 1.2 to 5.1).1096 Muscle fatigue has 
been associated with low serum vitamin D and magnesium.1097 
Other contributing factors should also be considered including 
pain, sleep disturbance, alcohol misuse and emotional stress. 
Medications should be reviewed for those that may contribute 
to fatigue. Corticosteroids have been demonstrated as a deter-
minant of fatigue,1085 although this may be a reflection of 
disease severity as opposed to a medication side effect. Avoid-
ance of steroids and cessation of immunomodulatory therapy 
in Crohn’s disease were predictors of improved physical and 
cognitive fatigue, respectively, in a longitudinal study.1084 
Recent data have demonstrated higher circulating frequencies 
of memory T-cells in fatigued patients with IBD.1098 Whole 
blood stimulation demonstrated higher production of the Th1 
cytokines TNF-alpha and IFN-gamma. Anti-TNF therapy with 
either infliximab or adalimumab has been shown to reduce the 
symptoms of fatigue.1099–1101
5.10.3.2 Non-pharmacological therapy for fatigue in IBD
A randomised controlled trial of solution-focused therapy for 
fatigue in quiescent IBD for 3 months showed a reduction in 
fatigue for up to 3 months following completion of therapy.1102 
However, the effect was lost by 6 months post therapy. A further 
randomised controlled trial of 45 Crohn’s disease patients 
compared professionally-led stress management versus self-di-
rected self-management versus conventional therapy. After 
eight sessions, a non- significant trend to reduced tiredness was 
observed.1103 A longitudinal study has shown a positive effect of 
regular exercise on physical fatigue in IBD.1084
Good Practice recommendation 22. Patients with IBD and 
pain should be investigated for stricturing disease, abscesses 
or uncontrolled inflammation. In the absence of an obvious 
cause of pain, other factors should be considered including 
adhesions, visceral hypersensitivity, functional bowel disorder or 
dysmotility, depression and/or anxiety, sleep disturbance, stress 
and psychosocial factors (Agreement: 95.7%).
statement 119. We suggest that psychological interventions 
may be useful for IBD patients with pain where no physical 
cause can be found, and may be discussed and offered as 
adjunctive therapy (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 93.5%).
Good Practice recommendation 23. Long-term opioid 
use is associated with poor outcomes in IBD and should be 
discouraged. Investigation for causes of pain, use of alternative 
non-opioid drugs and psychological support should be 
considered (Agreement: 100%).
Good Practice recommendation 24. IBD patients should be 
asked about symptoms of fatigue, as it is common and often 
not reported. Fatigue does not necessarily correlate with disease 
activity and can result in significantly worse quality of life 
(Agreement: 89.1%).
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5.11 Ibd-associated arthropathy
5.11.1 Treatment of type 1 arthropathy
The natural history and clinical features of IBD-related arthrop-
athies are described in the 2016 ECCO guidelines on extrain-
testinal manifestations of IBDe.1104 In patients with type one 
peripheral arthropathy, (joint pain with swelling or effusion, 
often asymmetric, affecting less than five joints, mainly weight-
bearing lower limb joints)1105, inflammation is usually associated 
with flares of IBD, and responds well to treatment of the under-
lying disease. Local injection of corticosteroids may be required 
if symptoms don’t resolve rapidly. A small proportion will go on 
to have more persistent problems, which may require sulfasala-
zine, methotrexate, or anti-TNF therapy.
5.11.2 Treatment of type two arthropathy
Type two arthropathy (more than five joints, symmetrical distri-
bution and mainly upper limbs) is usually independent of gut 
inflammation, and symptoms are more persistent. Referral to 
a rheumatologist is helpful for consideration of immunomod-
ulator or biological therapy, and it is important to discrimi-
nate between the other causes of joint pain which can include 
non-specific arthralgia, osteonecrosis, lupus-like syndrome in 
relation to anti-TNF therapy, and corticosteroid withdrawal 
arthralgia. Azathioprine-related arthralgia usually occurs early 
in treatment and resolves rapidly on stopping the drug. The 
axial spondyloarthropathy has a much more disabling long-term 
course, and early diagnosis is vital, but can be very delayed.1106 
Low back pain in young people (under 45 years), for more than 
3 months that is improved with exercise and not relieved by rest, 
pain that is worse in the latter part of the night, and morning 
stiffness lasting more than 30 min, should trigger investigation 
with MRI scanning (sagittal images of cervicothoracic and thora-
columbar regions with T1 and STIR images, and coronal/oblique 
sacroiliac joints with T1 and STIR) and referral to a rheumatolo-
gist, as plain radiology of the spine and sacroiliac joints will miss 
most early disease. HLA-B27 is less often positive in IBD-associ-
ated axial arthropathy. Specialist assessment and physiotherapy 
can prevent long-term disability,1107 and initial treatment is with 
NSAIDs, early progression to treatment with anti-TNF agents 
often being necessary, as sulfasalazine and methotrexate are not 
effective.1108 1109 Simple analgesia is preferable to NSAIDs, but 
NSAIDs are more effective.
5.11.3 Safety of NSAID use in IBD
Data on non-selective NSAIDs is conflicting. A long-term study 
in over 600 IBD patients showed that low-dose NSAIDs were 
safe, but standard doses caused a rise in disease activity scores 
(particularly in Crohn’s colitis), but not relapse.1110 Short-term 
use is safe, particularly using low doses where the IBD is well-con-
trolled, with a relapse risk of about 20%.1111 1112 A meta-analysis 
of seven studies of selective COX-2 inhibitors in IBD showed a 
risk of flare of 14% (95% CI 6.7 to 24.4) with no difference to 
placebo (relative risk 0.86, 95% CI 0.39 to 1.88)),1113 in keeping 
with a Cochrane analysis.1114 The risk of flare could be higher 
when given to patients with active IBD, as COX-2 is important 
in intestinal repair mechanisms.
5.12 other Ibd therapy
5.12.1 Probiotics, prebiotics and synbiotics in IBD
A systematic review assessed 21 studies in UC.1115 Nine were 
trials of induction therapy (seven using probiotics and one each 
prebiotic and synbiotics). The majority assessed the addition 
of the investigational treatment alongside standard therapy 
(mostly 5-ASA), with standard therapy alone being used in the 
control group. Study quality was variable, many being small 
trials, but overall the majority showed benefit, with statistical 
significance in 16 of the studies. The largest studies used a 
mixture containing eight probiotic organisms and overall there 
is evidence of benefit for this treatment in UC as an addition 
to standard therapy, with insufficient evidence to recommend 
other agents. A Cochrane review of probiotics in induction 
therapy published in 2007 (and so not including the largest 
studies reported in the systematic review) concluded that there 
was insufficient evidence to recommend probiotic therapy in 
induction of remission, but that it may improve symptoms in 
mild to moderate colitis.1116 The remaining trials evaluated 
maintenance therapy, some with remission induction followed 
by maintenance therapy. There was a modest benefit in a 
number of studies, and some showed equivalence to 5-ASA 
therapy. A variety of agents were used in these studies. Again, 
a Cochrane review in 2011 concluded that there is insufficient 
high quality evidence to show benefit in maintaining remis-
sion.1117 One study comparing a prebiotic, a probiotic and a 
synbiotic in UC using quality of life as an end-point concluded 
that synbiotic therapy was more effective than the other treat-
ments.1118 In conclusion, probiotic therapy may have modest 
benefits in UC, but should not be routinely used. By contrast to 
UC, there is no evidence of any benefit in the current literature 
for these treatments in Crohn's disease.1115
statement 120. We suggest that IBD patients with disabling 
fatigue in whom no correctable metabolic deficiency or active 
disease is found, or where fatigue persists despite addressing 
these factors, may be directed to non-pharmacological therapies. 
Patients may be interested in supportive psychotherapy, 
stress management or graded exercise (GRADE: weak 
recommendation, low-quality evidence. Agreement: 89.1%).
statement 121. We recommend that the mainstay of 
symptom relief for IBD-associated arthropathy which is 
related to IBD activity should be through control of intestinal 
inflammation, physiotherapy and simple analgesia (GRADE: 
strong recommendation, very low-quality evidence. Agreement: 
100%).
statement 122. We recommend that for IBD-related 
arthropathy which is not related to IBD activity, rheumatology 
referral, physiotherapy and simple analgesia should be offered 
(GRADE: strong recommendation, very low-quality evidence. 
Agreement: 93.6%).
Good Practice recommendation 25. IBD patients 
experiencing fatigue should be investigated for subclinical 
disease activity and other potentially modifiable factors 
considered such as sleep pattern, medication side effects, 
anaemia, iron deficiency, electrolyte disturbance, thyroid 
dysfunction, vitamin D and B12 deficiency and psychological 
symptoms (Agreement: 93.5%).
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5.12.2 Faecal microbial transplantation
To date there have been four randomised placebo-controlled 
trials of faecal microbiota transplantation (FMT) for the 
treatment of UC, with three meeting their primary end-point 
showing a significant improvement in remission compared with 
placebo.1119–1122 An open-label study showed that benefit is more 
evident in UC than Crohn’s disease.1123 The published trials 
vary greatly in route and frequency of FMT administration,1124 
with evidence that improved microbial diversity can persist 
for 4–8 weeks,1119 1125 but does not persist after 1 year,1119 and 
growing evidence that colonic rather than nasoduodenal admin-
istration may be safer and more effective.1126 In spite of these 
encouraging data, FMT remains an investigational treatment for 
use only in clinical trials in IBD.1127
5.12.3 Complementary and alternative therapy for IBD
Complementary and alternative medicines (CAMs) include 
diverse medical and healthcare strategies which are consid-
ered to fall outside conventional treatment. Such interven-
tions include herbal treatments, pre/probiotics, acupuncture 
and are often part of traditional Chinese medicine. There is 
evidence that 30–50% of patients with IBD use CAMs and this 
tends to be higher in women than men.1128 1129 While there is 
no evidence to recommend the routine use of CAMs, certain 
agents have shown early promising signals in pilot studies. 
Two promising candidates are curcumin, which is the active 
ingredient of turmeric (Curcuma longa)1130–1132 and fish oils, 
where there is good evidence of anti-inflammatory effects, but 
the largest and most rigorous trial (in Crohn’s disease) showed 
no benefit.1133 No recommendations can be made due to lack 
of sufficient high-quality evidence regarding efficacy and dose 
and larger studies are needed. Helminth therapy remains inter-
esting despite the negative result of a randomised controlled 
trial in UC.1134 The results of a similar trial in Crohn’s disease 
remain to be reported. Anecdotal evidence supports the use of 
acupuncture although there are no controlled trials and, in this 
case, blinding is an obvious problem. Moderate exercise has 
shown no harm in IBD and a positive benefit in terms of bone 
health.1135
Further data are required to move promising CAMs into the 
category of conventional treatment.1136 Despite the absence of 
robust evidence supporting the use of CAMs in IBD, there is 
evidence that many patients use CAMs.1128 It is good practice to 
enquire about the use of CAMs as patients are often either reluc-
tant to mention this, given the negative social and legal conno-
tations associated with cannabis for example,1137 or may not 
realise that they are worth mentioning (eg, acupuncture, herbal 
supplements, exercise). It should be emphasised that they should 
continue conventional treatments of proven value even if they 
choose to use CAMs in addition.
5.12.3.1 Cannabis extracts
There is increasing interest in use of cannabidiol (CBD) in medi-
cine. This does not have the psychotropic effects of the delta9-tet-
rahydrocannabionol (THC) component in cannabis. CBD can 
have beneficial effects in the gut including reduction in nausea, 
reduced gastric acid secretion, anti-inflammatory effects and 
reduction in intestinal motility. Cannabis use has been reported 
to improve IBD symptoms,1138 and many patients claim that it 
has beneficial effects.1139 A small double-blind randomised trial 
in 60 patients compared an oral CBD-rich botanical extract with 
placebo in mild-moderate active UC. At 10 weeks, the primary 
end-point of remission was achieved in 28% on CBD versus 26% 
on placebo (non-significant). The treatment caused side effects of 
dizziness and somnolence (likely due to the residual THC content 
of the botanical extract). There was some evidence of symptom 
improvement in the per protocol analysis.1140 A previous small 
randomised double-blind study in 21 Crohn’s disease patients 
compared smoking two marijuana cigarettes (containing 115 mg 
of THC) to a cannabis flower extract without THC over 8 weeks. 
The primary end-point of clinical remission was met in 45% on 
active treatment compared with 10% on placebo, but the differ-
ence was not significant.1141 Further adequately powered studies 
are needed, with rigorous blinding, and objective measures of 
inflammation as well as symptoms.
5.13 Chemoprevention and colorectal cancer surveillance
IBD is a widely accepted risk factor for the development of 
colorectal cancer (CRC). CRC accounts for one in six deaths 
in UC,1142 with median age younger than that of sporadic 
CRC.1143 There is a wealth of data from large national and 
international population-based studies demonstrating increased 
risk of CRC with UC, and CRC or small bowel neoplasia with 
Crohn’s disease.1144–1146 A case–control study of 68 cases and 
136 controls showed that the severity of inflammation, both 
endoscopic and histological, determines the risk of colorectal 
neoplasia in UC.1147 This has been supported by a cohort study 
demonstrating that histological inflammation predisposes to 
advanced neoplasia.1148 Case–control studies have shown that the 
presence of post-inflammatory polyps, as a marker of previous 
severe inflammation, increase the risk of CRC in UC.28 1149 1150 
However, a recently published retrospective multicentre cohort 
study including 462 patients with post-inflammatory polyps 
confirmed their association with greater severity and extent of 
colonic inflammation and colectomy risk but did not observe an 
association with colorectal neoplasia.1151 Finally, the age of onset 
at diagnosis and the influence therefore of the length of disease 
in individuals (as stratified by phenotypic classification systems) 
must be considered as important factors for surveillance, given 
the association between length of disease duration and the devel-
opment of cancer.1144 1152
5.13.1 Surveillance ileocolonoscopy
Long duration of disease increases the risk of developing IBD-as-
sociated CRC, with the risk starting to increase at about 10 years 
after diagnosis, by which time meta-analysis suggests the inci-
dence is 2–3%.1143 1153 Later studies have shown the cumula-
tive incidence to be 1% at 10 years, 3% at 20 years and 7% at 
30 years.1154 This change over time may reflect the increased 
statement 123. We suggest that short-term use of NSAIDs is 
safe if IBD is in remission, but long-term use or use in active 
disease carries more risk of worsening IBD symptoms. There is 
no high-quality evidence that COX-2 inhibitors are safer than 
non-selective agents (GRADE: weak recommendation, very 
low-quality evidence. Agreement: 81.4%).
statement 124. We suggest that faecal microbiota 
transplantation (FMT) shows some evidence of benefit in 
ulcerative colitis and should be used in the context of clinical 
trials until further high-quality evidence clarifies the potential 
for benefit and optimal administration protocol (GRADE: weak 
recommendation, moderate-quality evidence. Agreement: 
93.3%).
 o
n
 O
ctober 1, 2019 at University of G
lasgow. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-318484 on 27 September 2019. Downloaded from 
71Lamb CA, et al. Gut 2019;0:1–106. doi:10.1136/gutjnl-2019-318484
Guidelines
implementation of surveillance strategies, the introduction of 
drugs that control inflammation more effectively, or the changing 
approach to maintenance therapy or colectomy.1155 Current UK, 
European and USA endoscopy guidance suggests commencement 
of surveillance endoscopy for dysplasia in IBD should begin at 
between 6 and 10 years following diagnosis.1156–1158 A Cochrane 
review1159 evaluated three UC case–control studies1160–1162 and 
concluded there was evidence for surveillance resulting in earlier 
detection stage and better prognosis, with indirect evidence of 
cost-effectiveness. A study of 149 IBD-associated cancers (59 
Crohn’s disease, 90 UC) showed that those with prior surveil-
lance had greater 5-year survival and earlier tumour stage at 
detection.1163 A review of the St Mark’s programme showed 
surveillance may reduce the risk of advanced and interval 
colorectal cancer incidence.1164 Those with extensive disease 
carry the highest risk of colorectal cancer, whereas left-sided 
colitis patients have an intermediate risk and those with proctitis 
only have no increased risk.1165 Extent therefore should deter-
mine the appropriate surveillance interval. Patients with primary 
sclerosing cholangitis (PSC) should have annual surveillance 
colonoscopy from diagnosis.1166 For all other patients, surveil-
lance should begin 8 years after diagnosis, or after the onset 
of symptoms if there was a significant delay before diagnosis. 
Surveillance technique, including use of chromoendoscopy, is 
set out in the SCENIC consensus guidelines,1167 and the surveil-
lance interval after the initial surveillance should be determined 
according to degree of inflammation, extent, presence of post-in-
flammatory polyps or strictures, dysplasia, PSC or family history 
of colorectal cancer under the age of 50 years.1155 1156 Patients 
with proctitis and no evidence of proximal progression do not 
require ongoing surveillance colonoscopy. A summary adapted 
from the 2010 BSG and 2015 SCENIC guidance is presented 
in box 11.
5.13.2 IBD-related cancer chemoprevention with mesalazine
Although there is a lack of randomised prospective data 
regarding chemoprevention of CRC in IBD, a number of studies 
have shown a protective effect of 5-ASA on the risk of IBD-asso-
ciated CRC. A systematic review suggests the drug has multiple 
biological effects that protect against neoplasia.1168 These 
include stabilisation of cell cycle regulation, scavenging of reac-
tive oxygen or nitrogen species, inhibition of TNFα, NF-κB and 
TGFβ pathways, interference with Wnt/beta-catenin signalling 
and antimicrobial activity. A systematic review and meta-analysis 
of eight studies contained 867 cases of colorectal neoplasia and 
143 of non-cancer dysplasia. Prescription of 5-ASA is associated 
with OR of 0.6 (95% CI 0.4 to 0.9, p=0.04) for development of 
CRC,1169 although the advantage was only seen in studies from 
referral centres, not population-based studies.
Two more recent meta-analyses have been published in 2017, 
confirming that 5-ASA reduces the risk of CRC in UC.1170 1171 
Sulfasalazine was not protective. A dose-dependent protective 
effect was noted with 5-ASA with a minimum dose of 1.2 g1169 
or 2 g.1171 It remains unclear whether the protective effect of 
5-ASA simply represents more effective mucosal healing rather 
than a specific drug effect. In patients who are also taking 
immunosuppressive drug therapy there are no data to show 
that 5-ASA has additional benefits, whereas a recent retro-
spective study demonstrated that stopping 5-ASA in patients 
on anti-TNF therapy was not associated with a worse disease 
course.1172
5.13.3 IBD-related cancer chemoprevention with thiopurines
Inflammation may in part promote tumorigenesis,1173 so under-
standing the impact of immune-modifying therapy on cancer 
development is an important area of unmet clinical need. There 
are currently no randomised prospective data interrogating the 
effect of immunomodulatory agents (including thiopurines, 
methotrexate, calcineurin inhibitors, anti-TNF and anti-inte-
grin agents) on the risk of IBD-associated CRC, and evidence 
is based on cohort studies.1165 1174 1175 A recent meta-analysis 
from 2017 of 24 studies including 76 999 patients concluded 
there was evidence of a protective role of thiopurines in high-
grade dysplasia and CRC prevention in UC, but not Crohn’s 
disease.1176 Potential benefit in reducing colorectal cancer 
risk must be weighed against the very small increase in risk of 
lymphoma, particularly in older patients.
There are no randomised prospective data on the effect of folic 
acid or antioxidants (vitamin A, C, E, selenium and beta-caro-
tene) on the risk of CRC in IBD. Red blood cell folate is reduced 
in IBD patients who develop CRC compared with those who do 
not.1177 Two case–control studies have shown a non-significant 
dose-dependent reduction in CRC with folic acid supplementa-
tion.1178 1179
5.14 Anti-tnF, vedolizumab, ustekinumab and tofacitinib 
therapy during pregnancy
5.14.1 Fetal and infant exposure to anti-TNF drugs
Active transfer of IgG from the maternal to fetal circulation 
occurs at the surface of the syncytiotrophoblast placental layer 
through the selective binding of the Fc gamma portion of 
the maternal IgG antibody to the fetal circulation.1180 Active 
transport of IgG starts at approximately week 13 of gestation 
progressing continually until delivery with a preferential trans-
port of IgG1 followed by IgG4, IgG3 and then IgG2.1180 1181 
Infliximab, adalimumab and golimumab are IgG1 monoclonal 
antibodies, whereas certolizumab is a Fab fragment of IgG1 
(without the Fc portion of IgG1) and so there is significantly less 
transfer through the placenta. Infliximab levels were detectable 
for up to 7 months and adalimumab levels remained detectable 
for up to 11 weeks from birth.1181 The use of infliximab and 
adalimumab during pregnancy has been associated with fetal and 
cord blood levels of drug up to fourfold higher than in maternal 
blood.1181–1183 A recent study showed that median cord blood 
drug concentrations were more than the median maternal drug 
concentrations at the time of birth for infliximab and adalim-
umab, with a much longer time for drug clearance in infants with 
the mean time for drug clearance of 7.3 months for infliximab 
(95% CI 6.2 to 8.3) and 4 months (95% CI 2.9 to 5.0), respec-
tively (p<0.0001).1184 In some infants, drugs remained detect-
able until 12 months of age.
Discontinuing anti-TNF therapy in the second trimester will 
limit drug exposure during the time of highest transmission of 
immunoglobulins from the mother to the fetus. Although the 
timing of the last anti-TNF administration appears to correlate 
with maternal serum and cord blood levels, this is not so in a 
linear fashion with variability due to differences in maternal 
dose and interval, individual pharmacokinetics and the imma-
turity of the newborn reticuloendothelial system. There is 
statement 125. We recommend that IBD patients with colonic 
disease should be offered ileocolonoscopy 8 years after symptom 
onset to screen for neoplasia, to determine disease extent and 
decide on the frequency of ongoing surveillance (GRADE: strong 
recommendation, very low-quality evidence. Agreement: 89.1%).
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more variability for infliximab levels than for adalimumab in 
maternal blood during pregnancy.1185 This may suggest a role 
for therapeutic drug monitoring while using infliximab in 
pregnancy.
While low levels of infliximab, adalimumab, certolizumab, 
natalizumab and ustekinumab can be detected in breast milk 
from mothers receiving these biologics, breastfed infants of 
mothers receiving biologics, immunosuppressants or combina-
tion therapy have similar risks of infection and similar milestone 
achievement at 12 months to non-breastfed infants or infants 
unexposed to these drugs.1186
5.14.2 Cessation of anti-TNF therapy in the second trimester in 
quiescent IBD
Active IBD prior to conception is associated with poor preg-
nancy outcomes, including premature delivery, low birth weight 
and higher spontaneous abortion, compared with quiescent 
or controlled disease.1187–1190 Discontinuing anti-TNF therapy 
during pregnancy, in order to minimise exposure to the fetus, 
is feasible if there is no significant increase in the risk of disease 
flare. Case–control and cohort studies of pregnancy in women 
box 11 Continued
Colonoscopically targeted biopsies are recommended over 
random colonic biopsies.1289 If taking random biopsies, 2–4 
biopsies should be taken every 10 cm.1156
Management of dysplasia*:
Statements published as part of 2015 SCENIC international 
consensus:1167
 ► After complete removal of endoscopically resectable polypoid 
dysplastic lesions, surveillance colonoscopy is recommended 
rather than colectomy (strong recommendation, very-low 
quality evidence).
 ► After complete removal of endoscopically resectable 
non-polypoid dysplastic lesions, surveillance colonoscopy 
is suggested rather than colectomy (conditional 
recommendation, very-low quality evidence).
 ► For patients with endoscopically invisible dysplasia 
(confirmed by a GI pathologist), referral is suggested to 
an endoscopist with expertise in IBD surveillance using 
chromoendoscopy with high-definition colonoscopy 
(conditional recommendation, very low-quality evidence).
If dysplastic lesions cannot be resected completely due to 
extent or multiplicity, referral to MDT for discussion regarding 
definitive management including surgical options should be 
arranged.
*Neither extensive systematic review nor consensus voting has been 
undertaken as part of the current guideline development process 
regarding subsequent surveillance intervals after initial surveillance 
colonoscopy, or methods to detect dysplasia. Instead a summary is 
adapted/reproduced from the 2010 BSG1156 and 2015 SCENIC1167 
guidance.
box 11 Colonoscopy surveillance in patients with Ibd to 
detect and manage dysplasia/neoplasia
Commencement of colonoscopy surveillance:
 ► 8 years after IBD symptom onset
 ► From diagnosis if primary sclerosing cholangitis
next surveillance interval (summary of 2010 bsG update 
guidance)*:1156
 ► Lower risk: next surveillance in 5 years if extensive colitis 
with no active endoscopic or histological inflammation or left 
sided colitis or Crohn’s colitis affecting <50% of colon
 ► Intermediate risk: next surveillance in 3 years if extensive 
colitis with mildly active endoscopic or histological 
inflammation or post-inflammatory polyps (often termed 
‘pseudopolyps’) or family history of colorectal cancer in first 
degree relative aged ≥50 years
 ► Higher risk: next surveillance in 1 year if extensive colitis 
with moderate/severely active endoscopic or histological 
inflammation or if stricture or dysplasia in last 5 years or 
primary sclerosing cholangitis (including post-orthotopic 
liver transplant) or family history of colorectal cancer in first 
degree relative aged <50 years
In determining next surveillance interval, consider patient 
preference, presence of multiple post-inflammatory polyps, age 
and comorbidity, accuracy and completeness of examination. If 
previous colectomy and ileostomy, or colectomy and ileorectal 
anastomosis: retained rectum should have surveillance 
examination. Retained rectum after surgery is more difficult to 
inspect and so proctectomy with/without pouch reconstruction 
should normally be considered.
Methods of detection*:
 ► Surveillance should be performed where possible during 
disease remission, though may not be possible in some 
patients, and chronic active disease is a risk factor for 
dysplasia.
Statements published as part of 2015 SCENIC international 
consensus:1167
 ► When performing surveillance with white-light colonoscopy, 
high definition is recommended rather than standard 
definition (strong recommendation, low-quality evidence)
 ► When performing surveillance with standard-definition 
colonoscopy, chromoendoscopy is recommended rather than 
white-light colonoscopy (strong recommendation, moderate-
quality evidence)
 ► When performing surveillance with high-definition 
colonoscopy, chromoendoscopy is suggested rather than 
white-light colonoscopy (conditional recommendation, low-
quality evidence)
 ► When performing surveillance with standard-definition 
colonoscopy, narrow-band imaging is not suggested in place 
of white-light colonoscopy (conditional recommendation, 
low-quality evidence).
 ► When performing surveillance with high-definition 
colonoscopy, narrow-band imaging is not suggested in place 
of white-light colonoscopy (conditional recommendation, 
moderate-quality evidence).
 ► When performing surveillance with image-enhanced 
high-definition colonoscopy, narrow-band imaging is 
not suggested in place of chromoendoscopy (conditional 
recommendation, moderate-quality evidence).
Continued
statement 126. We recommend that patients with ulcerative 
colitis or IBD-U with left-sided or more extensive disease should 
be advised to take mesalazine in doses of at least 2 g daily to 
reduce risk of colorectal cancer (GRADE: strong recommendation, 
moderate-quality evidence. Agreement: 95.5%).
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with quiescent IBD do not show any increase in risk of flare if 
anti-TNF therapy is stopped at week 25–30.1182 1191 Anti-TNF 
medications therefore may be safely discontinued in the second 
trimester in women with quiescent disease.
5.14.3 Continuation throughout pregnancy in IBD patients at high 
risk of flare
A Danish study of 219 women with IBD treated in the third 
trimester with anti-TNF therapy revealed no increased risk of 
low birth weight or preterm birth associated with the drug.1192 
The same group found that, in women with moderate to severe 
IBD on anti-TNF during pregnancy, 66% experienced disease 
activity during their pregnancy. Disease activity was associated 
with low birth weight (OR 2.05) and preterm birth (OR 2.64, 
increasing to an OR of 3.6 in moderate to severe disease).1192 
There is also evidence that discontinuation of therapy may be 
associated with a risk of relapse during pregnancy and in the 
postpartum period.1181–1184 Additionally, low trough levels may 
lead to anti-drug antibody formation with subsequent loss of 
response to treatment.
5.14.4 Risk to the fetus of continuing anti-TNF until delivery
A recent UK study of 364 363 singleton pregnancies including 
1969 in women with IBD revealed only a small increased risk 
of preterm birth, and in Crohn’s disease a higher risk of low 
birth weight or post-partum haemorrhage.1193 Most women 
with IBD will have an uncomplicated pregnancy. Despite signif-
icant fetal exposure to anti-TNF drugs, there is no evidence that 
continuing anti-TNF therapy through pregnancy has a nega-
tive impact on the pregnancy or neonatal outcomes, including 
neonatal susceptibility to infection. Meta-analysis of six studies 
confirmed no increased risk of adverse pregnancy outcomes, 
congenital abnormality, preterm birth or low birth weight.1194 A 
study of all 1097 individual safety reports received by the Food 
and Drug Administration adverse event reporting system did not 
show an increased risk of maternal or neonatal adverse outcome 
for thiopurine, anti-TNF or combined therapy.1195 In contrast, 
a prospective study of 80 pregnancies in women exposed to 
anti-TNF showed no adverse neonatal outcome on anti-TNF 
monotherapy but did report an increased risk of neonatal infec-
tion (bacterial infections in 5% and viral infections in 20%, all 
with benign course) with combined therapy with thiopurines 
(relative risk 2.7, 95% CI 1.09 to 6.78, p=0.02).1184 The largest 
retrospective cohort study to date has recently published the 
outcomes in 1457 pregnancies in women exposed to anti-TNF 
therapy for IBD.1196 Treatment was associated with a higher risk 
of overall maternal complications (adjusted OR 1.49, 95% CI 
1.31 to 1.67) and infections (adjusted OR 1.31, 95% CI 1.16 to 
1.47). Ongoing use of anti-TNF therapy beyond 24 weeks did 
not increase maternal complications, but interrupting treatment 
was associated with relapse (adjusted OR 1.98, 95% CI 1.25 to 
3.15). No increased infection rates were seen in children born to 
mothers exposed to anti-TNF in this study (adjusted OR 0.89, 
95% CI 0.76 to 1.05).
5.14.5 Long-term outcomes of anti-TNF therapy during pregnancy
A multicentre retrospective study from the Netherlands has 
recently been presented in abstract form reviewing outcomes up 
to 5 years for children born to mothers with IBD.1197 Of 1000 
children born, 20% had been exposed to anti-TNF in utero, 
24% to thiopurine monotherapy and <1% to systemic steroids. 
Neither anti-TNF nor thiopurine exposure was associated with 
adverse birth outcomes, whereas use of steroids was associated 
with preterm birth (adjusted OR 2.67, 95% CI 1.59 to 4.47). 
Exposure to IBD therapy did not influence long-term adverse 
health outcomes, adverse reaction to vaccination or infection 
rates.
The TEDDY study, a retrospective multicentre study, 
followed children born to women with IBD who were exposed 
to anti-TNF either during pregnancy or within 3 months prior 
to conception and a non-exposed comparator group.1198 
The incidence rate of severe infections, however, was similar 
between groups and anti-TNF exposure during pregnancy was 
not associated with a higher risk of severe infections (HR 1.2, 
95% CI 0.8 to 1.8). The exposed group had more Caesarean 
sections, more with low birth weight and more intensive care 
unit admissions.
The PIANO registry (Pregnancy and Neonatal Outcomes in 
Women with IBD), a prospective USA registry with over 1000 
patients, has presented data on up to 4 years of follow-up in 
patients exposed to biological therapy during pregnancy. The 
use of anti-TNF during pregnancy was not associated with 
developmental delay or increased risk of infection in this 
cohort.1199
Although the majority of data are for infliximab and adali-
mumab, there are data to suggest that golimumab is also 
associated with a low risk of adverse maternal and neonatal 
outcome.1200
In conclusion, a decision to stop anti-TNF therapy between 
weeks 22 and 24 of gestation must hinge on disease quiescence 
(sustained remission for 12 months prior to conception with 
endoscopic and radiological evidence), driven by strong patient 
preference. Patients at increased risk of flare may continue 
anti-TNF therapy throughout pregnancy.
5.14.6 Infant vaccinations after exposure to biologics
Offspring exposed to anti-TNF drugs, vedolizumab and 
ustekinumab in utero are able to mount appropriate antibody 
responses to inactivated vaccines and should complete the 
inactivated vaccine programme as scheduled.1201 A multicentre 
observational retrospective study from 22 French gastroenter-
ology departments was recently presented in abstract form.1202 
The study aimed to determine the rate and tolerance of live 
vaccines in children before and following 6 months of life when 
exposed in utero to anti-TNF therapy and in children breastfed 
by mothers receiving anti-TNF. Anti-TNF therapy was stopped 
statement 127. We suggest that thiopurines may reduce risk 
of colorectal cancer in patients with ulcerative colitis and IBD-U, 
but evidence for a chemopreventative role from methotrexate, 
calcineurin inhibitors, anti-TNF and anti-integrin agents is 
lacking at present and they cannot be currently recommended 
solely for chemoprevention against colorectal cancer (GRADE: 
weak recommendation, low-quality evidence. Agreement: 93%).
statement 128. IBD patients receiving anti-TNF therapy 
should be counselled about the risks and benefits of continuing 
treatment throughout pregnancy. We suggest that, for patients 
with active disease or a high risk of relapse, it may be advisable 
to continue the drug throughout, while for those with inactive 
disease who wish to discontinue therapy it may be reasonable 
to stop at the start of the third trimester (GRADE: weak 
recommendation, very low-quality evidence. Agreement: 97.7%).
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before 26 weeks gestation in 74 (52%) women and resumed 
following delivery in 92%. Sixty-three women (45%) breastfed 
and no complications were reported. BCG vaccination was 
administered in 33 children (27.5%) prior to 6 months in 19 
children (16%). One local abscess was reported with ‘favour-
able evolution’. Seven children received rotavirus, five children 
before 6 months. One case of fever was reported. MMR was 
administered in 72 children (60%), before 6 months in six 
cases.
Data from the Dutch National Vaccination Programme in 
children exposed in utero to anti-TNF therapy shows that child 
vaccination against hepatitis B is effective compared with a 
control group.1203 There were no differences in birth outcomes, 
growth and infections in the first year of life.
Thus, non-live vaccination should be given as usual in infants 
exposed in utero to anti-TNF drugs, BCG should be deferred to 
6 months of age and rotavirus should not be given at all (as there 
is no value in giving rotavirus later than 6 months).
5.14.7 Vedolizumab, ustekinumab and tofactinib in pregnancy
There are very limited data about outcomes of pregnancies with 
vedolizumab. A review of pregnancies that occurred within the 
vedolizumab trials revealed 27 unintended pregnancies in female 
participants and 19 pregnancies in female partners of male 
participants.1204 No significant safety concerns were identified, 
although most women did not continue vedolizumab through 
to term. One case series presented four pregnancies while on 
vedolizumab, all successful (live offspring, not premature, 
normal APGAR scores, achieved developmental milestones).1205 
The data for ustekinumab in pregnancy are also limited to case 
studies and registry data. These data from rheumatology suggest 
that ustekinumab is not associated with increased risk of miscar-
riage or congenital malformation.1206 However, controlled 
data are lacking. Data in pregnancy in women with IBD preg-
nancy are limited to case reports.1207 Data are also limited for 
tofacitinib in pregnancy associated with UC, where 11 cases of 
maternal exposure and 14 cases of paternal exposure have been 
identified across intervention studies.1208 Outcomes include 15 
healthy infants, with no neonatal or fetal deaths, no congenital 
malformations, two spontaneous abortions and two medical 
terminations.
The lack of data confirming safety and the consequences of 
withdrawing treatment should be discussed as part of pre-con-
ception counselling. It is unknown whether exposed infants 
are susceptible to pathogenic infection from live vaccines. 
Until further data are available, it is recommended that the 
same practice that is used for anti-TNF drugs is applied to the 
newer biological agents. General guidance on pregnancy in IBD 
patients, summarised from ECCO and Toronto guidance,1209 1210 
is shown in box 12.
5.15 Genetics
Most children and the vast majority of adults with IBD do not 
have a monogenic predisposition to intestinal inflammation. 
However, this possibility should be considered in individuals 
either with very early onset of disease (ie, often in infancy, but 
up to 5 years old by the definition) or early onset in whom 
there are atypical features including susceptibility to unusual or 
frequent infections (suggesting a possible underlying immune 
deficiency). Mutations in the IL-10 signalling pathway have a 
Mendelian inheritance pattern and complete penetrance of the 
IBD-like phenotype, while a number of other genetic defects 
that disturb intestinal epithelial barrier function or affect innate 
and adaptive immune function have incomplete penetrance of 
intestinal inflammation. The importance of not missing such 
cases lies in the aggressive nature of the IBD-like phenotype and 
the fact that they are often very resistant to conventional IBD 
therapies. Some, such as XIAP and IL-10 receptor mutations, 
require allogeneic bone marrow transplantation for effective 
treatment and to prevent premature death. Increasingly, the 
diagnostic pathway relies on exome sequencing, but the analysis 
is complex and accurate diagnosis of the multiplicity of mono-
genic conditions that can produce IBD-like phenotypes in or 
soon after infancy relies on the laboratory being familiar with 
this clinical spectrum.1211
Pharmacogenetic testing for thiopurines is discussed in the 
Section on 5.2.2.1: Common Disease Considerations, Thiopu-
rine methyltransferase and NUDT15.
5.16 travel advice for Ibd patients
Patients can be very anxious about the risks of travelling abroad 
and issues surrounding vaccination during treatment for their 
IBD. Knowledge among patients and health professionals is 
poor, so education for both is important.1212 1213 The IBD Pass-
port website provides comprehensive information about travel 
with IBD ( www. ibdpassport. com). Comprehensive information, 
aimed at health professionals but available to the public, is also 
available in the CDC Travellers Health – Yellow Book (https:// 
wwwnc. cdc. gov/ travel/ page/ yellowbook- home). Live vaccina-
tions should not be given to patients on immunosuppressive 
drugs and can only be given a minimum of 3 months after stop-
ping this treatment. In relation to travel, this will include yellow 
fever and oral cholera vaccine. Clear advice is provided in the 
UK Green Book.730
Patients should also be counselled about dietary precautions 
when travelling, managing their medication, dealing with diar-
rhoea and travel insurance. They should be advised not to stop 
immunosuppressive therapy during an exacerbation of symp-
toms or potential infection.1214 In fact, immunosuppressed IBD 
patients who may be travelling abroad need to be optimised 
medically to try and prevent opportunistic infection where 
possible.1215
Travellers with IBD to developing countries (particularly if 
likely to be staying in accommodation with poor sanitation) are 
advised to carry a fluoroquinolone course (such as ciproflox-
acin 500 mg twice daily) for empirical self-treatment of travel-
ler’s diarrhoea. Azithromycin is comparable to quinolones for 
self-treatment of traveller’s diarrhoea in certain circumstances: 
(i) patients who take a fluoroquinolone as part of their treat-
ment for IBD; (ii) travellers to countries where endemic bacteria 
are known to have high levels of fluoroquinolone resistance; 
(iii) patients who have no response to a quinolone within 
36–48 hours; (iv) pregnant women and children <16 years (for 
whom a fluoroquinolone is contraindicated).1216 Currently, 
there is no evidence to support empirical treatment with rifax-
imin. Overall, the immunocompromised traveller with diarrhoea 
should have a lower threshold than immune competent travellers 
for initiating self-therapy, but stool samples should be obtained 
for microbiology in patients whose diarrhoeal symptoms do not 
statement 129. We suggest that BCG vaccination (if indicated) 
should be withheld until at least 6 months after birth, and 
rotavirus vaccine should not be given, for infants exposed in 
utero to biological therapies. Non-live vaccinations may be given 
according to standard vaccination schedules (GRADE: weak 
recommendation, very low-quality evidence. Agreement: 97.7%).
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respond to initial antibiotics.700 All patients should be advised to 
seek medical advice if they do not respond to simple measures. 
Returning travellers with diarrhoea should have stool tests for 
infection and a full blood count for eosinophilia. Travel and 
opportunistic infection are covered in more detail in recent 
ECCO guidance.700
6 servICe delIvery
6.1 Ibd service and the multidisciplinary team
A multidisciplinary team (MDT) approach to patient manage-
ment is recommended by NICE Quality Standards and by 
expert opinion.1217–1219 MDT management of IBD helps to 
provide optimised and personalised care, based on available 
professional expertise, infrastructure and funding.1 1220–1224 
Robust evidence in defining adult IBD MDT membership is 
lacking; however, best practice identifies a minimum per 
250 000 population of two gastroenterologists, two colorectal 
surgeons, 2.5 IBD nurses, 1.5 stoma nurses, 0.5 dietitian (allo-
cated to Gastroenterology), 0.5 administrative support, one 
histopathologist, one radiologist and one pharmacist – all with 
arrangements for cover in the event of absence.1225 The wider 
MDT (see figure 7) should include a psychologist, paediatric 
IBD team, obstetrician, rheumatologist and dermatologist.1224 
Input may be required from hepatology, oral medicine, ophthal-
mology, general practitioner, social workers and the nutrition 
support team.
The addition of an MDT coordinator has been shown to 
be effective in cancer management1226 and should be consid-
ered in IBD. However, patient advocacy has been shown to be 
lacking in some MDT meeting models. The systematic review 
of cancer MDTs demonstrated a biomedical approach to most 
decisions with nursing staff often not having an active role in 
decision-making and patient preferences frequently not consid-
ered as part of the process.1227 The IBD nurse is well placed to 
fulfil this role in the MDT. The patient should be provided with 
information and support at all stages of their illness to enable 
shared decision-making with the IBD specialist team.1225 In IBD 
cross-specialty discussion, decision-making and follow-up is of 
clear importance, especially in surgical management,1221 1228 and 
should be clearly documented.
6.1.1 MDT meetings
Timing of MDT meetings depends on the size of unit and 
should happen weekly, or frequently enough to ensure deci-
sion-making is not delayed, and should have enough capacity 
to deal with the number of patients. Acute or emergency care 
decisions should not be delayed for timetabled meetings but 
should happen separately between relevant specialists. In a 
UK nationwide audit, the presence of an IBD MDT was an 
independent factor associated with lower rates of steroid 
overuse.448
Good Practice recommendation 26. IBD patients 
travelling abroad should be advised to take adequate 
supplies of medication with them and should not stop their 
immunosuppressive therapy. Those on immunosuppressive 
drugs should be advised to have a low threshold for treating 
possible traveller's diarrhoea with quinolones or azithromycin 
(Agreement: 95.7%).
box 12 General guidance on pregnancy in Ibd patients
Prior to conception:
 ► Education: Importance of keeping well (‘you need to be 
well for your baby to be well’). Discuss potential adverse 
fetal outcomes of uncontrolled IBD (eg, pre-term birth and 
low birth weight), the risk of flare versus risk of current 
medications.
 ► Optimise: Is the patient as well as possible with their IBD? 
Investigate and, if necessary, treat.
 ► General health: Consider folic acid, nutrition, cervical smear, 
smoking cessation, vaccinations.
 ► Consider: Is the patient receiving the safest possible 
combination of medicines for pregnancy?
during pregnancy:
 ► Treat both maintenance and flares as normal with 5-ASA, 
thiopurines, anti-TNF, nutrition and steroids. Indications for 
surgery in pregnant women with IBD are the same for non-
pregnant patients
 ► Use therapies with the best evidence base for safety in 
pregnancy.
 ► Use imaging as needed but minimise radiation exposure with 
emphasis where possible on ultrasound and MR. Essential 
endoscopic investigations only when needed for clinical 
decision making (ideally in second trimester).
 ► VTE prophylaxis is particularly important if in hospital 
(including following Caesarean section) or unwell.
 ► Involve the MDT and patient in your decisions and include an 
obstetrician with appropriate experience.
delivery and postpartum:
 ► Mode of delivery should be determined by obstetric 
considerations and patient preference except active perianal 
disease and ileoanal pouch or ileorectal anastomosis where 
caesarean section is often preferred.
 ► VTE prophylaxis is important after Caesarean section.
 ► Medicines safe in pregnancy are also safe in breastfeeding 
and should continue.
 ► Breastfeeding is the preferred method of feeding and does 
not impact the course of IBD.
5-ASA, 5-aminosalicylic acid; IBD, inflammatory bowel disease; MDT, 
multidisciplinary team; TNF, tumour necrosis factor; UC, ulcerative colitis; 
VTE, venous thromboembolism.
Adapted from Van der Woude et al,1209 and Nguyen et al.1210
statement 130. We suggest that genetic testing for monogenic 
disorders should be considered in adolescents and young adults 
who have had early onset (before 5 years of age) or particularly 
aggressive, refractory or unusual IBD presentations (GRADE: 
weak recommendation, very low-quality evidence. Agreement: 
95%).
statement 131. We recommend that IBD patients 
travelling abroad should receive pre-travel health advice, 
taking into account any immunosuppressive medication. 
Standard vaccination advice should be given, but those on 
immunosuppressive drugs should not receive live vaccination 
unless treatment has been discontinued for a minimum of 
3 months (GRADE: strong recommendation, very low-quality 
evidence. Agreement: 95.7%).
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Limited evidence exists on the specific format of an MDT 
meeting; however, a colorectal MDT survey highlighted the need 
for a coordinator and the benefits of training in data manage-
ment.1226 The cost-effectiveness of the MDT in secondary care 
has not been demonstrated mainly due to heterogeneity in study 
methodology.1229 However, a recent Delphi consensus of IBD 
service quality indicators emphasised the importance of team 
working and this can be delivered effectively through an MDT 
process with administrative support, either by a secretary or cler-
ical officer.1230
6.2 Quality improvement and audit
There is much that can be done to improve the quality of care 
for IBD patients, both in adhering to evidence-based standards 
of care and also in improving the quality of patients’ experi-
ence of their healthcare by provision of information, shared 
decision-making and improving access to their IBD team.1222 
A recent Delphi consensus identified a core set of 56 quality 
indicators (12 structure, 20 process and 24 outcome).1230 
Structure and process quality indicators highlight the need for 
multidisciplinary management and continuity of care, and that 
IBD units should be able to provide both outpatient and inpa-
tient care. Outcome quality indicators focused on the adequate 
prophylaxis of disease complications and drug adverse events, 
the need to monitor appropriateness of treatment and the need 
to reinforce patient autonomy by providing adequate informa-
tion and facilitating patients’ participation in their own care. The 
IBD MDT is essential to this process.1218
6.2.1 Rapid assessment
All patients referred with suspected IBD should be seen by a 
specialist within 4 weeks of referral, but patients with severe 
symptoms may need urgent specialist assessment within a few 
days.1217 Patients experiencing a relapse of their IBD should have 
access to a member of the IBD team within five working days, 
and patients requiring radiological or endoscopic investigations 
should have tests performed within 4 weeks, or within 24 hours 
in an acute or emergency situation.1225
6.2.2 Adverse event monitoring
The UK National IBD Audit was a powerful tool to measure 
and enable IBD services to compare practice. Participation in 
the Audit was a catalyst for service improvement.1231 Monitoring 
and reporting adverse events are important aspects of service 
improvement.1232 1233
6.3 electronic patient data collection for clinical management 
and audit
The use of an IBD-specific patient management system is essential 
to capture clinical data on patients receiving immunosuppressive 
and biological drug therapy. It enables input and presentation 
of key information at point of care, facilitates effective drug 
monitoring, and collects data that can be used for audit and 
research.1234 1235 With the increasing availability of new drugs, 
including biosimilars, these data can be used locally, but also on 
a national basis to monitor safety and efficacy.
6.4 Ibd specialist nurses
The role of the IBD specialist nurse is integral to the provi-
sion of a multidisciplinary service for IBD patients.1230 1236 
Although there is little robust RCT evidence to demonstrate 
the cost-effectiveness of the role,1237 some suggest that the 
IBD nurse specialist role results in significant reduction in 
hospital admissions, emergency unit attendances and clinic 
visits as a result of contact with the nurse.1238 1239 Other 
small controlled studies suggest cost-effectiveness,1240 while 
some observational studies have suggested an improvement in 
patient care.1241–1243
IBD specialist nurses are often responsible for the manage-
ment of medication and provision of disease information for 
patients.1220 1239 1244 Adherence to medication can be improved 
Good Practice recommendation 27. The IBD multidisciplinary 
team (MDT) should include a core membership consisting of 
gastroenterologist, colorectal surgeon, IBD specialist nurse, 
radiologist, dietitian, histopathologist and pharmacist, all of 
whom should have expertise in IBD. The MDT should have 
a designated coordinator and be able to access advice from 
the following disciplines where necessary for decisions about 
specific patients: stoma nurse, paediatric gastroenterologist, 
hepatologist, nutrition support team, psychologist, primary care 
physician, ophthalmologist, rheumatologist, dermatologist, 
obstetrician and social worker (Agreement: 97.9%).
Figure 7 The IBD multidisciplinary team (MDT). It is important that 
the MDT meets regularly to review cases and make recommendations. 
All members of the team should have input as appropriate, but those 
in the inner box should be present at all regular MDT meetings. Staff in 
the middle box can and should be encouraged to attend these meetings, 
but this may not always be possible and they should nevertheless be 
encouraged to contribute reports or opinions. Staff in the outer box are 
part of the wider MDT and may contribute to team function through 
clinical input outside of these team meetings, such as through combined 
clinics or working to shared protocols. Staff in the grey circle should 
attend as a valuable part of their training.
statement 132. We recommend that regular multidisciplinary 
team (MDT) meetings should be held to discuss IBD patients 
with complex needs (GRADE: strong recommendation, very 
low-quality evidence. Agreement: 97.9%).
Good Practice recommendation 28. For each IBD patient 
discussed in the MDT meeting, a formal record should be kept of 
management decisions reached (Agreement: 100%).
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by multiple different interventions including patient education, 
behavioural change, dose simplification, cognitive behavioural 
therapy and use of telemedicine.1245 A study of nurse telephone 
counselling in 524 patients with UC using cognitive-behavioural 
and motivational interview techniques to address cognitive and 
emotional barriers to adherence showed significant improve-
ments in adherence, although there was no control group.1246 
A Norwegian randomised study of nurse follow-up compared 
with gastroenterologist follow-up showed that outcomes were 
as good over 1 year in the nurse follow-up clinics as they were 
in the gastroenterologist clinics.1236 Time between symptoms 
of relapse and starting treatment was shorter in the nurse-led 
clinic and may relate to improved patient access to the IBD 
service.
6.5 telephone advice lines/telephone and virtual clinics
IBD advice telephone or email services are an important 
communications pathway for IBD patients who need access 
to specialist support and advice, while not necessarily needing 
a clinic appointment or hospital admission. A Spanish study 
of >1200 calls showed that a specialist nurse could manage 
two-thirds, with the remainder requiring a doctor’s input.1247 
Nearly 90% were resolved by telephone call alone. 27% 
concerned IBD drug treatment, 25% related to disease 
concerns (mostly possible relapse), 25% related to adminis-
trative issues (such as appointment bookings) and 22% were 
queries regarding disease management. In an Irish survey, over 
one-third of calls related to flares or patient concerns, but 44% 
related to administrative issues, including blood test requests/
results and repeat prescriptions.1242 Having a system to divert 
administrative queries to a secretary or clerical staff would free 
up time for IBD specialist nurses for more appropriate use of 
their skills—for example, carrying out vigilance and rescue 
work.
Following introduction of a telephone advice line in 2013 in a 
Scottish hospital, avoidance of consultant clinic and general prac-
titioner appointments were estimated to have resulted in highly 
significant cost savings of over £42 000 in a 5-month period.1248 
A study in Spain also suggested significant cost savings from 
availability of telephone consultations with an IBD nurse.1249 In 
Canada, a survey of over 1000 patients showed that many felt it 
difficult contacting their physicians, and 77% stated they would 
make telephone contact with an IBD nurse if available in future, 
when having acute symptoms. The authors speculated that this 
would result in fewer emergency department attendances.1250 In 
a USA study a survey was undertaken of telephone calls to nurse 
coordinators supporting IBD providers in a tertiary centre.1251 
Patients with high call rates (>10 per year) had more complex 
disease and drug treatments, markers of increased disease activity 
and high service utilisation. In order to effectively run telephone 
and email services, adequate funding and administrative support 
must be available.
6.6 Alternatives to clinic attendance for follow-up
A recent USA study showed that patients attending outpatient 
clinic appointments travel more than 25 miles each way to 
attend, have to take half a day off work and incur personal 
out-of-pocket expense of 62 US dollars to attend.1252 Coupled 
with increasing demands on health service appointments, many 
strategies have been introduced to reduce the need for face-
to-face clinic appointments for patients in stable long-term 
remission. This includes telephone clinics, email contact and 
other electronic management or web-based systems. Telephone 
contact as an alternative to clinics are acceptable to most 
patients,1253 with a Danish survey showing that 87% approved, 
particularly in younger patients who were working.1254 Quality 
outcome measures have been shown as comparable with tele-
medicine clinic in comparison to standard in-office appoint-
ment.1252 A pharmacist-led telephone clinic for patients 
on immunomodulators has been shown to be popular and 
effective.1255
Supported self-management systems, including telephone 
contact, may improve monitoring and colonoscopic surveillance 
adherence for stable patients who could otherwise be lost to 
follow-up.1256 Other e-health technologies have gained popu-
larity in recent years including smart phone applications and 
web-based interventions. These tools may serve as a method 
of engaging rural or isolated populations.1257 A review of six 
randomised controlled trials of a variety of distance manage-
ment systems (web-based self-management and education, 
email contact, open-access clinics, and three that included tele-
phone contact) showed a significant reduction in clinic visits 
with an average reduction from two to three down to one clinic 
visit per year.1258 The review suggested that more interaction 
between patient and professionals may be associated with 
greater benefits in terms of quality of life, but overall there was 
no significant change in quality of life, relapse rates or hospital 
admissions. A further recent systematic review identified six 
randomised controlled trials and nine observational studies 
showing improvements in relapse duration (18 days vs 77 days, 
p<0.001 in one study), disease activity, improved medica-
tion adherence, quality of life, IBD knowledge, costs, reduced 
outpatient clinic attendance and high patient satisfaction with 
these technologies.1259 IBD services should have provision for 
remote follow-up methods, which should be offered to moti-
vated patients who are happy not to attend conventional clinic 
follow-up appointments.
Good Practice recommendation 29. IBD units should have 
quality improvement and audit processes embedded within 
regular clinical activity (Agreement: 100%).
Good Practice recommendation 30. IBD services should 
collect data on adverse events and near misses. The service 
should participate in local and national audit and engage in 
ongoing quality improvement (Agreement: 100%).
Good Practice recommendation 31. Patient data on 
treatment with biological therapies and immunomodulators 
should be recorded to provide information for clinical 
management and to monitor adverse events and clinical 
outcomes for both local and national audit. Biological treatments 
should be recorded by brand name where biosimilar drugs are 
also available (Agreement: 97.8%).
Good Practice recommendation 32. Clinical nurse 
specialists are a vital part of the IBD team, where their role may 
include provision of cost-effective patient education, disease 
management and therapy monitoring, patient support, continuity 
of care, audit and rapid access for advice and review during 
disease flares (Agreement: 100%).
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6.7 self-management
Guided self-management describes empowerment of patients 
to manage their condition and be involved in treatment deci-
sions through provision of written information in understand-
able terminology regarding anticipated treatment or surveillance 
algorithms or when and how to contact primary or secondary 
care professionals. A randomised trial of guided self-manage-
ment showed a reduction in clinic visits and more rapid treat-
ment of flares in the self-management group.1260 There was 
no significant increase in quality of life overall. A subsequent 
randomised controlled trial recruiting 700 patients demon-
strated that, over 1 year, self-management techniques led to 
fewer hospital visits (difference −1.04; 95% CI −1.43 to −0.65, 
p<0.001).1261 This was not associated with increased numbers 
of visits to primary care. Satisfaction and quality of life were 
similar between guided self-management and standard care. The 
self-management group reported increased confidence in being 
able to manage their condition. Longer term, specialist nurse 
contact was required in additional to guided self-management in 
order to ensure colorectal cancer surveillance is undertaken, that 
patients receive osteoporosis screening and that annual reviews 
are completed.1262
A systematic review, meta-analysis and meta-regression 
of 15 studies of self-management interventions showed that 
these strategies do result in some improvement in health-re-
lated quality of life, but there were no significant differences 
between the different components of the self-management 
strategy, perhaps because of the range of interventions that 
were included.1263 There was a trend for those with tailored 
management (eg, including guidance according to individual 
symptom diaries, personalised guided self-management 
advice, or individual psychotherapy support), for those with 
information components that improved IBD knowledge, and 
for those with detailed symptom management, to result in 
better outcomes. The only significant difference was shown 
between the two web-based programmes, which had a greater 
effect size compared with the remaining 13 with face-to-face 
interventions.
A multicentre controlled trial of telemedicine incorporating 
guided self-management has recently been published by a group 
in the Netherlands. The ‘myIBDcoach’ system utilises algorithms 
to request patients to complete questionnaires monitoring disease 
activity between 3 months when in remission and weekly during 
a flare. Questionnaires are undertaken in preparation for outpa-
tient review. Parameters above a pre-defined threshold were 
flagged to the IBD clinic. The system also includes a personalised 
output including visualised health parameters, PROs and quality 
metrics, and interactive patient-tailored information on topics 
including medications, adherence, smoking cessation, nutrition, 
self-management to prevent or reduce symptoms, fatigue, work 
productivity, anxiety and depression. It also contains a secure 
messaging service between patient and clinician. After 1 year, 
those assigned to telemedicine (n=465) compared with stan-
dard care (n=444) attended fewer outpatient clinics (1.55 vs 
2.34, p<0.0001) and had fewer hospital admissions (0.05 vs 
0.10, p=0.046). Quality of care scores did not vary between 
groups.1264
6.8 Primary care
Primary care is often the first point of contact for IBD patients 
with deteriorating symptoms. Clear and comprehensive commu-
nication between hospital and primary care is essential (box 13). 
Recommended information should be included in correspon-
dence between secondary and primary care. The development 
of local pathways taking into consideration available resources 
is encouraged. Patients with clinical features of severe disease, 
defined as six or more bloody stools per day plus one of tempera-
ture >37.8°C, heart rate >90 beats/min, anaemia <105 g/L or 
ESR >30 mm/hour should be admitted as an emergency for 
specialist assessment.102 1265 For patients with moderate or severe 
IBD not requiring urgent admission, it is important that early 
contact is made with their IBD clinic, either by the patient or 
the general practitioner (GP), to ensure that response to therapy 
is monitored. GPs often prescribe prednisolone, but may be less 
familiar with increasing the 5-ASA dose to manage flares of UC. 
An adequate response should be expected within 2–3 weeks1266 
and, if not evident, review is required to assess the need to esca-
late treatment or arrange hospital admission.
A recent study of IBD patients managed in primary care in 
London showed a high standard of monitoring blood tests and 
avoidance of unnecessary steroid use, but underprovision of 
vaccination where recommended by guidelines and overuse 
of 5-ASA in Crohn’s disease.1267 A primary care study of UC 
patients taking 5-ASA showed that dosage, monitoring and 
adherence were suboptimal,1268 and vaccination levels poor.1269 
Integrated referral pathways have been shown to reduce 
waiting times for advice and specialist investigations, improve 
clinical and patient reported outcomes and reduce costs to the 
healthcare system.1270 Internet-based programmes can facili-
tate structured monitoring for patients being followed up in 
the community.1271 Adherence to medication can be improved 
by simplifying dose regimens and promoting better under-
standing and communication between the patient, primary care 
and IBD clinic team.1272 Better education for patients and for 
community and hospital teams is likely to improve vaccination 
uptake.1239 1273–1276
statement 134. We recommend that telephone or video virtual 
clinics can allow for the timely follow-up of stable IBD patients 
as an alternative to face-to-face clinic visits. These clinics need 
adequate administrative support and documentation, and 
methods to ensure contact with patients is maintained. Patients 
must have easy access to telephone or email advice and clinic 
access in the event of disease flare or patient concern about 
their IBD (GRADE: strong recommendation, low-quality evidence. 
Agreement: 95.7%).
statement 135. We suggest that IBD patients who wish to 
participate in guided self-management should be provided 
with education sessions and written or electronic personalised 
information about their management, with ongoing support 
and access to the IBD service in the event of relapse (GRADE: 
weak recommendation, moderate-quality evidence. Agreement: 
93.6%).
statement 133. We recommend that IBD patients and 
primary care physicians should be provided with a dedicated 
IBD telephone line or email service to allow timely advice 
and care, particularly during times of relapse or to discuss 
managing medications or treatment side effects. Services must 
have adequate administrative and funding models (GRADE: 
strong recommendation, low-quality evidence. Agreement: 
100%).
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7 Future reseArCh PrIorItIes
By reviewing the original 414 clinical questions that the guide-
line development group defined as those facing multidisci-
plinary clinicians in everyday clinical practice, with comparison 
to evidence returned from the systematic review process and 
results from the eDelphi, 20 research priority themes have been 
determined and are presented in table 12. An essential aspect 
of any research priority identification process is determination 
of the importance of this research to those living with UC and 
Crohn’s disease. Accordingly, each research priority theme was 
drafted in healthcare professional language and for a general 
audience, with readability testing shown in online supplementary 
table 4. Feedback on the importance of each theme was received 
from two electronic surveys conducted by the UK patient 
charity Crohn’s and Colitis UK (table 12). The 931 respondents 
to survey 1 and 1448 respondents to survey 2 were anonymous 
but identified themselves as a UC or Crohn’s disease patient, 
a relative, partner, parent, friend or carer. Subgroup analyses 
of research priority theme importance are presented in online 
supplementary table 5. Identified as of particular importance 
to those living with UC and Crohn’s disease were: prevention, 
risk stratification, diagnosis and management of neoplasia; aeti-
ology and management of pain and fatigue; precision medicine; 
surgical techniques to minimise postoperative disease recur-
rence in Crohn’s disease; management of non-perianal fistulae 
in Crohn’s disease; and the microbiome including faecal micro-
bial transplantation and the impact of dietary modification in 
UC. All 20 research priority themes were found to be important 
to those living with UC and Crohn’s disease, with mean scores 
and confidence intervals for each falling in the upper tertile of 
the 1–9 Likert scale, with the exception of research regarding 
improvement of adherence to therapy and the impact on patient 
outcome. Our findings are complementary to those of the James 
Lind Alliance and build on the importance of a strong patient 
voice in research priority setting.1277 1278 It is hoped that this 
exercise will highlight to the academic community, research 
funders and policy makers where further high-quality research 
is required to support and advance future clinical practice in UC 
and Crohn’s disease.
8 ConCludInG reMArks
These British Society of Gastroenterology consensus guidelines 
on the management of inflammatory bowel disease in adults 
have been developed along with all major UK stakeholders in 
UC and Crohn’s disease healthcare, including patient repre-
sentation through close collaboration with Crohn’s and Colitis 
UK.
They are published at a time of rapid change in many aspects 
of IBD. Recent developments highlighted include new imaging 
techniques; increasing numbers of new drugs; changes in the 
way these drugs are used with accelerated treatment and reduc-
tion in prolonged use of older therapies with greater toxicity; 
the increasing importance of infection screening at diagnosis; 
changes in therapeutic goals (such as mucosal healing) and 
advances in therapeutic monitoring. This makes IBD treatment 
ever more complex and highlights the importance of multidis-
ciplinary working, and finding more effective ways to deliver 
services. We have also emphasised the vital importance of patient 
education, empowerment and partnership in order to ensure that 
the patient’s needs (and not the technology) remain the focus of 
all those treating IBD patients.
We have drawn together concise guidance and evidence 
supporting a wide range of statements that inform best practice 
in the care of patients with UC and Crohn’s disease, including 
the quality of the evidence available and the strength of recom-
mendations, with a Delphi consensus process to show level of 
agreement. Many areas are clearly in a state of rapid evolution, 
and there remain obvious gaps in our understanding. In refer-
ence to this, we have presented the key unmet research themes 
arising from our systematic review and have also presented 
the importance of each from a patient's perspective. We hope 
this exercise will highlight aspects of care that are of impor-
tance to IBD patients and the healthcare community, and thus 
may inform government, Research Councils, medical research 
funding bodies and industry as to areas of research priority in 
order to advance care for UC and Crohn’s disease patients in 
2019 and beyond.
Good Practice recommendation 33. Integrated care 
pathways and shared management guidelines should 
recommend primary care prescribing and monitoring of IBD 
treatments including mesalazine, thiopurines and methotrexate 
once patients are in remission on stable dose. Primary care 
physicians should arrange monitoring blood tests, relevant 
vaccinations and encourage treatment adherence, supported 
by regular communication with secondary care (Agreement: 
95.7%).
box 13 recommended information to be included in 
correspondence between secondary and primary care
Information to be included in correspondence from 
secondary to primary care:
 ► Main diagnosis/diagnoses: type and location of IBD and date 
of diagnosis
 ► Date(s) of surgery
 ► Secondary diagnosis/diagnoses—for example, anaemia, 
vitamin D deficiency, osteoporosis, extraintestinal 
manifestations
 ► Date of last endoscopy with findings and timing of next 
planned endoscopy
 ► Date of next planned contact with secondary care
 ► Current medical therapy including any previous treatments 
with thiopurines, methotrexate or biologics and reasons for 
discontinuation
 ► Recommended length of current medical therapy
 ► Treatment recommendations in case of a flare: 5-ASA dose 
increase, prednisolone, budesonide, calcium and vitamin D. 
Details of who to contact if treatment is initiated in primary 
care
 ► Contact details for local IBD team
 ► Weblink for advice and guidance for primary care (eg, RCGP 
Spotlight Project toolkit www.rcgp.org.uk/ibd)
Information to be included in correspondence from 
primary to secondary care:
 ► Date last prescription issued
 ► All current and recent medications. Any recent antibiotics
 ► Number of courses of oral prednisolone issued in last 
12 months
 ► Key results of last blood tests
 ► Functional impact for example, impact of IBD on 
employment, family and social functioning
 ► Any newly diagnosed comorbidities
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table 12 Research priority themes identified by guideline development group, with measures of importance determined from two surveys 
conducted by Crohn’s and Colitis UK
Mean theme 
importance to 
n=931 survey 
respondents 
(95% CI): 
min=1 max=9
Research priority themes regarding both ulcerative colitis and Crohn’s disease
1 how do we select the correct treatment, for the correct patient, at the correct time to achieve precision/stratified medicine in clinical practice? What is the 
comparative efficacy of different classes of biologics in Ibd patient subgroups?
With an increasing range of biologic treatments available for Crohn’s disease and ulcerative colitis, working out which are better suited for individual patients is more 
important than ever. How can doctors and other members of the healthcare team select the best treatment at the right time for each patient with IBD? Do some treatments 
work better or worse in patients with different types of IBD, or with different test results?
7.9
(7.8 to 8.0)
2 to achieve treatment to target, is intensification of immunosuppression in an otherwise asymptomatic patient acceptable and in what proportion of patients 
is mucosal healing an achievable goal?
IBD is less likely to flare up later if the bowel is fully healed. Some patients have no symptoms, but evidence of inflammation is seen during colonoscopy or scans. In these 
cases, how acceptable is it to increase or change treatment to try and heal this inflammation? How successful and safe is this?
7.2
(7.1 to 7.3)
3 What are the most appropriate longitudinal clinical, imaging and endoscopic indices, and what are the best patient reported outcome measures and 
biomarkers to assess disease activity and monitor response to therapy?
What are the best symptom questionnaires, blood tests, stool (faeces) tests, scans and camera tests (eg, colonoscopy) to determine accurately whether or not IBD is controlled? 
Which are the best tests to repeat over time to measure change and response to treatment?
7.7
(7.6 to 7.8)
4 What is the optimal 6tGn concentration when thiopurines are used as part of combination therapy with a biologic?
Blood tests (to measure 6TGN concentrations) can help doctors to decide on how much azathioprine and mercaptopurine to give to patients for the best chance of benefit and 
at the same time a low risk of side effects. How should these tests be used to get the best effect of these drugs when they are given in combination with newer biologics like 
infliximab, adalimumab, vedolizumab or ustekinumab?
7.4
(7.3 to 7.5)
5 What are the best strategies to prevent, risk stratify, diagnose and manage neoplasia in Ibd? What is the optimal strategy for endoscopic surveillance of 
dysplasia in patients with colitis?
Some people with IBD are at higher risk of developing colon cancer. What is the best way to measure whether someone is at higher risk? What is the best way to prevent, 
diagnose, treat, or look for cancer, or early changes that might develop into cancer? How frequently should patients with IBD be assessed in this way?
8.1
(8.0 to 8.2)
6 What causes the symptoms of fatigue and pain in Ibd, and what pharmacological and non-pharmacological therapies are beneficial?
Why do many IBD patients experience fatigue (tiredness not relieved by resting) and pain? What treatments (drugs or non-drug treatments) are best to help these symptoms? 
Why do these symptoms continue even if their Crohn’s disease or ulcerative colitis are no longer active?
7.9
(7.8 to 8.0)
7 What is the optimal operative technique to maintain fertility, fecundity, sexual function and continence in Ibd patients undergoing surgery?
Some operations for Crohn’s disease and ulcerative colitis can have an impact on sexual intercourse, fertility, pregnancy and bladder/bowel function. What are the best 
techniques doctors can carry out during surgery to minimise this happening in men and women?
7.6
(7.5 to 7.7)
8 What are the most effective strategies to empower patients towards effective self-management? how should patients' views, beliefs and attitude to risk best 
be considered when making treatment decisions in Ibd? In young adults can this be supported by dedicated transition models from paediatric to adult Ibd 
services?
Self-management in IBD refers to the practice of giving patients enough knowledge and support to manage their disease themselves most of the time. This can reduce the 
number of visits to the hospital, and patients can feel more in control. What is the best way to educate and empower patients to manage their own condition? How can the 
needs, views, wishes and feelings of each patient be included in decisions about their treatment? Does the approach need to be different for different groups of patients, 
including young adults moving from the children’s hospital service to the adult hospital service?
7.5
(7.4 to 7.6)
9 should ebv serology influence immunomodulatory therapy algorithms in subgroups of patients with Ibd?
Epstein Barr virus (EBV) causes glandular fever, which usually affects children and young people. Many catch the virus without any symptoms at all and may carry it without 
knowing. Patients who carry the EBV virus can, very rarely, develop severe complications including cancer of the lymph glands when treated with some drugs used in IBD 
(particularly azathioprine or mercaptopurine). Should knowing about whether an IBD patient has previously had EBV be used to decide the type of treatment they receive?
7.0
(6.8 to 7.1)
10 Is it safe and efficacious to administer live vaccination to patients on ‘low dose’ immunosuppression—for example, thiopurines and methotrexate?
Live vaccinations can theoretically cause infections in individuals with a suppressed immune system. Examples include shingles and yellow fever. This means that live 
vaccinations are often avoided if patients are taking immunosuppressants. Patients who have been recently vaccinated may not be started on treatments to suppress the 
immune system for many weeks or months to give time for the vaccination to take effect and for the risk of infection to reduce. This delay can cause problems for patients who 
are very ill. Is it safe to give live vaccines to patients who are receiving immunosuppressant drugs such as azathioprine, methotrexate or low doses of the steroid prednisolone?
6.9
(6.8 to 7.0)
11 What methods can improve adherence with therapy in Ibd, and does this improve patient outcome?
Some patients find it difficult to remember to take their medications, particularly if they feel well and have to take the treatments over a long period of time. How can patients 
be helped to remember to take their treatments regularly on a long-term basis? How much additional benefit will they get from taking their treatment most or all of the time?
5.8
(5.6 to 5.9)
12 What is the safety profile of vedolizumab, ustekinumab and tofacitinib in pregnancy and during breastfeeding?
How safe are the drugs vedolizumab, ustekinumab, and tofacitinib (all relatively new drugs used in IBD) for the fetus and mother during pregnancy? How safe are these drugs 
for the baby following birth if breastfeeding?
7.3
(7.1 to 7.4)
13 Can shared care algorithms between primary and secondary care improve outcomes for patients and make delivery of care more cost effective?
Systems of ‘shared care’ involve sharing of patient treatment plans between hospitals and GPs. They specify which drugs should be used and how treatment should be 
monitored. Do these help patients have better control of their disease? In addition, do shared care systems reduce the overall costs of treatment for the NHS?
7.1
(7.0 to 7.2)
Research priority themes regarding ulcerative colitis only
14 What is the optimal induction dose and drug administration interval for infliximab in acute severe ulcerative colitis, and how do we stratify this for the 
individual patient?
Some patients with ulcerative colitis have to be admitted to hospital for a severe flare. Standard treatment is with intravenous steroids (via injection into a vein). If this 
treatment doesn’t work, doctors sometimes use infliximab (a biologic drug) to treat them. When should infliximab be used and what is the best dose to give? Should the 
treatment be tailored to suit each individual patient’s condition, and what symptoms or tests are best used to decide this?
7.4
(7.3 to 7.6)
15 Which bacteria confer benefit in ulcerative colitis as probiotics or within faecal microbial transplantation, and is this patient-specific? Can dietary intervention 
improve patient outcome through alteration of the microbiome or other mechanisms?
Within the gut there is bacteria that may have an impact on ulcerative colitis, and altering this could reduce the inflammation caused by this condition. Which bacteria that 
lives in the gut can be changed and how can this be achieved (for example, by giving treatments containing types of bacteria, or giving bacteria from someone else’s bowel as 
a treatment). Are different bacteria important for different patients? Can changes to diet alter the bacteria in the gut and if so, is this beneficial?
7.8
(7.7 to 7.9)
Research priority themes regarding Crohn’s disease only
16 What is the optimal treatment strategy for mild Crohn’s disease?
What is the best way to treat mild Crohn’s disease?
7.2
(7.0 to 7.3)
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Mean theme 
importance to 
n=931 survey 
respondents 
(95% CI): 
min=1 max=9
17 What is the role of diet and nutrition (ie, oral, enteral and parenteral) in inducing and maintaining remission of adult Crohn’s disease? What is the mechanism 
of action of existing nutritional approaches to achieving remission in Ibd?
Dietary treatment may involve changing what we eat, adding dietary supplements or replacing everything we eat with special nutritional products designed to provide 
complete nutrition. These are likely to be in the form of milkshake-type drinks. Some patients also receive an intravenous diet, which means a tube provides nutrients directly 
into their blood stream. How effective is dietary treatment in controlling Crohn’s disease in adults? How effective is it in preventing Crohn’s disease from flaring after it has 
been fully controlled? How do these treatments work to heal the inflamed gut in Crohn’s disease?
7.5
(7.3 to 7.6)
18 What are the optimal techniques for resection and anastomosis during surgery for Crohn’s disease to minimise disease recurrence?
When patients with Crohn’s disease have an operation to remove part of the small or large bowel, the two ends of bowel are often joined back together again. How this is 
done can influence the risk of disease coming back. What is the most effective surgical technique to minimise recurrence?
8.0
(7.9 to 8.1)
19 What are the best methods to quantify fibrosis in Crohn’s disease strictures?
Patients with Crohn’s disease sometimes develop narrowed, scarred areas in the bowel, particularly in the small intestine. These are called strictures and can eventually lead 
to blockages. While current drugs can control the inflammation found in Crohn’s disease, they are not good at reversing this scarring process. What is the best way to measure 
how much scarring there is in areas of narrowed bowel?
7.7
(7.6 to 7.8)
Mean theme 
importance to 
n=1448 survey 
respondents 
(95% CI): 
min=1 max=9
20* Is there an optimal management strategy for non-perianal fistulae in Crohn’s disease?*
A fistula in Crohn’s disease is when a deep ulcer in the bowel forms a connection or track with another part of the body. They can lead to infection or abscesses. Perianal 
fistulas are when tracks link the rectum (lower bowel) with the skin around the anus. Non-perianal fistulas involve connections or tracks from the bowel to other structures 
like the bladder, the vagina, the skin of the tummy wall, or tracks running from one part of the bowel to another. There is less evidence about how to treat non-perianal fistulas 
with medication or surgery. What are the best treatments and combinations of treatments for Crohn’s disease when it causes non-perianal fistulas?*
8.0
(7.9 to 8.0)
Twenty research priority themes identified by the guideline development group are presented in healthcare professional language (plain text), with corresponding general audience versions (italics). Mean 
scores of importance, judged on a Likert scale of 1–9 (1=‘not important’ and 9=‘very important’) are shown with 95% CIs, determined from two electronic surveys conducted by Crohn’s and Colitis UK.
*Feedback regarding research priority themes 1–19 was the subject of the first survey from Crohn’s and Colitis UK, and research priority 20 was the subject of the second survey. Therefore, comparisons of 
the relative mean theme importance should not be made between themes 1–19 and theme 20 as they represent a potentially different cohort of respondents.
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